S8258289B2	NNP	O
-	:	O
Modulation	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
expression	NN	O
-	:	O
Google	NN	O
Patents	NNS	O
Info	NNP	O
Links	NNP	O
Classifications	NNP	O
Abstract	NNP	O
Description	NNP	O
CROSS-REFERENCE	NNP	O
TO	NNP	O
RELATED	NNP	O
APPLICATIONS	NNP	O
This	DT	O
application	NN	O
is	VBZ	O
a	DT	O
divisional	JJ	O
of	IN	O
U.S.	NNP	O
application	NN	O
Ser.	.	O
No.	.	O
11/066,725,	,	O
filed	VBN	O
Aug.	NNP	O
24,	,	O
2005,	,	O
which	WDT	O
is	VBZ	O
a	DT	O
continuation	NN	O
of	IN	O
International	NNP	O
Application	NNP	O
No.	.	O
PCT/US2004/024384,	,	O
filed	VBN	O
Aug.	NNP	O
18,	,	O
2004,	,	O
which	WDT	O
claims	VBZ	O
the	DT	O
benefit	NN	O
of	IN	O
U.S.	NNP	O
application	NN	O
Ser.	.	O
No.	.	O
10/643,801,	,	O
filed	VBN	O
Aug.	NNP	O
18,	,	O
2003,	,	O
the	DT	O
entire	JJ	O
contents	NNS	O
of	IN	O
each	DT	O
are	VBP	O
herein	RB	O
incorporated	VBN	O
by	IN	O
reference.	.	O
SEQUENCE	NNP	O
LISTING	NNP	O
The	DT	O
present	JJ	O
application	NN	O
is	VBZ	O
being	VBG	O
filed	VBN	O
along	IN	O
with	IN	O
a	DT	O
Sequence	NNP	O
Listing	NNP	O
in	IN	O
electronic	JJ	O
format.	.	O
The	DT	O
Sequence	NNP	O
Listing	NNP	O
is	VBZ	O
provided	VBN	O
as	IN	O
a	DT	O
file	NN	O
entitled	VBN	O
RTS0678USD1SEQ.txt,	,	O
created	VBD	O
on	IN	O
Mar.	.	O
26,	,	O
2010	CD	O
which	WDT	O
is	VBZ	O
164	CD	O
Kb	NNP	O
in	IN	O
size.	.	O
The	DT	O
information	NN	O
in	IN	O
the	DT	O
electronic	JJ	O
format	NN	O
of	IN	O
the	DT	O
sequence	NN	O
listing	NN	O
is	VBZ	O
incorporated	VBN	O
herein	NN	O
by	IN	O
reference	NN	O
in	IN	O
its	PRP$	O
entirety.	.	O
FIELD	NN	O
OF	IN	O
THE	NNP	O
INVENTION	NNP	O
The	DT	O
present	JJ	O
invention	NN	O
provides	VBZ	O
compositions	NNS	O
and	CC	O
methods	NNS	O
for	IN	O
modulating	VBG	O
the	DT	O
expression	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2.	.	O
In	IN	O
particular,	,	O
this	DT	O
invention	NN	O
relates	VBZ	O
to	TO	O
antisense	VB	O
compounds,	,	O
particularly	RB	O
oligonucleotide	JJ	O
compounds,	,	O
which,	,	O
in	IN	O
preferred	JJ	O
embodiments,	,	O
hybridize	NN	O
with	IN	O
nucleic	JJ	O
acid	NN	O
molecules	NNS	O
encoding	VBG	O
diacylglycerol	NN	O
acyltransferase	NN	O
2.	.	O
Such	JJ	O
compounds	NNS	O
are	VBP	O
shown	VBN	O
herein	NNS	O
to	TO	O
modulate	VB	O
the	DT	O
expression	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2.	.	O
BACKGROUND	NNP	O
OF	IN	O
THE	NNP	O
INVENTION	NNP	O
Triglycerides	NNP	O
are	VBP	O
one	CD	O
of	IN	O
the	DT	O
major	JJ	O
energy	NN	O
storage	NN	O
molecules	NNS	O
in	IN	O
eukaryotes.	.	O
The	DT	O
absorption	NN	O
of	IN	O
triglycerides	NNS	O
(also	RB	O
called	VBN	O
triacylglycerols)	)	O
from	IN	O
food	NN	O
is	VBZ	O
a	DT	O
very	RB	O
efficient	JJ	O
process	NN	O
which	WDT	O
occurs	VBZ	O
by	IN	O
a	DT	O
series	NN	O
of	IN	O
steps	NNS	O
wherein	VBP	O
the	DT	O
dietary	JJ	O
triacylglycerols	NNS	O
are	VBP	O
hydrolyzed	VBN	O
in	IN	O
the	DT	O
intestinal	JJ	O
lumen	NNS	O
and	CC	O
then	RB	O
resynthesized	VBD	O
within	IN	O
enterocytes.	.	O
The	DT	O
resynthesis	NN	O
of	IN	O
triacylglycerols	NNS	O
can	MD	O
occur	VB	O
via	IN	O
the	DT	O
monoacylglycerol	NN	O
pathway	NN	O
which	WDT	O
commences	VBZ	O
with	IN	O
monoacylglycerol	NN	O
acyltransferase	NN	O
(MGAT)	)	O
catalyzing	VBG	O
the	DT	O
synthesis	NN	O
of	IN	O
diacylglycerol	NN	O
from	IN	O
monoacylglycerol	NN	O
and	CC	O
fatty	JJ	O
acyl-CoA.	.	O
An	DT	O
alternative	JJ	O
synthesis	NN	O
of	IN	O
diacylglycerols	NNS	O
is	VBZ	O
provided	VBN	O
by	IN	O
the	DT	O
glycerol-phosphate	JJ	O
pathway	NN	O
which	WDT	O
describes	VBZ	O
the	DT	O
coupling	NN	O
of	IN	O
two	CD	O
molecules	NNS	O
of	IN	O
fatty	JJ	O
acyl-CoA	JJ	O
to	TO	O
glycerol-3-phosphate.	.	O
In	IN	O
either	DT	O
case,	,	O
diacylglycerol	NN	O
is	VBZ	O
then	RB	O
acylated	VBN	O
with	IN	O
another	DT	O
molecule	NN	O
of	IN	O
fatty	JJ	O
acyl-CoA	JJ	O
in	IN	O
a	DT	O
reaction	NN	O
catalyzed	VBN	O
by	IN	O
one	CD	O
of	IN	O
two	CD	O
diacylglycerol	NN	O
acyltransferase	NN	O
enzymes	VBZ	O
to	TO	O
form	VB	O
the	DT	O
triglyceride	NN	O
Farese	JJ	B
et	NN	I
al.,	,	I
Curr.	.	I
Opin.	.	I
Lipidol.,	,	I
2000,	,	I
11,	,	I
229-234).(	.	O
The	DT	O
reaction	NN	O
catalyzed	VBN	O
by	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
is	VBZ	O
the	DT	O
final	JJ	O
and	CC	O
only	RB	O
committed	JJ	O
step	NN	O
in	IN	O
triglyceride	JJ	O
synthesis.	.	O
As	IN	O
such,	,	O
diacylglycerol	JJ	O
acyltransferase	NN	O
is	VBZ	O
involved	VBN	O
in	IN	O
intestinal	JJ	O
fat	JJ	O
absorption,	,	O
lipoprotein	NN	O
assembly,	,	O
regulating	VBG	O
plasma	JJ	O
triglyceride	JJ	O
concentrations,	,	O
and	CC	O
fat	JJ	O
storage	NN	O
in	IN	O
adipocytes.	.	O
The	DT	O
first	JJ	O
diacylglycerol	NN	O
acyltransferase,	,	O
diacylglycerol	NN	O
transferase	NN	O
1,	,	O
was	VBD	O
identified	VBN	O
in	IN	O
1960	CD	O
and	CC	O
the	DT	O
human	JJ	O
and	CC	O
mouse	NN	O
genes	NNS	O
encoding	VBG	O
this	DT	O
protein	NN	O
were	VBD	O
isolated	VBN	O
in	IN	O
1998	CD	O
Cases	NNP	B
et	RB	I
al.,	,	I
Proc.	.	I
Natl.	.	I
Acad.	.	I
Sci.	.	I
U.S.A.,	,	I
1998,	,	I
95,	,	I
13018-13023;	:	I
Oelkers	NNP	B
et	FW	I
al.,	,	I
J.	NNP	I
Biol.	.	I
Chem.,	,	I
1998,	,	I
273,	,	I
26765-26771).(	.	O
Mice	NNP	O
lacking	VBG	O
diacylglycerol	NN	O
acyltransferase	NN	O
1	CD	O
are	VBP	O
viable	JJ	O
and	CC	O
can	MD	O
still	RB	O
synthesize	VB	O
triglycerides	NNS	O
through	IN	O
other	JJ	O
biological	JJ	O
routes,	,	O
suggesting	VBG	O
the	DT	O
existence	NN	O
of	IN	O
multiple	JJ	O
mechanisms	NNS	O
for	IN	O
triglyceride	JJ	O
synthesis	NN	O
Smith	NNP	B
et	FW	I
al.,	,	I
Nat.	.	I
Genet.,	,	I
2000,	,	I
25,	,	I
87-90).(	.	O
A	DT	O
second	JJ	O
diacylglycerol	NN	O
transferase,	,	O
diacylglycerol	NN	O
transferase	NN	O
2	CD	O
(also	RB	O
known	VBN	O
as	IN	O
DGAT2,	,	O
diacylglycerol	VBD	O
O-transferase	NNP	O
2,	,	O
acyl-CoA:diacylglycerol	NN	O
acyltransferase	IN	O
2),	,	O
was	VBD	O
subsequently	RB	O
identified	VBN	O
in	IN	O
the	DT	O
fungus	NN	O
Mortierella,	,	O
humans	NNS	O
and	CC	O
mice	NN	O
Cases	NNP	B
et	RB	I
al.,	,	I
J.	NNP	I
Biol.	.	I
Chem.,	,	I
2001,	,	I
276,	,	I
38870-38876;	:	I
Lardizabal	NNP	B
et	FW	I
al.,	,	I
J.	NNP	I
Biol.	.	I
Chem.,	,	I
2001,	,	I
276,	,	I
38862-38869).(	.	O
Enzymatic	JJ	O
assays	NNS	O
indicate	VBP	O
that	IN	O
this	DT	O
recently	RB	O
identified	VBN	O
protein	NN	O
does	VBZ	O
possess	VB	O
diacylglycerol	VB	O
transferase	JJ	O
activity	NN	O
that	WDT	O
utilizes	VBZ	O
a	DT	O
broad	JJ	O
range	NN	O
of	IN	O
long	JJ	O
chain	NN	O
fatty	JJ	O
acyl-CoA	JJ	O
substrates	NNS	O
Cases	NNP	B
et	RB	I
al.,	,	I
J.	NNP	I
Biol.	.	I
Chem.,	,	I
2001,	,	I
276,	,	I
38870-38876).(	.	O
Diacylglycerol	NNP	O
transferase	NN	O
2	CD	O
is	VBZ	O
a	DT	O
member	NN	O
of	IN	O
a	DT	O
family	NN	O
of	IN	O
genes	NNS	O
whose	WP$	O
sequences	NNS	O
are	VBP	O
unrelated	JJ	O
to	TO	O
diacylglycerol	VB	O
transferase	NN	O
1.	.	O
In	IN	O
addition	NN	O
to	TO	O
differing	VBG	O
in	IN	O
sequence	NN	O
compared	VBN	O
to	TO	O
diacylglycerol	VB	O
transferase	NN	O
1,	,	O
in	IN	O
vitro	JJ	O
assays	NNS	O
illustrate	VBP	O
that	IN	O
diacylglycerol	NN	O
transferase	NN	O
2	CD	O
has	VBZ	O
higher	JJR	O
activity	NN	O
at	IN	O
lower	JJR	O
concentrations	NNS	O
of	IN	O
magnesium	NN	O
chloride	NN	O
and	CC	O
oleoyl-CoA	NN	O
Cases	NNP	B
et	RB	I
al.,	,	I
J.	NNP	I
Biol.	.	I
Chem.,	,	I
2001,	,	I
276,	,	I
38870-38876).(	.	O
The	DT	O
predicted	JJ	O
protein	NN	O
sequence	NN	O
of	IN	O
diacylglycerol	NN	O
transferase	NN	O
2	CD	O
contains	NNS	O
at	IN	O
least	JJS	O
one	CD	O
putative	JJ	O
transmembrane	NN	O
domain,	,	O
three	CD	O
potential	JJ	O
N-linked	JJ	O
glycosylation	NN	O
sites,	,	O
six	CD	O
potential	JJ	O
protein	NN	O
kinase	NN	O
C	NNP	O
phosphorylation	NN	O
consensus	NN	O
sites,	,	O
as	RB	O
well	RB	O
as	IN	O
sequences	NNS	O
in	IN	O
common	JJ	O
with	IN	O
a	DT	O
putative	JJ	O
glycerol	NN	O
phosphorylation	NN	O
site	NN	O
found	VBN	O
in	IN	O
acyltransferase	NN	O
enzymes	NNS	O
Cases	NNP	B
et	RB	I
al.,	,	I
J.	NNP	I
Biol.	.	I
Chem.,	,	I
2001,	,	I
276,	,	I
38870-38876).(	.	O
The	DT	O
International	NNP	O
Radiation	NNP	O
Hybrid	NNP	O
Mapping	NNP	O
Consortium	NNP	O
has	VBZ	O
mapped	VBN	O
human	JJ	O
diacylglycerol	NN	O
transferase	NN	O
2	CD	O
to	TO	O
chromosome	VB	O
11q13.3.	.	O
In	IN	O
human	JJ	O
tissues,	,	O
the	DT	O
highest	JJS	O
levels	NNS	O
of	IN	O
diacylglycerol	NN	O
transferase	NN	O
2	CD	O
are	VBP	O
detected	VBN	O
in	IN	O
liver	NN	O
and	CC	O
white	JJ	O
adipose	JJ	O
tissues,	,	O
with	IN	O
lower	JJR	O
levels	NNS	O
found	VBN	O
in	IN	O
mammary	JJ	O
gland,	,	O
testis	NN	O
and	CC	O
peripheral	JJ	O
blood	NN	O
leukocytes	NNS	O
Cases	NNP	B
et	RB	I
al.,	,	I
J.	NNP	I
Biol.	.	I
Chem.,	,	I
2001,	,	I
276,	,	I
38870-38876).(	.	O
Two	CD	O
mRNA	JJ	O
species	NNS	O
of	IN	O
2.4	CD	O
and	CC	O
1.8	CD	O
kilobases	NNS	O
are	VBP	O
detected	VBN	O
in	IN	O
human	JJ	O
tissues,	,	O
whereas	IN	O
the	DT	O
major	JJ	O
diacylglycerol	NN	O
transferase	NN	O
2	CD	O
mRNA	NN	O
species	NNS	O
in	IN	O
mouse	NN	O
tissues	NNS	O
is	VBZ	O
2.4	CD	O
kilobases.	.	O
In	IN	O
addition	NN	O
to	TO	O
liver	VB	O
and	CC	O
white	JJ	O
adipose	JJ	O
tissues,	,	O
diacylglycerol	NN	O
transferase	NN	O
2	CD	O
is	VBZ	O
expressed	VBN	O
in	IN	O
all	DT	O
segments	NNS	O
of	IN	O
the	DT	O
small	JJ	O
intestine	NN	O
in	IN	O
mice,	,	O
with	IN	O
higher	JJR	O
expression	NN	O
in	IN	O
the	DT	O
proximal	JJ	O
intestine	NN	O
and	CC	O
lower	JJR	O
expression	NN	O
in	IN	O
the	DT	O
distal	JJ	O
intestine	NN	O
Cases	NNP	B
et	RB	I
al.,	,	I
J.	NNP	I
Biol.	.	I
Chem.,	,	I
2001,	,	I
276,	,	I
38870-38876).(	.	O
Diacylglycerol	NNP	O
transferase	NN	O
activity	NN	O
exhibits	VBZ	O
distinct	JJ	O
patterns	NNS	O
during	IN	O
postnatal	JJ	O
development	NN	O
of	IN	O
the	DT	O
rat	NN	O
liver.	.	O
As	IN	O
there	EX	O
is	VBZ	O
no	DT	O
correlation	NN	O
between	IN	O
the	DT	O
mRNA	NN	O
expression	NN	O
and	CC	O
activity	NN	O
patterns,	,	O
post-translational	JJ	O
modifications	NNS	O
may	MD	O
participate	VB	O
in	IN	O
the	DT	O
regulation	NN	O
of	IN	O
diacylglycerol	NN	O
transferase	NN	O
2	CD	O
activity	NN	O
during	IN	O
rat	NN	O
development	NN	O
Waterman	NNP	B
et	VBZ	I
al.,	,	I
J.	NNP	I
Lipid.	.	I
Res.,	,	I
2002,	,	I
43,	,	I
1555-1562).(	.	O
Diacylglycerol	NNP	O
transferase	VBD	O
2	CD	O
mRNA	NN	O
is	VBZ	O
preferentially	RB	O
upregulated	VBN	O
by	IN	O
insulin	NN	O
treatment,	,	O
as	IN	O
shown	VBN	O
by	IN	O
in	IN	O
vitro	NN	O
assays	NNS	O
measuring	VBG	O
the	DT	O
diacylglycerol	NN	O
activity	NN	O
from	IN	O
the	DT	O
membrane	NN	O
fraction	NN	O
of	IN	O
cultured	JJ	O
mouse	NN	O
adipocytes	NNS	O
Meegalla	NNP	B
et	RB	I
al.,	,	I
Biochem.	.	I
Biophys.	.	I
Res.	.	I
Commun.,	,	I
2002,	,	I
298,	,	I
317-323).(	.	O
In	IN	O
fasting	VBG	O
mice,	,	O
diacylglycerol	VB	O
transferase	NN	O
2	CD	O
expression	NN	O
is	VBZ	O
greatly	RB	O
reduced,	,	O
and	CC	O
dramatically	RB	O
increases	VBZ	O
upon	IN	O
refeeding.	.	O
The	DT	O
expression	NN	O
patterns	NNS	O
of	IN	O
two	CD	O
enzymes	NNS	O
that	WDT	O
participate	VBP	O
in	IN	O
fatty	JJ	O
acid	JJ	O
synthesis,	,	O
acetyl-CoA	JJ	O
carboxylase	NN	O
and	CC	O
fatty	JJ	O
acid	NN	O
synthase,	,	O
respond	NN	O
to	TO	O
fasting	NN	O
and	CC	O
refeeding	NN	O
in	IN	O
a	DT	O
similar	JJ	O
fashion.	.	O
These	DT	O
results,	,	O
combined	VBN	O
with	IN	O
the	DT	O
observation	NN	O
that	IN	O
diacylglycerol	NN	O
transferase	NN	O
2	CD	O
is	VBZ	O
abundantly	RB	O
expressed	VBN	O
in	IN	O
liver,	,	O
suggest	VBP	O
that	IN	O
diacylglycerol	NN	O
transferase	NN	O
2	CD	O
is	VBZ	O
tightly	RB	O
linked	VBN	O
to	TO	O
the	DT	O
endogenous	JJ	O
fatty	JJ	O
acid	JJ	O
synthesis	NN	O
pathway	NN	O
Meegalla	NNP	B
et	RB	I
al.,	,	I
Biochem.	.	I
Biophys.	.	I
Res.	.	I
Commun.,	,	I
2002,	,	I
298,	,	I
317-323).(	.	O
Studies	NNS	O
of	IN	O
mice	NNS	O
harboring	VBG	O
a	DT	O
disruption	NN	O
in	IN	O
the	DT	O
diacylglycerol	NN	O
acyltransferase	NN	O
1	CD	O
gene	NN	O
provide	VBP	O
evidence	NN	O
that	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
contributes	NNS	O
to	TO	O
triglyceride	VB	O
synthesis.	.	O
Levels	NNS	O
of	IN	O
diacylglycerol	NN	O
transferase	NN	O
2	CD	O
mRNA	NN	O
expression	NN	O
are	VBP	O
similar	JJ	O
in	IN	O
intestinal	JJ	O
segments	NNS	O
from	IN	O
both	DT	O
wild	JJ	O
type	NN	O
and	CC	O
diacylglycerol	VB	O
transferase	JJ	O
1-deficient	JJ	O
mice	NN	O
Buhman	NNP	B
et	VBZ	I
al.,	,	I
J.	NNP	I
Biol.	.	I
Chem.,	,	I
2002,	,	I
277,	,	I
25474-25479).(	.	O
Using	VBG	O
magnesium	NN	O
chloride	NN	O
to	TO	O
distinguish	VB	O
between	IN	O
diacylglycerol	NN	O
transferase	NN	O
1	CD	O
and	CC	O
2	CD	O
activity,	,	O
Buhman,	,	O
et	RB	O
al.	.	O
observed	VBN	O
that,	,	O
in	IN	O
diacylglycerol	JJ	O
transferase	NN	O
1-deficient	JJ	O
mice,	,	O
diacylglycerol	JJ	O
transferase	NN	O
activity	NN	O
is	VBZ	O
reduced	VBN	O
to	TO	O
50%	NN	O
in	IN	O
the	DT	O
proximal	JJ	O
intestine	NN	O
and	CC	O
to	TO	O
10-15%	NN	O
in	IN	O
the	DT	O
distal	JJ	O
intestine	NN	O
Buhman	NNP	B
et	VBZ	I
al.,	,	I
J.	NNP	I
Biol.	.	I
Chem.,	,	I
2002,	,	I
277,	,	I
25474-25479).(	.	O
Additionally,	,	O
diacylglycerol	VB	O
transferase	NN	O
2	CD	O
mRNA	NN	O
levels	NNS	O
are	VBP	O
not	RB	O
up-regulated	JJ	O
the	DT	O
liver	NN	O
or	CC	O
adipose	JJ	O
tissues	NNS	O
of	IN	O
diacylglycerol	NN	O
transferase	NN	O
1-deficient	JJ	O
mice,	,	O
even	RB	O
after	IN	O
weeks	NNS	O
of	IN	O
high-fat	JJ	O
diet	NN	O
Cases	NNP	B
et	RB	I
al.,	,	I
J.	NNP	I
Biol.	.	I
Chem.,	,	I
2001,	,	I
276,	,	I
38870-38876;	:	I
Chen	NNP	B
et	FW	I
al.,	,	I
J.	NNP	I
Clin.	.	I
Invest.,	,	I
2002,	,	I
109,	,	I
1049-1055).(	.	O
However,	,	O
in	IN	O
ob/ob	JJ	O
mice,	,	O
which	WDT	O
have	VBP	O
a	DT	O
mutation	NN	O
in	IN	O
the	DT	O
leptin	NN	O
gene	NN	O
that	WDT	O
results	NNS	O
in	IN	O
obesity,	,	O
diacylglycerol	NN	O
transferase	NN	O
2	CD	O
is	VBZ	O
more	RBR	O
highly	RB	O
expressed	VBN	O
than	IN	O
in	IN	O
wild	JJ	O
type	NN	O
mice,	,	O
suggesting	VBG	O
that	IN	O
diacylglycerol	NN	O
transferase	VBD	O
2	CD	O
may	MD	O
be	VB	O
partly	RB	O
responsible	JJ	O
for	IN	O
the	DT	O
highly	RB	O
accumulated	JJ	O
fat	JJ	O
mass	NN	O
seen	VBN	O
in	IN	O
these	DT	O
mice.	.	O
Furthermore,	,	O
the	DT	O
combined	JJ	O
mutations	NNS	O
of	IN	O
leptin	NN	O
and	CC	O
diacylglycerol	NN	O
transferase	NN	O
1	CD	O
leads	VBZ	O
to	TO	O
a	DT	O
three-fold	JJ	O
elevation	NN	O
in	IN	O
diacylglycerol	NN	O
transferase	NN	O
2	CD	O
expression	NN	O
in	IN	O
white	JJ	O
adipose	JJ	O
tissue,	,	O
compared	VBN	O
to	TO	O
the	DT	O
levels	NNS	O
in	IN	O
the	DT	O
same	JJ	O
tissue	NN	O
from	IN	O
diacylglycerol	NN	O
transferase	NN	O
1-deficient	JJ	O
mice	NN	O
Chen	NNP	B
et	VBZ	I
al.,	,	I
J.	NNP	I
Clin.	.	I
Invest.,	,	I
2002,	,	I
109,	,	I
1049-1055).(	.	O
Diacylglycerol	NNP	O
transferase	VBD	O
2	CD	O
mRNA	NN	O
is	VBZ	O
also	RB	O
upregulated	VBN	O
in	IN	O
the	DT	O
skin	NN	O
of	IN	O
these	DT	O
mice	NNS	O
Chen	NNP	B
et	VBZ	I
al.,	,	I
J.	NNP	I
Clin.	.	I
Invest.,	,	I
2002,	,	I
109,	,	I
175-181).(	.	O
These	DT	O
data	NNS	O
suggest	VBP	O
leptin	NN	O
normally	RB	O
downregulates	VBZ	O
diacylglycerol	JJ	O
transferase	NN	O
2	CD	O
expression,	,	O
and	CC	O
that	IN	O
the	DT	O
upregulation	NN	O
of	IN	O
diacylglycerol	NN	O
transferase	NN	O
2	CD	O
in	IN	O
white	JJ	O
adipose	JJ	O
tissue	NN	O
in	IN	O
these	DT	O
mice	NNS	O
may	MD	O
provide	VB	O
an	DT	O
alternate	JJ	O
pathway	NN	O
for	IN	O
the	DT	O
triglyceride	JJ	O
synthesis	NN	O
that	WDT	O
still	RB	O
occurs	VBZ	O
in	IN	O
leptin	NN	O
deficient/diacylglycerol	NN	O
transferase	NN	O
1-deficient	JJ	O
mice	NN	O
Chen	NNP	B
et	VBZ	I
al.,	,	I
J.	NNP	I
Clin.	.	I
Invest.,	,	I
2002,	,	I
109,	,	I
1049-1055).(	.	O
Diacylglycerol	NNP	O
acyltransferase	VBD	O
1	CD	O
knockout	NN	O
mice	NN	O
exhibit	NN	O
interesting	JJ	O
phenotypes	NNS	O
in	IN	O
that	DT	O
they	PRP	O
are	VBP	O
lean,	,	O
resistant	JJ	O
to	TO	O
diet-induce	JJ	O
obesity,	,	O
have	VBP	O
decreased	VBN	O
levels	NNS	O
of	IN	O
tissue	NN	O
triglycerides	NNS	O
and	CC	O
increased	JJ	O
sensitivity	NN	O
to	TO	O
insulin	VB	O
and	CC	O
leptin	VB	O
Chen	NNP	B
et	VBZ	I
al.,	,	I
J.	NNP	I
Clin.	.	I
Invest.,	,	I
2002,	,	I
109,	,	I
1049-1055;	:	I
Smith	NNP	B
et	FW	I
al.,	,	I
Nat.	.	I
Genet.,	,	I
2000,	,	I
25,	,	I
87-90).(	.	O
As	IN	O
diacylglycerol	NN	O
transferase	NN	O
2	CD	O
also	RB	O
participates	VBZ	O
in	IN	O
triglyceride	JJ	O
synthesis,	,	O
interfering	VBG	O
with	IN	O
diacylglycerol	NN	O
transferase	NN	O
2	CD	O
may	MD	O
similarly	RB	O
lead	VB	O
to	TO	O
reduced	VB	O
body	NN	O
fat	JJ	O
content.	.	O
The	DT	O
US	NNP	O
pre-grant	JJ	O
publications	NNS	O
20030124126	CD	O
and	CC	O
20020119138	CD	O
claim	NN	O
and	CC	O
disclose	VB	O
a	DT	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
encoding	VBG	O
human	JJ	O
diacylglycerol	NN	O
transferase	NN	O
2	CD	O
alpha,	,	O
as	RB	O
well	RB	O
as	IN	O
compositions,	,	O
including	VBG	O
antisense	NN	O
oligonucleotides,	,	O
for	IN	O
modulating	VBG	O
the	DT	O
activity	NN	O
of	IN	O
said	VBD	O
diacylglycerol	NN	O
transferase	NN	O
2	CD	O
alpha	NN	O
(Cases	NNP	O
et	RB	O
al.,	,	O
2003).	.	O
The	DT	O
US	NNP	O
pre-grant	JJ	O
publication	NN	O
20030104414	CD	O
refers	NNS	O
to	TO	O
nucleic	VB	O
acid	NN	O
sequences	NNS	O
which	WDT	O
are	VBP	O
members	NNS	O
of	IN	O
a	DT	O
group	NN	O
of	IN	O
genes	NNS	O
referred	VBN	O
to	TO	O
as	IN	O
“protein	NNP	O
cluster	NN	O
V”	NNP	O
as	RB	O
well	RB	O
as	IN	O
the	DT	O
method	NN	O
for	IN	O
identification	NN	O
of	IN	O
an	DT	O
agent	NN	O
capable	JJ	O
of	IN	O
modulating	VBG	O
nucleic	JJ	O
acid	NN	O
molecules	NNS	O
in	IN	O
the	DT	O
protein	NN	O
cluster	NN	O
V	NNP	O
group.	.	O
This	DT	O
application	NN	O
also	RB	O
refers	VBZ	O
to	TO	O
the	DT	O
use	NN	O
of	IN	O
RNA	NNP	O
interference	NN	O
or	CC	O
double-stranded	JJ	O
RNA	NNP	O
to	TO	O
disrupt	VB	O
the	DT	O
function	NN	O
of	IN	O
protein	NN	O
cluster	NN	O
V	NNP	O
gene	NN	O
family	NN	O
members	NNS	O
(Attersand,	,	O
2003).	.	O
The	DT	O
US	NNP	O
pre-grant	JJ	O
publication	NN	O
20030100480	CD	O
refers	NNS	O
to	TO	O
modifying	VBG	O
diacylglycerol	JJ	O
transferase	NN	O
activity,	,	O
including	VBG	O
that	IN	O
of	IN	O
diacylglycerol	NN	O
transferase	NN	O
2,	,	O
by	IN	O
a	DT	O
variety	NN	O
of	IN	O
methods,	,	O
including	VBG	O
antisense,	,	O
RNA	NNP	O
interference	NN	O
and	CC	O
diacylglycerol	NN	O
transferase	NN	O
2	CD	O
antisense	NN	O
plasmid	NN	O
constructs	NNS	O
(Smith	NNP	O
et	FW	O
al.,	,	O
2003).	.	O
The	DT	O
US	NNP	O
pre-grant	JJ	O
publication	NN	O
20030028923	CD	O
refers	NNS	O
to	TO	O
a	DT	O
method	NN	O
for	IN	O
modifying	VBG	O
the	DT	O
triacylglycerol	NN	O
composition	NN	O
in	IN	O
a	DT	O
plant	NN	O
cell,	,	O
comprising	VBG	O
transforming	VBG	O
a	DT	O
plant	NN	O
cell	NN	O
with	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
construct	NN	O
encoding	VBG	O
an	DT	O
enzyme	JJ	O
active	JJ	O
in	IN	O
the	DT	O
formation	NN	O
of	IN	O
triacylglycerol	NN	O
from	IN	O
diacylglycerol	NN	O
and	CC	O
fatty	JJ	O
acyl	NN	O
substrates,	,	O
including	VBG	O
nucleic	JJ	O
acid	JJ	O
constructs	NNS	O
in	IN	O
the	DT	O
antisense	JJ	O
orientation.	.	O
Also	RB	O
referred	VBN	O
to	TO	O
is	VBZ	O
a	DT	O
method	NN	O
for	IN	O
ameliorating	VBG	O
a	DT	O
disease	NN	O
or	CC	O
condition	NN	O
associated	VBN	O
with	IN	O
altered	JJ	O
diacylglycerol	NN	O
acyltransferase	NN	O
activity	NN	O
by	IN	O
administering	VBG	O
to	TO	O
a	DT	O
subject	NN	O
a	DT	O
therapeutically	RB	O
effective	JJ	O
amount	NN	O
of	IN	O
a	DT	O
diacylglycerol	NN	O
acyltransferase	NN	O
agonist.	.	O
This	DT	O
application	NN	O
indicates	VBZ	O
that	IN	O
such	JJ	O
antagonists	NNS	O
can	MD	O
include	VB	O
antisense	JJ	O
molecules	NNS	O
(Lardizabal	NNP	O
et	RB	O
al.,	,	O
2003).	.	O
The	DT	O
PCT	NNP	O
publication	NN	O
WO	NNP	O
00/78961	CD	O
refers	NNS	O
to	TO	O
isolated	VB	O
nucleic	JJ	O
acid	JJ	O
molecules	NNS	O
selected	VBN	O
from	IN	O
a	DT	O
group	NN	O
including	VBG	O
a	DT	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
encoding	VBG	O
diacylglycerol	JJ	O
acyltransferase	NN	O
2.	.	O
This	DT	O
publication	NN	O
also	RB	O
comments	NNS	O
that	IN	O
sense	NN	O
or	CC	O
antisense	NN	O
oligonucleotides	NNS	O
binding	VBG	O
to	TO	O
target	VB	O
nucleic	JJ	O
acid	JJ	O
sequences	NNS	O
can	MD	O
interfere	VB	O
with	IN	O
transcription	NN	O
or	CC	O
translation	NN	O
of	IN	O
the	DT	O
disclosed	VBN	O
and	CC	O
claimed	VBN	O
nucleic	JJ	O
acid	NN	O
molecules	NNS	O
(Baker	NNP	O
et	VBZ	O
al.,	,	O
2000).	.	O
The	DT	O
PCT	NNP	O
publication	NN	O
WO	NNP	O
01/77389	CD	O
refers	NNS	O
to	TO	O
polynucleotides	NNS	O
selected	VBN	O
from	IN	O
a	DT	O
group	NN	O
of	IN	O
sequences	NNS	O
including	VBG	O
a	DT	O
nucleotide	JJ	O
sequence	NN	O
encoding	VBG	O
a	DT	O
human	JJ	O
diacylglycerol	NN	O
acyltransferase.	.	O
A	DT	O
method	NN	O
for	IN	O
screening	VBG	O
for	IN	O
the	DT	O
altered	JJ	O
expression	NN	O
of	IN	O
said	VBD	O
polynucleotides	NNS	O
and	CC	O
a	DT	O
method	NN	O
for	IN	O
screening	VBG	O
a	DT	O
library	NN	O
of	IN	O
molecules	NNS	O
that	WDT	O
specifically	RB	O
bind	VBP	O
to	TO	O
said	VBD	O
polynucleotide	JJ	O
sequences	NNS	O
are	VBP	O
discussed	VBN	O
(Shiffman	NNP	O
et	VBZ	O
al.,	,	O
2001).	.	O
The	DT	O
PCT	NNP	O
publication	NN	O
WO	NNP	O
01/68848	CD	O
refers	NNS	O
to	TO	O
a	DT	O
nucleic	JJ	O
acid	NN	O
molecules	NNS	O
encoding	VBG	O
secreted	VBN	O
and	CC	O
transmembrane	JJ	O
polypeptides,	,	O
including	VBG	O
a	DT	O
human	JJ	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
nucleic	JJ	O
acid	NN	O
molecule,	,	O
and	CC	O
oligonucleotide	RB	O
probes	NNS	O
derived	VBN	O
from	IN	O
any	DT	O
of	IN	O
these	DT	O
sequences	NNS	O
(Baker	NNP	O
et	VBZ	O
al.,	,	O
2001).	.	O
European	JJ	O
Patent	NNP	O
Application	NNP	O
No.	.	O
EP	NNP	O
1	CD	O
308	CD	O
459	CD	O
refers	NNS	O
to	TO	O
a	DT	O
group	NN	O
of	IN	O
polynucleotide	NN	O
sequences,	,	O
including	VBG	O
a	DT	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
encoding	VBG	O
human	JJ	O
diacylglycerol	NN	O
acyltransferase	NN	O
2,	,	O
and	CC	O
antisense	JJ	O
polynucleotides	NNS	O
against	IN	O
this	DT	O
group	NN	O
of	IN	O
polynucleotide	NN	O
sequences	NNS	O
(Isogai	NNP	O
et	RB	O
al.,	,	O
2003).	.	O
The	DT	O
PCT	NNP	O
publication	NN	O
WO	NNP	O
02/08260	CD	O
refers	NNS	O
to	TO	O
an	DT	O
isolated,	,	O
purified	JJ	O
polynucleotide	NN	O
sequence	NN	O
with	IN	O
identity	NN	O
to	TO	O
a	DT	O
human	JJ	O
diacylglycerol	NN	O
transferase	NN	O
2	CD	O
nucleotide	JJ	O
sequence.	.	O
This	DT	O
application	NN	O
also	RB	O
refers	VBZ	O
to	TO	O
a	DT	O
substantially	RB	O
purified	VBN	O
oligonucleotide	IN	O
that	DT	O
includes	VBZ	O
a	DT	O
region	NN	O
of	IN	O
nucleotide	JJ	O
sequence	NN	O
that	WDT	O
hybridizes	VBZ	O
to	TO	O
at	IN	O
least	JJS	O
8	CD	O
consecutive	JJ	O
nucleotides	NNS	O
of	IN	O
sense	NN	O
or	CC	O
antisense	JJ	O
sequence	NN	O
of	IN	O
a	DT	O
nucleotide	JJ	O
sequence	NN	O
selected	VBN	O
from	IN	O
a	DT	O
group	NN	O
consisting	VBG	O
of	IN	O
sequences	NNS	O
with	IN	O
identity	NN	O
to	TO	O
human	JJ	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
(Botstein	NNP	O
et	VBZ	O
al.,	,	O
2002).	.	O
Currently,	,	O
there	EX	O
are	VBP	O
no	DT	O
known	JJ	O
therapeutic	JJ	O
agents	NNS	O
that	WDT	O
effectively	RB	O
inhibit	VBP	O
the	DT	O
synthesis	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2.	.	O
Consequently,	,	O
there	EX	O
remains	VBZ	O
a	DT	O
long	JJ	O
felt	NN	O
need	NN	O
for	IN	O
additional	JJ	O
agents	NNS	O
capable	JJ	O
of	IN	O
effectively	RB	O
inhibiting	VBG	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
function.	.	O
The	DT	O
present	JJ	O
invention	NN	O
provides	VBZ	O
compositions	NNS	O
and	CC	O
methods	NNS	O
for	IN	O
modulating	VBG	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
expression.	.	O
SUMMARY	NN	O
OF	IN	O
THE	NNP	O
INVENTION	NNP	O
The	DT	O
present	JJ	O
invention	NN	O
is	VBZ	O
directed	VBN	O
to	TO	O
compounds,	,	O
especially	RB	O
nucleic	JJ	O
acid	NN	O
and	CC	O
nucleic	JJ	O
acid-like	JJ	O
oligomers,	,	O
which	WDT	O
are	VBP	O
targeted	VBN	O
to	TO	O
a	DT	O
nucleic	JJ	O
acid	NN	O
encoding	VBG	O
diacylglycerol	NN	O
acyltransferase	NN	O
2,	,	O
and	CC	O
which	WDT	O
modulate	VBP	O
the	DT	O
expression	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2.	.	O
Pharmaceutical	NNP	O
and	CC	O
other	JJ	O
compositions	NNS	O
comprising	VBG	O
the	DT	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
are	VBP	O
also	RB	O
provided.	.	O
Further	RB	O
provided	VBN	O
are	VBP	O
methods	NNS	O
of	IN	O
screening	VBG	O
for	IN	O
modulators	NNS	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
and	CC	O
methods	NNS	O
of	IN	O
modulating	VBG	O
the	DT	O
expression	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
in	IN	O
cells,	,	O
tissues	NNS	O
or	CC	O
animals	NNS	O
comprising	VBG	O
contacting	NN	O
said	VBD	O
cells,	,	O
tissues	NNS	O
or	CC	O
animals	NNS	O
with	IN	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
compounds	NNS	O
or	CC	O
compositions	NNS	O
of	IN	O
the	DT	O
invention.	.	O
Antisense	NNP	O
technology	NN	O
is	VBZ	O
an	DT	O
effective	JJ	O
means	NNS	O
for	IN	O
reducing	VBG	O
the	DT	O
expression	NN	O
of	IN	O
specific	JJ	O
gene	NN	O
products	NNS	O
and	CC	O
may	MD	O
therefore	VB	O
prove	VB	O
to	TO	O
be	VB	O
uniquely	RB	O
useful	JJ	O
in	IN	O
a	DT	O
number	NN	O
of	IN	O
therapeutic,	,	O
diagnostic,	,	O
and	CC	O
research	NN	O
applications	NNS	O
for	IN	O
the	DT	O
modulation	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
expression.	.	O
Methods	NNS	O
of	IN	O
treating	VBG	O
an	DT	O
animal,	,	O
particularly	RB	O
a	DT	O
human,	,	O
suspected	VBN	O
of	IN	O
having	VBG	O
or	CC	O
being	VBG	O
prone	NN	O
to	TO	O
a	DT	O
disease	NN	O
or	CC	O
condition	NN	O
associated	VBN	O
with	IN	O
expression	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
are	VBP	O
also	RB	O
set	VBN	O
forth	NN	O
herein.	.	O
Such	JJ	O
methods	NNS	O
comprise	VBP	O
administering	VBG	O
a	DT	O
therapeutically	RB	O
or	CC	O
prophylactically	RB	O
effective	JJ	O
amount	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
compounds	NNS	O
or	CC	O
compositions	NNS	O
of	IN	O
the	DT	O
invention	NN	O
to	TO	O
the	DT	O
person	NN	O
in	IN	O
need	NN	O
of	IN	O
treatment.	.	O
In	IN	O
one	CD	O
aspect,	,	O
the	DT	O
invention	NN	O
provides	VBZ	O
the	DT	O
use	NN	O
of	IN	O
a	DT	O
compound	NN	O
or	CC	O
composition	NN	O
of	IN	O
the	DT	O
invention	NN	O
in	IN	O
the	DT	O
manufacture	NN	O
of	IN	O
a	DT	O
medicament	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
any	DT	O
and	CC	O
all	DT	O
conditions	NNS	O
disclosed	VBD	O
herein.	.	O
DETAILED	JJ	O
DESCRIPTION	NNP	O
OF	IN	O
THE	NNP	O
INVENTION	NNP	O
A.	NNP	O
Overview	NNP	O
of	IN	O
the	DT	O
Invention	NNP	O
The	DT	O
present	JJ	O
invention	NN	O
employs	VBZ	O
antisense	JJ	O
compounds,	,	O
preferably	RB	O
oligonucleotides	NNS	O
and	CC	O
similar	JJ	O
species	NNS	O
for	IN	O
use	NN	O
in	IN	O
modulating	VBG	O
the	DT	O
function	NN	O
or	CC	O
effect	NN	O
of	IN	O
nucleic	JJ	O
acid	NN	O
molecules	NNS	O
encoding	VBG	O
diacylglycerol	NN	O
acyltransferase	NN	O
2.	.	O
This	DT	O
is	VBZ	O
accomplished	VBN	O
by	IN	O
providing	VBG	O
oligonucleotides	NNS	O
that	WDT	O
specifically	RB	O
hybridize	VBP	O
with	IN	O
one	CD	O
or	CC	O
more	JJR	O
nucleic	JJ	O
acid	NN	O
molecules	NNS	O
encoding	VBG	O
diacylglycerol	NN	O
acyltransferase	NN	O
2.	.	O
As	IN	O
used	VBN	O
herein,	,	O
the	DT	O
terms	NNS	O
“target	VBP	O
nucleic	JJ	O
acid”	NN	O
and	CC	O
“nucleic	JJ	O
acid	NN	O
molecule	NN	O
encoding	VBG	O
diacylglycerol	NN	O
acyltransferase	NN	O
2”	CD	O
have	VBP	O
been	VBN	O
used	VBN	O
for	IN	O
convenience	NN	O
to	TO	O
encompass	VB	O
DNA	NNP	O
encoding	VBG	O
diacylglycerol	NN	O
acyltransferase	NN	O
2,	,	O
RNA	NNP	O
(including	VBG	O
pre-mRNA	NN	O
and	CC	O
mRNA	NN	O
or	CC	O
portions	NNS	O
thereof)	)	O
transcribed	VBN	O
from	IN	O
such	JJ	O
DNA,	,	O
and	CC	O
also	RB	O
cDNA	VBP	O
derived	VBN	O
from	IN	O
such	JJ	O
RNA.	.	O
The	DT	O
hybridization	NN	O
of	IN	O
a	DT	O
compound	NN	O
of	IN	O
this	DT	O
invention	NN	O
with	IN	O
its	PRP$	O
target	NN	O
nucleic	JJ	O
acid	NN	O
is	VBZ	O
generally	RB	O
referred	VBN	O
to	TO	O
as	IN	O
“antisense”.	.	O
Consequently,	,	O
the	DT	O
preferred	JJ	O
mechanism	NN	O
believed	VBN	O
to	TO	O
be	VB	O
included	VBN	O
in	IN	O
the	DT	O
practice	NN	O
of	IN	O
some	DT	O
preferred	JJ	O
embodiments	NNS	O
of	IN	O
the	DT	O
invention	NN	O
is	VBZ	O
referred	VBN	O
to	TO	O
herein	VB	O
as	IN	O
“antisense	JJ	O
inhibition.”	NN	O
Such	JJ	O
antisense	JJ	O
inhibition	NN	O
is	VBZ	O
typically	RB	O
based	VBN	O
upon	IN	O
hydrogen	JJ	O
bonding-based	JJ	O
hybridization	NN	O
of	IN	O
oligonucleotide	JJ	O
strands	NNS	O
or	CC	O
segments	NNS	O
such	JJ	O
that	IN	O
at	IN	O
least	JJS	O
one	CD	O
strand	NN	O
or	CC	O
segment	NN	O
is	VBZ	O
cleaved,	,	O
degraded,	,	O
or	CC	O
otherwise	RB	O
rendered	VBN	O
inoperable.	.	O
In	IN	O
this	DT	O
regard,	,	O
it	PRP	O
is	VBZ	O
presently	RB	O
preferred	VBN	O
to	TO	O
target	VB	O
specific	JJ	O
nucleic	JJ	O
acid	NN	O
molecules	NNS	O
and	CC	O
their	PRP$	O
functions	NNS	O
for	IN	O
such	JJ	O
antisense	JJ	O
inhibition.	.	O
The	DT	O
functions	NNS	O
of	IN	O
DNA	NN	O
to	TO	O
be	VB	O
interfered	VBN	O
with	IN	O
can	MD	O
include	VB	O
replication	NN	O
and	CC	O
transcription.	.	O
Replication	NN	O
and	CC	O
transcription,	,	O
for	IN	O
example,	,	O
can	MD	O
be	VB	O
from	IN	O
an	DT	O
endogenous	JJ	O
cellular	JJ	O
template,	,	O
a	DT	O
vector,	,	O
a	DT	O
plasmid	JJ	O
construct	NN	O
or	CC	O
otherwise.	.	O
The	DT	O
functions	NNS	O
of	IN	O
RNA	NNP	O
to	TO	O
be	VB	O
interfered	VBN	O
with	IN	O
can	MD	O
include	VB	O
functions	NNS	O
such	JJ	O
as	IN	O
translocation	NN	O
of	IN	O
the	DT	O
RNA	NNP	O
to	TO	O
a	DT	O
site	NN	O
of	IN	O
protein	JJ	O
translation,	,	O
translocation	NN	O
of	IN	O
the	DT	O
RNA	NNP	O
to	TO	O
sites	NNS	O
within	IN	O
the	DT	O
cell	NN	O
which	WDT	O
are	VBP	O
distant	JJ	O
from	IN	O
the	DT	O
site	NN	O
of	IN	O
RNA	NNP	O
synthesis,	,	O
translation	NN	O
of	IN	O
protein	NN	O
from	IN	O
the	DT	O
RNA,	,	O
splicing	NN	O
of	IN	O
the	DT	O
RNA	NNP	O
to	TO	O
yield	VB	O
one	CD	O
or	CC	O
more	JJR	O
RNA	JJ	O
species,	,	O
and	CC	O
catalytic	JJ	O
activity	NN	O
or	CC	O
complex	JJ	O
formation	NN	O
involving	VBG	O
the	DT	O
RNA	NNP	O
which	WDT	O
may	MD	O
be	VB	O
engaged	VBN	O
in	IN	O
or	CC	O
facilitated	VBN	O
by	IN	O
the	DT	O
RNA.	.	O
One	CD	O
preferred	JJ	O
result	NN	O
of	IN	O
such	JJ	O
interference	NN	O
with	IN	O
target	NN	O
nucleic	JJ	O
acid	JJ	O
function	NN	O
is	VBZ	O
modulation	NN	O
of	IN	O
the	DT	O
expression	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2.	.	O
In	IN	O
the	DT	O
context	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention,	,	O
“modulation”	NNP	O
and	CC	O
“modulation	NN	O
of	IN	O
expression”	JJ	O
mean	NN	O
either	DT	O
an	DT	O
increase	NN	O
(stimulation)	)	O
or	CC	O
a	DT	O
decrease	NN	O
(inhibition)	)	O
in	IN	O
the	DT	O
amount	NN	O
or	CC	O
levels	NNS	O
of	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
encoding	VBG	O
the	DT	O
gene,	,	O
e.g.,	,	O
DNA	NNP	O
or	CC	O
RNA.	.	O
Inhibition	NN	O
is	VBZ	O
often	RB	O
the	DT	O
preferred	JJ	O
form	NN	O
of	IN	O
modulation	NN	O
of	IN	O
expression	NN	O
and	CC	O
mRNA	NN	O
is	VBZ	O
often	RB	O
a	DT	O
preferred	JJ	O
target	NN	O
nucleic	JJ	O
acid.	.	O
In	IN	O
the	DT	O
context	NN	O
of	IN	O
this	DT	O
invention,	,	O
“hybridization”	NN	O
means	VBZ	O
the	DT	O
pairing	NN	O
of	IN	O
complementary	JJ	O
strands	NNS	O
of	IN	O
oligomeric	JJ	O
compounds.	.	O
In	IN	O
the	DT	O
present	JJ	O
invention,	,	O
the	DT	O
preferred	JJ	O
mechanism	NN	O
of	IN	O
pairing	VBG	O
involves	NNS	O
hydrogen	NN	O
bonding,	,	O
which	WDT	O
may	MD	O
be	VB	O
Watson-Crick,	,	O
Hoogsteen	NNP	O
or	CC	O
reversed	VBN	O
Hoogsteen	NNP	O
hydrogen	NN	O
bonding,	,	O
between	IN	O
complementary	JJ	O
nucleoside	NN	O
or	CC	O
nucleotide	JJ	O
bases	NNS	O
(nucleobases)	)	O
of	IN	O
the	DT	O
strands	NNS	O
of	IN	O
oligomeric	JJ	O
compounds.	.	O
For	IN	O
example,	,	O
adenine	NN	O
and	CC	O
thymine	NN	O
are	VBP	O
complementary	JJ	O
nucleobases	NNS	O
which	WDT	O
pair	VBP	O
through	IN	O
the	DT	O
formation	NN	O
of	IN	O
hydrogen	NN	O
bonds.	.	O
Hybridization	NN	O
can	MD	O
occur	VB	O
under	IN	O
varying	VBG	O
circumstances.	.	O
An	DT	O
antisense	NN	O
compound	NN	O
is	VBZ	O
specifically	RB	O
hybridizable	JJ	O
when	WRB	O
binding	NN	O
of	IN	O
the	DT	O
compound	NN	O
to	TO	O
the	DT	O
target	NN	O
nucleic	JJ	O
acid	JJ	O
interferes	NNS	O
with	IN	O
the	DT	O
normal	JJ	O
function	NN	O
of	IN	O
the	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
to	TO	O
cause	VB	O
a	DT	O
loss	NN	O
of	IN	O
activity,	,	O
and	CC	O
there	EX	O
is	VBZ	O
a	DT	O
sufficient	JJ	O
degree	NN	O
of	IN	O
complementarity	NN	O
to	TO	O
avoid	VB	O
non-specific	JJ	O
binding	NN	O
of	IN	O
the	DT	O
antisense	NN	O
compound	NN	O
to	TO	O
non-target	JJ	O
nucleic	JJ	O
acid	NN	O
sequences	NNS	O
under	IN	O
conditions	NNS	O
in	IN	O
which	WDT	O
specific	JJ	O
binding	NN	O
is	VBZ	O
desired,	,	O
e.g.,	,	O
under	IN	O
physiological	JJ	O
conditions	NNS	O
in	IN	O
the	DT	O
case	NN	O
of	IN	O
in	IN	O
vivo	NN	O
assays	NNS	O
or	CC	O
therapeutic	JJ	O
treatment,	,	O
and	CC	O
under	IN	O
conditions	NNS	O
in	IN	O
which	WDT	O
assays	NNS	O
are	VBP	O
performed	VBN	O
in	IN	O
the	DT	O
case	NN	O
of	IN	O
in	IN	O
vitro	NN	O
assays.	.	O
In	IN	O
the	DT	O
present	JJ	O
invention	NN	O
the	DT	O
phrase	NN	O
“stringent	JJ	O
hybridization	NN	O
conditions”	NN	O
or	CC	O
“stringent	JJ	O
conditions”	NN	O
refers	NNS	O
to	TO	O
conditions	NNS	O
under	IN	O
which	WDT	O
a	DT	O
compound	NN	O
of	IN	O
the	DT	O
invention	NN	O
will	MD	O
hybridize	VB	O
to	TO	O
its	PRP$	O
target	NN	O
sequence,	,	O
but	CC	O
to	TO	O
a	DT	O
minimal	JJ	O
number	NN	O
of	IN	O
other	JJ	O
sequences.	.	O
Stringent	JJ	O
conditions	NNS	O
are	VBP	O
sequence-dependent	JJ	O
and	CC	O
will	MD	O
be	VB	O
different	JJ	O
in	IN	O
different	JJ	O
circumstances	NNS	O
and	CC	O
in	IN	O
the	DT	O
context	NN	O
of	IN	O
this	DT	O
invention,	,	O
“stringent	JJ	O
conditions”	NN	O
under	IN	O
which	WDT	O
oligomeric	JJ	O
compounds	NNS	O
hybridize	VBP	O
to	TO	O
a	DT	O
target	NN	O
sequence	NN	O
are	VBP	O
determined	VBN	O
by	IN	O
the	DT	O
nature	NN	O
and	CC	O
composition	NN	O
of	IN	O
the	DT	O
oligomeric	JJ	O
compounds	NNS	O
and	CC	O
the	DT	O
assays	NNS	O
in	IN	O
which	WDT	O
they	PRP	O
are	VBP	O
being	VBG	O
investigated.	.	O
“Complementary,”	JJ	O
as	IN	O
used	JJ	O
herein,	,	O
refers	NNS	O
to	TO	O
the	DT	O
capacity	NN	O
hydrogen	NN	O
bonding	VBG	O
between	IN	O
the	DT	O
oligonucleotide	NN	O
and	CC	O
the	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
is	VBZ	O
considered	VBN	O
to	TO	O
be	VB	O
a	DT	O
complementary	JJ	O
position.	.	O
The	DT	O
oligonucleotide	NN	O
and	CC	O
the	DT	O
further	JJ	O
DNA,	,	O
RNA,	,	O
or	CC	O
oligonucleotide	IN	O
molecule	NN	O
are	VBP	O
complementary	JJ	O
to	TO	O
each	DT	O
other	JJ	O
when	WRB	O
a	DT	O
sufficient	JJ	O
number	NN	O
of	IN	O
complementary	JJ	O
positions	NNS	O
in	IN	O
each	DT	O
molecule	NN	O
are	VBP	O
occupied	VBN	O
by	IN	O
nucleobases	NNS	O
which	WDT	O
can	MD	O
hydrogen	VB	O
bond	NN	O
with	IN	O
each	DT	O
other.	.	O
Thus,	,	O
“specifically	RB	O
hybridizable”	JJ	O
and	CC	O
“complementary”	NNS	O
are	VBP	O
terms	NNS	O
which	WDT	O
are	VBP	O
used	VBN	O
to	TO	O
indicate	VB	O
a	DT	O
sufficient	JJ	O
degree	NN	O
of	IN	O
precise	NN	O
pairing	NN	O
or	CC	O
complementarity	NN	O
over	IN	O
a	DT	O
sufficient	JJ	O
number	NN	O
of	IN	O
nucleobases	NNS	O
such	JJ	O
that	IN	O
stable	JJ	O
and	CC	O
specific	JJ	O
binding	VBG	O
occurs	NN	O
between	IN	O
the	DT	O
oligonucleotide	NN	O
and	CC	O
a	DT	O
target	NN	O
nucleic	JJ	O
acid.	.	O
It	PRP	O
is	VBZ	O
understood	JJ	O
in	IN	O
the	DT	O
art	NN	O
that	IN	O
the	DT	O
sequence	NN	O
of	IN	O
an	DT	O
antisense	JJ	O
compound	NN	O
may	MD	O
be,	,	O
but	CC	O
need	MD	O
not	RB	O
be,	,	O
100%	NN	O
complementary	JJ	O
to	TO	O
that	DT	O
of	IN	O
its	PRP$	O
target	NN	O
nucleic	JJ	O
acid	NN	O
to	TO	O
be	VB	O
specifically	RB	O
hybridizable.	.	O
Moreover,	,	O
an	DT	O
oligonucleotide	NN	O
may	MD	O
hybridize	VB	O
over	RP	O
one	CD	O
or	CC	O
more	JJR	O
segments	NNS	O
such	JJ	O
that	IN	O
intervening	VBG	O
or	CC	O
adjacent	JJ	O
segments	NNS	O
are	VBP	O
not	RB	O
involved	VBN	O
in	IN	O
the	DT	O
hybridization	NN	O
event	NN	O
(e.g.,	,	O
a	DT	O
loop	JJ	O
structure	NN	O
or	CC	O
hairpin	NN	O
structure).	.	O
It	PRP	O
is	VBZ	O
preferred	VBN	O
that	IN	O
the	DT	O
antisense	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
comprise	NN	O
at	IN	O
least	JJS	O
70%,	,	O
or	CC	O
at	IN	O
least	JJS	O
75%,	,	O
or	CC	O
at	IN	O
least	JJS	O
80%,	,	O
or	CC	O
at	IN	O
least	JJS	O
85%	NN	O
sequence	NN	O
complementarity	NN	O
to	TO	O
a	DT	O
target	NN	O
region	NN	O
within	IN	O
the	DT	O
target	NN	O
nucleic	JJ	O
acid.	.	O
Moreover,	,	O
they	PRP	O
may	MD	O
comprise	VB	O
at	IN	O
least	JJS	O
90%	NN	O
sequence	NN	O
complementarity,	,	O
at	IN	O
least	JJS	O
95%	NN	O
or	CC	O
at	IN	O
least	JJS	O
99%	NN	O
sequence	NN	O
complementarity	NN	O
to	TO	O
the	DT	O
target	NN	O
region	NN	O
within	IN	O
the	DT	O
target	NN	O
nucleic	JJ	O
acid	JJ	O
sequence	NN	O
to	TO	O
which	WDT	O
they	PRP	O
are	VBP	O
targeted.	.	O
For	IN	O
example,	,	O
an	DT	O
antisense	NN	O
compound	NN	O
in	IN	O
which	WDT	O
18	CD	O
of	IN	O
20	CD	O
nucleobases	NNS	O
of	IN	O
the	DT	O
antisense	NN	O
compound	NN	O
are	VBP	O
complementary	JJ	O
to	TO	O
a	DT	O
target	NN	O
region,	,	O
and	CC	O
would	MD	O
therefore	VB	O
specifically	RB	O
hybridize,	,	O
would	MD	O
represent	VB	O
90	CD	O
percent	NN	O
complementarity.	.	O
In	IN	O
this	DT	O
example,	,	O
the	DT	O
remaining	VBG	O
noncomplementary	JJ	O
nucleobases	NNS	O
may	MD	O
be	VB	O
clustered	VBN	O
or	CC	O
interspersed	VBN	O
with	IN	O
complementary	JJ	O
nucleobases,	,	O
and	CC	O
need	MD	O
not	RB	O
be	VB	O
contiguous	JJ	O
to	TO	O
each	DT	O
other	JJ	O
or	CC	O
to	TO	O
complementary	JJ	O
nucleobases.	.	O
As	IN	O
such,	,	O
an	DT	O
antisense	NN	O
compound	NN	O
which	WDT	O
is	VBZ	O
18	CD	O
nucleobases	NNS	O
in	IN	O
length	NN	O
having	VBG	O
4	CD	O
(four)	)	O
noncomplementary	NN	O
nucleobases	NNS	O
which	WDT	O
are	VBP	O
flanked	VBN	O
by	IN	O
two	CD	O
regions	NNS	O
of	IN	O
complete	JJ	O
complementarity	NN	O
with	IN	O
the	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
would	MD	O
have	VB	O
77.8%	NN	O
overall	JJ	O
complementarity	NN	O
with	IN	O
the	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
and	CC	O
would	MD	O
thus	RB	O
fall	VB	O
within	IN	O
the	DT	O
scope	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention.	.	O
Percent	NNP	O
complementarity	NN	O
of	IN	O
an	DT	O
antisense	NN	O
compound	NN	O
with	IN	O
a	DT	O
region	NN	O
of	IN	O
a	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
can	MD	O
be	VB	O
determined	VBN	O
routinely	RB	O
using	VBG	O
BLAST	NNP	O
programs	NNS	O
(basic	JJ	O
local	JJ	O
alignment	NN	O
search	NN	O
tools)	)	O
and	CC	O
PowerBLAST	NNP	O
programs	NNS	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
Altschul	NNP	B
et	RB	I
al.,	,	I
J.	NNP	I
Mol.	.	I
Biol.,	,	I
1990,	,	I
215,	,	I
403-410;	:	I
Zhang	NNP	B
and	CC	I
Madden,	,	I
Genome	NNP	I
Res.,	,	I
1997,	,	I
7,	,	I
649-656).(	.	O
Percent	NNP	O
homology,	,	O
sequence	NN	O
identity,	,	O
or	CC	O
complementarity,	,	O
can	MD	O
be	VB	O
determined	VBN	O
by,	,	O
for	IN	O
example,	,	O
the	DT	O
Gap	NNP	O
program	NN	O
(Wisconsin	NNP	O
Sequence	NNP	O
Analysis	NNP	O
Package,	,	O
Version	NNP	O
8	CD	O
for	IN	O
Unix,	,	O
Genetics	NNP	O
Computer	NNP	O
Group,	,	O
University	NNP	O
Research	NNP	O
Park,	,	O
Madison	NNP	O
Wis.),	,	O
using	VBG	O
default	NN	O
settings,	,	O
which	WDT	O
uses	VBZ	O
the	DT	O
algorithm	NN	O
of	IN	O
Smith	NNP	O
and	CC	O
Waterman	NNP	O
Adv.	.	B
Appl.	.	I
Math.,	,	I
1981,	,	I
2,	,	I
482-489).(	.	O
In	IN	O
some	DT	O
preferred	JJ	O
embodiments,	,	O
homology,	,	O
sequence	NN	O
identity,	,	O
or	CC	O
complementarity,	,	O
between	IN	O
the	DT	O
oligomeric	JJ	O
compound	NN	O
and	CC	O
target	NN	O
is	VBZ	O
between	IN	O
about	RB	O
50%	NN	O
to	TO	O
about	RB	O
60%.	.	O
In	IN	O
some	DT	O
embodiments,	,	O
homology,	,	O
sequence	NN	O
identity	NN	O
or	CC	O
complementarity,	,	O
is	VBZ	O
between	IN	O
about	RB	O
60%	NN	O
to	TO	O
about	RB	O
70%.	.	O
In	IN	O
some	DT	O
embodiments,	,	O
homology,	,	O
sequence	NN	O
identity	NN	O
or	CC	O
complementarity,	,	O
is	VBZ	O
between	IN	O
about	RB	O
70%	NN	O
and	CC	O
about	IN	O
80%.	.	O
In	IN	O
further	JJ	O
embodiments,	,	O
homology,	,	O
sequence	NN	O
identity	NN	O
or	CC	O
complementarity,	,	O
is	VBZ	O
between	IN	O
about	RB	O
80%	NN	O
and	CC	O
about	IN	O
90%.	.	O
In	IN	O
some	DT	O
embodiments,	,	O
homology,	,	O
sequence	NN	O
identity	NN	O
or	CC	O
complementarity,	,	O
is	VBZ	O
about	IN	O
90%,	,	O
about	RB	O
92%,	,	O
about	RB	O
94%,	,	O
about	RB	O
95%,	,	O
about	RB	O
96%,	,	O
about	RB	O
97%,	,	O
about	RB	O
98%,	,	O
about	RB	O
99%	NN	O
or	CC	O
about	IN	O
100%.	.	O
B.	.	O
Compounds	NNS	O
of	IN	O
the	DT	O
Invention	NNP	O
According	VBG	O
to	TO	O
the	DT	O
present	JJ	O
invention,	,	O
antisense	JJ	O
compounds	NNS	O
include	VBP	O
antisense	JJ	O
oligomeric	JJ	O
compounds,	,	O
antisense	NN	O
oligonucleotides,	,	O
siRNAs,	,	O
external	JJ	O
guide	NN	O
sequence	NN	O
(EGS)	)	O
oligonucleotides,	,	O
alternate	JJ	O
splicers,	,	O
and	CC	O
other	JJ	O
oligomeric	JJ	O
compounds	NNS	O
which	WDT	O
hybridize	VBP	O
to	TO	O
at	IN	O
least	JJS	O
a	DT	O
portion	NN	O
of	IN	O
the	DT	O
target	NN	O
nucleic	JJ	O
acid.	.	O
As	IN	O
such,	,	O
these	DT	O
compounds	NNS	O
may	MD	O
be	VB	O
introduced	VBN	O
in	IN	O
the	DT	O
form	NN	O
of	IN	O
single-stranded,	,	O
double-stranded,	,	O
circular	JJ	O
or	CC	O
hairpin	JJ	O
oligomeric	JJ	O
compounds	NNS	O
and	CC	O
may	MD	O
contain	VB	O
structural	JJ	O
elements	NNS	O
such	JJ	O
as	IN	O
internal	JJ	O
or	CC	O
terminal	JJ	O
bulges	NNS	O
or	CC	O
loops.	.	O
Once	RB	O
introduced	VBN	O
to	TO	O
a	DT	O
system,	,	O
the	DT	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
may	MD	O
elicit	VB	O
the	DT	O
action	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
enzymes	NNS	O
or	CC	O
structural	JJ	O
proteins	NNS	O
to	TO	O
effect	NN	O
modification	NN	O
of	IN	O
the	DT	O
target	NN	O
nucleic	JJ	O
acid.	.	O
One	CD	O
non-limiting	JJ	O
example	NN	O
of	IN	O
such	JJ	O
an	DT	O
enzyme	NN	O
is	VBZ	O
RNase	NNP	O
H,	,	O
a	DT	O
cellular	JJ	O
endonuclease	NN	O
which	WDT	O
cleaves	VBZ	O
the	DT	O
RNA	NNP	O
strand	NN	O
of	IN	O
an	DT	O
RNA:DNA	NN	O
duplex.	.	O
It	PRP	O
is	VBZ	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
that	IN	O
single-stranded	JJ	O
antisense	NN	O
compounds	NNS	O
that	WDT	O
are	VBP	O
“DNA-like”	JJ	O
elicit	JJ	O
RNase	NNP	O
H.	NNP	O
Activation	NNP	O
of	IN	O
RNase	NNP	O
H,	,	O
therefore,	,	O
results	NNS	O
in	IN	O
cleavage	NN	O
of	IN	O
the	DT	O
RNA	NNP	O
target,	,	O
thereby	RB	O
greatly	RB	O
enhancing	VBG	O
the	DT	O
efficiency	NN	O
of	IN	O
oligonucleotide-mediated	JJ	O
inhibition	NN	O
of	IN	O
gene	NN	O
expression.	.	O
Similar	JJ	O
roles	NNS	O
have	VBP	O
been	VBN	O
postulated	VBN	O
for	IN	O
other	JJ	O
ribonucleases	NNS	O
such	JJ	O
as	IN	O
those	DT	O
in	IN	O
the	DT	O
RNase	NNP	O
III	NNP	O
and	CC	O
ribonuclease	VB	O
L	NNP	O
family	NN	O
of	IN	O
enzymes.	.	O
While	IN	O
the	DT	O
one	CD	O
form	NN	O
of	IN	O
antisense	NN	O
compound	NN	O
is	VBZ	O
a	DT	O
single-stranded	JJ	O
antisense	NN	O
oligonucleotide,	,	O
in	IN	O
many	JJ	O
species	NNS	O
the	DT	O
introduction	NN	O
of	IN	O
double-stranded	JJ	O
structures,	,	O
such	JJ	O
as	IN	O
double-stranded	JJ	O
RNA	NNP	O
(dsRNA)	)	O
molecules,	,	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
induce	VB	O
potent	NN	O
and	CC	O
specific	JJ	O
antisense-mediated	JJ	O
reduction	NN	O
of	IN	O
the	DT	O
function	NN	O
of	IN	O
a	DT	O
gene	NN	O
or	CC	O
its	PRP$	O
associated	VBN	O
gene	NN	O
products.	.	O
This	DT	O
phenomenon	NN	O
occurs	VBZ	O
in	IN	O
both	DT	O
plants	NNS	O
and	CC	O
animals	NNS	O
and	CC	O
is	VBZ	O
believed	VBN	O
to	TO	O
have	VB	O
an	DT	O
evolutionary	JJ	O
connection	NN	O
to	TO	O
viral	JJ	O
defense	NN	O
and	CC	O
transposon	NN	O
silencing.	.	O
The	DT	O
first	JJ	O
evidence	NN	O
that	IN	O
dsRNA	NN	O
could	MD	O
lead	VB	O
to	TO	O
gene	NN	O
silencing	VBG	O
in	IN	O
animals	NNS	O
came	VBD	O
in	IN	O
1995	CD	O
from	IN	O
work	NN	O
in	IN	O
the	DT	O
nematode,	,	O
Caenorhabditis	NNP	O
elegans	VBZ	O
(Guo	NNP	O
and	CC	O
Kempheus,	,	O
Cell,	,	O
1995,	,	O
81,	,	O
611-620).	.	O
The	DT	O
primary	JJ	O
interference	NN	O
effects	NNS	O
of	IN	O
dsRNA	NN	O
are	VBP	O
posttranscriptional	JJ	O
Montgomery	NNP	B
et	RB	I
al.,	,	I
Proc.	.	I
Natl.	.	I
Acad.	.	I
Sci.	.	I
USA,	,	I
1998,	,	I
95,	,	I
15502-15507).(	.	O
The	DT	O
posttranscriptional	JJ	O
antisense	NN	O
mechanism	NN	O
defined	VBN	O
in	IN	O
Caenorhabditis	NNP	O
elegans	NNS	O
resulting	VBG	O
from	IN	O
exposure	NN	O
to	TO	O
double-stranded	JJ	O
RNA	NNP	O
(dsRNA)	)	O
has	VBZ	O
since	IN	O
been	VBN	O
designated	VBN	O
RNA	NNP	O
interference	NN	O
(RNAi).	.	O
This	DT	O
term	NN	O
has	VBZ	O
been	VBN	O
generalized	VBN	O
to	TO	O
mean	VB	O
antisense-mediated	JJ	O
gene	NN	O
silencing	VBG	O
involving	VBG	O
the	DT	O
introduction	NN	O
of	IN	O
dsRNA	NN	O
leading	VBG	O
to	TO	O
the	DT	O
sequence-specific	JJ	O
reduction	NN	O
of	IN	O
endogenous	JJ	O
targeted	VBN	O
mRNA	NN	O
levels	NNS	O
Fire	NNP	B
et	VBZ	I
al.,	,	I
Nature,	,	I
1998,	,	I
391,	,	I
806-811).(	.	O
Recently,	,	O
the	DT	O
single-stranded	JJ	O
RNA	NNP	O
oligomers	NNS	O
of	IN	O
antisense	JJ	O
polarity	NN	O
of	IN	O
the	DT	O
dsRNAs	NN	O
have	VBP	O
been	VBN	O
reported	VBN	O
to	TO	O
be	VB	O
the	DT	O
potent	JJ	O
inducers	NNS	O
of	IN	O
RNAi	NNP	O
Tijsterman	NNP	B
et	VBZ	I
al.,	,	I
Science,	,	I
2002,	,	I
295,	,	I
694-697).(	.	O
The	DT	O
antisense	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
also	RB	O
include	VBP	O
modified	JJ	O
compounds	NNS	O
in	IN	O
which	WDT	O
a	DT	O
different	JJ	O
base	NN	O
is	VBZ	O
present	JJ	O
at	IN	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
nucleotide	JJ	O
positions	NNS	O
in	IN	O
the	DT	O
compound.	.	O
For	IN	O
example,	,	O
if	IN	O
the	DT	O
first	JJ	O
nucleotide	NN	O
is	VBZ	O
an	DT	O
adenosine,	,	O
modified	VBD	O
compounds	NNS	O
may	MD	O
be	VB	O
produced	VBN	O
which	WDT	O
contain	VBP	O
thymidine,	,	O
guanosine	NN	O
or	CC	O
cytidine	NN	O
at	IN	O
this	DT	O
position.	.	O
This	DT	O
may	MD	O
be	VB	O
done	VBN	O
at	IN	O
any	DT	O
of	IN	O
the	DT	O
positions	NNS	O
of	IN	O
the	DT	O
antisense	NN	O
compound.	.	O
These	DT	O
compounds	NNS	O
are	VBP	O
then	RB	O
tested	VBN	O
using	VBG	O
the	DT	O
methods	NNS	O
described	VBD	O
herein	NN	O
to	TO	O
determine	VB	O
their	PRP$	O
ability	NN	O
to	TO	O
inhibit	VB	O
expression	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
mRNA.	.	O
In	IN	O
the	DT	O
context	NN	O
of	IN	O
this	DT	O
invention,	,	O
the	DT	O
term	NN	O
“oligomeric	NNP	O
compound”	NN	O
refers	NNS	O
to	TO	O
a	DT	O
polymer	NN	O
or	CC	O
oligomer	NN	O
comprising	VBG	O
a	DT	O
plurality	NN	O
of	IN	O
monomeric	JJ	O
units.	.	O
In	IN	O
the	DT	O
context	NN	O
of	IN	O
this	DT	O
invention,	,	O
the	DT	O
term	NN	O
“oligonucleotide”	VBZ	O
refers	NNS	O
to	TO	O
an	DT	O
oligomer	NN	O
or	CC	O
polymer	NN	O
of	IN	O
ribonucleic	NN	O
acid	NN	O
(RNA)	)	O
or	CC	O
deoxyribonucleic	JJ	O
acid	NN	O
(DNA)	)	O
or	CC	O
mimetics,	,	O
chimeras,	,	O
analogs	NNS	O
and	CC	O
homologs	NNS	O
thereof.	.	O
This	DT	O
term	NN	O
includes	VBZ	O
oligonucleotides	NNS	O
composed	VBN	O
of	IN	O
naturally	RB	O
occurring	VBG	O
nucleobases,	,	O
sugars	NNS	O
and	CC	O
covalent	JJ	O
internucleoside	NN	O
(backbone)	)	O
linkages	VBZ	O
as	RB	O
well	RB	O
as	IN	O
oligonucleotides	NNS	O
having	VBG	O
non-naturally	RB	O
occurring	VBG	O
portions	NNS	O
which	WDT	O
function	VBP	O
similarly.	.	O
Such	JJ	O
modified	VBD	O
or	CC	O
substituted	VBN	O
oligonucleotides	NNS	O
are	VBP	O
often	RB	O
preferred	VBN	O
over	RP	O
native	JJ	O
forms	NNS	O
because	IN	O
of	IN	O
desirable	JJ	O
properties	NNS	O
such	JJ	O
as,	,	O
for	IN	O
example,	,	O
enhanced	VBD	O
cellular	JJ	O
uptake,	,	O
enhanced	VBD	O
affinity	NN	O
for	IN	O
a	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
and	CC	O
increased	JJ	O
stability	NN	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
nucleases.	.	O
While	IN	O
oligonucleotides	NNS	O
are	VBP	O
a	DT	O
preferred	JJ	O
form	NN	O
of	IN	O
the	DT	O
antisense	JJ	O
compounds	NNS	O
of	IN	O
this	DT	O
invention,	,	O
the	DT	O
present	JJ	O
invention	NN	O
comprehends	VBZ	O
other	JJ	O
families	NNS	O
of	IN	O
antisense	JJ	O
compounds	NNS	O
as	RB	O
well,	,	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
oligonucleotide	VB	O
analogs	NNS	O
and	CC	O
mimetics	NNS	O
such	JJ	O
as	IN	O
those	DT	O
described	JJ	O
herein.	.	O
The	DT	O
antisense	NN	O
compounds	VBZ	O
in	IN	O
accordance	NN	O
with	IN	O
this	DT	O
invention	NN	O
preferably	RB	O
comprise	NN	O
from	IN	O
about	RB	O
8	CD	O
to	TO	O
about	IN	O
80	CD	O
nucleobases	NNS	O
(i.e.	.	O
from	IN	O
about	RB	O
8	CD	O
to	TO	O
about	IN	O
80	CD	O
linked	VBD	O
nucleosides).	.	O
One	CD	O
of	IN	O
ordinary	JJ	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
will	MD	O
appreciate	VB	O
that	IN	O
the	DT	O
invention	NN	O
embodies	VBZ	O
compounds	NNS	O
of	IN	O
8,	,	O
9,	,	O
10,	,	O
11,	,	O
12,	,	O
13,	,	O
14,	,	O
15,	,	O
16,	,	O
17,	,	O
18,	,	O
19,	,	O
20,	,	O
21,	,	O
22,	,	O
23,	,	O
24,	,	O
25,	,	O
26,	,	O
27,	,	O
28,	,	O
29,	,	O
30,	,	O
31,	,	O
32,	,	O
33,	,	O
34,	,	O
35,	,	O
36,	,	O
37,	,	O
38,	,	O
39,	,	O
40,	,	O
41,	,	O
42,	,	O
43,	,	O
44,	,	O
45,	,	O
46,	,	O
47,	,	O
48,	,	O
49,	,	O
50,	,	O
51,	,	O
52,	,	O
53,	,	O
54,	,	O
55,	,	O
56,	,	O
57,	,	O
58,	,	O
59,	,	O
60,	,	O
61,	,	O
62,	,	O
63,	,	O
64,	,	O
65,	,	O
66,	,	O
67,	,	O
68,	,	O
69,	,	O
70,	,	O
71,	,	O
72,	,	O
73,	,	O
74,	,	O
75,	,	O
76,	,	O
77,	,	O
78,	,	O
79,	,	O
or	CC	O
80	CD	O
nucleobases	NNS	O
in	IN	O
length.	.	O
In	IN	O
one	CD	O
embodiment,	,	O
the	DT	O
antisense	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
are	VBP	O
12	CD	O
to	TO	O
50	CD	O
nucleobases	NNS	O
in	IN	O
length.	.	O
One	CD	O
having	VBG	O
ordinary	JJ	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
will	MD	O
appreciate	VB	O
that	IN	O
this	DT	O
embodies	VBZ	O
compounds	NNS	O
of	IN	O
12,	,	O
13,	,	O
14,	,	O
15,	,	O
16,	,	O
17,	,	O
18,	,	O
19,	,	O
20,	,	O
21,	,	O
22,	,	O
23,	,	O
24,	,	O
25,	,	O
26,	,	O
27,	,	O
28,	,	O
29,	,	O
30,	,	O
31,	,	O
32,	,	O
33,	,	O
34,	,	O
35,	,	O
36,	,	O
37,	,	O
38,	,	O
39,	,	O
40,	,	O
41,	,	O
42,	,	O
43,	,	O
44,	,	O
45,	,	O
46,	,	O
47,	,	O
48,	,	O
49,	,	O
or	CC	O
50	CD	O
nucleobases	NNS	O
in	IN	O
length.	.	O
In	IN	O
one	CD	O
embodiment,	,	O
the	DT	O
antisense	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
are	VBP	O
13	CD	O
to	TO	O
40	CD	O
nucleobases	NNS	O
in	IN	O
length.	.	O
One	CD	O
having	VBG	O
ordinary	JJ	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
will	MD	O
appreciate	VB	O
that	IN	O
this	DT	O
embodies	VBZ	O
compounds	NNS	O
of	IN	O
13,	,	O
14,	,	O
15,	,	O
16,	,	O
17,	,	O
18,	,	O
19,	,	O
20,	,	O
21,	,	O
22,	,	O
23,	,	O
24,	,	O
25,	,	O
26,	,	O
27,	,	O
28,	,	O
29,	,	O
30,	,	O
31,	,	O
32,	,	O
33,	,	O
34,	,	O
35,	,	O
36,	,	O
37,	,	O
38,	,	O
39	CD	O
or	CC	O
40	CD	O
nucleobases	NNS	O
in	IN	O
length.	.	O
In	IN	O
another	DT	O
embodiment,	,	O
the	DT	O
antisense	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
are	VBP	O
15	CD	O
to	TO	O
30	CD	O
nucleobases	NNS	O
in	IN	O
length.	.	O
One	CD	O
having	VBG	O
ordinary	JJ	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
will	MD	O
appreciate	VB	O
that	IN	O
this	DT	O
embodies	VBZ	O
compounds	NNS	O
of	IN	O
15,	,	O
16,	,	O
17,	,	O
18,	,	O
19,	,	O
20,	,	O
21,	,	O
22,	,	O
23,	,	O
24,	,	O
25,	,	O
26,	,	O
27,	,	O
28,	,	O
29,	,	O
or	CC	O
30	CD	O
nucleobases	NNS	O
in	IN	O
length.	.	O
In	IN	O
further	JJ	O
embodiments,	,	O
the	DT	O
antisense	NN	O
compounds	NNS	O
are	VBP	O
oligonucleotides	IN	O
from	IN	O
about	IN	O
12	CD	O
to	TO	O
about	IN	O
50	CD	O
nucleobases,	,	O
or	CC	O
from	IN	O
about	RB	O
13	CD	O
to	TO	O
40	CD	O
nucleobases,	,	O
or	CC	O
from	IN	O
about	RB	O
15	CD	O
to	TO	O
about	IN	O
30	CD	O
nucleobases.	.	O
In	IN	O
another	DT	O
embodiment,	,	O
the	DT	O
antisense	NN	O
compounds	VBZ	O
comprise	NN	O
at	IN	O
least	JJS	O
8	CD	O
contiguous	JJ	O
nucleobases	NNS	O
of	IN	O
an	DT	O
antisense	NN	O
compound	NN	O
disclosed	VBD	O
herein.	.	O
Antisense	NNP	O
compounds	VBZ	O
8-80	JJ	O
nucleobases	NNS	O
in	IN	O
length	NN	O
comprising	VBG	O
a	DT	O
stretch	NN	O
of	IN	O
at	IN	O
least	JJS	O
eight	CD	O
(8)	)	O
consecutive	JJ	O
nucleobases	NNS	O
selected	VBN	O
from	IN	O
within	IN	O
the	DT	O
illustrative	JJ	O
antisense	NN	O
compounds	NNS	O
are	VBP	O
considered	VBN	O
to	TO	O
be	VB	O
suitable	JJ	O
antisense	JJ	O
compounds	NNS	O
as	RB	O
well.	.	O
Further	JJ	O
antisense	NN	O
compounds	NNS	O
include	VBP	O
oligonucleotide	JJ	O
sequences	NNS	O
that	WDT	O
comprise	VBP	O
at	IN	O
least	JJS	O
the	DT	O
8	CD	O
consecutive	JJ	O
nucleobases	NNS	O
from	IN	O
the	DT	O
5′-terminus	CD	O
of	IN	O
one	CD	O
of	IN	O
the	DT	O
illustrative	JJ	O
preferred	JJ	O
antisense	NN	O
compounds	NNS	O
(the	DT	O
remaining	VBG	O
nucleobases	NNS	O
being	VBG	O
a	DT	O
consecutive	JJ	O
stretch	NN	O
of	IN	O
the	DT	O
same	JJ	O
oligonucleotide	IN	O
beginning	VBG	O
immediately	RB	O
upstream	NN	O
of	IN	O
the	DT	O
5′-terminus	NN	O
of	IN	O
the	DT	O
antisense	NN	O
compound	NN	O
that	WDT	O
is	VBZ	O
specifically	RB	O
hybridizable	JJ	O
to	TO	O
the	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
and	CC	O
continuing	VBG	O
until	IN	O
the	DT	O
oligonucleotide	NN	O
contains	VBZ	O
about	IN	O
8	CD	O
to	TO	O
about	IN	O
80	CD	O
nucleobases).	.	O
Similarly,	,	O
antisense	JJ	O
compounds	NNS	O
are	VBP	O
represented	VBN	O
by	IN	O
oligonucleotide	JJ	O
sequences	NNS	O
that	WDT	O
comprise	VBP	O
at	IN	O
least	JJS	O
the	DT	O
8	CD	O
consecutive	JJ	O
nucleobases	NNS	O
from	IN	O
the	DT	O
3′-terminus	CD	O
of	IN	O
one	CD	O
of	IN	O
the	DT	O
illustrative	JJ	O
preferred	JJ	O
antisense	NN	O
compounds	NNS	O
(the	DT	O
remaining	VBG	O
nucleobases	NNS	O
being	VBG	O
a	DT	O
consecutive	JJ	O
stretch	NN	O
of	IN	O
the	DT	O
same	JJ	O
oligonucleotide	IN	O
beginning	VBG	O
immediately	RB	O
downstream	NN	O
of	IN	O
the	DT	O
3′-terminus	CD	O
of	IN	O
the	DT	O
antisense	NN	O
compound	NN	O
that	WDT	O
is	VBZ	O
specifically	RB	O
hybridizable	JJ	O
to	TO	O
the	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
and	CC	O
continuing	VBG	O
until	IN	O
the	DT	O
oligonucleotide	NN	O
contains	VBZ	O
about	IN	O
8	CD	O
to	TO	O
about	IN	O
80	CD	O
nucleobases).	.	O
It	PRP	O
is	VBZ	O
also	RB	O
understood	JJ	O
that	IN	O
antisense	JJ	O
compounds	NNS	O
may	MD	O
be	VB	O
represented	VBN	O
by	IN	O
oligonucleotide	JJ	O
sequences	NNS	O
that	WDT	O
comprise	VBP	O
at	IN	O
least	JJS	O
8	CD	O
consecutive	JJ	O
nucleobases	NNS	O
from	IN	O
an	DT	O
internal	JJ	O
portion	NN	O
of	IN	O
the	DT	O
sequence	NN	O
of	IN	O
an	DT	O
illustrative	JJ	O
preferred	JJ	O
antisense	NN	O
compound,	,	O
and	CC	O
may	MD	O
extend	VB	O
in	IN	O
either	DT	O
or	CC	O
both	DT	O
directions	NNS	O
until	IN	O
the	DT	O
oligonucleotide	NN	O
contains	VBZ	O
about	IN	O
8	CD	O
to	TO	O
about	IN	O
80	CD	O
nucleobases.	.	O
In	IN	O
one	CD	O
embodiment,	,	O
the	DT	O
antisense	NN	O
compound	NN	O
includes	VBZ	O
SEQ	NNP	O
ID	NNP	O
NOS:	:	O
20,	,	O
21,	,	O
23,	,	O
24,	,	O
25,	,	O
26,	,	O
27,	,	O
28,	,	O
29,	,	O
30,	,	O
31,	,	O
32,	,	O
33,	,	O
34,	,	O
35,	,	O
36,	,	O
37,	,	O
38,	,	O
39,	,	O
40,	,	O
41,	,	O
42,	,	O
43,	,	O
44,	,	O
45,	,	O
46,	,	O
47,	,	O
48,	,	O
49,	,	O
50,	,	O
51,	,	O
52,	,	O
53,	,	O
54,	,	O
56,	,	O
57,	,	O
58,	,	O
60,	,	O
61,	,	O
62,	,	O
63,	,	O
64,	,	O
65,	,	O
66,	,	O
68,	,	O
69,	,	O
70,	,	O
71,	,	O
72,	,	O
73,	,	O
75,	,	O
76,	,	O
77,	,	O
78,	,	O
80,	,	O
81,	,	O
82,	,	O
83,	,	O
84,	,	O
85,	,	O
86,	,	O
87,	,	O
88,	,	O
89,	,	O
90,	,	O
91,	,	O
92,	,	O
94,	,	O
95,	,	O
96,	,	O
97,	,	O
101,	,	O
109,	,	O
114,	,	O
115,	,	O
120,	,	O
121,	,	O
122,	,	O
123,	,	O
124,	,	O
127,	,	O
128,	,	O
130,	,	O
133,	,	O
136	CD	O
or	CC	O
142.	.	O
In	IN	O
still	RB	O
other	JJ	O
embodiments,	,	O
the	DT	O
antisense	NN	O
compounds	NNS	O
are	VBP	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
SEQ	NNP	O
ID	NNP	O
NOS:	:	O
277	CD	O
through	IN	O
411.	.	O
In	IN	O
another	DT	O
embodiment,	,	O
the	DT	O
antisense	NN	O
compound	NN	O
includes	VBZ	O
SEQ	NNP	O
ID	NNP	O
NOS:	:	O
21,	,	O
24,	,	O
25,	,	O
26,	,	O
28,	,	O
29,	,	O
35,	,	O
36,	,	O
47,	,	O
49,	,	O
57,	,	O
62,	,	O
65,	,	O
66,	,	O
71,	,	O
73,	,	O
77,	,	O
81,	,	O
82,	,	O
90,	,	O
92	CD	O
or	CC	O
94	CD	O
One	CD	O
having	VBG	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
armed	VBN	O
with	IN	O
the	DT	O
preferred	JJ	O
antisense	NN	O
compounds	NNS	O
illustrated	VBN	O
herein	NN	O
will	MD	O
be	VB	O
able,	,	O
without	IN	O
undue	JJ	O
experimentation,	,	O
to	TO	O
identify	VB	O
further	RB	O
preferred	JJ	O
antisense	JJ	O
compounds.	.	O
C.	NNP	O
Targets	NNP	O
of	IN	O
the	DT	O
Invention	NNP	O
“Targeting”	NNP	O
an	DT	O
antisense	NN	O
compound	NN	O
to	TO	O
a	DT	O
particular	JJ	O
nucleic	NN	O
acid	NN	O
molecule,	,	O
in	IN	O
the	DT	O
context	NN	O
of	IN	O
this	DT	O
invention,	,	O
can	MD	O
be	VB	O
a	DT	O
multistep	NN	O
process.	.	O
The	DT	O
process	NN	O
usually	RB	O
begins	VBZ	O
with	IN	O
the	DT	O
identification	NN	O
of	IN	O
a	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
whose	WP$	O
function	NN	O
is	VBZ	O
to	TO	O
be	VB	O
modulated.	.	O
This	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
may	MD	O
be,	,	O
for	IN	O
example,	,	O
a	DT	O
cellular	JJ	O
gene	NN	O
(or	CC	O
mRNA	VB	O
transcribed	VBN	O
from	IN	O
the	DT	O
gene)	)	O
whose	WP$	O
expression	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
a	DT	O
particular	JJ	O
disorder	NN	O
or	CC	O
disease	NN	O
state,	,	O
or	CC	O
a	DT	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
from	IN	O
an	DT	O
infectious	JJ	O
agent.	.	O
In	IN	O
the	DT	O
present	JJ	O
invention,	,	O
the	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
encodes	NNS	O
diacylglycerol	VBP	O
acyltransferase	JJ	O
2.	.	O
The	DT	O
targeting	VBG	O
process	NN	O
usually	RB	O
also	RB	O
includes	VBZ	O
determination	NN	O
of	IN	O
at	IN	O
least	JJS	O
one	CD	O
target	NN	O
region,	,	O
segment,	,	O
or	CC	O
site	NN	O
within	IN	O
the	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
for	IN	O
the	DT	O
antisense	JJ	O
interaction	NN	O
to	TO	O
occur	VB	O
such	JJ	O
that	IN	O
the	DT	O
desired	JJ	O
effect,	,	O
e.g.,	,	O
modulation	NN	O
of	IN	O
expression,	,	O
will	MD	O
result.	.	O
Within	IN	O
the	DT	O
context	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention,	,	O
the	DT	O
term	NN	O
“region”	NNP	O
is	VBZ	O
defined	VBN	O
as	IN	O
a	DT	O
portion	NN	O
of	IN	O
the	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
having	VBG	O
at	IN	O
least	JJS	O
one	CD	O
identifiable	JJ	O
structure,	,	O
function,	,	O
or	CC	O
characteristic.	.	O
Within	IN	O
regions	NNS	O
of	IN	O
target	NN	O
nucleic	JJ	O
acids	NNS	O
are	VBP	O
segments.	.	O
“Segments”	NNS	O
are	VBP	O
defined	VBN	O
as	IN	O
smaller	JJR	O
or	CC	O
sub-portions	NNS	O
of	IN	O
regions	NNS	O
within	IN	O
a	DT	O
target	NN	O
nucleic	JJ	O
acid.	.	O
“Sites,”	NN	O
as	IN	O
used	VBN	O
in	IN	O
the	DT	O
present	JJ	O
invention,	,	O
are	VBP	O
defined	VBN	O
as	IN	O
positions	NNS	O
within	IN	O
a	DT	O
target	NN	O
nucleic	JJ	O
acid.	.	O
Since,	,	O
as	IN	O
is	VBZ	O
known	VBN	O
in	IN	O
the	DT	O
art,	,	O
the	DT	O
translation	NN	O
initiation	NN	O
codon	NN	O
is	VBZ	O
typically	RB	O
5′-AUG	JJ	O
(in	IN	O
transcribed	VBN	O
mRNA	NN	O
molecules;	:	O
5′-ATG	JJ	O
in	IN	O
the	DT	O
corresponding	JJ	O
DNA	NNP	O
molecule),	,	O
the	DT	O
translation	NN	O
initiation	NN	O
codon	NN	O
is	VBZ	O
also	RB	O
referred	VBN	O
to	TO	O
as	IN	O
the	DT	O
“AUG	NNP	O
codon,”	VBP	O
the	DT	O
“start	NNP	O
codon”	NN	O
or	CC	O
the	DT	O
“AUG	JJ	O
start	NN	O
codon”.	.	O
A	DT	O
minority	NN	O
of	IN	O
genes	NNS	O
having	VBG	O
a	DT	O
translation	NN	O
initiation	NN	O
codon	NN	O
with	IN	O
the	DT	O
RNA	NNP	O
sequence	NN	O
5′-GUG,	,	O
5′-UUG	CD	O
or	CC	O
5′-CUG,	,	O
and	CC	O
5′-AUA,	,	O
5′-ACG	JJ	O
and	CC	O
5′-CUG	JJ	O
have	VBP	O
been	VBN	O
shown	VBN	O
to	TO	O
function	NN	O
in	IN	O
vivo.	.	O
Thus,	,	O
the	DT	O
terms	NNS	O
“translation	VBP	O
initiation	NN	O
codon”	NN	O
and	CC	O
“start	JJ	O
codon”	NN	O
can	MD	O
encompass	VB	O
many	JJ	O
codon	NN	O
sequences,	,	O
even	RB	O
though	IN	O
the	DT	O
initiator	NN	O
amino	NN	O
acid	NN	O
in	IN	O
each	DT	O
instance	NN	O
is	VBZ	O
typically	RB	O
methionine	JJ	O
(in	IN	O
eukaryotes)	)	O
or	CC	O
formylmethionine	NN	O
(in	IN	O
prokaryotes).	.	O
It	PRP	O
is	VBZ	O
also	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
that	WDT	O
eukaryotic	JJ	O
and	CC	O
prokaryotic	JJ	O
genes	NNS	O
may	MD	O
have	VB	O
two	CD	O
or	CC	O
more	JJR	O
alternative	JJ	O
start	NN	O
codons,	,	O
any	DT	O
one	CD	O
of	IN	O
which	WDT	O
may	MD	O
be	VB	O
preferentially	RB	O
utilized	JJ	O
for	IN	O
translation	NN	O
initiation	NN	O
in	IN	O
a	DT	O
particular	JJ	O
cell	NN	O
type	NN	O
or	CC	O
tissue,	,	O
or	CC	O
under	IN	O
a	DT	O
particular	JJ	O
set	NN	O
of	IN	O
conditions.	.	O
In	IN	O
the	DT	O
context	NN	O
of	IN	O
the	DT	O
invention,	,	O
“start	NNP	O
codon”	NN	O
and	CC	O
“translation	NN	O
initiation	NN	O
codon”	NN	O
refer	NN	O
to	TO	O
the	DT	O
codon	NN	O
or	CC	O
codons	NNS	O
that	WDT	O
are	VBP	O
used	VBN	O
in	IN	O
vivo	NN	O
to	TO	O
initiate	VB	O
translation	NN	O
of	IN	O
an	DT	O
mRNA	NN	O
transcribed	NN	O
from	IN	O
a	DT	O
gene	NN	O
encoding	VBG	O
diacylglycerol	JJ	O
acyltransferase	NN	O
2,	,	O
regardless	RB	O
of	IN	O
the	DT	O
sequence(s)	)	O
of	IN	O
such	JJ	O
codons.	.	O
It	PRP	O
is	VBZ	O
also	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
that	IN	O
a	DT	O
translation	NN	O
termination	NN	O
codon	NN	O
(or	CC	O
“stop	VB	O
codon”)	)	O
of	IN	O
a	DT	O
gene	NN	O
may	MD	O
have	VB	O
one	CD	O
of	IN	O
three	CD	O
sequences,	,	O
i.e.,	,	O
5′-UAA,	,	O
5′-UAG	JJ	O
and	CC	O
5′-UGA	JJ	O
(the	DT	O
corresponding	NN	O
DNA	NN	O
sequences	NNS	O
are	VBP	O
5′-TAA,	,	O
5′-TAG	JJ	O
and	CC	O
5′-TGA,	,	O
respectively).	.	O
The	DT	O
terms	NNS	O
“start	VBP	O
codon	NN	O
region”	NN	O
and	CC	O
“translation	NN	O
initiation	NN	O
codon	NN	O
region”	NN	O
refer	VBP	O
to	TO	O
a	DT	O
portion	NN	O
of	IN	O
such	JJ	O
an	DT	O
mRNA	NN	O
or	CC	O
gene	NN	O
that	WDT	O
encompasses	VBZ	O
from	IN	O
about	RB	O
25	CD	O
to	TO	O
about	IN	O
50	CD	O
contiguous	JJ	O
nucleotides	NNS	O
in	IN	O
either	DT	O
direction	NN	O
(i.e.,	,	O
5′	CD	O
or	CC	O
3′)	)	O
from	IN	O
a	DT	O
translation	NN	O
initiation	NN	O
codon.	.	O
Similarly,	,	O
the	DT	O
terms	NNS	O
“stop	VBP	O
codon	NN	O
region”	NN	O
and	CC	O
“translation	NN	O
termination	NN	O
codon	NN	O
region”	NN	O
refer	VBP	O
to	TO	O
a	DT	O
portion	NN	O
of	IN	O
such	JJ	O
an	DT	O
mRNA	NN	O
or	CC	O
gene	NN	O
that	WDT	O
encompasses	VBZ	O
from	IN	O
about	RB	O
25	CD	O
to	TO	O
about	IN	O
50	CD	O
contiguous	JJ	O
nucleotides	NNS	O
in	IN	O
either	DT	O
direction	NN	O
(i.e.,	,	O
5′	CD	O
or	CC	O
3′)	)	O
from	IN	O
a	DT	O
translation	NN	O
termination	NN	O
codon.	.	O
Consequently,	,	O
the	DT	O
“start	NNP	O
codon	NN	O
region”	NN	O
(or	CC	O
“translation	NN	O
initiation	NN	O
codon	NN	O
region”)	)	O
and	CC	O
the	DT	O
“stop	JJ	O
codon	NN	O
region”	NN	O
(or	CC	O
“translation	NN	O
termination	NN	O
codon	NN	O
region”)	)	O
are	VBP	O
all	DT	O
regions	NNS	O
which	WDT	O
may	MD	O
be	VB	O
targeted	VBN	O
effectively	RB	O
with	IN	O
the	DT	O
antisense	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention.	.	O
The	DT	O
open	JJ	O
reading	NN	O
frame	NN	O
(ORF)	)	O
or	CC	O
“coding	VBG	O
region,”	NNP	O
which	WDT	O
is	VBZ	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
to	TO	O
refer	VB	O
to	TO	O
the	DT	O
region	NN	O
between	IN	O
the	DT	O
translation	NN	O
initiation	NN	O
codon	NN	O
and	CC	O
the	DT	O
translation	NN	O
termination	NN	O
codon,	,	O
is	VBZ	O
also	RB	O
a	DT	O
region	NN	O
which	WDT	O
may	MD	O
be	VB	O
targeted	VBN	O
effectively.	.	O
Within	IN	O
the	DT	O
context	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention,	,	O
a	DT	O
preferred	JJ	O
region	NN	O
is	VBZ	O
the	DT	O
intragenic	JJ	O
region	NN	O
encompassing	VBG	O
the	DT	O
translation	NN	O
initiation	NN	O
or	CC	O
termination	NN	O
codon	NN	O
of	IN	O
the	DT	O
open	JJ	O
reading	NN	O
frame	NN	O
(ORF)	)	O
of	IN	O
a	DT	O
gene.	.	O
Other	JJ	O
target	NN	O
regions	NNS	O
include	VBP	O
the	DT	O
5′	CD	O
untranslated	JJ	O
region	NN	O
(5′UTR),	,	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
to	TO	O
refer	VB	O
to	TO	O
the	DT	O
portion	NN	O
of	IN	O
an	DT	O
mRNA	NN	O
in	IN	O
the	DT	O
5′	CD	O
direction	NN	O
from	IN	O
the	DT	O
translation	NN	O
initiation	NN	O
codon,	,	O
and	CC	O
thus	RB	O
including	VBG	O
nucleotides	NNS	O
between	IN	O
the	DT	O
5′	CD	O
cap	NN	O
site	NN	O
and	CC	O
the	DT	O
translation	NN	O
initiation	NN	O
codon	NN	O
of	IN	O
an	DT	O
mRNA	NN	O
(or	CC	O
corresponding	VBG	O
nucleotides	NNS	O
on	IN	O
the	DT	O
gene),	,	O
and	CC	O
the	DT	O
3′	CD	O
untranslated	JJ	O
region	NN	O
(3′UTR),	,	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
to	TO	O
refer	VB	O
to	TO	O
the	DT	O
portion	NN	O
of	IN	O
an	DT	O
mRNA	NN	O
in	IN	O
the	DT	O
3′	CD	O
direction	NN	O
from	IN	O
the	DT	O
translation	NN	O
termination	NN	O
codon,	,	O
and	CC	O
thus	RB	O
including	VBG	O
nucleotides	NNS	O
between	IN	O
the	DT	O
translation	NN	O
termination	NN	O
codon	NN	O
and	CC	O
3′	CD	O
end	NN	O
of	IN	O
an	DT	O
mRNA	NN	O
(or	CC	O
corresponding	VBG	O
nucleotides	NNS	O
on	IN	O
the	DT	O
gene).	.	O
The	DT	O
5′	CD	O
cap	NN	O
site	NN	O
of	IN	O
an	DT	O
mRNA	NN	O
comprises	VBZ	O
an	DT	O
N7-methylated	JJ	O
guanosine	NN	O
residue	NN	O
joined	VBD	O
to	TO	O
the	DT	O
5′-most	JJ	O
residue	NN	O
of	IN	O
the	DT	O
mRNA	NN	O
via	IN	O
a	DT	O
5′-5′	JJ	O
triphosphate	NN	O
linkage.	.	O
The	DT	O
5′	CD	O
cap	NN	O
region	NN	O
of	IN	O
an	DT	O
mRNA	NN	O
is	VBZ	O
considered	VBN	O
to	TO	O
include	VB	O
the	DT	O
5′	CD	O
cap	NN	O
structure	NN	O
itself	PRP	O
as	RB	O
well	RB	O
as	IN	O
the	DT	O
first	JJ	O
50	CD	O
nucleotides	NNS	O
adjacent	JJ	O
to	TO	O
the	DT	O
cap	NN	O
site.	.	O
It	PRP	O
is	VBZ	O
also	RB	O
preferred	VBN	O
to	TO	O
target	VB	O
the	DT	O
5′	CD	O
cap	NN	O
region.	.	O
Accordingly,	,	O
the	DT	O
present	JJ	O
invention	NN	O
provides	VBZ	O
antisense	JJ	O
compounds	NNS	O
that	WDT	O
target	VBP	O
a	DT	O
portion	NN	O
of	IN	O
nucleotides	NNS	O
1-2439	JJ	O
as	IN	O
set	NN	O
forth	NN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO:	:	O
4.	.	O
In	IN	O
another	DT	O
embodiment,	,	O
the	DT	O
antisense	NN	O
compounds	VBZ	O
target	NN	O
at	IN	O
least	JJS	O
an	DT	O
8-nucleobase	JJ	O
portion	NN	O
of	IN	O
nucleotides	NNS	O
1-230,	,	O
comprising	VBG	O
the	DT	O
5′UTR	CD	O
as	IN	O
set	VBN	O
forth	NN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO:	:	O
4.	.	O
In	IN	O
another	DT	O
embodiment,	,	O
the	DT	O
antisense	NN	O
compounds	VBZ	O
target	NN	O
at	IN	O
least	JJS	O
an	DT	O
8-nucleobase	JJ	O
portion	NN	O
of	IN	O
nucleotides	NNS	O
1395-2439,	,	O
comprising	VBG	O
the	DT	O
3′UTR	CD	O
as	IN	O
set	VBN	O
forth	NN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO:	:	O
4.	.	O
In	IN	O
another	DT	O
embodiment,	,	O
the	DT	O
antisense	NN	O
compounds	VBZ	O
target	NN	O
at	IN	O
least	JJS	O
an	DT	O
8-nucleobase	JJ	O
portion	NN	O
of	IN	O
nucleotides	NNS	O
231-1394,	,	O
comprising	VBG	O
the	DT	O
coding	VBG	O
region	NN	O
as	IN	O
set	NN	O
forth	NN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO:	:	O
4.	.	O
In	IN	O
still	RB	O
other	JJ	O
embodiments,	,	O
the	DT	O
antisense	NN	O
compounds	VBZ	O
target	NN	O
at	IN	O
least	JJS	O
an	DT	O
8-nucleobase	JJ	O
portion	NN	O
of	IN	O
a	DT	O
“preferred	JJ	O
target	NN	O
segment”	NN	O
(as	IN	O
defined	VBN	O
herein)	)	O
as	IN	O
set	VBN	O
forth	NN	O
in	IN	O
Table	JJ	O
3	CD	O
or	CC	O
additional	JJ	O
Tables	NNS	O
in	IN	O
the	DT	O
Examples	NNP	O
below.	.	O
Although	IN	O
some	DT	O
eukaryotic	JJ	O
mRNA	NN	O
transcripts	NNS	O
are	VBP	O
directly	RB	O
translated,	,	O
many	JJ	O
contain	VBP	O
one	CD	O
or	CC	O
more	JJR	O
regions,	,	O
known	VBN	O
as	IN	O
“introns,”	NN	O
which	WDT	O
are	VBP	O
excised	VBN	O
from	IN	O
a	DT	O
transcript	NN	O
before	IN	O
it	PRP	O
is	VBZ	O
translated.	.	O
The	DT	O
remaining	VBG	O
(and	CC	O
therefore	RB	O
translated)	)	O
regions	NNS	O
are	VBP	O
known	VBN	O
as	IN	O
“exons”	NN	O
and	CC	O
are	VBP	O
spliced	VBN	O
together	RB	O
to	TO	O
form	VB	O
a	DT	O
continuous	JJ	O
mRNA	NN	O
sequence,	,	O
resulting	VBG	O
in	IN	O
exon-exon	JJ	O
junctions	NNS	O
at	IN	O
the	DT	O
sites	NNS	O
where	WRB	O
exons	NNS	O
are	VBP	O
joined.	.	O
Targeting	VBG	O
exon-exon	JJ	O
junctions	NNS	O
can	MD	O
be	VB	O
useful	JJ	O
in	IN	O
situations	NNS	O
where	WRB	O
the	DT	O
overproduction	NN	O
of	IN	O
a	DT	O
normal	JJ	O
splice	NN	O
product	NN	O
is	VBZ	O
implicated	VBN	O
in	IN	O
disease,	,	O
or	CC	O
where	WRB	O
the	DT	O
overproduction	NN	O
of	IN	O
an	DT	O
aberrant	JJ	O
splice	NN	O
product	NN	O
is	VBZ	O
implicated	VBN	O
in	IN	O
disease.	.	O
Targeting	VBG	O
splice	NN	O
sites,	,	O
i.e.,	,	O
intron-exon	JJ	O
junctions	NNS	O
or	CC	O
exon-intron	JJ	O
junctions,	,	O
may	MD	O
also	RB	O
be	VB	O
particularly	RB	O
useful	JJ	O
in	IN	O
situations	NNS	O
where	WRB	O
aberrant	JJ	O
splicing	NN	O
is	VBZ	O
implicated	VBN	O
in	IN	O
disease,	,	O
or	CC	O
where	WRB	O
an	DT	O
overproduction	NN	O
of	IN	O
a	DT	O
particular	JJ	O
splice	NN	O
product	NN	O
is	VBZ	O
implicated	VBN	O
in	IN	O
disease.	.	O
Aberrant	JJ	O
fusion	NN	O
junctions	NNS	O
due	JJ	O
to	TO	O
rearrangements	NNS	O
or	CC	O
deletions	NNS	O
are	VBP	O
also	RB	O
preferred	JJ	O
target	NN	O
sites.	.	O
mRNA	NN	O
transcripts	NNS	O
produced	VBD	O
via	IN	O
the	DT	O
process	NN	O
of	IN	O
splicing	VBG	O
of	IN	O
two	CD	O
(or	CC	O
more)	)	O
mRNAs	NN	O
from	IN	O
different	JJ	O
gene	NN	O
sources,	,	O
known	VBN	O
as	IN	O
“fusion	NN	O
transcripts”,	,	O
are	VBP	O
also	RB	O
suitable	JJ	O
target	NN	O
sites.	.	O
It	PRP	O
is	VBZ	O
also	RB	O
known	VBN	O
that	IN	O
introns	NNS	O
can	MD	O
be	VB	O
effectively	RB	O
targeted	VBN	O
using	VBG	O
antisense	JJ	O
compounds	NNS	O
targeted	VBN	O
to,	,	O
for	IN	O
example,	,	O
DNA	NNP	O
or	CC	O
pre-mRNA.	.	O
It	PRP	O
is	VBZ	O
also	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
that	WDT	O
alternative	JJ	O
RNA	NNP	O
transcripts	NNS	O
can	MD	O
be	VB	O
produced	VBN	O
from	IN	O
the	DT	O
same	JJ	O
genomic	JJ	O
region	NN	O
of	IN	O
DNA.	.	O
These	DT	O
alternative	JJ	O
transcripts	NNS	O
are	VBP	O
generally	RB	O
known	VBN	O
as	IN	O
“variants”.	.	O
More	RBR	O
specifically,	,	O
“pre-mRNA	JJ	O
variants”	NN	O
are	VBP	O
transcripts	NNS	O
produced	VBN	O
from	IN	O
the	DT	O
same	JJ	O
genomic	JJ	O
DNA	NN	O
that	WDT	O
differ	VBP	O
from	IN	O
other	JJ	O
transcripts	NNS	O
produced	VBN	O
from	IN	O
the	DT	O
same	JJ	O
genomic	JJ	O
DNA	NN	O
in	IN	O
either	CC	O
their	PRP$	O
start	NN	O
or	CC	O
stop	VB	O
position	NN	O
and	CC	O
contain	VB	O
both	DT	O
intronic	JJ	O
and	CC	O
exonic	JJ	O
sequence.	.	O
Upon	IN	O
excision	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
exon	NNS	O
or	CC	O
intron	NN	O
regions,	,	O
or	CC	O
portions	NNS	O
thereof	VBP	O
during	IN	O
splicing,	,	O
pre-mRNA	JJ	O
variants	NNS	O
produce	VBP	O
smaller	JJR	O
“mRNA	NN	O
variants”.	.	O
Consequently,	,	O
mRNA	JJ	O
variants	NNS	O
are	VBP	O
processed	VBN	O
pre-mRNA	JJ	O
variants,	,	O
and	CC	O
each	DT	O
unique	JJ	O
pre-mRNA	JJ	O
variant	NN	O
must	MD	O
always	RB	O
produce	VB	O
a	DT	O
unique	JJ	O
mRNA	NN	O
variant	NN	O
as	IN	O
a	DT	O
result	NN	O
of	IN	O
splicing.	.	O
These	DT	O
mRNA	JJ	O
variants	NNS	O
are	VBP	O
also	RB	O
known	VBN	O
as	IN	O
“alternative	JJ	O
splice	NN	O
variants”.	.	O
If	IN	O
no	DT	O
splicing	NN	O
of	IN	O
the	DT	O
pre-mRNA	JJ	O
variant	NN	O
occurs	VBZ	O
then	RB	O
the	DT	O
pre-mRNA	JJ	O
variant	NN	O
is	VBZ	O
identical	JJ	O
to	TO	O
the	DT	O
mRNA	NN	O
variant.	.	O
It	PRP	O
is	VBZ	O
also	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
that	IN	O
variants	NNS	O
can	MD	O
be	VB	O
produced	VBN	O
through	IN	O
the	DT	O
use	NN	O
of	IN	O
alternative	JJ	O
signals	NNS	O
to	TO	O
start	VB	O
or	CC	O
stop	VB	O
transcription	NN	O
and	CC	O
that	IN	O
pre-mRNAs	JJ	O
and	CC	O
mRNAs	NN	O
can	MD	O
possess	VB	O
more	JJR	O
that	DT	O
one	CD	O
start	NN	O
codon	NN	O
or	CC	O
stop	VB	O
codon.	.	O
Variants	NNS	O
that	WDT	O
originate	VBP	O
from	IN	O
a	DT	O
pre-mRNA	NN	O
or	CC	O
mRNA	NN	O
that	IN	O
use	NN	O
alternative	JJ	O
start	NN	O
codons	NNS	O
are	VBP	O
known	VBN	O
as	IN	O
“alternative	JJ	O
start	NN	O
variants”	NN	O
of	IN	O
that	DT	O
pre-mRNA	NN	O
or	CC	O
mRNA.	.	O
Those	DT	O
transcripts	NNS	O
that	WDT	O
use	VBP	O
an	DT	O
alternative	JJ	O
stop	NN	O
codon	NN	O
are	VBP	O
known	VBN	O
as	IN	O
“alternative	JJ	O
stop	NN	O
variants”	NN	O
of	IN	O
that	DT	O
pre-mRNA	NN	O
or	CC	O
mRNA.	.	O
One	CD	O
specific	JJ	O
type	NN	O
of	IN	O
alternative	JJ	O
stop	NN	O
variant	NN	O
is	VBZ	O
the	DT	O
“polyA	JJ	O
variant”	NN	O
in	IN	O
which	WDT	O
the	DT	O
multiple	NN	O
transcripts	NNS	O
produced	VBD	O
result	NN	O
from	IN	O
the	DT	O
alternative	JJ	O
selection	NN	O
of	IN	O
one	CD	O
of	IN	O
the	DT	O
“polyA	NNP	O
stop	NN	O
signals”	NN	O
by	IN	O
the	DT	O
transcription	NN	O
machinery,	,	O
thereby	RB	O
producing	VBG	O
transcripts	NNS	O
that	WDT	O
terminate	VBP	O
at	IN	O
unique	JJ	O
polyA	NN	O
sites.	.	O
Within	IN	O
the	DT	O
context	NN	O
of	IN	O
the	DT	O
invention,	,	O
the	DT	O
types	NNS	O
of	IN	O
variants	NNS	O
described	VBN	O
herein	NNS	O
are	VBP	O
also	RB	O
preferred	JJ	O
target	NN	O
nucleic	JJ	O
acids.	.	O
The	DT	O
locations	NNS	O
on	IN	O
the	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
to	TO	O
which	WDT	O
the	DT	O
preferred	JJ	O
antisense	NN	O
compounds	NNS	O
hybridize	VBP	O
are	VBP	O
hereinbelow	JJ	O
referred	VBN	O
to	TO	O
as	IN	O
“preferred	JJ	O
target	NN	O
segments.”	NN	O
As	IN	O
used	VBN	O
herein	PDT	O
the	DT	O
term	NN	O
“preferred	VBD	O
target	NN	O
segment”	NN	O
is	VBZ	O
defined	VBN	O
as	IN	O
at	IN	O
least	JJS	O
an	DT	O
8-nucleobase	JJ	O
portion	NN	O
of	IN	O
a	DT	O
target	NN	O
region	NN	O
to	TO	O
which	WDT	O
an	DT	O
active	JJ	O
antisense	NN	O
compound	NN	O
is	VBZ	O
targeted.	.	O
While	IN	O
not	RB	O
wishing	VBG	O
to	TO	O
be	VB	O
bound	VBN	O
by	IN	O
theory,	,	O
it	PRP	O
is	VBZ	O
presently	RB	O
believed	VBN	O
that	IN	O
these	DT	O
target	NN	O
segments	NNS	O
represent	JJ	O
portions	NNS	O
of	IN	O
the	DT	O
target	NN	O
nucleic	NN	O
acid	NN	O
which	WDT	O
are	VBP	O
accessible	JJ	O
for	IN	O
hybridization.	.	O
While	IN	O
the	DT	O
specific	JJ	O
sequences	NNS	O
of	IN	O
certain	JJ	O
preferred	JJ	O
target	NN	O
segments	NNS	O
are	VBP	O
set	VBN	O
forth	JJ	O
herein,	,	O
one	CD	O
of	IN	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
will	MD	O
recognize	VB	O
that	IN	O
these	DT	O
serve	VBP	O
to	TO	O
illustrate	VB	O
and	CC	O
describe	VB	O
particular	JJ	O
embodiments	NNS	O
within	IN	O
the	DT	O
scope	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention.	.	O
Additional	JJ	O
preferred	VBD	O
target	NN	O
segments	NNS	O
may	MD	O
be	VB	O
identified	VBN	O
by	IN	O
one	CD	O
having	VBG	O
ordinary	JJ	O
skill.	.	O
Target	NN	O
segments	NNS	O
8-80	JJ	O
nucleobases	NNS	O
in	IN	O
length	NN	O
comprising	VBG	O
a	DT	O
stretch	NN	O
of	IN	O
at	IN	O
least	JJS	O
eight	CD	O
(8)	)	O
consecutive	JJ	O
nucleobases	NNS	O
selected	VBN	O
from	IN	O
within	IN	O
the	DT	O
illustrative	JJ	O
preferred	JJ	O
target	NN	O
segments	NNS	O
are	VBP	O
considered	VBN	O
to	TO	O
be	VB	O
suitable	JJ	O
for	IN	O
targeting	VBG	O
as	RB	O
well.	.	O
Target	NN	O
segments	NNS	O
can	MD	O
include	VB	O
DNA	NNP	O
or	CC	O
RNA	NNP	O
sequences	NNS	O
that	WDT	O
comprise	VBP	O
at	IN	O
least	JJS	O
the	DT	O
8	CD	O
consecutive	JJ	O
nucleobases	NNS	O
from	IN	O
the	DT	O
5′-terminus	CD	O
of	IN	O
one	CD	O
of	IN	O
the	DT	O
illustrative	JJ	O
preferred	JJ	O
target	NN	O
segments	NNS	O
(the	DT	O
remaining	VBG	O
nucleobases	NNS	O
being	VBG	O
a	DT	O
consecutive	JJ	O
stretch	NN	O
of	IN	O
the	DT	O
same	JJ	O
DNA	NNP	O
or	CC	O
RNA	NNP	O
beginning	VBG	O
immediately	RB	O
upstream	NN	O
of	IN	O
the	DT	O
5′-terminus	NN	O
of	IN	O
the	DT	O
target	NN	O
segment	NN	O
and	CC	O
continuing	VBG	O
until	IN	O
the	DT	O
DNA	NN	O
or	CC	O
RNA	NNP	O
contains	VBZ	O
about	IN	O
8	CD	O
to	TO	O
about	IN	O
80	CD	O
nucleobases).	.	O
Similarly	RB	O
preferred	VBN	O
target	NN	O
segments	NNS	O
are	VBP	O
represented	VBN	O
by	IN	O
DNA	NNP	O
or	CC	O
RNA	NNP	O
sequences	NNS	O
that	WDT	O
comprise	VBP	O
at	IN	O
least	JJS	O
the	DT	O
8	CD	O
consecutive	JJ	O
nucleobases	NNS	O
from	IN	O
the	DT	O
3′-terminus	CD	O
of	IN	O
one	CD	O
of	IN	O
the	DT	O
illustrative	JJ	O
preferred	JJ	O
target	NN	O
segments	NNS	O
(the	DT	O
remaining	VBG	O
nucleobases	NNS	O
being	VBG	O
a	DT	O
consecutive	JJ	O
stretch	NN	O
of	IN	O
the	DT	O
same	JJ	O
DNA	NNP	O
or	CC	O
RNA	NNP	O
beginning	VBG	O
immediately	RB	O
downstream	NN	O
of	IN	O
the	DT	O
3′-terminus	CD	O
of	IN	O
the	DT	O
target	NN	O
segment	NN	O
and	CC	O
continuing	VBG	O
until	IN	O
the	DT	O
DNA	NN	O
or	CC	O
RNA	NNP	O
contains	VBZ	O
about	IN	O
8	CD	O
to	TO	O
about	IN	O
80	CD	O
nucleobases).	.	O
It	PRP	O
is	VBZ	O
also	RB	O
understood	JJ	O
that	IN	O
preferred	JJ	O
antisense	NN	O
target	NN	O
segments	NNS	O
may	MD	O
be	VB	O
represented	VBN	O
by	IN	O
DNA	NNP	O
or	CC	O
RNA	NNP	O
sequences	NNS	O
that	WDT	O
comprise	VBP	O
at	IN	O
least	JJS	O
8	CD	O
consecutive	JJ	O
nucleobases	NNS	O
from	IN	O
an	DT	O
internal	JJ	O
portion	NN	O
of	IN	O
the	DT	O
sequence	NN	O
of	IN	O
an	DT	O
illustrative	JJ	O
preferred	JJ	O
target	NN	O
segment,	,	O
and	CC	O
may	MD	O
extend	VB	O
in	IN	O
either	DT	O
or	CC	O
both	DT	O
directions	NNS	O
until	IN	O
the	DT	O
oligonucleotide	NN	O
contains	VBZ	O
about	IN	O
8	CD	O
to	TO	O
about	IN	O
80	CD	O
nucleobases.	.	O
One	CD	O
having	VBG	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
armed	VBN	O
with	IN	O
the	DT	O
preferred	JJ	O
target	NN	O
segments	NNS	O
illustrated	VBD	O
herein	NN	O
will	MD	O
be	VB	O
able,	,	O
without	IN	O
undue	JJ	O
experimentation,	,	O
to	TO	O
identify	VB	O
further	RB	O
preferred	JJ	O
target	NN	O
segments.	.	O
Once	RB	O
one	CD	O
or	CC	O
more	JJR	O
target	NN	O
regions,	,	O
segments	NNS	O
or	CC	O
sites	NNS	O
have	VBP	O
been	VBN	O
identified,	,	O
antisense	JJ	O
compounds	NNS	O
are	VBP	O
chosen	VBN	O
which	WDT	O
are	VBP	O
sufficiently	RB	O
complementary	JJ	O
to	TO	O
the	DT	O
target,	,	O
i.e.,	,	O
hybridize	VB	O
sufficiently	RB	O
well	RB	O
and	CC	O
with	IN	O
sufficient	JJ	O
specificity,	,	O
to	TO	O
give	VB	O
the	DT	O
desired	JJ	O
effect.	.	O
The	DT	O
oligomeric	JJ	O
antisense	NN	O
compounds	NNS	O
can	MD	O
also	RB	O
be	VB	O
targeted	VBN	O
to	TO	O
regions	NNS	O
of	IN	O
a	DT	O
target	NN	O
nucleobase	JJ	O
sequence,	,	O
such	JJ	O
as	IN	O
those	DT	O
disclosed	VBN	O
herein	NN	O
(e.g.,	,	O
in	IN	O
Example	NNP	O
13)	)	O
All	DT	O
regions	NNS	O
of	IN	O
a	DT	O
nucleobase	JJ	O
sequence	NN	O
to	TO	O
which	WDT	O
an	DT	O
oligomeric	JJ	O
antisense	NN	O
compound	NN	O
can	MD	O
be	VB	O
targeted,	,	O
wherein	VBZ	O
the	DT	O
regions	NNS	O
are	VBP	O
greater	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
8	CD	O
and	CC	O
less	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
80	CD	O
nucleobases,	,	O
are	VBP	O
described	VBN	O
as	IN	O
follows:	:	O
Let	VB	O
R(n,	,	O
n+m−1)	)	O
be	VB	O
a	DT	O
region	NN	O
from	IN	O
a	DT	O
target	NN	O
nucleobase	JJ	O
sequence,	,	O
where	WRB	O
“n”	NN	O
is	VBZ	O
the	DT	O
5′-most	JJ	O
nucleobase	JJ	O
position	NN	O
of	IN	O
the	DT	O
region,	,	O
where	WRB	O
“n+m−1”	NN	O
is	VBZ	O
the	DT	O
3′-most	JJ	O
nucleobase	JJ	O
position	NN	O
of	IN	O
the	DT	O
region	NN	O
and	CC	O
where	WRB	O
“m”	NN	O
is	VBZ	O
the	DT	O
length	NN	O
of	IN	O
the	DT	O
region.	.	O
A	DT	O
set	NN	O
“S(m)”,	,	O
of	IN	O
regions	NNS	O
of	IN	O
length	NN	O
“m”	NN	O
is	VBZ	O
defined	VBN	O
as	IN	O
the	DT	O
regions	NNS	O
where	WRB	O
n	JJ	O
ranges	NNS	O
from	IN	O
1	CD	O
to	TO	O
L−m+1,	,	O
where	WRB	O
L	NNP	O
is	VBZ	O
the	DT	O
length	NN	O
of	IN	O
the	DT	O
target	NN	O
nucleobase	JJ	O
sequence	NN	O
and	CC	O
L>m.	.	O
A	DT	O
set,	,	O
“A”,	,	O
of	IN	O
all	DT	O
regions	NNS	O
can	MD	O
be	VB	O
constructed	VBN	O
as	IN	O
a	DT	O
union	NN	O
of	IN	O
the	DT	O
sets	NNS	O
of	IN	O
regions	NNS	O
for	IN	O
each	DT	O
length	NN	O
from	IN	O
where	WRB	O
m	NN	O
is	VBZ	O
greater	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
8	CD	O
and	CC	O
is	VBZ	O
less	RBR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
80.	.	O
This	DT	O
set	NN	O
of	IN	O
regions	NNS	O
can	MD	O
be	VB	O
represented	VBN	O
using	VBG	O
the	DT	O
following	JJ	O
mathematical	JJ	O
notation:	:	O
where	WRB	O
the	DT	O
mathematical	JJ	O
operator	NN	O
|	NN	O
indicates	VBZ	O
“such	JJ	O
that”,	,	O
where	WRB	O
the	DT	O
mathematical	JJ	O
operator	NN	O
ε	NN	O
indicates	VBZ	O
“a	JJ	O
member	NN	O
of	IN	O
a	DT	O
set”	NN	O
(e.g.	.	O
yεZ	NN	O
indicates	VBZ	O
that	IN	O
element	NN	O
y	NN	O
is	VBZ	O
a	DT	O
member	NN	O
of	IN	O
set	VBN	O
Z),	,	O
where	WRB	O
x	NN	O
is	VBZ	O
a	DT	O
variable,	,	O
where	WRB	O
N	NNP	O
indicates	VBZ	O
all	DT	O
natural	JJ	O
numbers,	,	O
defined	VBD	O
as	IN	O
positive	JJ	O
integers,	,	O
and	CC	O
where	WRB	O
the	DT	O
mathematical	JJ	O
operator	NN	O
∪	NN	O
indicates	VBZ	O
“the	NNP	O
union	NN	O
of	IN	O
sets”.	.	O
For	IN	O
example,	,	O
the	DT	O
set	NN	O
of	IN	O
regions	NNS	O
for	IN	O
m	JJ	O
equal	JJ	O
to	TO	O
8,	,	O
20	CD	O
and	CC	O
80	CD	O
can	MD	O
be	VB	O
constructed	VBN	O
in	IN	O
the	DT	O
following	JJ	O
manner.	.	O
The	DT	O
set	NN	O
of	IN	O
regions,	,	O
each	DT	O
8	CD	O
nucleobases	NNS	O
in	IN	O
length,	,	O
S(m=8),	,	O
in	IN	O
a	DT	O
target	NN	O
nucleobase	JJ	O
sequence	NN	O
100	CD	O
nucleobases	NNS	O
in	IN	O
length	NN	O
(L=100),	,	O
beginning	VBG	O
at	IN	O
position	NN	O
1	CD	O
(n=1)	)	O
of	IN	O
the	DT	O
target	NN	O
nucleobase	JJ	O
sequence,	,	O
can	MD	O
be	VB	O
created	VBN	O
using	VBG	O
the	DT	O
following	JJ	O
expression:S(8)={R	NNP	O
1,8	CD	O
|n	NNP	O
ε{1,2,3,	,	O
.	.	O
.	.	O
.	.	O
,	,	O
93}}and	CC	O
describes	VBZ	O
the	DT	O
set	NN	O
of	IN	O
regions	NNS	O
comprising	VBG	O
nucleobases	NNS	O
1-8,	,	O
2-9,	,	O
3-10,	,	O
4-11,	,	O
5-12,	,	O
6-13,	,	O
7-14,	,	O
8-15,	,	O
9-16,	,	O
10-17,	,	O
11-18,	,	O
12-19,	,	O
13-20,	,	O
14-21,	,	O
15-22,	,	O
16-23,	,	O
17-24,	,	O
18-25,	,	O
19-26,	,	O
20-27,	,	O
21-28,	,	O
22-29,	,	O
23-30,	,	O
24-31,	,	O
25-32,	,	O
26-33,	,	O
27-34,	,	O
28-35,	,	O
29-36,	,	O
30-37,	,	O
31-38,	,	O
32-39,	,	O
33-40,	,	O
34-41,	,	O
35-42,	,	O
36-43,	,	O
37-44,	,	O
38-45,	,	O
39-46,	,	O
40-47,	,	O
41-48,	,	O
42-49,	,	O
43-50,	,	O
44-51,	,	O
45-52,	,	O
46-53,	,	O
47-54,	,	O
48-55,	,	O
49-56,	,	O
50-57,	,	O
51-58,	,	O
52-59,	,	O
53-60,	,	O
54-61,	,	O
55-62,	,	O
56-63,	,	O
57-64,	,	O
58-65,	,	O
59-66,	,	O
60-67,	,	O
61-68,	,	O
62-69,	,	O
63-70,	,	O
64-71,	,	O
65-72,	,	O
66-73,	,	O
67-74,	,	O
68-75,	,	O
69-76,	,	O
70-77,	,	O
71-78,	,	O
72-79,	,	O
73-80,	,	O
74-81,	,	O
75-82,	,	O
76-83,	,	O
77-84,	,	O
78-85,	,	O
79-86,	,	O
80-87,	,	O
81-88,	,	O
82-89,	,	O
83-90,	,	O
84-91,	,	O
85-92,	,	O
86-93,	,	O
87-94,	,	O
88-95,	,	O
89-96,	,	O
90-97,	,	O
91-98,	,	O
92-99,	,	O
93-100.	.	O
An	DT	O
additional	JJ	O
set	NN	O
for	IN	O
regions	NNS	O
20	CD	O
nucleobases	NNS	O
in	IN	O
length,	,	O
in	IN	O
a	DT	O
target	NN	O
sequence	NN	O
100	CD	O
nucleobases	NNS	O
in	IN	O
length,	,	O
beginning	VBG	O
at	IN	O
position	NN	O
1	CD	O
of	IN	O
the	DT	O
target	NN	O
nucleobase	JJ	O
sequence,	,	O
can	MD	O
be	VB	O
described	VBN	O
using	VBG	O
the	DT	O
following	JJ	O
expression:S(20)={R	NNP	O
1,20	CD	O
|n	NNP	O
ε{1,2,3,	,	O
.	.	O
.	.	O
.	.	O
,	,	O
81}}and	CC	O
describes	VBZ	O
the	DT	O
set	NN	O
of	IN	O
regions	NNS	O
comprising	VBG	O
nucleobases	NNS	O
1-20,	,	O
2-21,	,	O
3-22,	,	O
4-23,	,	O
5-24,	,	O
6-25,	,	O
7-26,	,	O
8-27,	,	O
9-28,	,	O
10-29,	,	O
11-30,	,	O
12-31,	,	O
13-32,	,	O
14-33,	,	O
15-34,	,	O
16-35,	,	O
17-36,	,	O
18-37,	,	O
19-38,	,	O
20-39,	,	O
21-40,	,	O
22-41,	,	O
23-42,	,	O
24-43,	,	O
25-44,	,	O
26-45,	,	O
27-46,	,	O
28-47,	,	O
29-48,	,	O
30-49,	,	O
31-50,	,	O
32-51,	,	O
33-52,	,	O
34-53,	,	O
35-54,	,	O
36-55,	,	O
37-56,	,	O
38-57,	,	O
39-58,	,	O
40-59,	,	O
41-60,	,	O
42-61,	,	O
43-62,	,	O
44-63,	,	O
45-64,	,	O
46-65,	,	O
47-66,	,	O
48-67,	,	O
49-68,	,	O
50-69,	,	O
51-70,	,	O
52-71,	,	O
53-72,	,	O
54-73,	,	O
55-74,	,	O
56-75,	,	O
57-76,	,	O
58-77,	,	O
59-78,	,	O
60-79,	,	O
61-80,	,	O
62-81,	,	O
63-82,	,	O
64-83,	,	O
65-84,	,	O
66-85,	,	O
67-86,	,	O
68-87,	,	O
69-88,	,	O
70-89,	,	O
71-90,	,	O
72-91,	,	O
73-92,	,	O
74-93,	,	O
75-94,	,	O
76-95,	,	O
77-96,	,	O
78-97,	,	O
79-98,	,	O
80-99,	,	O
81-100.	.	O
An	DT	O
additional	JJ	O
set	NN	O
for	IN	O
regions	NNS	O
80	CD	O
nucleobases	NNS	O
in	IN	O
length,	,	O
in	IN	O
a	DT	O
target	NN	O
sequence	NN	O
100	CD	O
nucleobases	NNS	O
in	IN	O
length,	,	O
beginning	VBG	O
at	IN	O
position	NN	O
1	CD	O
of	IN	O
the	DT	O
target	NN	O
nucleobase	JJ	O
sequence,	,	O
can	MD	O
be	VB	O
described	VBN	O
using	VBG	O
the	DT	O
following	JJ	O
expression:S(80)={R	NNP	O
1,80	CD	O
|n	NNP	O
γ{1,2,3,	,	O
.	.	O
.	.	O
.	.	O
,	,	O
21}}and	CC	O
describes	VBZ	O
the	DT	O
set	NN	O
of	IN	O
regions	NNS	O
comprising	VBG	O
nucleobases	NNS	O
1-80,	,	O
2-81,	,	O
3-82,	,	O
4-83,	,	O
5-84,	,	O
6-85,	,	O
7-86,	,	O
8-87,	,	O
9-88,	,	O
10-89,	,	O
11-90,	,	O
12-91,	,	O
13-92,	,	O
14-93,	,	O
15-94,	,	O
16-95,	,	O
17-96,	,	O
18-97,	,	O
19-98,	,	O
20-99,	,	O
21-100.	.	O
Thus,	,	O
in	IN	O
this	DT	O
example,	,	O
A	NNP	O
would	MD	O
include	VB	O
regions	NNS	O
1-8,	,	O
2-9,	,	O
3-10	JJ	O
.	.	O
.	.	O
.	.	O
93-100,	,	O
1-20,	,	O
2-21,	,	O
3-22	JJ	O
.	.	O
.	.	O
.	.	O
81-100,	,	O
1-80,	,	O
2-81,	,	O
3-82	JJ	O
.	.	O
.	.	O
.	.	O
21-100.	.	O
The	DT	O
union	NN	O
of	IN	O
these	DT	O
aforementioned	JJ	O
example	NN	O
sets	NNS	O
and	CC	O
other	JJ	O
sets	NNS	O
for	IN	O
lengths	NNS	O
from	IN	O
10	CD	O
to	TO	O
19	CD	O
and	CC	O
21	CD	O
to	TO	O
79	CD	O
can	MD	O
be	VB	O
described	VBN	O
using	VBG	O
the	DT	O
mathematical	JJ	O
expression:	:	O
where	WRB	O
∪	NN	O
represents	VBZ	O
the	DT	O
union	NN	O
of	IN	O
the	DT	O
sets	NNS	O
obtained	VBN	O
by	IN	O
combining	VBG	O
all	DT	O
members	NNS	O
of	IN	O
all	DT	O
sets.	.	O
The	DT	O
mathematical	JJ	O
expressions	NNS	O
described	VBD	O
herein	JJ	O
define	NN	O
all	DT	O
possible	JJ	O
target	NN	O
regions	NNS	O
in	IN	O
a	DT	O
target	NN	O
nucleobase	JJ	O
sequence	NN	O
of	IN	O
any	DT	O
length	NN	O
L,	,	O
where	WRB	O
the	DT	O
region	NN	O
is	VBZ	O
of	IN	O
length	NN	O
m,	,	O
and	CC	O
where	WRB	O
m	NN	O
is	VBZ	O
greater	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
8	CD	O
and	CC	O
less	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
80	CD	O
nucleobases,	,	O
and	CC	O
where	WRB	O
m	NN	O
is	VBZ	O
less	JJR	O
than	IN	O
L,	,	O
and	CC	O
where	WRB	O
n	NN	O
is	VBZ	O
less	JJR	O
than	IN	O
L−m+1.	.	O
D.	NNP	O
Screening	NNP	O
and	CC	O
Target	NNP	O
Validation	NNP	O
In	IN	O
a	DT	O
further	JJ	O
embodiment,	,	O
the	DT	O
“preferred	NNP	O
target	NN	O
segments”	NN	O
identified	VBN	O
herein	NN	O
may	MD	O
be	VB	O
employed	VBN	O
in	IN	O
a	DT	O
screen	NN	O
for	IN	O
additional	JJ	O
compounds	NNS	O
that	WDT	O
modulate	VBP	O
the	DT	O
expression	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2.	.	O
“Modulators”	NNS	O
are	VBP	O
those	DT	O
compounds	NNS	O
that	WDT	O
decrease	VBP	O
or	CC	O
increase	VB	O
the	DT	O
expression	NN	O
of	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
encoding	VBG	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
and	CC	O
which	WDT	O
comprise	VBP	O
at	IN	O
least	JJS	O
an	DT	O
8-nucleobase	JJ	O
portion	NN	O
which	WDT	O
is	VBZ	O
complementary	JJ	O
to	TO	O
a	DT	O
preferred	JJ	O
target	NN	O
segment.	.	O
The	DT	O
screening	NN	O
method	NN	O
comprises	VBZ	O
the	DT	O
steps	NNS	O
of	IN	O
contacting	VBG	O
a	DT	O
preferred	JJ	O
target	NN	O
segment	NN	O
of	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
encoding	VBG	O
diacylglycerol	NN	O
acyltransferase	VBD	O
2	CD	O
with	IN	O
one	CD	O
or	CC	O
more	JJR	O
candidate	JJ	O
modulators,	,	O
and	CC	O
selecting	VBG	O
for	IN	O
one	CD	O
or	CC	O
more	JJR	O
candidate	NN	O
modulators	NNS	O
which	WDT	O
decrease	VBP	O
or	CC	O
increase	VB	O
the	DT	O
expression	NN	O
of	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
encoding	VBG	O
diacylglycerol	NN	O
acyltransferase	NN	O
2.	.	O
Once	IN	O
it	PRP	O
is	VBZ	O
shown	VBN	O
that	IN	O
the	DT	O
candidate	NN	O
modulator	NN	O
or	CC	O
modulators	NNS	O
are	VBP	O
capable	JJ	O
of	IN	O
modulating	VBG	O
(e.g.	.	O
either	DT	O
decreasing	NN	O
or	CC	O
increasing)	)	O
the	DT	O
expression	NN	O
of	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
encoding	VBG	O
diacylglycerol	NN	O
acyltransferase	NN	O
2,	,	O
the	DT	O
modulator	NN	O
may	MD	O
then	RB	O
be	VB	O
employed	VBN	O
in	IN	O
further	JJ	O
investigative	JJ	O
studies	NNS	O
of	IN	O
the	DT	O
function	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2,	,	O
or	CC	O
for	IN	O
use	NN	O
as	IN	O
a	DT	O
research,	,	O
diagnostic,	,	O
or	CC	O
therapeutic	JJ	O
agent	NN	O
in	IN	O
accordance	NN	O
with	IN	O
the	DT	O
present	JJ	O
invention.	.	O
The	DT	O
preferred	JJ	O
target	NN	O
segments	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
may	MD	O
be	VB	O
also	RB	O
be	VB	O
combined	VBN	O
with	IN	O
their	PRP$	O
respective	JJ	O
complementary	JJ	O
antisense	NN	O
compounds	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
to	TO	O
form	VB	O
stabilized	VBN	O
double-stranded	JJ	O
(duplexed)	)	O
oligonucleotides.	.	O
Such	JJ	O
double	JJ	O
stranded	VBN	O
oligonucleotide	NN	O
moieties	NNS	O
have	VBP	O
been	VBN	O
shown	VBN	O
in	IN	O
the	DT	O
art	NN	O
to	TO	O
modulate	VB	O
target	NN	O
expression	NN	O
and	CC	O
regulate	VB	O
translation	NN	O
as	RB	O
well	RB	O
as	IN	O
RNA	NNP	O
processing	VBG	O
via	IN	O
an	DT	O
antisense	NN	O
mechanism.	.	O
Moreover,	,	O
the	DT	O
double-stranded	JJ	O
moieties	NNS	O
may	MD	O
be	VB	O
subject	JJ	O
to	TO	O
chemical	JJ	O
modifications	NNS	O
Fire	NNP	B
et	VBZ	I
al.,	,	I
Nature,	,	I
1998,	,	I
391,	,	I
806-811;	:	I
Timmons	NNS	B
and	CC	I
Fire,	,	I
Nature	NNP	I
1998,	,	I
395,	,	I
854;	:	I
Timmons	NNP	B
et	FW	I
al.,	,	I
Gene,	,	I
2001,	,	I
263,	,	I
103-112;	:	I
Tabara	NNP	B
et	FW	I
al.,	,	I
Science,	,	I
1998,	,	I
282,	,	I
430-431;	:	I
Montgomery	NNP	B
et	FW	I
al.,	,	I
Proc.	.	I
Natl.	.	I
Acad.	.	I
Sci.	.	I
USA,	,	I
1998,	,	I
95,	,	I
15502-15507;	:	I
Tuschl	NNP	B
et	FW	I
al.,	,	I
Genes	NNP	I
Dev.,	,	I
1999,	,	I
13,	,	I
3191-3197;	:	I
Elbashir	NNP	B
et	FW	I
al.,	,	I
Nature,	,	I
2001,	,	I
411,	,	I
494-498;	:	I
Elbashir	NNP	B
et	FW	I
al.,	,	I
Genes	NNP	I
Dev.	.	I
2001,	,	I
15,	,	I
188-200).(	.	O
For	IN	O
example,	,	O
such	JJ	O
double-stranded	JJ	O
moieties	NNS	O
have	VBP	O
been	VBN	O
shown	VBN	O
to	TO	O
inhibit	VB	O
the	DT	O
target	NN	O
by	IN	O
the	DT	O
classical	JJ	O
hybridization	NN	O
of	IN	O
the	DT	O
antisense	JJ	O
strand	NN	O
of	IN	O
the	DT	O
duplex	NN	O
to	TO	O
the	DT	O
target,	,	O
thereby	RB	O
triggering	VBG	O
enzymatic	JJ	O
degradation	NN	O
of	IN	O
the	DT	O
target	NN	O
Tijsterman	NNP	B
et	VBZ	I
al.,	,	I
Science,	,	I
2002,	,	I
295,	,	I
694-697).(	.	O
The	DT	O
compounds	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
can	MD	O
also	RB	O
be	VB	O
applied	VBN	O
in	IN	O
the	DT	O
areas	NNS	O
of	IN	O
drug	NN	O
discovery	NN	O
and	CC	O
target	NN	O
validation.	.	O
The	DT	O
present	JJ	O
invention	NN	O
comprehends	VBZ	O
the	DT	O
use	NN	O
of	IN	O
the	DT	O
compounds	NNS	O
and	CC	O
preferred	JJ	O
target	NN	O
segments	NNS	O
identified	VBN	O
herein	NN	O
in	IN	O
drug	NN	O
discovery	NN	O
efforts	NNS	O
to	TO	O
elucidate	VB	O
relationships	NNS	O
that	WDT	O
exist	VBP	O
between	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
and	CC	O
a	DT	O
disease	NN	O
state,	,	O
phenotype,	,	O
or	CC	O
condition.	.	O
These	DT	O
methods	NNS	O
include	VBP	O
detecting	VBG	O
or	CC	O
modulating	VBG	O
diacylglycerol	JJ	O
acyltransferase	NN	O
2	CD	O
comprising	VBG	O
contacting	VBG	O
a	DT	O
sample,	,	O
tissue,	,	O
cell,	,	O
or	CC	O
organism	NN	O
with	IN	O
the	DT	O
compounds	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention,	,	O
measuring	VBG	O
the	DT	O
nucleic	JJ	O
acid	NN	O
or	CC	O
protein	JJ	O
level	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
and/or	NN	O
a	DT	O
related	JJ	O
phenotypic	NN	O
or	CC	O
chemical	NN	O
endpoint	NN	O
at	IN	O
some	DT	O
time	NN	O
after	IN	O
treatment,	,	O
and	CC	O
optionally	RB	O
comparing	VBG	O
the	DT	O
measured	VBN	O
value	NN	O
to	TO	O
a	DT	O
non-treated	JJ	O
sample	NN	O
or	CC	O
sample	NN	O
treated	VBN	O
with	IN	O
a	DT	O
further	JJ	O
compound	NN	O
of	IN	O
the	DT	O
invention.	.	O
These	DT	O
methods	NNS	O
can	MD	O
also	RB	O
be	VB	O
performed	VBN	O
in	IN	O
parallel	NN	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
other	JJ	O
experiments	NNS	O
to	TO	O
determine	VB	O
the	DT	O
function	NN	O
of	IN	O
unknown	JJ	O
genes	NNS	O
for	IN	O
the	DT	O
process	NN	O
of	IN	O
target	NN	O
validation	NN	O
or	CC	O
to	TO	O
determine	VB	O
the	DT	O
validity	NN	O
of	IN	O
a	DT	O
particular	JJ	O
gene	NN	O
product	NN	O
as	IN	O
a	DT	O
target	NN	O
for	IN	O
treatment	NN	O
or	CC	O
prevention	NN	O
of	IN	O
a	DT	O
particular	JJ	O
disease,	,	O
condition,	,	O
or	CC	O
phenotype.	.	O
E.	NNP	O
Kits,	,	O
Research	NNP	O
Reagents,	,	O
Diagnostics,	,	O
and	CC	O
Therapeutics	NNPS	O
The	DT	O
antisense	NN	O
compounds	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
are	VBP	O
utilized	VBN	O
for	IN	O
diagnostics,	,	O
therapeutics,	,	O
prophylaxis	NN	O
and	CC	O
as	IN	O
research	NN	O
reagents	NNS	O
and	CC	O
kits.	.	O
Furthermore,	,	O
antisense	JJ	O
oligonucleotides,	,	O
which	WDT	O
are	VBP	O
able	JJ	O
to	TO	O
inhibit	VB	O
gene	NN	O
expression	NN	O
with	IN	O
exquisite	JJ	O
specificity,	,	O
are	VBP	O
often	RB	O
used	VBN	O
by	IN	O
those	DT	O
of	IN	O
ordinary	JJ	O
skill	NN	O
to	TO	O
elucidate	VB	O
the	DT	O
function	NN	O
of	IN	O
particular	JJ	O
genes	NNS	O
or	CC	O
to	TO	O
distinguish	VB	O
between	IN	O
functions	NNS	O
of	IN	O
various	JJ	O
members	NNS	O
of	IN	O
a	DT	O
biological	JJ	O
pathway.	.	O
For	IN	O
use	NN	O
in	IN	O
kits	NNS	O
and	CC	O
diagnostics,	,	O
the	DT	O
compounds	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention,	,	O
either	CC	O
alone	RB	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
other	JJ	O
compounds	NNS	O
or	CC	O
therapeutics,	,	O
are	VBP	O
used	VBN	O
as	IN	O
tools	NNS	O
in	IN	O
differential	JJ	O
and/or	JJ	O
combinatorial	JJ	O
analyses	NNS	O
to	TO	O
elucidate	VB	O
expression	NN	O
patterns	NNS	O
of	IN	O
a	DT	O
portion	NN	O
or	CC	O
the	DT	O
entire	JJ	O
complement	NN	O
of	IN	O
genes	NNS	O
expressed	VBN	O
within	IN	O
cells	NNS	O
and	CC	O
tissues.	.	O
As	IN	O
one	CD	O
nonlimiting	VBG	O
example,	,	O
expression	NN	O
patterns	NNS	O
within	IN	O
cells	NNS	O
or	CC	O
tissues	NNS	O
treated	VBN	O
with	IN	O
one	CD	O
or	CC	O
more	JJR	O
antisense	JJ	O
compounds	NNS	O
are	VBP	O
compared	VBN	O
to	TO	O
control	VB	O
cells	NNS	O
or	CC	O
tissues	NNS	O
not	RB	O
treated	VBN	O
with	IN	O
antisense	JJ	O
compounds	NNS	O
and	CC	O
the	DT	O
patterns	NNS	O
produced	VBN	O
are	VBP	O
analyzed	VBN	O
for	IN	O
differential	JJ	O
levels	NNS	O
of	IN	O
gene	NN	O
expression	NN	O
as	IN	O
they	PRP	O
pertain,	,	O
for	IN	O
example,	,	O
to	TO	O
disease	VB	O
association,	,	O
signaling	VBG	O
pathway,	,	O
cellular	JJ	O
localization,	,	O
expression	NN	O
level,	,	O
size,	,	O
structure	NN	O
or	CC	O
function	NN	O
of	IN	O
the	DT	O
genes	NNS	O
examined.	.	O
These	DT	O
analyses	NNS	O
can	MD	O
be	VB	O
performed	VBN	O
on	IN	O
stimulated	JJ	O
or	CC	O
unstimulated	JJ	O
cells	NNS	O
and	CC	O
in	IN	O
the	DT	O
presence	NN	O
or	CC	O
absence	NN	O
of	IN	O
other	JJ	O
compounds	NNS	O
which	WDT	O
affect	VBP	O
expression	NN	O
patterns.	.	O
Examples	NNS	O
of	IN	O
methods	NNS	O
of	IN	O
gene	NN	O
expression	NN	O
analysis	NN	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
include	VBP	O
DNA	NNP	O
arrays	NNS	O
or	CC	O
microarrays	NNS	O
Brazma	NNP	B
and	CC	I
Vilo,	,	I
FEBS	NNP	I
Lett.,	,	I
2000,	,	I
480,	,	I
17-24;	:	I
Celis,	,	B
et	FW	I
al.,	,	I
FEBS	NNP	I
Lett.,	,	I
2000,	,	I
480,	,	I
2-16),(	,	O
SAGE	NNP	O
(serial	JJ	O
analysis	NN	O
of	IN	O
gene	NN	O
Madden,	,	B
et	FW	I
al.,	,	I
Drug	NNP	I
Discov.	.	I
Today,	,	I
2000,	,	I
5,	,	I
415-425),expression)(	,	O
READS	NNP	O
(restriction	NN	O
enzyme	DT	O
amplification	NN	O
of	IN	O
digested	JJ	O
cDNAs)	)	O
Prashar	NNP	B
and	CC	I
Weissman,	,	I
Methods	NNP	I
Enzymol.,	,	I
1999,	,	I
303,	,	I
258-72),(	,	O
TOGA	NNP	O
(total	JJ	O
gene	NN	O
expression	NN	O
analysis)	)	O
Sutcliffe,	,	B
et	FW	I
al.,	,	I
Proc.	.	I
Natl.	.	I
Acad.	.	I
Sci.	.	I
U.S.A.,	,	I
2000,	,	I
97,	,	I
1976-81),(	,	O
protein	JJ	O
arrays	NNS	O
and	CC	O
proteomics	NNS	O
Celis,	,	B
et	FW	I
al.,	,	I
FEBS	NNP	I
Lett.,	,	I
2000,	,	I
480,	,	I
2-16;	:	I
Jungblut,	,	B
et	FW	I
al.,	,	I
Electrophoresis,	,	I
1999,	,	I
20,	,	I
2100-10),(	,	O
expressed	VBD	O
sequence	NN	O
tag	NN	O
(EST)	)	O
sequencing	NN	O
Celis,	,	B
et	FW	I
al.,	,	I
FEBS	NNP	I
Lett.,	,	I
2000,	,	I
480,	,	I
2-16;	:	I
Larsson,	,	B
et	FW	I
al.,	,	I
J.	.	I
Biotechnol.,	,	I
2000,	,	I
80,	,	I
143-57),(	,	O
subtractive	JJ	O
RNA	NNP	O
fingerprinting	NN	O
(SuRF)	)	O
Fuchs,	,	B
et	FW	I
al.,	,	I
Anal.	.	I
Biochem.,	,	I
2000,	,	I
286,	,	I
91-98;	:	I
Larson,	,	B
et	FW	I
al.,	,	I
Cytometry,	,	I
2000,	,	I
41,	,	I
203-208),(	,	O
subtractive	JJ	O
cloning,	,	O
differential	JJ	O
display	NN	O
(DD)	)	O
Jurecic	NNP	B
and	CC	I
Belmont,	,	I
Curr.	.	I
Opin.	.	I
Microbiol.,	,	I
2000,	,	I
3,	,	I
316-21),(	,	O
comparative	JJ	O
genomic	JJ	O
hybridization	NN	O
Carulli,	,	B
et	FW	I
al.,	,	I
J.	.	I
Cell	NNP	I
Biochem.	.	I
Suppl.,	,	I
1998,	,	I
31,	,	I
286-96),(	,	O
FISH	NNP	O
(fluorescent	NN	O
in	IN	O
situ	JJ	O
hybridization)	)	O
techniques	NNS	O
Going	VBG	B
and	CC	I
Gusterson,	,	I
Eur.	.	I
J.	.	I
Cancer,	,	I
1999,	,	I
35,	,	I
1895-904)	)	I
(and	CC	O
mass	$	O
spectrometry	NN	O
methods	NNS	O
To,	,	B
Comb.	.	I
Chem.	.	I
High	JJ	I
Throughput	NNP	I
Screen,	,	I
2000,	,	I
3,	,	I
235-41).(	.	O
The	DT	O
antisense	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
are	VBP	O
useful	JJ	O
for	IN	O
research	NN	O
and	CC	O
diagnostics,	,	O
because	IN	O
these	DT	O
compounds	NNS	O
hybridize	VBP	O
to	TO	O
nucleic	VB	O
acids	NNS	O
encoding	VBG	O
diacylglycerol	NN	O
acyltransferase	NN	O
2.	.	O
The	DT	O
primers	NNS	O
and	CC	O
probes	NNS	O
disclosed	VBN	O
herein	NNS	O
are	VBP	O
useful	JJ	O
in	IN	O
methods	NNS	O
requiring	VBG	O
the	DT	O
specific	JJ	O
detection	NN	O
of	IN	O
nucleic	JJ	O
acid	NN	O
molecules	NNS	O
encoding	VBG	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
and	CC	O
in	IN	O
the	DT	O
amplification	NN	O
of	IN	O
said	VBD	O
nucleic	JJ	O
acid	NN	O
molecules	NNS	O
for	IN	O
detection	NN	O
or	CC	O
for	IN	O
use	NN	O
in	IN	O
further	JJ	O
studies	NNS	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2.	.	O
Hybridization	NN	O
of	IN	O
the	DT	O
primers	NNS	O
and	CC	O
probes	NNS	O
with	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
encoding	VBG	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
can	MD	O
be	VB	O
detected	VBN	O
by	IN	O
means	NNS	O
known	VBN	O
in	IN	O
the	DT	O
art.	.	O
Such	JJ	O
means	NNS	O
may	MD	O
include	VB	O
conjugation	NN	O
of	IN	O
an	DT	O
enzyme	NN	O
to	TO	O
the	DT	O
primer	NN	O
or	CC	O
probe	NN	O
or	CC	O
any	DT	O
other	JJ	O
suitable	JJ	O
detection	NN	O
means.	.	O
Kits	NNS	O
using	VBG	O
such	JJ	O
detection	NN	O
means	NNS	O
for	IN	O
detecting	VBG	O
the	DT	O
level	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
in	IN	O
a	DT	O
sample	NN	O
may	MD	O
also	RB	O
be	VB	O
prepared.	.	O
The	DT	O
invention	NN	O
further	RBR	O
provides	VBZ	O
for	IN	O
the	DT	O
use	NN	O
of	IN	O
a	DT	O
compound	NN	O
or	CC	O
composition	NN	O
of	IN	O
the	DT	O
invention	NN	O
in	IN	O
the	DT	O
manufacture	NN	O
of	IN	O
a	DT	O
medicament	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
any	DT	O
and	CC	O
all	DT	O
conditions	NNS	O
disclosed	VBD	O
herein.	.	O
The	DT	O
specificity	NN	O
and	CC	O
sensitivity	NN	O
of	IN	O
antisense	NN	O
are	VBP	O
also	RB	O
harnessed	VBN	O
by	IN	O
those	DT	O
of	IN	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
for	IN	O
therapeutic	JJ	O
uses.	.	O
Antisense	NNP	O
compounds	NNS	O
have	VBP	O
been	VBN	O
employed	VBN	O
as	IN	O
therapeutic	JJ	O
moieties	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
disease	NN	O
states	NNS	O
in	IN	O
animals,	,	O
including	VBG	O
humans.	.	O
Antisense	NNP	O
oligonucleotide	MD	O
drugs,	,	O
including	VBG	O
ribozymes,	,	O
have	VBP	O
been	VBN	O
safely	RB	O
and	CC	O
effectively	RB	O
administered	VBN	O
to	TO	O
humans	NNS	O
and	CC	O
numerous	JJ	O
clinical	JJ	O
trials	NNS	O
are	VBP	O
underway.	.	O
It	PRP	O
is	VBZ	O
thus	RB	O
established	VBN	O
that	IN	O
antisense	JJ	O
compounds	NNS	O
can	MD	O
be	VB	O
useful	JJ	O
therapeutic	JJ	O
modalities	NNS	O
that	WDT	O
can	MD	O
be	VB	O
configured	VBN	O
to	TO	O
be	VB	O
useful	JJ	O
in	IN	O
treatment	NN	O
regimes	NNS	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
cells,	,	O
tissues	NNS	O
and	CC	O
animals,	,	O
especially	RB	O
humans.	.	O
For	IN	O
therapeutics,	,	O
an	DT	O
animal,	,	O
preferably	RB	O
a	DT	O
human,	,	O
suspected	VBN	O
of	IN	O
having	VBG	O
a	DT	O
disease	NN	O
or	CC	O
disorder	NN	O
which	WDT	O
can	MD	O
be	VB	O
treated	VBN	O
by	IN	O
modulating	VBG	O
the	DT	O
expression	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
is	VBZ	O
treated	VBN	O
by	IN	O
administering	VBG	O
antisense	JJ	O
compounds	NNS	O
in	IN	O
accordance	NN	O
with	IN	O
this	DT	O
invention.	.	O
For	IN	O
example,	,	O
in	IN	O
one	CD	O
non-limiting	JJ	O
embodiment,	,	O
the	DT	O
methods	NNS	O
comprise	VBP	O
the	DT	O
step	NN	O
of	IN	O
administering	VBG	O
to	TO	O
the	DT	O
animal	NN	O
in	IN	O
need	NN	O
of	IN	O
treatment,	,	O
a	DT	O
therapeutically	RB	O
effective	JJ	O
amount	NN	O
of	IN	O
a	DT	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
inhibitor.	.	O
The	DT	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
inhibitors	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
effectively	RB	O
inhibit	VB	O
the	DT	O
activity	NN	O
of	IN	O
the	DT	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
protein	NN	O
or	CC	O
inhibit	VB	O
the	DT	O
expression	NN	O
of	IN	O
the	DT	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
protein.	.	O
In	IN	O
one	CD	O
embodiment,	,	O
the	DT	O
activity	NN	O
or	CC	O
expression	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
in	IN	O
an	DT	O
animal	NN	O
is	VBZ	O
inhibited	VBN	O
by	IN	O
about	IN	O
10%.	.	O
Preferably,	,	O
the	DT	O
activity	NN	O
or	CC	O
expression	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
in	IN	O
an	DT	O
animal	NN	O
is	VBZ	O
inhibited	VBN	O
by	IN	O
about	IN	O
30%.	.	O
More	RBR	O
preferably,	,	O
the	DT	O
activity	NN	O
or	CC	O
expression	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
in	IN	O
an	DT	O
animal	NN	O
is	VBZ	O
inhibited	VBN	O
by	IN	O
50%	NN	O
or	CC	O
more.	.	O
Thus,	,	O
the	DT	O
antisense	NN	O
compounds	VBZ	O
modulate	JJ	O
expression	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
mRNA	NN	O
by	IN	O
at	IN	O
least	JJS	O
10%,	,	O
by	IN	O
at	IN	O
least	JJS	O
20%,	,	O
by	IN	O
at	IN	O
least	JJS	O
25%,	,	O
by	IN	O
at	IN	O
least	JJS	O
30%,	,	O
by	IN	O
at	IN	O
least	JJS	O
40%,	,	O
by	IN	O
at	IN	O
least	JJS	O
50%,	,	O
by	IN	O
at	IN	O
least	JJS	O
60%,	,	O
by	IN	O
at	IN	O
least	JJS	O
70%,	,	O
by	IN	O
at	IN	O
least	JJS	O
75%,	,	O
by	IN	O
at	IN	O
least	JJS	O
80%,	,	O
by	IN	O
at	IN	O
least	JJS	O
85%,	,	O
by	IN	O
at	IN	O
least	JJS	O
90%,	,	O
by	IN	O
at	IN	O
least	JJS	O
95%,	,	O
by	IN	O
at	IN	O
least	JJS	O
98%,	,	O
by	IN	O
at	IN	O
least	JJS	O
99%,	,	O
or	CC	O
by	IN	O
100%.	.	O
For	IN	O
example,	,	O
the	DT	O
reduction	NN	O
of	IN	O
the	DT	O
expression	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
may	MD	O
be	VB	O
measured	VBN	O
in	IN	O
serum,	,	O
adipose	JJ	O
tissue,	,	O
liver	RB	O
or	CC	O
any	DT	O
other	JJ	O
body	NN	O
fluid,	,	O
tissue	NN	O
or	CC	O
organ	NN	O
of	IN	O
the	DT	O
animal.	.	O
Preferably,	,	O
the	DT	O
cells	NNS	O
contained	VBN	O
within	IN	O
said	VBD	O
fluids,	,	O
tissues	NNS	O
or	CC	O
organs	NNS	O
being	VBG	O
analyzed	VBN	O
contain	VBP	O
a	DT	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
encoding	VBG	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
protein	NN	O
and/or	VBD	O
the	DT	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
protein	NN	O
itself.	.	O
The	DT	O
antisense	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
can	MD	O
be	VB	O
utilized	VBN	O
in	IN	O
pharmaceutical	JJ	O
compositions	NNS	O
by	IN	O
adding	VBG	O
an	DT	O
effective	JJ	O
amount	NN	O
of	IN	O
a	DT	O
compound	NN	O
to	TO	O
a	DT	O
suitable	JJ	O
pharmaceutically	RB	O
acceptable	JJ	O
diluent	NN	O
or	CC	O
carrier.	.	O
The	DT	O
compounds	NNS	O
and	CC	O
methods	NNS	O
of	IN	O
the	DT	O
invention	NN	O
may	MD	O
also	RB	O
be	VB	O
useful	JJ	O
prophylactically.	.	O
The	DT	O
antisense	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
are	VBP	O
also	RB	O
useful	JJ	O
for	IN	O
identifying	VBG	O
diseased	JJ	O
states	NNS	O
associated	VBN	O
with	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
expression.	.	O
The	DT	O
methods	NNS	O
include	VBP	O
identifying	VBG	O
the	DT	O
presence	NN	O
of	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
encoding	VBG	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
in	IN	O
a	DT	O
sample	NN	O
using	VBG	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
the	DT	O
primers	NNS	O
comprising	VBG	O
SEQ	NNP	O
ID	NNP	O
NOs:	:	O
6	CD	O
or	CC	O
7,	,	O
or	CC	O
the	DT	O
probe	NN	O
comprising	VBG	O
SEQ	NNP	O
ID	NNP	O
NO:	:	O
8.	.	O
The	DT	O
antisense	NN	O
compounds	NNS	O
are	VBP	O
further	JJ	O
useful	JJ	O
for	IN	O
treating	VBG	O
or	CC	O
preventing	VBG	O
a	DT	O
variety	NN	O
of	IN	O
conditions.	.	O
Typically,	,	O
the	DT	O
compounds	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
are	VBP	O
utilized	VBN	O
to	TO	O
ameliorate	VB	O
or	CC	O
lessen	VB	O
the	DT	O
severity	NN	O
of	IN	O
a	DT	O
condition	NN	O
in	IN	O
an	DT	O
animal.	.	O
The	DT	O
conditions	NNS	O
can	MD	O
include	VB	O
cardiovascular	JJ	O
disorder,	,	O
obesity	NN	O
such	JJ	O
as	IN	O
diet	JJ	O
induced	JJ	O
obesity,	,	O
diabetes,	,	O
cholesterolemia,	,	O
and	CC	O
liver	RB	O
steatosis,	,	O
among	IN	O
others.	.	O
There	EX	O
are	VBP	O
several	JJ	O
physical	JJ	O
indicia	NN	O
of	IN	O
obesity	NN	O
and	CC	O
include	VBP	O
increased	VBN	O
fat,	,	O
among	IN	O
others.	.	O
The	DT	O
treatment	NN	O
or	CC	O
prevention	NN	O
of	IN	O
a	DT	O
condition	NN	O
using	VBG	O
the	DT	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
can	MD	O
include	VB	O
contacting	VBG	O
an	DT	O
animal	NN	O
with	IN	O
an	DT	O
effective	JJ	O
amount	NN	O
of	IN	O
a	DT	O
compound	NN	O
of	IN	O
the	DT	O
invention.	.	O
Preferably,	,	O
expression	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
is	VBZ	O
inhibited	VBN	O
and	CC	O
the	DT	O
measurement	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
physical	JJ	O
indicia	NN	O
of	IN	O
the	DT	O
condition	NN	O
indicates	VBZ	O
a	DT	O
lessening	NN	O
of	IN	O
the	DT	O
severity	NN	O
of	IN	O
the	DT	O
condition.	.	O
Typically,	,	O
the	DT	O
animal	NN	O
is	VBZ	O
obese.	.	O
The	DT	O
antisense	NN	O
compounds	NNS	O
are	VBP	O
additionally	RB	O
utilized	JJ	O
for	IN	O
lowering	VBG	O
certain	JJ	O
components	NNS	O
of	IN	O
blood	NN	O
from	IN	O
an	DT	O
animal.	.	O
Typically,	,	O
the	DT	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
are	VBP	O
useful	JJ	O
for	IN	O
lowering	VBG	O
serum	JJ	O
free	JJ	O
fatty	NN	O
acids,	,	O
serum	NN	O
triglycerides,	,	O
lowering	VBG	O
HDL	NNP	O
cholesterol,	,	O
lowering	VBG	O
total	JJ	O
serum	NN	O
cholesterol,	,	O
plasma	NN	O
or	CC	O
serum	NN	O
insulin,	,	O
or	CC	O
hepatic	JJ	O
triglycerides	NNS	O
in	IN	O
an	DT	O
animal.	.	O
Typically,	,	O
the	DT	O
animal	NN	O
is	VBZ	O
contacted	VBN	O
with	IN	O
an	DT	O
effective	JJ	O
amount	NN	O
of	IN	O
a	DT	O
compound	NN	O
of	IN	O
the	DT	O
invention.	.	O
Preferably,	,	O
the	DT	O
plasma	JJ	O
insulin	NN	O
levels	NNS	O
are	VBP	O
lowered	VBN	O
at	IN	O
about	RB	O
two	CD	O
or	CC	O
four	CD	O
weeks	NNS	O
after	IN	O
contacting	VBG	O
the	DT	O
animal	NN	O
with	IN	O
a	DT	O
compound	NN	O
of	IN	O
the	DT	O
invention.	.	O
The	DT	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
are	VBP	O
also	RB	O
useful	JJ	O
in	IN	O
inhibiting	VBG	O
the	DT	O
expression	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
in	IN	O
a	DT	O
cell	NN	O
or	CC	O
tissue	NN	O
of	IN	O
an	DT	O
animal.	.	O
The	DT	O
method	NN	O
includes	VBZ	O
contacting	VBG	O
the	DT	O
cell	NN	O
or	CC	O
tissue	NN	O
with	IN	O
a	DT	O
compound	NN	O
of	IN	O
the	DT	O
invention.	.	O
Preferably,	,	O
expression	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
is	VBZ	O
inhibited	VBN	O
in	IN	O
the	DT	O
present	JJ	O
method.	.	O
Typically,	,	O
the	DT	O
tissue	NN	O
of	IN	O
the	DT	O
animal	NN	O
is	VBZ	O
white	JJ	O
adipose	JJ	O
tissue	NN	O
or	CC	O
brown	NN	O
adipose	JJ	O
tissue.	.	O
The	DT	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
are	VBP	O
further	JJ	O
useful	JJ	O
in	IN	O
methods	NNS	O
for	IN	O
modulating	VBG	O
fatty	JJ	O
acid	JJ	O
synthesis,	,	O
lipogenesis,	,	O
or	CC	O
gluconeogenesis,	,	O
among	IN	O
others,	,	O
in	IN	O
an	DT	O
animal.	.	O
Typically,	,	O
the	DT	O
animal	NN	O
is	VBZ	O
contacted	VBN	O
with	IN	O
a	DT	O
compound	NN	O
of	IN	O
the	DT	O
invention.	.	O
The	DT	O
modulation	NN	O
of	IN	O
lipogenesis	NN	O
can	MD	O
be	VB	O
determined	VBN	O
by	IN	O
a	DT	O
change	NN	O
in	IN	O
the	DT	O
mRNA	JJ	O
level	NN	O
of	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
encoding	VBG	O
a	DT	O
lipogenic	JJ	O
gene.	.	O
The	DT	O
lipogenic	JJ	O
gene	NN	O
is	VBZ	O
selected	VBN	O
from	IN	O
among	IN	O
glycerol	JJ	O
kinase,	,	O
ATP-citrate	NNP	O
lyase,	,	O
acetyl-CoA	JJ	O
carboxylase	NN	O
1,	,	O
acetyl-CoA	JJ	O
carboxylase	NN	O
2,	,	O
fatty	JJ	O
acid	JJ	O
synthase,	,	O
carnitine	JJ	O
palmitoyltransferase	NN	O
I,	,	O
stearoyl-CoA	JJ	O
desaturase,	,	O
HMG-CoA	NNP	O
reductase,	,	O
lipoprotein	JJ	O
lipase	NN	O
and	CC	O
sterol	NN	O
regulatory	JJ	O
binding	NN	O
element	NN	O
protein	NN	O
1.	.	O
The	DT	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
are	VBP	O
additionally	RB	O
useful	JJ	O
for	IN	O
reducing	VBG	O
the	DT	O
liver	NN	O
weight	NN	O
of	IN	O
an	DT	O
animal.	.	O
For	IN	O
this	DT	O
use,	,	O
the	DT	O
animal	NN	O
is	VBZ	O
contacted	VBN	O
with	IN	O
a	DT	O
compound	NN	O
of	IN	O
the	DT	O
invention.	.	O
Typically,	,	O
the	DT	O
animal	NN	O
is	VBZ	O
obese	JJ	O
or	CC	O
diabetic.	.	O
F.	NNP	O
Modifications	NNP	O
As	NNP	O
is	VBZ	O
known	VBN	O
in	IN	O
the	DT	O
art,	,	O
a	DT	O
nucleoside	NN	O
is	VBZ	O
a	DT	O
base-sugar	JJ	O
combination.	.	O
The	DT	O
base	JJ	O
portion	NN	O
of	IN	O
the	DT	O
nucleoside	NN	O
is	VBZ	O
normally	RB	O
a	DT	O
heterocyclic	JJ	O
base	NN	O
sometimes	RB	O
referred	VBD	O
to	TO	O
as	IN	O
a	DT	O
“nucleobase”	NN	O
or	CC	O
simply	RB	O
a	DT	O
“base”.	.	O
The	DT	O
two	CD	O
most	JJS	O
common	JJ	O
classes	NNS	O
of	IN	O
such	JJ	O
heterocyclic	JJ	O
bases	NNS	O
are	VBP	O
the	DT	O
purines	NNS	O
and	CC	O
the	DT	O
pyrimidines.	.	O
Nucleotides	NNS	O
are	VBP	O
nucleosides	NNS	O
that	IN	O
further	JJ	O
include	VBP	O
a	DT	O
phosphate	JJ	O
group	NN	O
covalently	RB	O
linked	VBN	O
to	TO	O
the	DT	O
sugar	NN	O
portion	NN	O
of	IN	O
the	DT	O
nucleoside.	.	O
For	IN	O
those	DT	O
nucleosides	NNS	O
that	WDT	O
include	VBP	O
a	DT	O
pentofuranosyl	NN	O
sugar,	,	O
the	DT	O
phosphate	NN	O
group	NN	O
can	MD	O
be	VB	O
linked	VBN	O
to	TO	O
the	DT	O
2′,	,	O
3′	CD	O
or	CC	O
5′	CD	O
hydroxyl	JJ	O
moiety	NN	O
of	IN	O
the	DT	O
sugar.	.	O
In	IN	O
forming	VBG	O
oligonucleotides,	,	O
the	DT	O
phosphate	NN	O
groups	NNS	O
covalently	RB	O
link	VBP	O
adjacent	JJ	O
nucleosides	NNS	O
to	TO	O
one	CD	O
another	DT	O
to	TO	O
form	VB	O
a	DT	O
linear	JJ	O
polymeric	JJ	O
compound.	.	O
In	IN	O
turn,	,	O
the	DT	O
respective	JJ	O
ends	NNS	O
of	IN	O
this	DT	O
linear	JJ	O
polymeric	JJ	O
compound	NN	O
can	MD	O
be	VB	O
further	RB	O
joined	VBN	O
to	TO	O
form	VB	O
a	DT	O
circular	JJ	O
compound,	,	O
however,	,	O
linear	JJ	O
compounds	NNS	O
are	VBP	O
generally	RB	O
preferred.	.	O
In	IN	O
addition,	,	O
linear	JJ	O
compounds	NNS	O
may	MD	O
have	VB	O
internal	JJ	O
nucleobase	NN	O
complementarity	NN	O
and	CC	O
may	MD	O
therefore	VB	O
fold	NN	O
in	IN	O
a	DT	O
manner	NN	O
as	IN	O
to	TO	O
produce	VB	O
a	DT	O
fully	RB	O
or	CC	O
partially	RB	O
double-stranded	JJ	O
compound.	.	O
Within	IN	O
oligonucleotides,	,	O
the	DT	O
phosphate	NN	O
groups	NNS	O
are	VBP	O
commonly	RB	O
referred	VBN	O
to	TO	O
as	IN	O
forming	VBG	O
the	DT	O
internucleoside	JJ	O
backbone	NN	O
of	IN	O
the	DT	O
oligonucleotide.	.	O
The	DT	O
normal	JJ	O
linkage	NN	O
or	CC	O
backbone	NN	O
of	IN	O
RNA	NNP	O
and	CC	O
DNA	NNP	O
is	VBZ	O
a	DT	O
3′	CD	O
to	TO	O
5′	CD	O
phosphodiester	NN	O
linkage.	.	O
Modified	NNP	O
Internucleoside	NNP	O
Linkages	NNP	O
(Backbones)	)	O
Antisense	NNP	O
compounds	VBZ	O
useful	JJ	O
in	IN	O
this	DT	O
invention	NN	O
include	VBP	O
oligonucleotides	NNS	O
containing	VBG	O
modified	JJ	O
backbones	NNS	O
or	CC	O
non-natural	JJ	O
internucleoside	NN	O
linkages.	.	O
As	IN	O
used	VBN	O
herein,	,	O
and	CC	O
“oligonucleotide	VB	O
mimetic”	NN	O
or	CC	O
“mimetic”	JJ	O
refers	NNS	O
to	TO	O
any	DT	O
compound	NN	O
of	IN	O
the	DT	O
invention	NN	O
which	WDT	O
is	VBZ	O
modified	VBN	O
from	IN	O
the	DT	O
naturally	RB	O
occurring	VBG	O
RNA	NNP	O
or	CC	O
DNA	NNP	O
nucleic	JJ	O
acids.	.	O
As	IN	O
defined	VBN	O
herein,	,	O
oligonucleotides	IN	O
having	VBG	O
modified	VBN	O
backbones	NNS	O
include	VBP	O
those	DT	O
that	WDT	O
retain	VBP	O
a	DT	O
phosphorus	NN	O
atom	NN	O
in	IN	O
the	DT	O
backbone	NN	O
and	CC	O
those	DT	O
that	WDT	O
do	VBP	O
not	RB	O
have	VB	O
a	DT	O
phosphorus	NN	O
atom	NN	O
in	IN	O
the	DT	O
backbone.	.	O
For	IN	O
the	DT	O
purposes	NNS	O
of	IN	O
this	DT	O
specification,	,	O
and	CC	O
as	IN	O
sometimes	RB	O
referenced	VBN	O
in	IN	O
the	DT	O
art,	,	O
modified	VBD	O
oligonucleotides	NNS	O
that	WDT	O
do	VBP	O
not	RB	O
have	VB	O
a	DT	O
phosphorus	NN	O
atom	NN	O
in	IN	O
their	PRP$	O
internucleoside	JJ	O
backbone	NN	O
can	MD	O
also	RB	O
be	VB	O
considered	VBN	O
to	TO	O
be	VB	O
oligonucleosides.	.	O
Preferred	NNP	O
modified	VBD	O
oligonucleotide	JJ	O
backbones	NNS	O
containing	VBG	O
a	DT	O
phosphorus	NN	O
atom	NN	O
therein	NN	O
include,	,	O
for	IN	O
example,	,	O
phosphorothioates,	,	O
chiral	JJ	O
phosphorothioates,	,	O
phosphorodithioates,	,	O
phosphotriesters,	,	O
aminoalkyl-phosphotriesters,	,	O
methyl	NN	O
and	CC	O
other	JJ	O
alkyl	NN	O
phosphonates	NNS	O
including	VBG	O
3′-alkylene	JJ	O
phosphonates,	,	O
5′-alkylene	JJ	O
phosphonates	NNS	O
and	CC	O
chiral	JJ	O
phosphonates,	,	O
phosphinates,	,	O
phosphoramidates	NNS	O
including	VBG	O
3′-amino	JJ	O
phosphoramidate	NN	O
and	CC	O
aminoalkylphosphoramidates,	,	O
thionophosphoramidates,	,	O
thionoalkylphosphonates,	,	O
thionoalkylphosphotriesters,	,	O
selenophosphates	NNS	O
and	CC	O
boranophosphates	NNS	O
having	VBG	O
normal	JJ	O
3′-5′	JJ	O
linkages,	,	O
2′-5′	JJ	O
linked	VBD	O
analogs	NNS	O
of	IN	O
these,	,	O
and	CC	O
those	DT	O
having	VBG	O
inverted	VBN	O
polarity	NN	O
wherein	VBP	O
one	CD	O
or	CC	O
more	JJR	O
internucleotide	JJ	O
linkages	NNS	O
is	VBZ	O
a	DT	O
3′	CD	O
to	TO	O
3′,	,	O
5′	CD	O
to	TO	O
5′	CD	O
or	CC	O
2′	CD	O
to	TO	O
2′	CD	O
linkage.	.	O
Preferred	NNP	O
oligonucleotides	VBZ	O
having	VBG	O
inverted	VBN	O
polarity	NN	O
comprise	NN	O
a	DT	O
single	JJ	O
3′	CD	O
to	TO	O
3′	CD	O
linkage	NN	O
at	IN	O
the	DT	O
3′-most	JJ	O
internucleotide	JJ	O
linkage	NN	O
i.e.	.	O
a	DT	O
single	JJ	O
inverted	JJ	O
nucleoside	NN	O
residue	NN	O
which	WDT	O
may	MD	O
be	VB	O
abasic	JJ	O
(the	DT	O
nucleobase	NN	O
is	VBZ	O
missing	VBG	O
or	CC	O
has	VBZ	O
a	DT	O
hydroxyl	NN	O
group	NN	O
in	IN	O
place	NN	O
thereof).	.	O
Various	JJ	O
salts,	,	O
mixed	JJ	O
salts	NNS	O
and	CC	O
free	JJ	O
acid	NN	O
forms	NNS	O
are	VBP	O
also	RB	O
included.	.	O
Representative	JJ	O
United	NNP	O
States	NNPS	O
patents	NNS	O
that	WDT	O
teach	VBP	O
the	DT	O
preparation	NN	O
of	IN	O
the	DT	O
above	JJ	O
phosphorus-containing	NN	O
linkages	NNS	O
include,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to,	,	O
U.S.	NNP	O
Pat.	.	O
Nos.	.	O
3,687,808;	:	O
4,469,863;	:	O
4,476,301;	:	O
5,023,243;	:	O
5,177,196;	:	O
5,188,897;	:	O
5,264,423;	:	O
5,276,019;	:	O
5,278,302;	:	O
5,286,717;	:	O
5,321,131;	:	O
5,399,676;	:	O
5,405,939;	:	O
5,453,496;	:	O
5,455,233;	:	O
5,466,677;	:	O
5,476,925;	:	O
5,519,126;	:	O
5,536,821;	:	O
5,541,306;	:	O
5,550,111;	:	O
5,563,253;	:	O
5,571,799;	:	O
5,587,361;	:	O
5,194,599;	:	O
5,565,555;	:	O
5,527,899;	:	O
5,721,218;	:	O
5,672,697	CD	O
and	CC	O
5,625,050,	,	O
each	DT	O
of	IN	O
which	WDT	O
is	VBZ	O
herein	RB	O
incorporated	VBN	O
by	IN	O
reference.	.	O
Preferred	NNP	O
modified	VBD	O
oligonucleotide	JJ	O
backbones	NNS	O
that	WDT	O
do	VBP	O
not	RB	O
include	VB	O
a	DT	O
phosphorus	JJ	O
atom	NN	O
therein	NNS	O
have	VBP	O
backbones	NNS	O
that	WDT	O
are	VBP	O
formed	VBN	O
by	IN	O
short	JJ	O
chain	NN	O
alkyl	NN	O
or	CC	O
cycloalkyl	NN	O
internucleoside	NN	O
linkages,	,	O
mixed	JJ	O
heteroatom	NN	O
and	CC	O
alkyl	NN	O
or	CC	O
cycloalkyl	NN	O
internucleoside	NN	O
linkages,	,	O
or	CC	O
one	CD	O
or	CC	O
more	JJR	O
short	JJ	O
chain	NN	O
heteroatomic	VBD	O
or	CC	O
heterocyclic	JJ	O
internucleoside	NN	O
linkages.	.	O
These	DT	O
include	VBP	O
those	DT	O
having	VBG	O
morpholino	NN	O
linkages	NNS	O
(formed	VBN	O
in	IN	O
part	NN	O
from	IN	O
the	DT	O
sugar	NN	O
portion	NN	O
of	IN	O
a	DT	O
nucleoside);	:	O
siloxane	JJ	O
backbones;	:	O
sulfide,	,	O
sulfoxide	NN	O
and	CC	O
sulfone	NN	O
backbones;	:	O
formacetyl	NNS	O
and	CC	O
thioformacetyl	JJ	O
backbones;	:	O
methylene	CC	O
formacetyl	NN	O
and	CC	O
thioformacetyl	JJ	O
backbones;	:	O
riboacetyl	VB	O
backbones;	:	O
alkene	VBZ	O
containing	VBG	O
backbones;	:	O
sulfamate	VB	O
backbones;	:	O
methyleneimino	NN	O
and	CC	O
methylenehydrazino	NN	O
backbones;	:	O
sulfonate	NN	O
and	CC	O
sulfonamide	JJ	O
backbones;	:	O
amide	IN	O
backbones;	:	O
and	CC	O
others	NNS	O
having	VBG	O
mixed	JJ	O
N,	,	O
O,	,	O
S	NNP	O
and	CC	O
CH2	NNP	O
component	NN	O
parts.	.	O
Representative	JJ	O
United	NNP	O
States	NNPS	O
patents	NNS	O
that	WDT	O
teach	VBP	O
the	DT	O
preparation	NN	O
of	IN	O
the	DT	O
above	JJ	O
oligonucleosides	NNS	O
include,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to,	,	O
U.S.	NNP	O
Pat.	.	O
Nos.	.	O
5,034,506;	:	O
5,166,315;	:	O
5,185,444;	:	O
5,214,134;	:	O
5,216,141;	:	O
5,235,033;	:	O
5,264,562;	:	O
5,264,564;	:	O
5,405,938;	:	O
5,434,257;	:	O
5,466,677;	:	O
5,470,967;	:	O
5,489,677;	:	O
5,541,307;	:	O
5,561,225;	:	O
5,596,086;	:	O
5,602,240;	:	O
5,610,289;	:	O
5,602,240;	:	O
5,608,046;	:	O
5,610,289;	:	O
5,618,704;	:	O
5,623,070;	:	O
5,663,312;	:	O
5,633,360;	:	O
5,677,437;	:	O
5,792,608;	:	O
5,646,269	CD	O
and	CC	O
5,677,439,	,	O
each	DT	O
of	IN	O
which	WDT	O
is	VBZ	O
herein	RB	O
incorporated	VBN	O
by	IN	O
reference.	.	O
Modified	VBN	O
Sugar	NNP	O
and	CC	O
Internucleoside	NNP	O
Linkages-Mimetics	NNP	O
In	IN	O
other	JJ	O
preferred	JJ	O
antisense	NN	O
compounds,	,	O
e.g.,	,	O
oligonucleotide	IN	O
mimetics,	,	O
both	CC	O
the	DT	O
sugar	NN	O
and	CC	O
the	DT	O
internucleoside	JJ	O
linkage	NN	O
(i.e.	.	O
the	DT	O
backbone)	)	O
of	IN	O
the	DT	O
nucleotide	JJ	O
units	NNS	O
are	VBP	O
replaced	VBN	O
with	IN	O
novel	JJ	O
groups.	.	O
The	DT	O
nucleobase	JJ	O
units	NNS	O
are	VBP	O
maintained	VBN	O
for	IN	O
hybridization	NN	O
with	IN	O
an	DT	O
appropriate	JJ	O
target	NN	O
nucleic	JJ	O
acid.	.	O
One	CD	O
such	JJ	O
oligonucleotide	JJ	O
mimetic	NN	O
that	WDT	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
have	VB	O
excellent	JJ	O
hybridization	NN	O
properties,	,	O
is	VBZ	O
referred	VBN	O
to	TO	O
as	IN	O
a	DT	O
peptide	NN	O
nucleic	JJ	O
acid	NN	O
(PNA).	.	O
In	IN	O
PNA	NNP	O
compounds,	,	O
the	DT	O
sugar-backbone	NN	O
of	IN	O
an	DT	O
oligonucleotide	NN	O
is	VBZ	O
replaced	VBN	O
with	IN	O
an	DT	O
amide	NN	O
containing	VBG	O
backbone,	,	O
in	IN	O
particular	JJ	O
an	DT	O
aminoethylglycine	JJ	O
backbone.	.	O
The	DT	O
nucleobases	NNS	O
are	VBP	O
retained	VBN	O
and	CC	O
are	VBP	O
bound	VBN	O
directly	RB	O
or	CC	O
indirectly	RB	O
to	TO	O
aza	VB	O
nitrogen	NN	O
atoms	NNS	O
of	IN	O
the	DT	O
amide	JJ	O
portion	NN	O
of	IN	O
the	DT	O
backbone.	.	O
Representative	JJ	O
United	NNP	O
States	NNPS	O
patents	NNS	O
that	WDT	O
teach	VBP	O
the	DT	O
preparation	NN	O
of	IN	O
PNA	NNP	O
compounds	NNS	O
include,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to,	,	O
U.S.	NNP	O
Pat.	.	O
Nos.	.	O
5,539,082;	:	O
5,714,331;	:	O
and	CC	O
5,719,262,	,	O
each	DT	O
of	IN	O
which	WDT	O
is	VBZ	O
herein	RB	O
incorporated	VBN	O
by	IN	O
reference.	.	O
Further	RB	O
teaching	NN	O
of	IN	O
PNA	NNP	O
compounds	NNS	O
can	MD	O
be	VB	O
found	VBN	O
in	IN	O
Nielsen	NNP	B
et	CC	I
al.,	,	I
Science,	,	I
1991,	,	I
254,	,	I
1497-1500.
In	.	O
certain	IN	O
embodiments	JJ	O
of	NNS	O
the	IN	O
invention	DT	O
are	NN	O
oligonucleotides	VBP	O
with	NNS	O
phosphorothioate	IN	O
backbones	JJ	O
and	NNS	O
oligonucleotides	CC	O
with	NNS	O
heteroatom	IN	O
backbones,	JJ	O
and	,	O
in	CC	O
particular	IN	O
—CH2—NH—O—CH2—,	JJ	O
—CH2—N(CH3)—O—CH2—[known	,	O
as	VBN	O
a	IN	O
methylene	DT	O
(methylimino)	NN	O
or	)	O
MMI	CC	O
backbone],	NNP	O
—CH2—O—N(CH3)—CH2—,	,	O
—CH2—N(CH3)—N(CH3)—CH2—	,	O
and	NN	O
—O—N(CH3)—CH2—CH2—	CC	O
[wherein	VBP	O
the	IN	O
native	DT	O
phosphodiester	JJ	O
backbone	NN	O
is	NN	O
represented	VBZ	O
as	VBN	O
—O—P—O—CH2—]	IN	O
of	NN	O
the	IN	O
above	DT	O
referenced	NN	O
U.S.	VBD	O
Pat.	NNP	O
No.	.	O
5,489,677,	.	O
and	,	O
the	CC	O
amide	DT	O
backbones	JJ	O
of	NNS	O
the	IN	O
above	DT	O
referenced	NN	O
U.S.	VBD	O
Pat.	NNP	O
No.	.	O
5,602,240.	.	O
Also	.	O
included	RB	O
are	VBN	O
oligonucleotides	VBP	O
having	NNS	O
morpholino	VBG	O
backbone	NN	O
structures	NN	O
of	NNS	O
the	IN	O
above-referenced	DT	O
U.S.	JJ	O
Pat.	NNP	O
No.	.	O
5,034,506.	.	O
Modified	.	O
Sugars	NNP	O
Oligonucleotide	NNP	O
mimetics	NNP	O
may	NNS	O
also	MD	O
contain	RB	O
one	VB	O
or	CD	O
more	CC	O
substituted	JJR	O
sugar	JJ	O
moieties.	NN	O
As	.	O
such	IN	O
these	JJ	O
may	DT	O
comprise	MD	O
one	VB	O
of	CD	O
the	IN	O
following	DT	O
at	VBG	O
the	IN	O
2′	DT	O
position:	CD	O
OH;	:	O
F;	:	O
O—,	:	O
S—,	,	O
or	,	O
N-alkyl;	CC	O
O—,	:	O
S—,	,	O
or	,	O
N-alkenyl;	CC	O
O—,	:	O
S—	,	O
or	NNP	O
N-alkynyl;	CC	O
or	:	O
O-alkyl-O-alkyl,	CC	O
wherein	,	O
the	VBZ	O
alkyl,	DT	O
alkenyl	,	O
and	NN	O
alkynyl	CC	O
may	NN	O
be	MD	O
substituted	VB	O
or	VBN	O
unsubstituted	CC	O
C1	VBN	O
to	NNP	O
C10	TO	O
alkyl	NNP	O
or	NN	O
C2	CC	O
to	NNP	O
C10	TO	O
alkenyl	NNP	O
and	NN	O
alkynyl.	CC	O
Particularly	.	O
preferred	RB	O
are	VBN	O
O[(CH2)nO]mCH3,	VBP	O
O(CH2)nOCH3,	,	O
O(CH2)nNH2,	,	O
O(CH2)nCH3,	,	O
O(CH2)nONH2,	,	O
and	,	O
O(CH2)nON[(CH2)nCH3]2,	CC	O
where	,	O
n	WRB	O
and	NN	O
m	CC	O
are	NN	O
from	VBP	O
1	IN	O
to	CD	O
about	TO	O
10.	IN	O
Other	.	O
oligonucleotide	JJ	O
mimetics	IN	O
may	NNS	O
comprise	MD	O
one	VB	O
of	CD	O
the	IN	O
following	DT	O
at	VBG	O
the	IN	O
2′	DT	O
position:	CD	O
C1	:	O
to	NN	O
C10	TO	O
lower	NNP	O
alkyl,	JJR	O
substituted	,	O
lower	VBD	O
alkyl,	JJR	O
alkenyl,	,	O
alkynyl,	,	O
alkaryl,	,	O
aralkyl,	,	O
O-alkaryl	,	O
or	NNP	O
O-aralkyl,	CC	O
SH,	,	O
SCH3,	,	O
OCN,	,	O
Cl,	,	O
Br,	,	O
CN,	,	O
CF3,	,	O
OCF3,	,	O
SOCH3,	,	O
SO2CH3,	,	O
ONO2,	,	O
NO2,	,	O
N3,	,	O
NH2,	,	O
heterocycloalkyl,	,	O
heterocycloalkaryl,	,	O
aminoalkylamino,	,	O
polyalkylamino,	,	O
substituted	,	O
silyl,	VBD	O
an	,	O
RNA	DT	O
cleaving	NNP	O
group,	NN	O
a	,	O
reporter	DT	O
group,	NN	O
an	,	O
intercalator,	DT	O
a	,	O
group	DT	O
for	NN	O
improving	IN	O
the	VBG	O
pharmacokinetic	DT	O
properties	JJ	O
of	NNS	O
an	IN	O
oligonucleotide,	DT	O
or	,	O
a	CC	O
group	DT	O
for	NN	O
improving	IN	O
the	VBG	O
pharmacodynamic	DT	O
properties	JJ	O
of	NNS	O
an	IN	O
oligonucleotide,	DT	O
and	,	O
other	CC	O
substituents	JJ	O
having	NNS	O
similar	VBG	O
properties.	JJ	O
One	.	O
modification	CD	O
includes	NN	O
2′-methoxyethoxy	VBZ	O
(2′-O—CH2CH2OCH3,	JJ	O
also	,	O
known	RB	O
as	VBN	O
2′-O-(2-methoxyethyl)	IN	O
or	)	O
2′-O-methoxyethyl	CC	O
or	JJ	O
2′-MOE)	CC	O
(Martin	)	O
et	NNP	O
al.,	RB	O
Helv.	,	O
Chim.	.	O
Acta,	.	O
1995,	,	O
78,	,	O
486-504)	,	O
i.e.,	)	O
an	,	O
alkoxyalkoxy	DT	O
group.	JJ	O
A	.	O
further	DT	O
modification	JJ	O
includes	NN	O
2′-dimethylaminooxyethoxy,	VBZ	O
i.e.,	,	O
a	,	O
O(CH2)2ON(CH3)2	DT	O
group,	CD	O
also	,	O
known	RB	O
as	VBN	O
2′-DMAOE,	IN	O
as	,	O
described	IN	O
in	VBN	O
examples	IN	O
hereinbelow,	NNS	O
and	,	O
2′-dimethylaminoethoxyethoxy	CC	O
(also	JJ	O
known	RB	O
in	VBN	O
the	IN	O
art	DT	O
as	NN	O
2′-O-dimethyl-amino-ethoxy-ethyl	IN	O
or	JJ	O
2′-DMAEOE),	CC	O
i.e.,	,	O
2′-O—CH2—O—CH2—N(CH3)2,	,	O
also	,	O
described	RB	O
in	VBN	O
examples	IN	O
hereinbelow.	NNS	O
Other	.	O
modifications	JJ	O
include	NNS	O
2′-methoxy	VBP	O
(2′-O—CH3),	JJ	O
2′-amino	,	O
(2′—NH2)2′-aminopropoxy	JJ	O
(2′-OCH2CH2CH2NH2),	JJ	O
2′-allyl	,	O
(2′-CH2—CH═CH2),	JJ	O
2′-O-allyl	,	O
(2′-O—CH2—CH═CH2)	JJ	O
and	)	O
2′-fluoro	CC	O
(2′-F).	JJ	O
The	.	O
2′modification	DT	O
may	CD	O
be	MD	O
in	VB	O
the	IN	O
arabino	DT	O
(up)	NN	O
position	)	O
or	NN	O
ribo	CC	O
(down)	NN	O
position.	)	O
One	.	O
2′-arabino	CD	O
modification	JJ	O
is	NN	O
2′-F.	VBZ	O
Similar	.	O
modifications	JJ	O
may	NNS	O
also	MD	O
be	RB	O
made	VB	O
at	VBN	O
other	IN	O
positions	JJ	O
on	NNS	O
the	IN	O
oligonucleotide,	DT	O
particularly	,	O
the	RB	O
3′	DT	O
position	CD	O
of	NN	O
the	IN	O
sugar	DT	O
on	NN	O
the	IN	O
3′	DT	O
terminal	CD	O
nucleotide	JJ	O
or	NN	O
in	CC	O
2′-5′	IN	O
linked	JJ	O
oligonucleotides	VBN	O
and	NNS	O
the	CC	O
5′	DT	O
position	CD	O
of	NN	O
5′	IN	O
terminal	CD	O
nucleotide.	JJ	O
Oligonucleotide	.	O
mimetics	IN	O
involving	NNS	O
the	VBG	O
sugar,	DT	O
such	,	O
as	JJ	O
cyclobutyl	IN	O
moieties	NN	O
in	NNS	O
place	IN	O
of	NN	O
the	IN	O
pentofuranosyl	DT	O
sugar,	NN	O
are	,	O
also	VBP	O
within	RB	O
the	IN	O
scope	DT	O
of	NN	O
the	IN	O
present	DT	O
invention.	JJ	O
Representative	.	O
United	JJ	O
States	NNP	O
patents	NNPS	O
that	NNS	O
teach	WDT	O
the	VBP	O
preparation	DT	O
of	NN	O
such	IN	O
modified	JJ	O
sugar	VBN	O
structures	NN	O
include,	NNS	O
but	,	O
are	CC	O
not	VBP	O
limited	RB	O
to,	VBN	O
U.S.	,	O
Pat.	NNP	O
Nos.	.	O
4,981,957;	.	O
5,118,800;	:	O
5,319,080;	:	O
5,359,044;	:	O
5,393,878;	:	O
5,446,137;	:	O
5,466,786;	:	O
5,514,785;	:	O
5,519,134;	:	O
5,567,811;	:	O
5,576,427;	:	O
5,591,722;	:	O
5,597,909;	:	O
5,610,300;	:	O
5,627,053;	:	O
5,639,873;	:	O
5,646,265;	:	O
5,658,873;	:	O
5,670,633;	:	O
5,792,747;	:	O
and	:	O
5,700,920,	CC	O
each	,	O
of	DT	O
which	IN	O
is	WDT	O
herein	VBZ	O
incorporated	RB	O
by	VBN	O
reference	IN	O
in	NN	O
its	IN	O
entirety.	PRP$	O
A	.	O
further	DT	O
modification	JJ	O
of	NN	O
the	IN	O
sugar	DT	O
includes	NN	O
Locked	VBZ	O
Nucleic	NNP	O
Acids	NNP	O
(LNAs)	NNP	O
in	)	O
which	IN	O
the	WDT	O
2′-hydroxyl	DT	O
group	JJ	O
is	NN	O
linked	VBZ	O
to	VBN	O
the	TO	O
3′	DT	O
or	CD	O
4′	CC	O
carbon	CD	O
atom	NN	O
of	NN	O
the	IN	O
sugar	DT	O
ring,	NN	O
thereby	,	O
forming	RB	O
a	VBG	O
bicyclic	DT	O
sugar	JJ	O
moiety.	NN	O
The	.	O
linkage	DT	O
is	NN	O
preferably	VBZ	O
a	RB	O
methylene	DT	O
(—CH2—)n	NN	O
group	FW	O
bridging	NN	O
the	VBG	O
2′	DT	O
oxygen	CD	O
atom	NN	O
and	NN	O
the	CC	O
4′	DT	O
carbon	CD	O
atom	NN	O
wherein	NN	O
n	NN	O
is	NN	O
1	VBZ	O
or	CD	O
2.	CC	O
However,	.	O
the	,	O
present	DT	O
invention	JJ	O
comprehends	NN	O
ethylene	NNS	O
linkages	JJ	O
as	NNS	O
well.	RB	O
LNAs	.	O
and	NNP	O
preparation	CC	O
thereof	NN	O
are	NNS	O
described	VBP	O
in	VBN	O
International	IN	O
Patent	NNP	O
Publication	NNP	O
Nos.	NNP	O
WO	.	O
98/39352	$	O
and	CD	O
WO	CC	O
99/14226.	NNP	O
Natural	.	O
and	NNP	O
Modified	CC	O
Nucleobases	NNP	O
Oligonucleotide	NNP	O
mimetics	NNP	O
also	NNS	O
include	RB	O
nucleobase	VBP	O
(often	JJ	O
referred	RB	O
to	VBN	O
in	TO	O
the	IN	O
art	DT	O
as	NN	O
heterocyclic	IN	O
base	JJ	O
or	NN	O
simply	CC	O
as	RB	O
“base”)	IN	O
modifications	)	O
or	NNS	O
substitutions.	CC	O
As	.	O
used	IN	O
herein,	VBN	O
“unmodified”	,	O
or	''	O
“natural”	CC	O
nucleobases	JJ	O
include	NNS	O
the	VBP	O
purine	DT	O
bases	NN	O
adenine	VBZ	O
(A)	NN	O
and	)	O
guanine	CC	O
(G),	NN	O
and	,	O
the	CC	O
pyrimidine	DT	O
bases	NN	O
thymine	VBZ	O
(T),	NN	O
cytosine	,	O
(C)	NN	O
and	)	O
uracil	CC	O
(U).	JJ	O
Modified	.	O
nucleobases	VBN	O
include	NNS	O
other	VBP	O
synthetic	JJ	O
and	JJ	O
natural	CC	O
nucleobases	JJ	O
such	NNS	O
as	JJ	O
5-methylcytosine	IN	O
(5-me-C),	JJ	O
5-hydroxymethyl	,	O
cytosine,	JJ	O
xanthine,	,	O
hypoxanthine,	,	O
2-aminoadenine,	,	O
6-methyl	,	O
and	JJ	O
other	CC	O
alkyl	JJ	O
derivatives	JJ	O
of	NNS	O
adenine	IN	O
and	NN	O
guanine,	CC	O
2-propyl	,	O
and	JJ	O
other	CC	O
alkyl	JJ	O
derivatives	JJ	O
of	NNS	O
adenine	IN	O
and	NN	O
guanine,	CC	O
2-thiouracil,	,	O
2-thiothymine	,	O
and	JJ	O
2-thiocytosine,	CC	O
5-halouracil	,	O
and	JJ	O
cytosine,	CC	O
5-propynyl	,	O
(—C≡C—CH3)	JJ	O
uracil	)	O
and	NN	O
cytosine	CC	O
and	NN	O
other	CC	O
alkynyl	JJ	O
derivatives	JJ	O
of	NNS	O
pyrimidine	IN	O
bases,	NN	O
6-azo	,	O
uracil,	JJ	O
cytosine	,	O
and	NN	O
thymine,	CC	O
5-uracil	,	O
(pseudouracil),	JJ	O
4-thiouracil,	,	O
8-halo,	,	O
8-amino,	,	O
8-thiol,	,	O
8-thioalkyl,	,	O
8-hydroxyl	,	O
and	JJ	O
other	CC	O
8-substituted	JJ	O
adenines	JJ	O
and	NNS	O
guanines,	CC	O
5-halo	,	O
particularly	JJ	O
5-bromo,	RB	O
5-trifluoromethyl	,	O
and	JJ	O
other	CC	O
5-substituted	JJ	O
uracils	JJ	O
and	NNS	O
cytosines,	CC	O
7-methylguanine	,	O
and	JJ	O
7-methyladenine,	CC	O
2-F-adenine,	,	O
2-amino-adenine,	,	O
8-azaguanine	,	O
and	JJ	O
8-azaadenine,	CC	O
7-deazaguanine	,	O
and	JJ	O
7-deazaadenine	CC	O
and	JJ	O
3-deazaguanine	CC	O
and	JJ	O
3-deazaadenine.	CC	O
Further	.	O
modified	RB	O
nucleobases	VBN	O
include	NNS	O
tricyclic	VBP	O
pyrimidines	JJ	O
such	NNS	O
as	JJ	O
phenoxazine	IN	O
cytidine	JJ	O
(1H-pyrimido[5,4-b][1,4]benzoxazin-2(3H)-one),	NN	O
phenothiazine	,	O
cytidine	JJ	O
(1H-pyrimido[5,4-b][1,4]benzothiazin-2(3H)-one),	NN	O
G-clamps	,	O
such	NNP	O
as	JJ	O
a	IN	O
substituted	DT	O
phenoxazine	JJ	O
cytidine	NN	O
(e.g.	NN	O
9-(2-aminoethoxy)-H-pyrimido[5,4-b][1,4]benzoxazin-2(3H)-one),	.	O
carbazole	,	O
cytidine	JJ	O
(2H-pyrimido[4,5-b]indol-2-one),	NN	O
pyridoindole	,	O
cytidine	JJ	O
(H-pyrido[3′,2′:4,5]pyrrolo[2,3-d]pyrimidin-2-one).	NN	O
Modified	.	O
nucleobases	VBN	O
may	NNS	O
also	MD	O
include	RB	O
those	VB	O
in	DT	O
which	IN	O
the	WDT	O
purine	DT	O
or	NN	O
pyrimidine	CC	O
base	JJ	O
is	NN	O
replaced	VBZ	O
with	VBN	O
other	IN	O
heterocycles,	JJ	O
for	,	O
example	IN	O
7-deaza-adenine,	NN	O
7-deazaguanosine,	,	O
2-aminopyridine	,	O
and	JJ	O
2-pyridone.	CC	O
Further	.	O
nucleobases	JJ	O
include	NNS	O
those	VBP	O
disclosed	DT	O
in	VBN	O
U.S.	IN	O
Pat.	NNP	O
No.	.	O
3,687,808,	.	O
those	,	O
disclosed	DT	O
in	VBN	O
The	IN	O
Concise	DT	O
Encyclopedia	NNP	O
Of	NNP	O
Polymer	IN	O
Science	NNP	O
And	NNP	O
Engineering,	CC	O
pages	,	O
858-859,	VBZ	O
Kroschwitz,	,	O
J.	,	O
I.,	NNP	O
ed.	,	O
John	.	O
Wiley	NNP	O
&	NNP	O
Sons,	CC	O
1990,	,	O
those	,	O
disclosed	DT	O
by	VBN	O
Englisch	IN	O
et	NNP	O
al.,	FW	O
Angewandte	,	O
Chemie,	NNP	O
International	,	O
Edition,	NNP	O
1991,	,	O
30,	,	O
613,	,	O
and	,	O
those	CC	O
disclosed	DT	O
by	VBN	O
Sanghvi,	IN	B
Y.	,	I
S.,	NNP	I
Chapter	,	I
15,	NNP	I
Antisense	,	I
Research	NNP	I
and	NNP	I
Applications,	CC	I
pages	,	I
289-302,	VBZ	I
Crooke,	,	I
S.	,	I
T.	NNP	I
and	NNP	I
Lebleu,	CC	I
B.,	,	I
ed.,	,	I
CRC	,	I
Press,	NNP	I
1993.	,	I
Certain	.	O
of	NN	O
these	IN	O
nucleobases	DT	O
are	NNS	O
particularly	VBP	O
useful	RB	O
for	JJ	O
increasing	IN	O
the	VBG	O
binding	DT	O
affinity	NN	O
of	NN	O
the	IN	O
compounds	DT	O
of	NNS	O
the	IN	O
invention.	DT	O
These	.	O
include	DT	O
5-substituted	VBP	O
pyrimidines,	JJ	O
6-azapyrimidines	,	O
and	NNS	O
N-2,	CC	O
N-6	,	O
and	NNP	O
O-6	CC	O
substituted	NNP	O
purines,	VBD	O
including	,	O
2-aminopropyladenine,	VBG	O
5-propynyluracil	,	O
and	JJ	O
5-propynylcytosine.	CC	O
5-methylcytosine	.	O
substitutions	JJ	O
have	NNS	O
been	VBP	O
shown	VBN	O
to	VBN	O
increase	TO	O
nucleic	VB	O
acid	JJ	O
duplex	JJ	O
stability	JJ	O
by	NN	O
0.6-1.2°	IN	O
C.	JJ	O
and	NNP	O
are	CC	O
presently	VBP	O
preferred	RB	O
base	JJ	O
substitutions,	NN	O
even	,	O
more	RB	O
particularly	RBR	O
when	RB	O
combined	WRB	O
with	VBN	O
2′-O-methoxyethyl	IN	O
sugar	JJ	O
modifications.	NN	O
Representative	.	O
United	JJ	O
States	NNP	O
patents	NNPS	O
that	NNS	O
teach	WDT	O
the	VBP	O
preparation	DT	O
of	NN	O
certain	IN	O
of	JJ	O
the	IN	O
above	DT	O
noted	NN	O
modified	VBD	O
nucleobases	JJ	O
as	NNS	O
well	RB	O
as	RB	O
other	IN	O
modified	JJ	O
nucleobases	JJ	O
include,	NNS	O
but	,	O
are	CC	O
not	VBP	O
limited	RB	O
to,	VBN	O
the	,	O
above	DT	O
noted	NN	O
U.S.	VBD	O
Pat.	NNP	O
No.	.	O
3,687,808,	.	O
as	,	O
well	RB	O
as	RB	O
U.S.	IN	O
Pat.	NNP	O
Nos.	.	O
4,845,205;	.	O
5,130,302;	:	O
5,134,066;	:	O
5,175,273;	:	O
5,367,066;	:	O
5,432,272;	:	O
5,457,187;	:	O
5,459,255;	:	O
5,484,908;	:	O
5,502,177;	:	O
5,525,711;	:	O
5,552,540;	:	O
5,587,469;	:	O
5,594,121,	:	O
5,596,091;	,	O
5,614,617;	:	O
5,645,985;	:	O
5,830,653;	:	O
5,763,588;	:	O
6,005,096;	:	O
5,681,941;	:	O
and	:	O
5,570,692,	CC	O
each	,	O
of	DT	O
which	IN	O
is	WDT	O
herein	VBZ	O
incorporated	RB	O
by	VBN	O
reference.	IN	O
Conjugates	.	O
Another	VBZ	O
modification	DT	O
of	NN	O
the	IN	O
antisense	DT	O
compounds	JJ	O
of	NNS	O
the	IN	O
invention	DT	O
involves	NN	O
chemically	VBZ	O
linking	RB	O
to	VBG	O
the	TO	O
antisense	DT	O
compound	NN	O
one	NN	O
or	CD	O
more	CC	O
moieties	JJR	O
or	NNS	O
conjugates	CC	O
which	NNS	O
enhance	WDT	O
the	VBP	O
activity,	DT	O
cellular	,	O
distribution	JJ	O
or	NN	O
cellular	CC	O
uptake	JJ	O
of	NN	O
the	IN	O
oligonucleotide.	DT	O
These	.	O
moieties	DT	O
or	NNS	O
conjugates	CC	O
can	NNS	O
include	MD	O
conjugate	VB	O
groups	JJ	O
covalently	NNS	O
bound	RB	O
to	IN	O
functional	TO	O
groups	JJ	O
such	NNS	O
as	JJ	O
primary	IN	O
or	JJ	O
secondary	CC	O
hydroxyl	JJ	O
groups.	NN	O
Conjugate	.	O
groups	NNP	O
of	NNS	O
the	IN	O
invention	DT	O
include	NN	O
intercalators,	VBP	O
reporter	,	O
molecules,	NN	O
polyamines,	,	O
polyamides,	,	O
polyethylene	,	O
glycols,	NN	O
polyethers,	,	O
groups	,	O
that	NNS	O
enhance	WDT	O
the	VBP	O
pharmacodynamic	DT	O
properties	JJ	O
of	NNS	O
oligomers,	IN	O
and	,	O
groups	CC	O
that	NNS	O
enhance	WDT	O
the	VBP	O
pharmacokinetic	DT	O
properties	JJ	O
of	NNS	O
oligomers.	IN	O
Typical	.	O
conjugate	JJ	O
groups	NN	O
include	NNS	O
cholesterol,	VBP	O
lipids,	,	O
phospholipids,	,	O
biotin,	,	O
phenazine,	,	O
folate,	,	O
phenanthridine,	,	O
anthraquinone,	,	O
acridine,	,	O
fluoresceins,	,	O
rhodamines,	,	O
coumarins,	,	O
and	,	O
dyes.	CC	O
Groups	.	O
that	NNS	O
enhance	WDT	O
the	VBP	O
pharmacodynamic	DT	O
properties,	JJ	O
in	,	O
the	IN	O
context	DT	O
of	NN	O
this	IN	O
invention,	DT	O
include	,	O
groups	VBP	O
that	NNS	O
improve	WDT	O
uptake,	VBP	O
enhance	,	O
resistance	NN	O
to	NN	O
degradation,	TO	O
and/or	,	O
strengthen	JJ	O
sequence-specific	NN	O
hybridization	JJ	O
with	NN	O
the	IN	O
target	DT	O
nucleic	NN	O
acid.	JJ	O
Groups	.	O
that	NNS	O
enhance	WDT	O
the	VBP	O
pharmacokinetic	DT	O
properties,	JJ	O
in	,	O
the	IN	O
context	DT	O
of	NN	O
this	IN	O
invention,	DT	O
include	,	O
groups	VBP	O
that	NNS	O
improve	WDT	O
uptake,	VBP	O
distribution,	,	O
metabolism	,	O
or	NN	O
excretion	CC	O
of	NN	O
the	IN	O
compounds	DT	O
of	NNS	O
the	IN	O
present	DT	O
invention.	JJ	O
Representative	.	O
conjugate	JJ	O
groups	NN	O
are	NNS	O
disclosed	VBP	O
in	VBN	O
International	IN	O
Patent	NNP	O
Application	NNP	O
No.	NNP	O
PCT/US92/09196,	.	O
filed	,	O
Oct.	VBD	O
23,	NNP	O
1992,	,	O
and	,	O
U.S.	CC	O
Pat.	NNP	O
No.	.	O
6,287,860,	.	O
the	,	O
entire	DT	O
disclosures	JJ	O
of	NNS	O
which	IN	O
are	WDT	O
incorporated	VBP	O
herein	VBN	O
by	NN	O
reference.	IN	O
Conjugate	.	O
moieties	NNP	O
include	NNS	O
but	VBP	O
are	CC	O
not	VBP	O
limited	RB	O
to	VBN	O
lipid	TO	O
moieties	VB	O
such	NNS	O
as	JJ	O
a	IN	O
cholesterol	DT	O
moiety,	NN	O
cholic	,	O
acid,	JJ	O
a	,	O
thioether,	DT	O
e.g.,	,	O
hexyl-5-tritylthiol,	,	O
a	,	O
thiocholesterol,	DT	O
an	,	O
aliphatic	DT	O
chain,	JJ	O
e.g.,	,	O
dodecandiol	,	O
or	NN	O
undecyl	CC	O
residues,	JJ	O
a	,	O
phospholipid,	DT	O
e.g.,	,	O
di-hexadecyl-rac-glycerol	,	O
or	NN	O
triethylammonium	CC	O
1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate,	NN	O
a	,	O
polyamine	DT	O
or	NN	O
a	CC	O
polyethylene	DT	O
glycol	JJ	O
chain,	NN	O
or	,	O
adamantane	CC	O
acetic	RB	O
acid,	JJ	O
a	,	O
palmityl	DT	O
moiety,	NN	O
or	,	O
an	CC	O
octadecylamine	DT	O
or	JJ	O
hexylamino-carbonyl-oxycholesterol	CC	O
moiety.	JJ	O
Antisense	.	O
compounds	NNP	O
of	NNS	O
the	IN	O
invention	DT	O
may	NN	O
also	MD	O
be	RB	O
conjugated	VB	O
to	VBN	O
drug	TO	O
substances,	NN	O
for	,	O
example,	IN	O
aspirin,	,	O
warfarin,	,	O
phenylbutazone,	,	O
ibuprofen,	,	O
suprofen,	,	O
fenbufen,	,	O
ketoprofen,	,	O
(S)-(+)-pranoprofen,	,	O
carprofen,	,	O
dansylsarcosine,	,	O
2,3,5-triiodobenzoic	,	O
acid,	JJ	O
flufenamic	,	O
acid,	JJ	O
folinic	,	O
acid,	JJ	O
a	,	O
benzothiadiazide,	DT	O
chlorothiazide,	,	O
a	,	O
diazepine,	DT	O
indomethicin,	,	O
a	,	O
barbiturate,	DT	O
a	,	O
cephalosporin,	DT	O
a	,	O
sulfa	DT	O
drug,	JJ	O
an	,	O
antidiabetic,	DT	O
an	,	O
antibacterial	DT	O
or	NN	O
an	CC	O
antibiotic.	DT	O
Oligonucleotide-drug	.	O
conjugates	JJ	O
and	NNS	O
their	CC	O
preparation	PRP$	O
are	NN	O
described	VBP	O
in	VBN	O
U.S.	IN	O
Pat.	NNP	O
No.	.	O
6,656,730	.	O
which	CD	O
is	WDT	O
incorporated	VBZ	O
herein	VBN	O
by	NN	O
reference	IN	O
in	NN	O
its	IN	O
entirety.	PRP$	O
Representative	.	O
United	JJ	O
States	NNP	O
patents	NNPS	O
that	NNS	O
teach	WDT	O
the	VBP	O
preparation	DT	O
of	NN	O
such	IN	O
oligonucleotide	JJ	O
conjugates	JJ	O
include,	NNS	O
but	,	O
are	CC	O
not	VBP	O
limited	RB	O
to,	VBN	O
U.S.	,	O
Pat.	NNP	O
Nos.	.	O
4,828,979;	.	O
4,948,882;	:	O
5,218,105;	:	O
5,525,465;	:	O
5,541,313;	:	O
5,545,730;	:	O
5,552,538;	:	O
5,578,717,	:	O
5,580,731;	,	O
5,580,731;	:	O
5,591,584;	:	O
5,109,124;	:	O
5,118,802;	:	O
5,138,045;	:	O
5,414,077;	:	O
5,486,603;	:	O
5,512,439;	:	O
5,578,718;	:	O
5,608,046;	:	O
4,587,044;	:	O
4,605,735;	:	O
4,667,025;	:	O
4,762,779;	:	O
4,789,737;	:	O
4,824,941;	:	O
4,835,263;	:	O
4,876,335;	:	O
4,904,582;	:	O
4,958,013;	:	O
5,082,830;	:	O
5,112,963;	:	O
5,214,136;	:	O
5,082,830;	:	O
5,112,963;	:	O
5,214,136;	:	O
5,245,022;	:	O
5,254,469;	:	O
5,258,506;	:	O
5,262,536;	:	O
5,272,250;	:	O
5,292,873;	:	O
5,317,098;	:	O
5,371,241,	:	O
5,391,723;	,	O
5,416,203,	:	O
5,451,463;	,	O
5,510,475;	:	O
5,512,667;	:	O
5,514,785;	:	O
5,565,552;	:	O
5,567,810;	:	O
5,574,142;	:	O
5,585,481;	:	O
5,587,371;	:	O
5,595,726;	:	O
5,597,696;	:	O
5,599,923;	:	O
5,599,928	:	O
and	CD	O
5,688,941,	CC	O
each	,	O
of	DT	O
which	IN	O
is	WDT	O
herein	VBZ	O
incorporated	RB	O
by	VBN	O
reference.	IN	O
Oligomeric	.	O
compounds	NNP	O
used	NNS	O
in	VBN	O
the	IN	O
compositions	DT	O
of	NNS	O
the	IN	O
present	DT	O
invention	JJ	O
can	NN	O
also	MD	O
be	RB	O
modified	VB	O
to	VBN	O
have	TO	O
one	VB	O
or	CD	O
more	CC	O
stabilizing	JJR	O
groups	VBG	O
that	NNS	O
are	WDT	O
generally	VBP	O
attached	RB	O
to	VBN	O
one	TO	O
or	CD	O
both	CC	O
termini	DT	O
of	NNS	O
oligomeric	IN	O
compounds	JJ	O
to	NNS	O
enhance	TO	O
properties	VB	O
such	NNS	O
as	JJ	O
for	IN	O
example	IN	O
nuclease	NN	O
stability.	NN	O
Included	.	O
in	VBN	O
stabilizing	IN	O
groups	VBG	O
are	NNS	O
cap	VBP	O
structures.	JJ	O
By	.	O
“cap	IN	O
structure	JJ	O
or	NN	O
terminal	CC	O
cap	JJ	O
moiety”	NN	O
is	NN	O
meant	VBZ	O
chemical	JJ	O
modifications,	JJ	O
which	,	O
have	WDT	O
been	VBP	O
incorporated	VBN	O
at	VBN	O
either	IN	O
terminus	DT	O
of	NN	O
oligonucleotides	IN	O
(see	NNS	O
for	VB	O
example	IN	O
Wincott	NN	O
et	NNP	O
al.	VBZ	O
and	.	O
International	CC	O
Patent	NNP	O
Publication	NNP	O
No.	NNP	O
WO	.	O
97/26270,	NNP	O
incorporated	,	O
by	VBN	O
reference	IN	O
herein).	NN	O
These	.	O
terminal	DT	O
modifications	JJ	O
protect	NNS	O
the	VBP	O
oligomeric	DT	O
compounds	JJ	O
having	NNS	O
terminal	VBG	O
nucleic	JJ	O
acid	JJ	O
molecules	NN	O
from	NNS	O
exonuclease	IN	O
degradation,	JJ	O
and	,	O
can	CC	O
help	MD	O
in	VB	O
delivery	IN	O
and/or	NN	O
localization	NN	O
within	NN	O
a	IN	O
cell.	DT	O
The	.	O
cap	DT	O
can	NN	O
be	MD	O
present	VB	O
at	JJ	O
the	IN	O
5′-terminus	DT	O
(5′-cap)	JJ	O
or	)	O
at	CC	O
the	IN	O
3′-terminus	DT	O
(3′-cap)	JJ	O
or	)	O
at	CC	O
both	IN	O
termini.	DT	O
In	.	O
non-limiting	IN	O
examples,	JJ	O
the	,	O
5′-cap	DT	O
includes	JJ	O
inverted	VBZ	O
abasic	JJ	O
residue	JJ	O
(moiety),	NN	O
4′,5′-methylene	,	O
nucleotide;	JJ	O
1-(beta-D-erythrofuranosyl)	:	O
nucleotide,	)	O
4′-thio	,	O
nucleotide,	JJ	O
carbocyclic	,	O
nucleotide;	JJ	O
1,5-anhydrohexitol	:	O
nucleotide;	JJ	O
L-nucleotides;	:	O
alpha-nucleotides;	:	O
modified	:	O
base	VBN	O
nucleotide;	NN	O
phosphorodithioate	:	O
linkage;	JJ	O
threo-pentofuranosyl	:	O
nucleotide;	JJ	O
acyclic	:	O
3′,4′-seco	JJ	O
nucleotide;	JJ	O
acyclic	:	O
3,4-dihydroxybutyl	JJ	O
nucleotide;	JJ	O
acyclic	:	O
3,5-dihydroxypentyl	JJ	O
ribonucleotide,	JJ	O
3′-3′-inverted	,	O
nucleotide	JJ	O
moiety;	JJ	O
3′-3′-inverted	:	O
abasic	JJ	O
moiety;	JJ	O
3′-2′-inverted	:	O
nucleotide	JJ	O
moiety;	IN	O
3′-2′-inverted	:	O
abasic	JJ	O
moiety;	JJ	O
1,4-butanediol	:	O
phosphate;	JJ	O
3′-phosphoramidate;	:	O
hexylphosphate;	:	O
aminohexyl	:	O
phosphate;	JJ	O
3′-phosphate;	:	O
3′-phosphorothioate;	:	O
phosphorodithioate;	:	O
or	:	O
bridging	CC	O
or	VBG	O
non-bridging	CC	O
methylphosphonate	JJ	O
moiety	NN	O
(for	NN	O
more	IN	O
details	JJR	O
see	NNS	O
Wincott	VBP	O
et	NNP	O
al.,	FW	O
International	,	O
Patent	NNP	O
Publication	NNP	O
No.	NNP	O
WO	.	O
97/26270,	NNP	O
incorporated	,	O
by	VBN	O
reference	IN	O
herein).	NN	O
Particularly	.	O
preferred	RB	O
3′-cap	VBN	O
structures	JJ	O
of	NNS	O
the	IN	O
present	DT	O
invention	JJ	O
include,	NN	O
for	,	O
example	IN	O
4′,5′-methylene	NN	O
nucleotide;	JJ	O
1-(beta-D-erythrofuranosyl)	:	O
nucleotide;	)	O
4′-thio	:	O
nucleotide,	JJ	O
carbocyclic	,	O
nucleotide;	JJ	O
5′-amino-alkyl	:	O
phosphate;	JJ	O
1,3-diamino-2-propyl	:	O
phosphate,	JJ	O
3-aminopropyl	,	O
phosphate;	JJ	O
6-aminohexyl	:	O
phosphate;	JJ	O
1,2-aminododecyl	:	O
phosphate;	JJ	O
hydroxypropyl	:	O
phosphate;	JJ	O
1,5-anhydrohexitol	:	O
nucleotide;	JJ	O
L-nucleotide;	:	O
alpha-nucleotide;	:	O
modified	:	O
base	VBN	O
nucleotide;	NN	O
phosphorodithioate;	:	O
threo-pentofuranosyl	:	O
nucleotide;	JJ	O
acyclic	:	O
3′,4′-seco	JJ	O
nucleotide;	JJ	O
3,4-dihydroxybutyl	:	O
nucleotide;	JJ	O
3,5-dihydroxypentyl	:	O
nucleotide,	JJ	O
5′-5′-inverted	,	O
nucleotide	JJ	O
moiety;	JJ	O
5′-5′-inverted	:	O
abasic	JJ	O
moiety;	JJ	O
5′-phosphoramidate;	:	O
5′-phosphorothioate;	:	O
1,4-butanediol	:	O
phosphate;	JJ	O
5′-amino;	:	O
bridging	:	O
and/or	VBG	O
non-bridging	IN	O
5′-phosphoramidate,	JJ	O
phosphorothioate	,	O
and/or	JJ	O
phosphorodithioate,	NN	O
bridging	,	O
or	VBG	O
non	CC	O
bridging	JJ	O
methylphosphonate	NN	O
and	NN	O
5′-mercapto	CC	O
moieties	JJ	O
(for	NNS	O
more	IN	O
details	JJR	O
see	NNS	O
Beaucage	VBP	O
and	NNP	O
Tyer,	CC	O
1993,	,	O
Tetrahedron	,	O
49,	NNP	O
1925;	,	O
incorporated	:	O
by	VBN	O
reference	IN	O
herein).	NN	O
Further	.	O
3′	RB	O
and	CD	O
5′-stabilizing	CC	O
groups	JJ	O
that	NNS	O
can	WDT	O
be	MD	O
used	VB	O
to	VBN	O
cap	TO	O
one	VB	O
or	CD	O
both	CC	O
ends	DT	O
of	NNS	O
an	IN	O
oligomeric	DT	O
compound	JJ	O
to	NN	O
impart	TO	O
nuclease	VB	O
stability	JJ	O
include	NN	O
those	VBP	O
disclosed	DT	O
in	VBN	O
International	IN	O
Patent	NNP	O
Publication	NNP	O
No.	NNP	O
WO	.	O
03/004602,	NNP	O
published	,	O
Jan.	VBN	O
16,	NNP	O
2003.	,	O
Chimeric	.	O
Compounds	NNP	O
It	NNP	O
is	PRP	O
not	VBZ	O
necessary	RB	O
for	JJ	O
all	IN	O
positions	DT	O
in	NNS	O
a	IN	O
given	DT	O
compound	VBN	O
or	NN	O
oligonucleotide	CC	O
mimetic	JJ	O
to	JJ	O
be	TO	O
uniformly	VB	O
modified,	RB	O
and	,	O
in	CC	O
fact	IN	O
one	NN	O
or	CD	O
more	CC	O
of	JJR	O
the	IN	O
aforementioned	DT	O
modifications	JJ	O
may	NNS	O
be	MD	O
incorporated	VB	O
in	VBN	O
a	IN	O
single	DT	O
compound	JJ	O
or	NN	O
even	CC	O
at	RB	O
a	IN	O
single	DT	O
nucleoside	JJ	O
within	NN	O
an	IN	O
oligonucleotide.	DT	O
The	.	O
present	DT	O
invention	JJ	O
also	NN	O
includes	RB	O
antisense	VBZ	O
compounds	JJ	O
or	NNS	O
mimetics	CC	O
which	NNS	O
are	WDT	O
chimeric	VBP	O
compounds.	JJ	O
“Chimeric”	.	O
antisense	JJ	O
compounds	NN	O
or	NNS	O
“chimeras,”	CC	O
in	NN	O
the	IN	O
context	DT	O
of	NN	O
this	IN	O
invention,	DT	O
are	,	O
antisense	VBP	O
compounds,	JJ	O
particularly	,	O
oligonucleotides,	RB	O
which	,	O
contain	WDT	O
at	VBP	O
least	IN	O
two	JJS	O
chemically	CD	O
distinct	RB	O
regions,	JJ	O
each	,	O
made	DT	O
up	VBD	O
of	IN	O
at	IN	O
least	IN	O
one	JJS	O
monomer	CD	O
unit,	NN	O
i.e.,	,	O
a	,	O
nucleotide	DT	O
in	NN	O
the	IN	O
case	DT	O
of	NN	O
an	IN	O
oligonucleotide	DT	O
compound.	JJ	O
Chimeric	.	O
antisense	NNP	O
oligonucleotides	NN	O
are	NNS	O
thus	VBP	O
a	RB	O
form	DT	O
of	NN	O
antisense	IN	O
compound.	JJ	O
These	.	O
oligonucleotides	DT	O
typically	NNS	O
contain	RB	O
at	VBP	O
least	IN	O
one	JJS	O
chemically	CD	O
distinct	RB	O
region	JJ	O
wherein	NN	O
the	IN	O
oligonucleotide	DT	O
is	NN	O
modified	VBZ	O
so	VBN	O
as	RB	O
to	IN	O
confer	TO	O
upon	VB	O
the	IN	O
oligonucleotide	DT	O
increased	NN	O
resistance	VBD	O
to	NN	O
nuclease	TO	O
degradation,	VB	O
increased	,	O
cellular	VBD	O
uptake,	JJ	O
increased	,	O
stability	VBN	O
and/or	NN	O
increased	NN	O
binding	VBD	O
affinity	JJ	O
for	NN	O
the	IN	O
target	DT	O
nucleic	NN	O
acid.	JJ	O
An	.	O
additional	DT	O
chemically	JJ	O
distinct	NN	O
region	JJ	O
of	NN	O
the	IN	O
oligonucleotide	DT	O
may	NN	O
serve	MD	O
as	VB	O
a	IN	O
substrate	DT	O
for	NN	O
enzymes	IN	O
capable	NNS	O
of	JJ	O
cleaving	IN	O
RNA:DNA	VBG	O
or	NN	O
RNA:RNA	CC	O
hybrids.	JJ	O
By	.	O
way	IN	O
of	NN	O
example,	IN	O
RNase	,	O
H	NNP	O
is	NNP	O
a	VBZ	O
cellular	DT	O
endonuclease	JJ	O
which	NN	O
cleaves	WDT	O
the	VBZ	O
RNA	DT	O
strand	NNP	O
of	NN	O
an	IN	O
RNA:DNA	DT	O
duplex.	NN	O
Modifications	.	O
that	NNS	O
activate,	WDT	O
recruit	,	O
or	NN	O
trigger	CC	O
RNase	NN	O
H	NNP	O
and	NNP	O
result	CC	O
in	NN	O
cleavage	IN	O
of	NN	O
the	IN	O
RNA	DT	O
target	NNP	O
thereby	NN	O
greatly	RB	O
enhance	RB	O
the	VB	O
efficiency	DT	O
of	NN	O
oligonucleotide-mediated	IN	O
inhibition	JJ	O
of	NN	O
gene	IN	O
expression.	NN	O
The	.	O
cleavage	DT	O
of	NN	O
RNA:RNA	IN	O
hybrids	JJ	O
can,	NNS	O
in	,	O
like	IN	O
fashion,	JJ	O
be	,	O
accomplished	VB	O
through	VBN	O
the	IN	O
actions	DT	O
of	NNS	O
endoribonucleases	IN	O
such	NNS	O
as	JJ	O
RnaseL,	IN	O
which	,	O
cleaves	WDT	O
both	VBZ	O
cellular	DT	O
and	JJ	O
viral	CC	O
RNA.	JJ	O
Cleavage	.	O
of	NN	O
the	IN	O
RNA	DT	O
target	NNP	O
can	NN	O
be	MD	O
routinely	VB	O
detected	RB	O
by	VBN	O
gel	IN	O
electrophoresis	JJ	O
and,	NN	O
if	,	O
necessary,	IN	O
associated	,	O
nucleic	VBN	O
acid	JJ	O
hybridization	JJ	O
techniques	NN	O
known	NNS	O
in	VBN	O
the	IN	O
art.	DT	O
Preferred	.	O
chimeric	NNP	O
oligonucleotides	JJ	O
are	NNS	O
those	VBP	O
disclosed	DT	O
in	VBN	O
the	IN	O
Examples	DT	O
herein.	NNP	O
Particularly	.	O
preferred	RB	O
chimeric	VBN	O
oligonucleotides	JJ	O
are	NNS	O
those	VBP	O
referred	DT	O
to	JJ	O
as	TO	O
SEQ	IN	O
ID	NNP	O
NOS:	NNP	O
65,	:	O
26,	,	O
29,	,	O
and	,	O
35,	CC	O
as	,	O
well	RB	O
as	RB	O
those	IN	O
chimeric	DT	O
oligonucleotides	JJ	O
set	NNS	O
forth	VBD	O
in	NN	O
Tables	IN	O
2,	NNP	O
3,	,	O
14,	,	O
and	,	O
15	CC	O
and	CD	O
specified	CC	O
in	VBN	O
the	IN	O
Examples	DT	O
below.	NNP	O
Preferred	.	O
siRNAs	VBN	O
are	NNS	O
those	VBP	O
referred	DT	O
to	JJ	O
as	TO	O
SEQ	IN	O
ID	NNP	O
Nos:	NNP	O
238,	:	O
242,	,	O
243,	,	O
251,	,	O
and	,	O
252,	CC	O
as	,	O
well	RB	O
as	RB	O
those	IN	O
set	DT	O
forth	VBN	O
in	NN	O
Table	IN	O
11	JJ	O
and	CD	O
specified	CC	O
in	VBN	O
the	IN	O
Examples	DT	O
below.	NNP	O
Chimeric	.	O
antisense	NNP	O
compounds	NN	O
of	NNS	O
the	IN	O
invention	DT	O
may	NN	O
be	MD	O
formed	VB	O
as	VBN	O
composite	IN	O
structures	JJ	O
of	NNS	O
two	IN	O
or	CD	O
more	CC	O
oligonucleotides,	JJR	O
modified	,	O
oligonucleotides,	VBD	O
oligonucleosides	,	O
and/or	NNS	O
oligonucleotide	VBP	O
mimetics	RB	O
as	NNS	O
described	IN	O
above.	VBN	O
Chimeric	.	O
antisense	NNP	O
compounds	NN	O
can	NNS	O
be	MD	O
of	VB	O
several	IN	O
different	JJ	O
types.	JJ	O
These	.	O
include	DT	O
a	VBP	O
first	DT	O
type	JJ	O
wherein	NN	O
the	VBP	O
“gap”	DT	O
segment	NNP	O
of	NN	O
linked	IN	O
nucleosides	VBN	O
is	NNS	O
positioned	VBZ	O
between	VBN	O
5′	IN	O
and	CD	O
3′	CC	O
“wing”	CD	O
segments	JJ	O
of	NNS	O
linked	IN	O
nucleosides	VBN	O
and	NNS	O
a	CC	O
second	DT	O
“open	JJ	O
end”	JJ	O
type	NN	O
wherein	NN	O
the	VBD	O
“gap”	DT	O
segment	NNP	O
is	NN	O
located	VBZ	O
at	VBN	O
either	IN	O
the	CC	O
3′	DT	O
or	CD	O
the	CC	O
5′	DT	O
terminus	CD	O
of	NN	O
the	IN	O
chimeric	DT	O
antisense	JJ	O
compound.	NN	O
Compounds	.	O
of	NNS	O
the	IN	O
first	DT	O
type	JJ	O
are	NN	O
also	VBP	O
known	RB	O
in	VBN	O
the	IN	O
art	DT	O
as	NN	O
“gapmers”	IN	O
or	NN	O
gapped	CC	O
oligonucleotides.	VBD	O
Compounds	.	O
of	NNS	O
the	IN	O
second	DT	O
type	JJ	O
are	NN	O
also	VBP	O
known	RB	O
in	VBN	O
the	IN	O
art	DT	O
as	NN	O
“hemimers”	IN	O
or	NN	O
“wingmers”.	CC	O
Such	.	O
compounds	JJ	O
have	NNS	O
also	VBP	O
been	RB	O
referred	VBN	O
to	VBN	O
in	TO	O
the	IN	O
art	DT	O
as	NN	O
hybrids.	IN	O
In	.	O
a	IN	O
gapmer	DT	O
that	NN	O
is	WDT	O
20	VBZ	O
nucleotides	CD	O
in	NNS	O
length,	IN	O
a	,	O
gap	DT	O
or	NN	O
wing	CC	O
can	NN	O
be	MD	O
1,	VB	O
2,	,	O
3,	,	O
4,	,	O
5,	,	O
6,	,	O
7,	,	O
8,	,	O
9,	,	O
10,	,	O
11,	,	O
12,	,	O
13,	,	O
14,	,	O
15,	,	O
16,	,	O
17	,	O
or	CD	O
18	CC	O
nucleotides	CD	O
in	NNS	O
length.	IN	O
In	.	O
one	IN	O
embodiment,	CD	O
a	,	O
20-nucleotide	DT	O
gapmer	JJ	O
is	NN	O
comprised	VBZ	O
of	VBN	O
a	IN	O
gap	DT	O
8	NN	O
nucleotides	CD	O
in	NNS	O
length,	IN	O
flanked	,	O
on	VBN	O
both	IN	O
the	DT	O
5′	DT	O
and	CD	O
3′	CC	O
sides	CD	O
by	NNS	O
wings	IN	O
6	NNS	O
nucleotides	CD	O
in	NNS	O
length.	IN	O
In	.	O
another	IN	O
embodiment,	DT	O
a	,	O
20-nucleotide	DT	O
gapmer	JJ	O
is	NN	O
comprised	VBZ	O
of	VBN	O
a	IN	O
gap	DT	O
10	NN	O
nucleotides	CD	O
in	NNS	O
length,	IN	O
flanked	,	O
on	VBN	O
both	IN	O
the	DT	O
5′	DT	O
and	CD	O
3′	CC	O
sides	CD	O
by	NNS	O
wings	IN	O
5	NNS	O
nucleotides	CD	O
in	NNS	O
length.	IN	O
In	.	O
another	IN	O
embodiment,	DT	O
a	,	O
20-nucleotide	DT	O
gapmer	JJ	O
is	NN	O
comprised	VBZ	O
of	VBN	O
a	IN	O
gap	DT	O
12	NN	O
nucleotides	CD	O
in	NNS	O
length	IN	O
flanked	NN	O
on	VBN	O
both	IN	O
the	DT	O
5′	DT	O
and	CD	O
3′	CC	O
sides	CD	O
by	NNS	O
wings	IN	O
4	NNS	O
nucleotides	CD	O
in	NNS	O
length.	IN	O
In	.	O
a	IN	O
further	DT	O
embodiment,	JJ	O
a	,	O
20-nucleotide	DT	O
gapmer	JJ	O
is	NN	O
comprised	VBZ	O
of	VBN	O
a	IN	O
gap	DT	O
14	NN	O
nucleotides	CD	O
in	NNS	O
length	IN	O
flanked	NN	O
on	VBN	O
both	IN	O
the	DT	O
5′	DT	O
and	CD	O
3′	CC	O
sides	CD	O
by	NNS	O
wings	IN	O
3	NNS	O
nucleotides	CD	O
in	NNS	O
length.	IN	O
In	.	O
another	IN	O
embodiment,	DT	O
a	,	O
20-nucleotide	DT	O
gapmer	JJ	O
is	NN	O
comprised	VBZ	O
of	VBN	O
a	IN	O
gap	DT	O
16	NN	O
nucleotides	CD	O
in	NNS	O
length	IN	O
flanked	NN	O
on	VBN	O
both	IN	O
the	DT	O
5′	DT	O
and	CD	O
3′	CC	O
sides	CD	O
by	NNS	O
wings	IN	O
2	NNS	O
nucleotides	CD	O
in	NNS	O
length.	IN	O
In	.	O
a	IN	O
further	DT	O
embodiment,	JJ	O
a	,	O
20-nucleotide	DT	O
gapmer	JJ	O
is	NN	O
comprised	VBZ	O
of	VBN	O
a	IN	O
gap	DT	O
18	NN	O
nucleotides	CD	O
in	NNS	O
length	IN	O
flanked	NN	O
on	VBN	O
both	IN	O
the	DT	O
5′	DT	O
and	CD	O
3′	CC	O
ends	CD	O
by	NNS	O
wings	IN	O
1	NNS	O
nucleotide	CD	O
in	RB	O
length.	IN	O
Alternatively,	.	O
the	,	O
wings	DT	O
are	NNS	O
of	VBP	O
different	IN	O
lengths,	JJ	O
for	,	O
example,	IN	O
a	,	O
20-nucleotide	DT	O
gapmer	JJ	O
may	NN	O
be	MD	O
comprised	VB	O
of	VBN	O
a	IN	O
gap	DT	O
10	NN	O
nucleotides	CD	O
in	NNS	O
length,	IN	O
flanked	,	O
by	VBN	O
a	IN	O
6-nucleotide	DT	O
wing	JJ	O
on	NN	O
one	IN	O
side	CD	O
(5′	NN	O
or	CD	O
3′)	CC	O
and	)	O
a	CC	O
4-nucleotide	DT	O
wing	JJ	O
on	NN	O
the	IN	O
other	DT	O
side	JJ	O
(5′	NN	O
or	CD	O
3′).	CC	O
In	.	O
a	IN	O
hemimer,	DT	O
an	,	O
“open	DT	O
end”	JJ	O
chimeric	NN	O
antisense	JJ	O
compound	NN	O
having	NN	O
two	VBG	O
chemically	CD	O
distinct	RB	O
regions,	JJ	O
a	,	O
first	DT	O
chemically	JJ	O
distinct	RB	O
region,	JJ	O
or	,	O
the	CC	O
gap	DT	O
segment,	NN	O
in	,	O
a	IN	O
compound	DT	O
20	NN	O
nucleotides	CD	O
in	NNS	O
length	IN	O
can	NN	O
be	MD	O
located	VB	O
at	VBN	O
either	IN	O
the	CC	O
5′	DT	O
or	CD	O
3′	CC	O
terminus	CD	O
of	NN	O
the	IN	O
oligomeric	DT	O
compound,	JJ	O
can	,	O
be	MD	O
1,	VB	O
2,	,	O
3,	,	O
4,	,	O
5,	,	O
6,	,	O
7,	,	O
8,	,	O
9,	,	O
10,	,	O
11,	,	O
12,	,	O
13,	,	O
14,	,	O
15,	,	O
16,	,	O
17,	,	O
18	,	O
or	CD	O
19	CC	O
nucleotides	CD	O
in	NNS	O
length.	IN	O
A	.	O
second	DT	O
chemically	JJ	O
distinct	RB	O
region	JJ	O
in	NN	O
a	IN	O
compound	DT	O
20	NN	O
nucleotides	CD	O
in	NNS	O
length	IN	O
can	NN	O
be	MD	O
located	VB	O
at	VBN	O
the	IN	O
3′	DT	O
terminus	CD	O
of	NN	O
the	IN	O
compound	DT	O
and	NN	O
can	CC	O
be	MD	O
1,	VB	O
2,	,	O
3,	,	O
4,	,	O
5,	,	O
6,	,	O
7,	,	O
8,	,	O
9,	,	O
10,	,	O
11,	,	O
12,	,	O
13,	,	O
14,	,	O
15,	,	O
16,	,	O
17,	,	O
18	,	O
or	CD	O
19	CC	O
nucleotides	CD	O
in	NNS	O
length.	IN	O
For	.	O
example,	IN	O
a	,	O
20-nucleotide	DT	O
hemimer	JJ	O
can	NN	O
have	MD	O
a	VB	O
first	DT	O
chemically	JJ	O
distinct	RB	O
region,	JJ	O
or	,	O
a	CC	O
gap	DT	O
segment,	NN	O
of	,	O
10	IN	O
nucleotides	CD	O
at	NNS	O
the	IN	O
5′	DT	O
end	CD	O
and	NN	O
a	CC	O
second	DT	O
segment	JJ	O
of	NN	O
10	IN	O
nucleotides	CD	O
at	NNS	O
the	IN	O
3′	DT	O
end.	CD	O
Representative	.	O
United	JJ	O
States	NNP	O
patents	NNPS	O
that	NNS	O
teach	WDT	O
the	VBP	O
preparation	DT	O
of	NN	O
such	IN	O
hybrid	JJ	O
structures	JJ	O
include,	NNS	O
but	,	O
are	CC	O
not	VBP	O
limited	RB	O
to,	VBN	O
U.S.	,	O
Pat.	NNP	O
Nos.	.	O
5,013,830;	.	O
5,149,797;	:	O
5,220,007;	:	O
5,256,775;	:	O
5,366,878;	:	O
5,403,711;	:	O
5,491,133;	:	O
5,565,350;	:	O
5,623,065;	:	O
5,652,355;	:	O
5,652,356;	:	O
and	:	O
5,700,922,	CC	O
each	,	O
of	DT	O
which	IN	O
is	WDT	O
herein	VBZ	O
incorporated	RB	O
by	VBN	O
reference	IN	O
in	NN	O
its	IN	O
entirety.	PRP$	O
G.	.	O
Formulations	NNP	O
The	NNP	O
compounds	DT	O
of	NNS	O
the	IN	O
invention	DT	O
may	NN	O
also	MD	O
be	RB	O
admixed,	VB	O
encapsulated,	,	O
conjugated	,	O
or	VBD	O
otherwise	CC	O
associated	RB	O
with	VBN	O
other	IN	O
molecules,	JJ	O
molecule	,	O
structures	NN	O
or	NNS	O
mixtures	CC	O
of	NNS	O
compounds,	IN	O
as	,	O
for	IN	O
example,	IN	O
liposomes,	,	O
receptor-targeted	,	O
molecules,	JJ	O
oral,	,	O
rectal,	,	O
topical	,	O
or	JJ	O
other	CC	O
formulations,	JJ	O
for	,	O
assisting	IN	O
in	VBG	O
uptake,	IN	O
distribution	,	O
and/or	NN	O
absorption.	NN	O
Representative	.	O
United	JJ	O
States	NNP	O
patents	NNPS	O
that	NNS	O
teach	WDT	O
the	VBP	O
preparation	DT	O
of	NN	O
such	IN	O
uptake,	JJ	O
distribution	,	O
and/or	NN	O
absorption-assisting	IN	O
formulations	JJ	O
include,	NNS	O
but	,	O
are	CC	O
not	VBP	O
limited	RB	O
to,	VBN	O
U.S.	,	O
Pat.	NNP	O
Nos.	.	O
5,108,921;	.	O
5,354,844;	:	O
5,416,016;	:	O
5,459,127;	:	O
5,521,291;	:	O
5,543,158;	:	O
5,547,932;	:	O
5,583,020;	:	O
5,591,721;	:	O
4,426,330;	:	O
4,534,899;	:	O
5,013,556;	:	O
5,108,921;	:	O
5,213,804;	:	O
5,227,170;	:	O
5,264,221;	:	O
5,356,633;	:	O
5,395,619;	:	O
5,416,016;	:	O
5,417,978;	:	O
5,462,854;	:	O
5,469,854;	:	O
5,512,295;	:	O
5,527,528;	:	O
5,534,259;	:	O
5,543,152;	:	O
5,556,948;	:	O
5,580,575;	:	O
and	:	O
5,595,756,	CC	O
each	,	O
of	DT	O
which	IN	O
is	WDT	O
herein	VBZ	O
incorporated	RB	O
by	VBN	O
reference.	IN	O
The	.	O
antisense	DT	O
compounds	JJ	O
of	NNS	O
the	IN	O
invention	DT	O
encompass	NN	O
any	NN	O
pharmaceutically	DT	O
acceptable	RB	O
salts,	JJ	O
esters,	,	O
or	,	O
salts	CC	O
of	NNS	O
such	IN	O
esters,	JJ	O
or	,	O
any	CC	O
other	DT	O
compound	JJ	O
which,	NN	O
upon	,	O
administration	IN	O
to	NN	O
an	TO	O
animal,	DT	O
including	,	O
a	VBG	O
human,	DT	O
is	,	O
capable	VBZ	O
of	JJ	O
providing	IN	O
(directly	VBG	O
or	RB	O
indirectly)	CC	O
the	)	O
biologically	DT	O
active	RB	O
metabolite	JJ	O
or	NN	O
residue	CC	O
thereof.	JJ	O
Accordingly,	.	O
for	,	O
example,	IN	O
the	,	O
disclosure	DT	O
is	NN	O
also	VBZ	O
drawn	RB	O
to	VBN	O
prodrugs	TO	O
and	NNS	O
pharmaceutically	CC	O
acceptable	RB	O
salts	JJ	O
of	NNS	O
the	IN	O
compounds	DT	O
of	NNS	O
the	IN	O
invention,	DT	O
pharmaceutically	,	O
acceptable	RB	O
salts	JJ	O
of	NNS	O
such	IN	O
prodrugs,	JJ	O
and	,	O
other	CC	O
bioequivalents.	JJ	O
The	.	O
term	DT	O
“prodrug”	NN	O
indicates	NNP	O
a	VBZ	O
therapeutic	DT	O
agent	JJ	O
that	NN	O
is	WDT	O
prepared	VBZ	O
in	VBN	O
an	IN	O
inactive	DT	O
form	JJ	O
that	NN	O
is	WDT	O
converted	VBZ	O
to	VBN	O
an	TO	O
active	DT	O
form	JJ	O
(i.e.,	NN	O
drug)	,	O
within	)	O
the	IN	O
body	DT	O
or	NN	O
cells	CC	O
thereof	NNS	O
by	VBN	O
the	IN	O
action	DT	O
of	NN	O
endogenous	IN	O
enzymes	JJ	O
or	NNS	O
other	CC	O
chemicals	JJ	O
and/or	NNS	O
conditions.	JJ	O
In	.	O
particular,	IN	O
prodrug	,	O
versions	JJ	O
of	NNS	O
the	IN	O
oligonucleotides	DT	O
of	NNS	O
the	IN	O
invention	DT	O
are	NN	O
prepared	VBP	O
as	VBN	O
SATE	IN	O
[(S-acetyl-2-thioethyl)	NNP	O
phosphate]	)	O
derivatives	NN	O
according	NNS	O
to	VBG	O
the	TO	O
methods	DT	O
disclosed	NNS	O
in	VBN	O
International	IN	O
Patent	NNP	O
Publication	NNP	O
No.	NNP	O
WO	.	O
93/24510	$	O
to	CD	O
Gosselin	TO	O
et	NNP	O
al.,	FW	O
published	,	O
Dec.	VBN	O
9,	NNP	O
1993	,	O
or	CD	O
in	CC	O
International	IN	O
Patent	NNP	O
Publication	NNP	O
No.	NNP	O
WO	.	O
94/26764	$	O
and	CD	O
U.S.	CC	O
Pat.	NNP	O
No.	.	O
5,770,713	.	O
to	CD	O
Imbach	TO	O
et	NNP	O
al.	FW	O
The	.	O
term	DT	O
“pharmaceutically	NN	O
acceptable	RB	O
salts”	JJ	O
refers	NN	O
to	NNS	O
physiologically	TO	O
and	RB	O
pharmaceutically	CC	O
acceptable	RB	O
salts	JJ	O
of	NNS	O
the	IN	O
compounds	DT	O
of	NNS	O
the	IN	O
invention:	DT	O
i.e.,	:	O
salts	,	O
that	NNS	O
retain	WDT	O
the	VBP	O
desired	DT	O
biological	JJ	O
activity	JJ	O
of	NN	O
the	IN	O
parent	DT	O
compound	NN	O
and	NN	O
do	CC	O
not	VBP	O
impart	RB	O
undesired	VB	O
toxicological	JJ	O
effects	JJ	O
thereto.	NNS	O
For	.	O
oligonucleotides,	IN	O
preferred	,	O
examples	JJ	O
of	NNS	O
pharmaceutically	IN	O
acceptable	RB	O
salts	JJ	O
and	NNS	O
their	CC	O
uses	PRP$	O
are	NNS	O
further	VBP	O
described	JJ	O
in	VBN	O
U.S.	IN	O
Pat.	NNP	O
No.	.	O
6,287,860,	.	O
which	,	O
is	WDT	O
incorporated	VBZ	O
herein	VBN	O
in	NN	O
its	IN	O
entirety.	PRP$	O
Pharmaceutically	.	O
acceptable	RB	O
base	JJ	O
addition	NN	O
salts	NN	O
are	NNS	O
formed	VBP	O
with	VBN	O
metals	IN	O
or	NNS	O
amines,	CC	O
such	,	O
as	JJ	O
alkali	IN	O
and	NN	O
alkaline	CC	O
earth	JJ	O
metals	NN	O
or	NNS	O
organic	CC	O
amines.	JJ	O
Examples	.	O
of	NNS	O
metals	IN	O
used	NNS	O
as	VBN	O
cations	IN	O
are	NNS	O
sodium,	VBP	O
potassium,	,	O
magnesium,	,	O
calcium,	,	O
and	,	O
the	CC	O
like.	DT	O
Examples	.	O
of	NNS	O
suitable	IN	O
amines	JJ	O
are	NNS	O
N,N′-dibenzylethylenediamine,	VBP	O
chloroprocaine,	,	O
choline,	,	O
diethanolamine,	,	O
dicyclohexylamine,	,	O
ethylenediamine,	,	O
N-methylglucamine,	,	O
and	,	O
procaine	CC	O
(see,	NN	O
for	,	O
example,	IN	O
Berge	,	B
et	NNP	I
al.,	FW	I
“Pharmaceutical	,	I
Salts,”	JJ	I
J.	NNP	I
of	NNP	I
Pharma	IN	I
Sci.,	NNP	I
1977,	,	I
66,	,	I
1-19).The	,	O
base	.	O
addition	DT	O
salts	NN	O
of	NN	O
said	NNS	O
acidic	IN	O
compounds	VBD	O
are	JJ	O
prepared	NNS	O
by	VBP	O
contacting	VBN	O
the	IN	O
free	VBG	O
acid	DT	O
form	JJ	O
with	NN	O
a	NN	O
sufficient	IN	O
amount	DT	O
of	JJ	O
the	NN	O
desired	IN	O
base	DT	O
to	JJ	O
produce	NN	O
the	TO	O
salt	VB	O
in	DT	O
the	NN	O
conventional	IN	O
manner.	DT	O
The	JJ	O
free	.	O
acid	DT	O
form	JJ	O
may	NN	O
be	NN	O
regenerated	MD	O
by	VB	O
contacting	VBN	O
the	IN	O
salt	VBG	O
form	DT	O
with	NN	O
an	NN	O
acid	IN	O
and	DT	O
isolating	NN	O
the	CC	O
free	VBG	O
acid	DT	O
in	JJ	O
the	NN	O
conventional	IN	O
manner.	DT	O
The	JJ	O
free	.	O
acid	DT	O
forms	JJ	O
differ	NN	O
from	NNS	O
their	VBP	O
respective	IN	O
salt	PRP$	O
forms	JJ	O
somewhat	NN	O
in	NNS	O
certain	RB	O
physical	IN	O
properties	JJ	O
such	JJ	O
as	NNS	O
solubility	JJ	O
in	IN	O
polar	NN	O
solvents,	IN	O
but	JJ	O
otherwise	,	O
the	CC	O
salts	RB	O
are	DT	O
equivalent	NNS	O
to	VBP	O
their	JJ	O
respective	TO	O
free	PRP$	O
acid	JJ	O
for	JJ	O
purposes	NN	O
of	IN	O
the	NNS	O
present	IN	O
invention.	DT	O
As	JJ	O
used	.	O
herein,	IN	O
a	VBN	O
“pharmaceutical	,	O
addition	DT	O
salt”	JJ	O
includes	NN	O
a	NN	O
pharmaceutically	VBZ	O
acceptable	DT	O
salt	RB	O
of	JJ	O
an	NN	O
acid	IN	O
form	DT	O
of	JJ	O
one	NN	O
of	IN	O
the	CD	O
components	IN	O
of	DT	O
the	NNS	O
compositions	IN	O
of	DT	O
the	NNS	O
invention.	IN	O
These	DT	O
include	.	O
organic	DT	O
or	VBP	O
inorganic	JJ	O
acid	CC	O
salts	JJ	O
of	NN	O
the	NNS	O
amines.	IN	O
Preferred	DT	O
acid	.	O
salts	NNP	O
are	NN	O
the	NNS	O
hydrochlorides,	VBP	O
acetates,	DT	O
salicylates,	,	O
nitrates	,	O
and	,	O
phosphates.	NNS	O
Other	CC	O
suitable	.	O
pharmaceutically	JJ	O
acceptable	JJ	O
salts	RB	O
are	JJ	O
well	NNS	O
known	VBP	O
to	RB	O
those	VBN	O
skilled	TO	O
in	DT	O
the	VBN	O
art	IN	O
and	DT	O
include	NN	O
basic	CC	O
salts	VBP	O
of	JJ	O
a	NNS	O
variety	IN	O
of	DT	O
inorganic	NN	O
and	IN	O
organic	JJ	O
acids,	CC	O
such	JJ	O
as,	,	O
for	JJ	O
example,	,	O
with	IN	O
inorganic	,	O
acids,	IN	O
such	JJ	O
as	,	O
for	JJ	O
example	IN	O
hydrochloric	IN	O
acid,	NN	O
hydrobromic	JJ	O
acid,	,	O
sulfuric	JJ	O
acid	,	O
or	JJ	O
phosphoric	NN	O
acid;	CC	O
with	JJ	O
organic	:	O
carboxylic,	IN	O
sulfonic,	JJ	O
sulfo	,	O
or	,	O
phospho	JJ	O
acids	CC	O
or	JJ	O
N-substituted	NNS	O
sulfamic	CC	O
acids,	JJ	O
for	JJ	O
example	,	O
acetic	IN	O
acid,	NN	O
propionic	JJ	O
acid,	,	O
glycolic	JJ	O
acid,	,	O
succinic	JJ	O
acid,	,	O
maleic	JJ	O
acid,	,	O
hydroxymaleic	JJ	O
acid,	,	O
methylmaleic	JJ	O
acid,	,	O
fumaric	JJ	O
acid,	,	O
malic	JJ	O
acid,	,	O
tartaric	JJ	O
acid,	,	O
lactic	JJ	O
acid,	,	O
oxalic	JJ	O
acid,	,	O
gluconic	JJ	O
acid,	,	O
glucaric	JJ	O
acid,	,	O
glucuronic	JJ	O
acid,	,	O
citric	JJ	O
acid,	,	O
benzoic	JJ	O
acid,	,	O
cinnamic	NN	O
acid,	,	O
mandelic	JJ	O
acid,	,	O
salicylic	JJ	O
acid,	,	O
4-aminosalicylic	JJ	O
acid,	,	O
2-phenoxybenzoic	JJ	O
acid,	,	O
2-acetoxybenzoic	JJ	O
acid,	,	O
embonic	JJ	O
acid,	,	O
nicotinic	JJ	O
acid	,	O
or	JJ	O
isonicotinic	NN	O
acid;	CC	O
and	JJ	O
with	:	O
amino	CC	O
acids,	IN	O
such	JJ	O
as	,	O
the	JJ	O
20	IN	O
alpha-amino	DT	O
acids	CD	O
involved	JJ	O
in	NNS	O
the	VBN	O
synthesis	IN	O
of	DT	O
proteins	NN	O
in	IN	O
nature,	NNS	O
for	IN	O
example	,	O
glutamic	IN	O
acid	NN	O
or	JJ	O
aspartic	NN	O
acid,	CC	O
and	JJ	O
also	,	O
with	CC	O
phenylacetic	RB	O
acid,	IN	O
methanesulfonic	JJ	O
acid,	,	O
ethanesulfonic	JJ	O
acid,	,	O
2-hydroxyethanesulfonic	JJ	O
acid,	,	O
ethane-1,2-disulfonic	JJ	O
acid,	,	O
benzenesulfonic	JJ	O
acid,	,	O
4-methylbenzenesulfonic	JJ	O
acid,	,	O
naphthalene-2-sulfonic	JJ	O
acid,	,	O
naphthalene-1,5-disulfonic	JJ	O
acid,	,	O
2-	JJ	O
or	,	O
3-phosphoglycerate,	JJ	O
glucose-6-phosphate,	CC	O
N-cyclohexylsulfamic	,	O
acid	,	O
(with	JJ	O
the	NN	O
formation	IN	O
of	DT	O
cyclamates),	NN	O
or	IN	O
with	,	O
other	CC	O
acid	IN	O
organic	JJ	O
compounds,	JJ	O
such	JJ	O
as	,	O
ascorbic	JJ	O
acid.	IN	O
Pharmaceutically	JJ	O
acceptable	.	O
salts	RB	O
of	JJ	O
compounds	NNS	O
may	IN	O
also	NNS	O
be	MD	O
prepared	RB	O
with	VB	O
a	VBN	O
pharmaceutically	IN	O
acceptable	DT	O
cation.	RB	O
Suitable	JJ	O
pharmaceutically	.	O
acceptable	JJ	O
cations	RB	O
are	JJ	O
well	NNS	O
known	VBP	O
to	RB	O
those	VBN	O
skilled	TO	O
in	DT	O
the	VBN	O
art	IN	O
and	DT	O
include	NN	O
alkaline,	CC	O
alkaline	VBP	O
earth,	,	O
ammonium	JJ	O
and	,	O
quaternary	NN	O
ammonium	CC	O
cations.	JJ	O
Carbonates	NN	O
or	.	O
hydrogen	NNS	O
carbonates	CC	O
are	NN	O
also	NNS	O
possible.	VBP	O
For	RB	O
oligonucleotides,	.	O
preferred	IN	O
examples	,	O
of	JJ	O
pharmaceutically	NNS	O
acceptable	IN	O
salts	RB	O
include	JJ	O
but	NNS	O
are	VBP	O
not	CC	O
limited	VBP	O
to	RB	O
(a)	VBN	O
salts	TO	O
formed	)	O
with	NNS	O
cations	VBN	O
such	IN	O
as	NNS	O
sodium,	JJ	O
potassium,	IN	O
ammonium,	,	O
magnesium,	,	O
calcium,	,	O
polyamines	,	O
such	,	O
as	NNS	O
spermine	JJ	O
and	IN	O
spermidine,	NN	O
etc.;	CC	O
(b)	,	O
acid	:	O
addition	)	O
salts	NN	O
formed	NN	O
with	NNS	O
inorganic	VBN	O
acids,	IN	O
for	JJ	O
example	,	O
hydrochloric	IN	O
acid,	NN	O
hydrobromic	JJ	O
acid,	,	O
sulfuric	JJ	O
acid,	,	O
phosphoric	JJ	O
acid,	,	O
nitric	JJ	O
acid	,	O
and	JJ	O
the	NN	O
like;	CC	O
(c)	DT	O
salts	:	O
formed	)	O
with	NNS	O
organic	VBN	O
acids	IN	O
such	JJ	O
as,	NNS	O
for	JJ	O
example,	,	O
acetic	IN	O
acid,	,	O
oxalic	JJ	O
acid,	,	O
tartaric	JJ	O
acid,	,	O
succinic	JJ	O
acid,	,	O
maleic	JJ	O
acid,	,	O
fumaric	JJ	O
acid,	,	O
gluconic	JJ	O
acid,	,	O
citric	JJ	O
acid,	,	O
malic	JJ	O
acid,	,	O
ascorbic	JJ	O
acid,	,	O
benzoic	JJ	O
acid,	,	O
tannic	NN	O
acid,	,	O
palmitic	JJ	O
acid,	,	O
alginic	JJ	O
acid,	,	O
polyglutamic	JJ	O
acid,	,	O
naphthalenesulfonic	JJ	O
acid,	,	O
methanesulfonic	JJ	O
acid,	,	O
p-toluenesulfonic	JJ	O
acid,	,	O
naphthalenedisulfonic	JJ	O
acid,	,	O
polygalacturonic	JJ	O
acid,	,	O
and	JJ	O
the	,	O
like;	CC	O
and	DT	O
(d)	:	O
salts	CC	O
formed	)	O
from	NNS	O
elemental	VBN	O
anions	IN	O
such	JJ	O
as	NNS	O
chlorine,	JJ	O
bromine,	IN	O
and	,	O
iodine.	,	O
The	CC	O
present	.	O
invention	DT	O
also	JJ	O
includes	NN	O
pharmaceutical	RB	O
compositions	VBZ	O
and	JJ	O
formulations	NNS	O
which	CC	O
include	NNS	O
the	WDT	O
antisense	VBP	O
compounds	DT	O
of	JJ	O
the	NNS	O
invention.	IN	O
The	DT	O
pharmaceutical	.	O
compositions	DT	O
of	JJ	O
the	NNS	O
present	IN	O
invention	DT	O
may	JJ	O
be	NN	O
administered	MD	O
in	VB	O
a	VBN	O
number	IN	O
of	DT	O
ways	NN	O
depending	IN	O
upon	NNS	O
whether	VBG	O
local	IN	O
or	IN	O
systemic	JJ	O
treatment	CC	O
is	JJ	O
desired	NN	O
and	VBZ	O
upon	VBN	O
the	CC	O
area	IN	O
to	DT	O
be	NN	O
treated.	TO	O
Administration	VB	O
may	.	O
be	NN	O
topical	MD	O
(including	VB	O
ophthalmic	JJ	O
and	VBG	O
to	JJ	O
mucous	CC	O
membranes	TO	O
including	JJ	O
vaginal	NNS	O
and	VBG	O
rectal	JJ	O
delivery),	CC	O
pulmonary,	JJ	O
e.g.,	,	O
by	,	O
inhalation	,	O
or	IN	O
insufflation	NN	O
of	CC	O
powders	NN	O
or	IN	O
aerosols,	NNS	O
including	CC	O
by	,	O
nebulizer;	VBG	O
intratracheal,	IN	O
intranasal,	:	O
epidermal	,	O
and	,	O
transdermal),	JJ	O
oral	CC	O
or	,	O
parenteral.	JJ	O
Parenteral	CC	O
administration	.	O
includes	JJ	O
intravenous,	NN	O
intraarterial,	VBZ	O
subcutaneous,	,	O
intraperitoneal	,	O
or	,	O
intramuscular	JJ	O
injection	CC	O
or	JJ	O
infusion;	NN	O
or	CC	O
intracranial,	:	O
e.g.,	CC	O
intrathecal	,	O
or	,	O
intraventricular,	JJ	O
administration.	CC	O
Oligonucleotides	,	O
with	.	O
at	NNS	O
least	IN	O
one	IN	O
2′-O-methoxyethyl	JJS	O
modification	CD	O
are	JJ	O
believed	NN	O
to	VBP	O
be	VBN	O
particularly	TO	O
useful	VB	O
for	RB	O
oral	JJ	O
administration.	IN	O
Pharmaceutical	JJ	O
compositions	.	O
and	JJ	O
formulations	NNS	O
for	CC	O
topical	NNS	O
administration	IN	O
may	JJ	O
include	NN	O
transdermal	MD	O
patches,	VB	O
ointments,	JJ	O
lotions,	,	O
creams,	,	O
gels,	,	O
drops,	,	O
suppositories,	,	O
sprays,	,	O
liquids	,	O
and	,	O
powders.	NNS	O
Conventional	CC	O
pharmaceutical	.	O
carriers,	JJ	O
aqueous,	JJ	O
powder	,	O
or	,	O
oily	NN	O
bases,	CC	O
thickeners	RB	O
and	,	O
the	NNS	O
like	CC	O
may	DT	O
be	JJ	O
necessary	MD	O
or	VB	O
desirable.	JJ	O
Coated	CC	O
condoms,	.	O
gloves	VBN	O
and	,	O
the	NNS	O
like	CC	O
may	DT	O
also	JJ	O
be	MD	O
useful.	RB	O
Preferred	VB	O
topical	.	O
formulations	NNP	O
include	JJ	O
those	NNS	O
in	VBP	O
which	DT	O
the	IN	O
oligonucleotides	WDT	O
of	DT	O
the	NNS	O
invention	IN	O
are	DT	O
in	NN	O
admixture	VBP	O
with	IN	O
a	NN	O
topical	IN	O
delivery	DT	O
agent	JJ	O
such	NN	O
as	NN	O
lipids,	JJ	O
liposomes,	IN	O
fatty	,	O
acids,	,	O
fatty	JJ	O
acid	,	O
esters,	JJ	O
steroids,	NN	O
chelating	,	O
agents	,	O
and	VBG	O
surfactants.	NNS	O
Preferred	CC	O
lipids	.	O
and	NNP	O
liposomes	NNS	O
include	CC	O
neutral	NNS	O
(e.g.	VBP	O
dioleoylphosphatidyl	JJ	O
DOPE	.	O
ethanolamine,	NNS	O
dimyristoylphosphatidyl	NNP	O
choline	,	O
DMPC,	JJ	O
distearolyphosphatidyl	NN	O
choline)	,	O
negative	JJ	O
(e.g.	)	O
dimyristoylphosphatidyl	NN	O
glycerol	.	O
DMPG)	NN	O
and	NN	O
cationic	)	O
(e.g.	CC	O
dioleoyltetramethylaminopropyl	JJ	O
DOTAP	.	O
and	NN	O
dioleoylphosphatidyl	NNP	O
ethanolamine	CC	O
DOTMA).	JJ	O
Oligonucleotides	NN	O
of	.	O
the	NNS	O
invention	IN	O
may	DT	O
be	NN	O
encapsulated	MD	O
within	VB	O
liposomes	VBN	O
or	IN	O
may	NNS	O
form	CC	O
complexes	MD	O
thereto,	VB	O
in	NNS	O
particular	,	O
to	IN	O
cationic	JJ	O
liposomes.	TO	O
Alternatively,	JJ	O
oligonucleotides	.	O
may	,	O
be	NNS	O
complexed	MD	O
to	VB	O
lipids,	VBN	O
in	TO	O
particular	,	O
to	IN	O
cationic	JJ	O
lipids.	TO	O
Preferred	JJ	O
fatty	.	O
acids	NNP	O
and	JJ	O
esters	NNS	O
include	CC	O
but	NNS	O
are	VBP	O
not	CC	O
limited	VBP	O
arachidonic	RB	O
acid,	JJ	O
oleic	JJ	O
acid,	,	O
eicosanoic	JJ	O
acid,	,	O
lauric	JJ	O
acid,	,	O
caprylic	JJ	O
acid,	,	O
capric	JJ	O
acid,	,	O
myristic	JJ	O
acid,	,	O
palmitic	JJ	O
acid,	,	O
stearic	JJ	O
acid,	,	O
linoleic	JJ	O
acid,	,	O
linolenic	JJ	O
acid,	,	O
dicaprate,	JJ	O
tricaprate,	,	O
monoolein,	,	O
dilaurin,	,	O
glyceryl	,	O
1-monocaprate,	,	O
1-dodecylazacycloheptan-2-one,	JJ	O
an	,	O
acylcarnitine,	,	O
an	DT	O
acylcholine,	,	O
or	DT	O
a	,	O
C1-10alkyl	CC	O
ester	DT	O
(e.g.	JJ	O
isopropylmyristate	NN	O
IPM),	.	O
monoglyceride,	VB	O
diglyceride	,	O
or	,	O
pharmaceutically	NN	O
acceptable	CC	O
salt	RB	O
thereof.	JJ	O
Topical	NN	O
formulations	.	O
are	JJ	O
described	NNS	O
in	VBP	O
detail	VBN	O
in	IN	O
U.S.	NN	O
Pat.	IN	O
No.	NNP	O
6,747,014,	.	O
which	.	O
is	,	O
incorporated	WDT	O
herein	VBZ	O
by	VBN	O
reference	NN	O
in	IN	O
its	NN	O
entirety.	IN	O
In	PRP$	O
some	.	O
embodiments,	IN	O
an	DT	O
oligonucleotide	,	O
may	DT	O
be	NN	O
administered	MD	O
to	VB	O
a	VBN	O
subject	TO	O
via	DT	O
an	NN	O
oral	IN	O
route	DT	O
of	JJ	O
administration.	NN	O
The	IN	O
subjects	.	O
of	DT	O
the	NNS	O
present	IN	O
invention	DT	O
comprise	JJ	O
animals.	NN	O
An	NN	O
animal	.	O
subject	DT	O
may	JJ	O
be	NN	O
a	MD	O
mammal,	VB	O
such	DT	O
as	,	O
a	JJ	O
mouse,	IN	O
a	DT	O
rat,	,	O
a	DT	O
dog,	,	O
a	DT	O
guinea	,	O
pig,	DT	O
a	NN	O
human,	,	O
a	DT	O
non-human	,	O
primate,	DT	O
a	JJ	O
cat	,	O
or	DT	O
a	NN	O
pig.	CC	O
Non-human	DT	O
primates	.	O
include	JJ	O
monkeys	NNS	O
and	VBP	O
chimpanzees.	NNS	O
A	CC	O
suitable	.	O
animal	DT	O
subject	JJ	O
may	NN	O
be	NN	O
an	MD	O
experimental	VB	O
animal,	DT	O
such	JJ	O
as	,	O
a	JJ	O
mouse,	IN	O
a	DT	O
rat,	,	O
a	DT	O
dog,	,	O
a	DT	O
non-human	,	O
primate,	DT	O
a	JJ	O
cat	,	O
or	DT	O
a	NN	O
pig.	CC	O
In	DT	O
some	.	O
embodiments,	IN	O
the	DT	O
subject	,	O
may	DT	O
be	NN	O
a	MD	O
human.	VB	O
In	DT	O
certain	.	O
embodiments,	IN	O
the	JJ	O
subject	,	O
may	DT	O
be	NN	O
a	MD	O
human	VB	O
patient	DT	O
as	JJ	O
discussed	NN	O
in	IN	O
more	VBN	O
detail	IN	O
herein.	JJR	O
In	NN	O
certain	.	O
embodiments,	IN	O
it	JJ	O
may	,	O
be	PRP	O
necessary	MD	O
to	VB	O
modulate	JJ	O
the	TO	O
expression	VB	O
of	DT	O
one	NN	O
or	IN	O
more	CD	O
genes	CC	O
of	JJR	O
the	NNS	O
human	IN	O
patient.	DT	O
In	JJ	O
some	.	O
particular	IN	O
embodiments,	DT	O
it	JJ	O
may	,	O
be	PRP	O
necessary	MD	O
to	VB	O
inhibit	JJ	O
expression	TO	O
of	VB	O
one	NN	O
or	IN	O
more	CD	O
genes	CC	O
of	JJR	O
the	NNS	O
human	IN	O
patient.	DT	O
In	JJ	O
particular	.	O
embodiments,	IN	O
it	JJ	O
may	,	O
be	PRP	O
necessary	MD	O
to	VB	O
modulate,	JJ	O
i.e.	TO	O
inhibit	,	O
or	.	O
enhance,	NN	O
diacylglycerol	CC	O
acyltransferase	,	O
2	NN	O
in	NN	O
order	CD	O
to	IN	O
obtain	NN	O
therapeutic	TO	O
outcomes	VB	O
discussed	JJ	O
herein.	NNS	O
In	VBN	O
some	.	O
embodiments,	IN	O
non-parenteral	DT	O
(e.g.	,	O
oral)	JJ	O
oligonucleotide	.	O
formulations	)	O
according	IN	O
to	NNS	O
the	VBG	O
present	TO	O
invention	DT	O
result	JJ	O
in	NN	O
enhanced	NN	O
bioavailability	IN	O
of	JJ	O
the	NN	O
oligonucleotide.	IN	O
In	DT	O
this	.	O
context,	IN	O
the	DT	O
term	,	O
“bioavailability”	DT	O
refers	NN	O
to	VBZ	O
a	NNS	O
measurement	TO	O
of	DT	O
that	NN	O
portion	IN	O
of	DT	O
an	NN	O
administered	IN	O
drug	DT	O
which	VBN	O
reaches	NN	O
the	WDT	O
circulatory	VBZ	O
system	DT	O
(e.g.	NN	O
blood,	NN	O
especially	.	O
blood	,	O
plasma)	RB	O
when	JJ	O
a	)	O
particular	WRB	O
mode	DT	O
of	JJ	O
administration	NN	O
is	IN	O
used	NN	O
to	VBZ	O
deliver	VBN	O
the	TO	O
drug.	VB	O
Enhanced	DT	O
bioavailability	.	O
refers	NNP	O
to	NN	O
a	NNS	O
particular	TO	O
mode	DT	O
of	JJ	O
administration's	NN	O
ability	IN	O
to	POS	O
deliver	NN	O
oligonucleotide	TO	O
to	VB	O
the	RB	O
peripheral	TO	O
blood	DT	O
plasma	JJ	O
of	NN	O
a	NN	O
subject	IN	O
relative	DT	O
to	JJ	O
another	NN	O
mode	TO	O
of	DT	O
administration.	NN	O
For	IN	O
example,	.	O
when	IN	O
a	,	O
non-parenteral	WRB	O
mode	DT	O
of	JJ	O
administration	NN	O
(e.g.	IN	O
an	NN	O
oral	.	O
mode)	DT	O
is	JJ	O
used	)	O
to	VBZ	O
introduce	VBN	O
the	TO	O
drug	VB	O
into	DT	O
a	NN	O
subject,	IN	O
the	DT	O
bioavailability	,	O
for	DT	O
that	NN	O
mode	IN	O
of	DT	O
administration	NN	O
may	IN	O
be	NN	O
compared	MD	O
to	VB	O
a	VBN	O
different	TO	O
mode	DT	O
of	JJ	O
administration,	NN	O
e.g.	IN	O
an	,	O
IV	.	O
mode	DT	O
of	NNP	O
administration.	NN	O
In	IN	O
some	.	O
embodiments,	IN	O
the	DT	O
area	,	O
under	DT	O
a	NN	O
compound's	IN	O
blood	DT	O
plasma	POS	O
concentration	NN	O
curve	NN	O
(AUC0)	NN	O
after	NN	O
non-parenteral	)	O
administration	IN	O
may	JJ	O
be	NN	O
divided	MD	O
by	VB	O
the	VBN	O
area	IN	O
under	DT	O
the	NN	O
drug's	IN	O
plasma	DT	O
concentration	POS	O
curve	JJ	O
after	NN	O
intravenous	NN	O
(i.v.)	IN	O
administration	JJ	O
(AUCiv)	)	O
to	NN	O
provide	)	O
a	TO	O
dimensionless	VB	O
quotient	DT	O
(relative	JJ	O
bioavailability,	NN	O
RB)	JJ	O
that	,	O
represents	)	O
fraction	WDT	O
of	VBZ	O
compound	NN	O
absorbed	IN	O
via	NN	O
the	VBN	O
non-parenteral	IN	O
route	DT	O
as	JJ	O
compared	NN	O
to	IN	O
the	VBN	O
IV	TO	O
route.	DT	O
A	NNP	O
composition's	.	O
bioavailability	DT	O
is	POS	O
said	NN	O
to	VBZ	O
be	VBD	O
enhanced	TO	O
in	VB	O
comparison	VBN	O
to	IN	O
another	NN	O
composition's	TO	O
bioavailability	DT	O
when	POS	O
the	NN	O
first	WRB	O
composition's	DT	O
relative	JJ	O
bioavailability	POS	O
(RB1)	JJ	O
is	NN	O
greater	)	O
than	VBZ	O
the	JJR	O
second	IN	O
composition's	DT	O
relative	JJ	O
bioavailability	POS	O
(RB2).	JJ	O
In	NN	O
general,	.	O
bioavailability	IN	O
correlates	,	O
with	NN	O
therapeutic	NNS	O
efficacy	IN	O
when	JJ	O
a	NN	O
compound's	WRB	O
therapeutic	DT	O
efficacy	POS	O
is	JJ	O
related	NN	O
to	VBZ	O
the	VBN	O
blood	TO	O
concentration	DT	O
achieved,	NN	O
even	NN	O
if	,	O
the	RB	O
drug's	IN	O
ultimate	DT	O
site	POS	O
of	JJ	O
action	NN	O
is	IN	O
intracellular	NN	O
(van	VBZ	O
Berge-Henegouwen	JJ	O
et	JJ	O
al.,	NNP	O
Gastroenterol.,	NN	O
1977,	,	O
73,	,	O
300).	,	O
Bioavailability	,	O
studies	.	O
have	NNP	O
been	NNS	O
used	VBP	O
to	VBN	O
determine	VBN	O
the	TO	O
degree	VB	O
of	DT	O
intestinal	NN	O
absorption	IN	O
of	JJ	O
a	NN	O
drug	IN	O
by	DT	O
measuring	NN	O
the	IN	O
change	VBG	O
in	DT	O
peripheral	NN	O
blood	IN	O
levels	JJ	O
of	NN	O
the	NNS	O
drug	IN	O
after	DT	O
an	NN	O
oral	IN	O
dose	DT	O
DiSanto,	JJ	B
Chapter	NN	I
76	,	I
In:	NNP	I
Remington's	CD	I
Pharmaceutical	:	I
Sciences,	POS	I
18th	NNP	I
Ed.,	,	I
Gennaro,	CD	I
ed.,	,	I
Mack	,	I
Publishing	,	I
Co.,	NNP	I
Easton,	NNP	I
Pa.,	,	I
1990,	,	I
pages	,	I
1451-1458).(	,	O
In	VBZ	O
general,	.	O
the	IN	O
bioavailability	,	O
of	DT	O
an	NN	O
oral	IN	O
composition	DT	O
(comprising	JJ	O
an	NN	O
oligonucleotide)	VBG	O
is	DT	O
said	)	O
to	VBZ	O
be	VBD	O
“enhanced”	TO	O
when	VB	O
its	JJ	O
relative	WRB	O
bioavailability	PRP$	O
is	JJ	O
greater	NN	O
than	VBZ	O
the	JJR	O
bioavailability	IN	O
of	DT	O
a	NN	O
composition	IN	O
substantially	DT	O
consisting	NN	O
of	RB	O
pure	VBG	O
oligonucleotide,	IN	O
i.e.	JJ	O
oligonucleotide	,	O
in	.	O
the	RB	O
absence	IN	O
of	DT	O
a	NN	O
penetration	IN	O
enhancer.	DT	O
Organ	NN	O
bioavailability	.	O
refers	NNP	O
to	NN	O
the	NNS	O
concentration	TO	O
of	DT	O
compound	NN	O
in	IN	O
an	NN	O
organ.	IN	O
Organ	DT	O
bioavailability	.	O
may	NNP	O
be	NN	O
measured	MD	O
in	VB	O
test	VBN	O
subjects	IN	O
by	NN	O
a	NNS	O
number	IN	O
of	DT	O
means,	NN	O
such	IN	O
as	,	O
by	JJ	O
whole-body	IN	O
radiography.	IN	O
Organ	NN	O
bioavailability	.	O
may	NNP	O
be	NN	O
modified,	MD	O
e.g.	VB	O
enhanced,	,	O
by	.	O
one	,	O
or	IN	O
more	CD	O
modifications	CC	O
to	JJR	O
the	NNS	O
oligonucleotide,	TO	O
by	DT	O
use	,	O
of	IN	O
one	NN	O
or	IN	O
more	CD	O
carrier	CC	O
compounds	JJR	O
or	NN	O
excipients,	NNS	O
etc.	CC	O
as	,	O
discussed	.	O
in	IN	O
more	VBN	O
detail	IN	O
herein.	JJR	O
In	NN	O
general,	.	O
an	IN	O
increase	,	O
in	DT	O
bioavailability	NN	O
will	IN	O
result	NN	O
in	MD	O
an	VB	O
increase	IN	O
in	DT	O
organ	NN	O
bioavailability.	IN	O
Oral	JJ	O
oligonucleotide	.	O
compositions	NNP	O
according	NN	O
to	NNS	O
the	VBG	O
present	TO	O
invention	DT	O
may	JJ	O
comprise	NN	O
one	MD	O
or	VB	O
more	CD	O
“mucosal	CC	O
penetration	JJR	O
enhancers,”	JJ	O
also	NN	O
known	NNP	O
as	RB	O
“absorption	VBN	O
enhancers”	IN	O
or	NN	O
simply	NN	O
as	CC	O
“penetration	RB	O
enhancers.”	IN	O
Accordingly,	NN	O
some	NN	O
embodiments	,	O
of	DT	O
the	NNS	O
invention	IN	O
comprise	DT	O
at	NN	O
least	NN	O
one	IN	O
oligonucleotide	JJS	O
in	CD	O
combination	NN	O
with	IN	O
at	NN	O
least	IN	O
one	IN	O
penetration	JJS	O
enhancer.	CD	O
In	NN	O
general,	.	O
a	IN	O
penetration	,	O
enhancer	DT	O
is	NN	O
a	NN	O
substance	VBZ	O
that	DT	O
facilitates	NN	O
the	WDT	O
transport	VBZ	O
of	DT	O
a	NN	O
drug	IN	O
across	DT	O
mucous	NN	O
membrane(s)	IN	O
associated	JJ	O
with	)	O
the	VBN	O
desired	IN	O
mode	DT	O
of	JJ	O
administration,	NN	O
e.g.	IN	O
intestinal	,	O
epithelial	.	O
membranes.	JJ	O
Accordingly	JJ	O
it	.	O
is	RB	O
desirable	PRP	O
to	VBZ	O
select	JJ	O
one	TO	O
or	VB	O
more	CD	O
penetration	CC	O
enhancers	JJR	O
that	NN	O
facilitate	NNS	O
the	WDT	O
uptake	VBP	O
of	DT	O
an	NN	O
oligonucleotide,	IN	O
without	DT	O
interfering	,	O
with	IN	O
the	VBG	O
activity	IN	O
of	DT	O
the	NN	O
oligonucleotide,	IN	O
and	DT	O
in	,	O
such	CC	O
a	IN	O
manner	JJ	O
the	DT	O
oligonucleotide	NN	O
can	DT	O
be	NN	O
introduced	MD	O
into	VB	O
the	VBN	O
body	IN	O
of	DT	O
an	NN	O
animal	IN	O
without	DT	O
unacceptable	NN	O
degrees	IN	O
of	JJ	O
side-effects	NNS	O
such	IN	O
as	NNS	O
toxicity,	JJ	O
irritation	IN	O
or	,	O
allergic	NN	O
response.	CC	O
Embodiments	JJ	O
of	.	O
the	NNS	O
present	IN	O
invention	DT	O
provide	JJ	O
compositions	NN	O
comprising	VBP	O
one	NNS	O
or	VBG	O
more	CD	O
pharmaceutically	CC	O
acceptable	JJR	O
penetration	RB	O
enhancers,	JJ	O
and	NN	O
methods	,	O
of	CC	O
using	NNS	O
such	IN	O
compositions,	VBG	O
which	JJ	O
result	,	O
in	WDT	O
the	VBP	O
improved	IN	O
bioavailability	DT	O
of	JJ	O
oligonucleotides	NN	O
administered	IN	O
via	NNS	O
non-parenteral	VBN	O
modes	IN	O
of	JJ	O
administration.	NNS	O
Heretofore,	IN	O
certain	.	O
penetration	,	O
enhancers	JJ	O
have	NN	O
been	NNS	O
used	VBP	O
to	VBN	O
improve	VBN	O
the	TO	O
bioavailability	VB	O
of	DT	O
certain	NN	O
drugs.	IN	O
See	JJ	O
Muranishi,	.	B
Crit.	NNP	I
Rev.	,	I
Ther.	.	I
Drug	.	I
Carrier	.	I
Systems,	NN	I
1990,	NNP	I
7,	,	I
1	,	I
and	,	O
Lee	CD	B
et	CC	I
al.,	NNP	I
Crit.	NNP	I
Rev.	,	I
Ther.	.	I
Drug	.	I
Carrier	.	I
Systems,	NN	I
1991,	NNP	I
8,	,	I
91.	,	I
It	,	O
has	.	O
been	PRP	O
found	VBZ	O
that	VBN	O
the	VBN	O
uptake	IN	O
and	DT	O
delivery	NN	O
of	CC	O
oligonucleotides	NN	O
can	IN	O
be	NNS	O
greatly	MD	O
improved	VB	O
even	RB	O
when	VBN	O
administered	RB	O
by	WRB	O
non-parenteral	VBN	O
means	IN	O
through	JJ	O
the	NNS	O
use	IN	O
of	DT	O
a	NN	O
number	IN	O
of	DT	O
different	NN	O
classes	IN	O
of	JJ	O
penetration	NNS	O
enhancers.	IN	O
In	NN	O
some	.	O
embodiments,	IN	O
compositions	DT	O
for	,	O
non-parenteral	NNS	O
administration	IN	O
include	JJ	O
one	NN	O
or	VBP	O
more	CD	O
modifications	CC	O
to	JJR	O
naturally-occurring	NNS	O
oligonucleotides	TO	O
(i.e.	JJ	O
full-phosphodiester	NNS	O
deoxyribosyl	.	O
or	JJ	O
full-phosphodiester	NN	O
ribosyl	CC	O
oligonucleotides).	JJ	O
Such	NN	O
modifications	.	O
may	JJ	O
increase	NNS	O
binding	MD	O
affinity,	VB	O
nuclease	VBG	O
stability,	,	O
cell	JJ	O
or	,	O
tissue	NN	O
permeability,	CC	O
tissue	NN	O
distribution,	,	O
or	NN	O
other	,	O
biological	CC	O
or	JJ	O
pharmacokinetic	JJ	O
property.	CC	O
Modifications	JJ	O
may	.	O
be	NNS	O
made	MD	O
to	VB	O
the	VBN	O
base,	TO	O
the	DT	O
linker,	,	O
or	DT	O
the	,	O
sugar,	CC	O
in	DT	O
general,	,	O
as	IN	O
discussed	,	O
in	IN	O
more	VBN	O
detail	IN	O
herein	JJR	O
with	NN	O
regards	NN	O
to	IN	O
oligonucleotide	NNS	O
chemistry.	TO	O
In	VB	O
some	.	O
embodiments	IN	O
of	DT	O
the	NNS	O
invention,	IN	O
compositions	DT	O
for	,	O
administration	NNS	O
to	IN	O
a	NN	O
subject,	TO	O
and	DT	O
in	,	O
particular	CC	O
oral	IN	O
compositions	JJ	O
for	JJ	O
administration	NNS	O
to	IN	O
an	NN	O
animal	TO	O
(human	DT	O
or	NN	O
non-human)	JJ	O
subject,	CC	O
will	)	O
comprise	,	O
modified	MD	O
oligonucleotides	VB	O
having	VBN	O
one	IN	O
or	VBG	O
more	CD	O
modifications	CC	O
for	JJR	O
enhancing	NNS	O
affinity,	IN	O
stability,	VBG	O
tissue	,	O
distribution,	,	O
or	NN	O
other	,	O
biological	CC	O
property.	JJ	O
Suitable	JJ	O
modified	.	O
linkers	JJ	O
include	VBD	O
phosphorothioate	NNS	O
linkers.	VBP	O
In	JJ	O
some	.	O
embodiments	IN	O
according	DT	O
to	NNS	O
the	VBG	O
invention,	TO	O
the	DT	O
oligonucleotide	,	O
has	DT	O
at	NN	O
least	VBZ	O
one	IN	O
phosphorothioate	JJS	O
linker.	CD	O
Phosphorothioate	NN	O
linkers	.	O
provide	NNP	O
nuclease	NNS	O
stability	VBP	O
as	JJ	O
well	NN	O
as	RB	O
plasma	RB	O
protein	IN	O
binding	NN	O
characteristics	NN	O
to	VBG	O
the	NNS	O
oligonucleotide.	TO	O
Nuclease	DT	O
stability	.	O
is	NNP	O
useful	NN	O
for	VBZ	O
increasing	JJ	O
the	IN	O
in	VBG	O
vivo	DT	O
lifetime	IN	O
of	JJ	O
oligonucleotides,	NN	O
while	IN	O
plasma	,	O
protein	IN	O
binding	JJ	O
decreases	NN	O
the	NN	O
rate	VBZ	O
of	DT	O
first	NN	O
pass	IN	O
clearance	JJ	O
of	NN	O
oligonucleotide	NN	O
via	IN	O
renal	JJ	O
excretion.	IN	O
In	JJ	O
some	.	O
embodiments	IN	O
according	DT	O
to	NNS	O
the	VBG	O
present	TO	O
invention,	DT	O
the	JJ	O
oligonucleotide	,	O
has	DT	O
at	NN	O
least	VBZ	O
two	IN	O
phosphorothioate	JJS	O
linkers.	CD	O
In	JJ	O
some	.	O
embodiments,	IN	O
wherein	DT	O
the	,	O
oligonucleotide	VBP	O
has	DT	O
exactly	NN	O
n	VBZ	O
nucleosides,	RB	O
the	VBN	O
oligonucleotide	,	O
has	DT	O
from	NN	O
one	VBZ	O
to	IN	O
n−1	CD	O
phosphorothioate	TO	O
linkages.	VB	O
In	NN	O
some	.	O
embodiments,	IN	O
wherein	DT	O
the	,	O
oligonucleotide	VBP	O
has	DT	O
exactly	NN	O
n	VBZ	O
nucleosides,	RB	O
the	VBN	O
oligonucleotide	,	O
has	DT	O
n−1	NN	O
phosphorothioate	VBZ	O
linkages.	VBN	O
In	JJ	O
other	.	O
embodiments	IN	O
wherein	JJ	O
the	NNS	O
oligonucleotide	IN	O
has	DT	O
exactly	NN	O
n	VBZ	O
nucleoside,	RB	O
and	VBN	O
n	,	O
is	CC	O
even,	NN	O
the	VBZ	O
oligonucleotide	,	O
has	DT	O
from	NN	O
1	VBZ	O
to	IN	O
n/2	CD	O
phosphorothioate	TO	O
linkages,	VB	O
or,	NN	O
when	,	O
n	,	O
is	WRB	O
odd,	NN	O
from	VBZ	O
1	,	O
to	IN	O
(n−1)/2	CD	O
phosphorothioate	TO	O
linkages.	NN	O
In	NN	O
some	.	O
embodiments,	IN	O
the	DT	O
oligonucleotide	,	O
has	DT	O
alternating	NN	O
phosphodiester	VBZ	O
(PO)	VBG	O
and	NN	O
phosphorothioate	)	O
(PS)	CC	O
linkages.	NN	O
In	)	O
other	.	O
embodiments,	IN	O
the	JJ	O
oligonucleotide	,	O
has	DT	O
at	NN	O
least	VBZ	O
one	IN	O
stretch	JJS	O
of	CD	O
two	NN	O
or	IN	O
more	CD	O
consecutive	CC	O
PO	JJR	O
linkages	JJ	O
and	NNP	O
at	NNS	O
least	CC	O
one	IN	O
stretch	JJS	O
of	CD	O
two	NN	O
or	IN	O
more	CD	O
PS	CC	O
linkages.	JJR	O
In	NNP	O
other	.	O
embodiments,	IN	O
the	JJ	O
oligonucleotide	,	O
has	DT	O
at	NN	O
least	VBZ	O
two	IN	O
stretches	JJS	O
of	CD	O
PO	NNS	O
linkages	IN	O
interrupted	NNP	O
by	NNS	O
at	VBN	O
least	IN	O
one	IN	O
PS	JJS	O
linkage.	CD	O
In	NNP	O
some	.	O
embodiments,	IN	O
at	DT	O
least	,	O
one	IN	O
of	JJS	O
the	CD	O
nucleosides	IN	O
is	DT	O
modified	NNS	O
on	VBZ	O
the	VBN	O
ribosyl	IN	O
sugar	DT	O
unit	NN	O
by	NN	O
a	NN	O
modification	IN	O
that	DT	O
imparts	NN	O
nuclease	WDT	O
stability,	VBZ	O
binding	DT	O
affinity	,	O
or	VBG	O
some	NN	O
other	CC	O
beneficial	DT	O
biological	JJ	O
property	JJ	O
to	JJ	O
the	NN	O
sugar.	TO	O
In	DT	O
some	.	O
cases,	IN	O
the	DT	O
sugar	,	O
modification	DT	O
includes	NN	O
a	NN	O
2′-modification,	VBZ	O
e.g.	DT	O
the	,	O
2′-OH	.	O
of	DT	O
the	CD	O
ribosyl	IN	O
sugar	DT	O
is	NN	O
replaced	NN	O
or	VBZ	O
substituted.	VBN	O
Suitable	CC	O
replacements	.	O
for	JJ	O
2′-OH	NNS	O
include	IN	O
2′-F	JJ	O
and	VBP	O
2′-arabino-F.	JJ	O
Suitable	CC	O
substitutions	.	O
for	JJ	O
OH	NNS	O
include	IN	O
2′-O-alkyl,	NNP	O
e.g.	VBP	O
2-O-methyl,	,	O
and	.	O
2′-O-substituted	,	O
alkyl,	CC	O
e.g.	JJ	O
2′-O-methoxyethyl,	,	O
2′-NH2,	.	O
2′-O-aminopropyl,	,	O
etc.	,	O
In	,	O
some	.	O
embodiments,	IN	O
the	DT	O
oligonucleotide	,	O
contains	DT	O
at	NN	O
least	VBZ	O
one	IN	O
2′-modification.	JJS	O
In	CD	O
some	.	O
embodiments,	IN	O
the	DT	O
oligonucleotide	,	O
contains	DT	O
at	NN	O
least	VBZ	O
two	IN	O
2′-modifications.	JJS	O
In	CD	O
some	.	O
embodiments,	IN	O
the	DT	O
oligonucleotide	,	O
has	DT	O
at	NN	O
least	VBZ	O
one	IN	O
2′-modification	JJS	O
at	CD	O
each	NN	O
of	IN	O
the	DT	O
termini	IN	O
(i.e.	DT	O
the	NN	O
3′-	.	O
and	DT	O
5′-terminal	JJ	O
nucleosides	CC	O
each	JJ	O
have	NNS	O
the	DT	O
same	VBP	O
or	DT	O
different	JJ	O
2′-modifications).	CC	O
In	JJ	O
some	.	O
embodiments,	IN	O
the	DT	O
oligonucleotide	,	O
has	DT	O
at	NN	O
least	VBZ	O
two	IN	O
sequential	JJS	O
2′-modifications	CD	O
at	JJ	O
each	NNS	O
end	IN	O
of	DT	O
the	NN	O
oligonucleotide.	IN	O
In	DT	O
some	.	O
embodiments,	IN	O
oligonucleotides	DT	O
further	,	O
comprise	IN	O
at	JJ	O
least	NN	O
one	IN	O
deoxynucleoside.	JJS	O
In	CD	O
particular	.	O
embodiments,	IN	O
oligonucleotides	JJ	O
comprise	,	O
a	NNS	O
stretch	VBP	O
of	DT	O
deoxynucleosides	NN	O
such	IN	O
that	NNS	O
the	JJ	O
stretch	IN	O
is	DT	O
capable	NN	O
of	VBZ	O
activating	JJ	O
RNase	IN	O
(e.g.	VBG	O
RNase	NNP	O
H)	.	O
cleavage	NNP	O
of	)	O
an	NN	O
RNA	IN	O
to	DT	O
which	NNP	O
the	TO	O
oligonucleotide	WDT	O
is	DT	O
capable	NN	O
of	VBZ	O
hybridizing.	JJ	O
In	IN	O
some	.	O
embodiments,	IN	O
a	DT	O
stretch	,	O
of	DT	O
deoxynucleosides	NN	O
capable	IN	O
of	NNS	O
activating	JJ	O
RNase-mediated	IN	O
cleavage	VBG	O
of	JJ	O
RNA	NN	O
comprises	IN	O
about	NNP	O
6	VBZ	O
to	RB	O
about	CD	O
16,	TO	O
e.g.	IN	O
about	,	O
8	.	O
to	RB	O
about	CD	O
16	TO	O
consecutive	IN	O
deoxynucleosides.	CD	O
In	JJ	O
further	.	O
embodiments,	IN	O
oligonucleotides	JJ	O
are	,	O
capable	NNS	O
of	VBP	O
eliciting	JJ	O
cleaveage	IN	O
by	VBG	O
dsRNAse	NN	O
enzymes	IN	O
which	NN	O
act	NNS	O
on	WDT	O
RNA:RNA	VBP	O
hybrids.	IN	O
Oligonucleotide	NNP	O
compositions	.	O
of	NNP	O
the	NNS	O
present	IN	O
invention	DT	O
may	JJ	O
be	NN	O
formulated	MD	O
in	VB	O
various	VBN	O
dosage	IN	O
forms	JJ	O
such	NN	O
as,	NNS	O
but	JJ	O
not	,	O
limited	CC	O
to,	RB	O
tablets,	JJ	O
capsules,	,	O
liquid	,	O
syrups,	,	O
soft	NN	O
gels,	,	O
suppositories,	JJ	O
and	,	O
enemas.	,	O
The	CC	O
term	.	O
“alimentary	DT	O
delivery”	NN	O
encompasses	JJ	O
e.g.	NN	O
oral,	VBZ	O
rectal,	.	O
endoscopic	,	O
and	,	O
sublingual/buccal	NN	O
administration.	CC	O
A	JJ	O
common	.	O
requirement	DT	O
for	JJ	O
these	NN	O
modes	IN	O
of	DT	O
administration	NNS	O
is	IN	O
absorption	NN	O
over	VBZ	O
some	NN	O
portion	IN	O
or	DT	O
all	NN	O
of	CC	O
the	DT	O
alimentary	IN	O
tract	DT	O
and	JJ	O
a	NN	O
need	CC	O
for	DT	O
efficient	NN	O
mucosal	IN	O
penetration	JJ	O
of	JJ	O
the	NN	O
oligonucleotides	IN	O
or	DT	O
mimetics	NNS	O
thereof	CC	O
so	NNS	O
administered.	VBP	O
Delivery	RB	O
of	.	O
a	NN	O
drug	IN	O
via	DT	O
the	NN	O
oral	IN	O
mucosa,	DT	O
as	JJ	O
in	,	O
the	IN	O
case	IN	O
of	DT	O
buccal	NN	O
and	IN	O
sublingual	JJ	O
administration,	CC	O
has	JJ	O
several	,	O
desirable	VBZ	O
features,	JJ	O
including,	JJ	O
in	,	O
many	,	O
instances,	IN	O
a	JJ	O
more	,	O
rapid	DT	O
rise	RBR	O
in	JJ	O
plasma	NN	O
concentration	IN	O
of	JJ	O
the	NN	O
drug	IN	O
Harvey,	DT	B
Chapter	NN	I
35	,	I
In:	NNP	I
Remington's	CD	I
Pharmaceutical	:	I
Sciences,	POS	I
18th	NNP	I
Ed.,	,	I
Gennaro,	CD	I
ed.,	,	I
Mack	,	I
Publishing	,	I
Co.,	NNP	I
Easton,	NNP	I
Pa.,	,	I
1990,	,	I
page	,	I
711).(	,	O
Endoscopy	VB	O
may	.	O
be	NN	O
used	MD	O
for	VB	O
drug	VBN	O
delivery	IN	O
directly	NN	O
to	NN	O
an	RB	O
interior	TO	O
portion	DT	O
of	JJ	O
the	NN	O
alimentary	IN	O
tract.	DT	O
For	JJ	O
example,	.	O
endoscopic	IN	O
retrograde	,	O
cystopancreatography	FW	O
(ERCP)	NN	O
takes	NN	O
advantage	)	O
of	VBZ	O
extended	NN	O
gastroscopy	IN	O
and	VBN	O
permits	NN	O
selective	CC	O
access	NNS	O
to	JJ	O
the	NN	O
biliary	TO	O
tract	DT	O
and	JJ	O
the	NN	O
pancreatic	CC	O
duct	DT	O
Hirahata	JJ	B
et	NN	I
al.,	NNP	I
Gan	RB	I
To	,	I
Kagaku	NNP	I
Ryoho,	TO	I
1992,	NNP	I
19(10	,	I
Suppl.),	,	I
1591).(	CD	O
Pharmaceutical	,	O
compositions,	.	O
including	JJ	O
liposomal	,	O
formulations,	VBG	O
can	JJ	O
be	,	O
delivered	MD	O
directly	VB	O
into	VBN	O
portions	RB	O
of	IN	O
the	NNS	O
alimentary	IN	O
canal,	DT	O
such	JJ	O
as,	,	O
e.g.,	JJ	O
the	,	O
duodenum	,	O
Somogyi	DT	B
et	NN	I
al.,	NNP	I
Pharm.	RB	I
Res.,	,	I
1995,	.	I
12,	,	I
149)	,	I
(or	,	O
the	)	O
gastric	CC	O
submucosa	DT	O
Akamo	JJ	B
et	NN	I
al.,	NNP	I
Japanese	RB	I
J.	,	I
Cancer	JJ	I
Res.,	.	I
1994,	NNP	I
85,	,	I
652)	,	I
(via	,	O
endoscopic	)	O
means.	IN	O
Gastric	NN	O
lavage	.	O
devices	NNP	O
Inoue	NN	B
et	NNS	I
al.,	NNP	I
Artif.	RB	I
Organs,	,	I
1997,	.	I
21,	,	I
28)	,	I
(and	,	O
percutaneous	)	O
endoscopic	CC	O
feeding	JJ	O
devices	NN	O
Pennington	VBG	B
et	NNS	I
al.,	NNP	I
Ailment	VBZ	I
Pharmacol.	,	I
Ther.,	NNP	I
1995,	.	I
9,	,	I
471)	,	I
(can	,	O
also	)	O
be	MD	O
used	RB	O
for	VB	O
direct	VBN	O
alimentary	IN	O
delivery	JJ	O
of	JJ	O
pharmaceutical	NN	O
compositions.	IN	O
In	JJ	O
some	.	O
embodiments,	IN	O
oligonucleotide	DT	O
formulations	,	O
may	IN	O
be	NNS	O
administered	MD	O
through	VB	O
the	VBN	O
anus	IN	O
into	DT	O
the	NN	O
rectum	IN	O
or	DT	O
lower	NN	O
intestine.	CC	O
Rectal	JJR	O
suppositories,	.	O
retention	JJ	O
enemas	,	O
or	NN	O
rectal	NN	O
catheters	CC	O
can	JJ	O
be	NNS	O
used	MD	O
for	VB	O
this	VBN	O
purpose	IN	O
and	DT	O
may	NN	O
be	CC	O
preferred	MD	O
when	VB	O
patient	VBN	O
compliance	WRB	O
might	JJ	O
otherwise	NN	O
be	MD	O
difficult	RB	O
to	VB	O
achieve	JJ	O
(e.g.,	TO	O
in	VB	O
pediatric	,	O
and	IN	O
geriatric	JJ	O
applications,	CC	O
or	JJ	O
when	,	O
the	CC	O
patient	WRB	O
is	DT	O
vomiting	NN	O
or	VBZ	O
unconscious).	VBG	O
Rectal	CC	O
administration	.	O
can	JJ	O
result	NN	O
in	MD	O
more	VB	O
prompt	IN	O
and	JJR	O
higher	NN	O
blood	CC	O
levels	JJR	O
than	NN	O
the	NNS	O
oral	IN	O
route.	DT	O
Harvey,	JJ	B
Chapter	.	I
35	,	I
In:	NNP	I
Remington's	CD	I
Pharmaceutical	:	I
Sciences,	POS	I
18th	NNP	I
Ed.,	,	I
Gennaro,	CD	I
ed.,	,	I
Mack	,	I
Publishing	,	I
Co.,	NNP	I
Easton,	NNP	I
Pa.,	,	I
1990,	,	I
page	,	I
711).(	,	O
Because	VB	O
about	.	O
50%	IN	O
of	RB	O
the	NN	O
drug	IN	O
that	DT	O
is	NN	O
absorbed	WDT	O
from	VBZ	O
the	VBN	O
rectum	IN	O
will	DT	O
likely	NN	O
bypass	MD	O
the	RB	O
liver,	VB	O
administration	DT	O
by	,	O
this	NN	O
route	IN	O
significantly	DT	O
reduces	NN	O
the	RB	O
potential	VBZ	O
for	DT	O
first-pass	JJ	O
metabolism	IN	O
Benet	JJ	B
et	NN	I
al.,	NNP	I
Chapter	RB	I
1	,	I
In:	NNP	I
Goodman	CD	I
&	:	I
Gilman's	NNP	I
The	CC	I
Pharmacological	POS	I
Basis	DT	I
of	JJ	I
Therapeutics,	NNP	I
9th	IN	I
Ed.,	,	I
Hardman	CD	I
et	,	I
al.,	NNP	I
eds.,	VBZ	I
McGraw-Hill,	,	I
New	,	I
York,	,	I
N.Y.,	NNP	I
1996).(	,	O
Some	,	O
embodiments	.	O
employ	DT	O
various	NNS	O
penetration	VBP	O
enhancers	JJ	O
in	NN	O
order	NNS	O
to	IN	O
effect	NN	O
transport	TO	O
of	NN	O
oligonucleotides	NN	O
and	IN	O
other	NNS	O
nucleic	CC	O
acids	JJ	O
across	JJ	O
mucosal	NNS	O
and	IN	O
epithelial	NN	O
membranes.	CC	O
Penetration	JJ	O
enhancers	.	O
may	NN	O
be	NNS	O
classified	MD	O
as	VB	O
belonging	VBN	O
to	IN	O
one	NN	O
of	TO	O
five	CD	O
broad	IN	O
categories—surfactants,	CD	O
fatty	JJ	O
acids,	,	O
bile	JJ	O
salts,	,	O
chelating	NN	O
agents,	,	O
and	VBG	O
non-chelating	,	O
non-surfactants	CC	O
Lee	JJ	B
et	NNS	I
al.,	NNP	I
Critical	RB	I
Reviews	,	I
in	JJ	I
Therapeutic	NNP	I
Drug	IN	I
Carrier	NNP	I
Systems,	NNP	I
1991,	NNP	I
p.	,	I
92).(	,	O
Accordingly,	VBZ	O
some	.	O
embodiments	,	O
comprise	DT	O
oral	NNS	O
oligonucleotide	VBP	O
compositions	JJ	O
comprising	IN	O
at	NNS	O
least	VBG	O
one	IN	O
member	JJS	O
of	CD	O
the	NN	O
group	IN	O
consisting	DT	O
of	NN	O
surfactants,	VBG	O
fatty	IN	O
acids,	,	O
bile	JJ	O
salts,	,	O
chelating	NN	O
agents,	,	O
and	VBG	O
non-chelating	,	O
surfactants.	CC	O
Further	JJ	O
embodiments	.	O
comprise	JJ	O
oral	NNS	O
oligonucleotide	VB	O
compositions	JJ	O
comprising	IN	O
at	NNS	O
least	VBG	O
one	IN	O
fatty	JJS	O
acid,	CD	O
e.g.	JJ	O
capric	,	O
or	.	O
lauric	NN	O
acid,	CC	O
or	JJ	O
combinations	,	O
or	CC	O
salts	NNS	O
thereof.	CC	O
Other	NNS	O
embodiments	.	O
comprise	JJ	O
methods	NNS	O
of	VBP	O
enhancing	NNS	O
the	IN	O
oral	VBG	O
bioavailability	DT	O
of	JJ	O
an	NN	O
oligonucleotide,	IN	O
the	DT	O
method	,	O
comprising	DT	O
co-administering	NN	O
the	VBG	O
oligonucleotide	VBG	O
and	DT	O
at	NN	O
least	CC	O
one	IN	O
penetration	JJS	O
enhancer.	CD	O
Other	NN	O
excipients	.	O
that	JJ	O
may	NNS	O
be	WDT	O
added	MD	O
to	VB	O
oral	VBN	O
oligonucleotide	TO	O
compositions	JJ	O
include	JJ	O
surfactants	NNS	O
(or	VBP	O
“surface-active	NNS	O
agents”).	CC	O
These	JJ	O
are	.	O
chemical	DT	O
entities	VBP	O
which,	NN	O
when	NNS	O
dissolved	,	O
in	WRB	O
an	VBN	O
aqueous	IN	O
solution,	DT	O
reduce	JJ	O
the	,	O
surface	VB	O
tension	DT	O
of	NN	O
the	NN	O
solution	IN	O
or	DT	O
the	NN	O
interfacial	CC	O
tension	DT	O
between	JJ	O
the	NN	O
aqueous	IN	O
solution	DT	O
and	JJ	O
another	NN	O
liquid,	CC	O
with	DT	O
the	,	O
result	IN	O
that	DT	O
absorption	NN	O
of	IN	O
oligonucleotides	NN	O
through	IN	O
the	NNS	O
alimentary	IN	O
mucosa	DT	O
and	JJ	O
other	NN	O
epithelial	CC	O
membranes	JJ	O
is	JJ	O
enhanced.	NNS	O
In	VBZ	O
addition	.	O
to	IN	O
bile	NN	O
salts	TO	O
and	VB	O
fatty	NNS	O
acids,	CC	O
surfactants	JJ	O
include,	,	O
for	NNS	O
example,	,	O
sodium	IN	O
lauryl	,	O
sulfate,	NN	O
polyoxyethylene-9-lauryl	NN	O
ether	,	O
and	JJ	O
polyoxyethylene-20-cetyl	NN	O
ether	CC	O
Lee	NN	B
et	NN	I
al.,	NNP	I
Critical	RB	I
Reviews	,	I
in	JJ	I
Therapeutic	NNP	I
Drug	IN	I
Carrier	NNP	I
Systems,	NNP	I
1991,	NNP	I
page	,	I
92);(	,	O
and	VB	O
perfluorohemical	:	O
emulsions,	CC	O
such	JJ	O
as	,	O
FC-43	JJ	O
Takahashi	IN	B
et	NNP	I
al.,	NNP	I
J.	VBZ	I
Pharm.	,	I
Phamacol.,	NNP	I
1988,	.	I
40,	,	I
252).(	,	O
Fatty	,	O
acids	.	O
and	NNP	O
their	NNS	O
derivatives	CC	O
which	PRP$	O
act	NNS	O
as	WDT	O
penetration	VBP	O
enhancers	IN	O
and	NN	O
may	NNS	O
be	CC	O
used	MD	O
in	VB	O
compositions	VBN	O
of	IN	O
the	NNS	O
present	IN	O
invention	DT	O
include,	JJ	O
for	NN	O
example,	,	O
oleic	IN	O
acid,	,	O
lauric	JJ	O
acid,	,	O
capric	JJ	O
acid	,	O
(n-decanoic	JJ	O
acid),	NN	O
myristic	JJ	O
acid,	,	O
palmitic	JJ	O
acid,	,	O
stearic	JJ	O
acid,	,	O
linoleic	JJ	O
acid,	,	O
linolenic	JJ	O
acid,	,	O
dicaprate,	JJ	O
tricaprate,	,	O
monoolein	,	O
(1-monooleoyl-rac-glycerol),	,	O
dilaurin,	NN	O
caprylic	,	O
acid,	,	O
arachidonic	JJ	O
acid,	,	O
glyceryl	JJ	O
1-monocaprate,	,	O
1-dodecylazacycloheptan-2-one,	JJ	O
acylcarnitines,	,	O
acylcholines	,	O
and	,	O
mono-	NNS	O
and	CC	O
di-glycerides	JJ	O
thereof	CC	O
and/or	JJ	O
physiologically	NN	O
acceptable	NN	O
salts	RB	O
thereof	JJ	O
(i.e.,	NNS	O
oleate,	NN	O
laurate,	,	O
caprate,	,	O
myristate,	,	O
palmitate,	,	O
stearate,	,	O
linoleate,	,	O
etc.)	,	O
Lee	,	B
et	)	I
al.,	NNP	I
Critical	RB	I
Reviews	,	I
in	JJ	I
Therapeutic	NNP	I
Drug	IN	I
Carrier	NNP	I
Systems,	NNP	I
1991,	NNP	I
page	,	I
92;	,	I
Muranishi,	NN	B
Critical	:	I
Reviews	,	I
in	NNP	I
Therapeutic	NNP	I
Drug	IN	I
Carrier	NNP	I
Systems,	NNP	I
1990,	NNP	I
7,	,	I
1;	,	I
El-Hariri	,	B
et	:	I
al.,	JJ	I
J.	NN	I
Pharm.	,	I
Pharmacol.,	NNP	I
1992,	.	I
44,	,	I
651).(	,	O
A	,	O
variety	.	O
of	DT	O
bile	NN	O
salts	IN	O
also	NN	O
function	NNS	O
as	RB	O
penetration	VBP	O
enhancers	IN	O
to	NN	O
facilitate	NNS	O
the	TO	O
uptake	VB	O
and	DT	O
bioavailability	NN	O
of	CC	O
drugs.	NN	O
The	IN	O
physiological	.	O
roles	DT	O
of	JJ	O
bile	NNS	O
include	IN	O
the	NN	O
facilitation	VBP	O
of	DT	O
dispersion	NN	O
and	IN	O
absorption	NN	O
of	CC	O
lipids	NN	O
and	IN	O
fat-soluble	NNS	O
vitamins	CC	O
Brunton,	JJ	B
Chapter	NNS	I
38	,	I
In	NNP	I
Goodman	CD	I
&	IN	I
Gilman's	NNP	I
The	CC	I
Pharmacological	POS	I
Basis	DT	I
of	JJ	I
Therapeutics,	NNP	I
9th	IN	I
Ed.,	,	I
Hardman	CD	I
et	,	I
al.,	NNP	I
eds.,	VBZ	I
McGraw-Hill,	,	I
New	,	I
York,	,	I
N.Y.,	NNP	I
1996,	,	I
pages	,	I
934-935).(	,	O
Various	VBZ	O
natural	.	O
bile	JJ	O
salts,	JJ	O
and	NN	O
their	,	O
synthetic	CC	O
derivatives,	PRP$	O
act	JJ	O
as	,	O
penetration	NN	O
enhancers.	IN	O
Thus,	NN	O
the	.	O
term	,	O
“bile	DT	O
salt”	NN	O
includes	NNP	O
any	NN	O
of	VBZ	O
the	DT	O
naturally	IN	O
occurring	DT	O
components	RB	O
of	VBG	O
bile	NNS	O
as	IN	O
well	NN	O
as	RB	O
any	RB	O
of	IN	O
their	DT	O
synthetic	IN	O
derivatives.	PRP$	O
The	JJ	O
bile	.	O
salts	DT	O
of	NN	O
the	NNS	O
invention	IN	O
include,	DT	O
for	NN	O
example,	,	O
cholic	IN	O
acid	,	O
(or	JJ	O
its	NN	O
pharmaceutically	CC	O
acceptable	PRP$	O
sodium	RB	O
salt,	JJ	O
sodium	NN	O
cholate),	,	O
dehydrocholic	NN	O
acid	,	O
(sodium	JJ	O
dehydrocholate),	NN	O
deoxycholic	JJ	O
acid	,	O
(sodium	JJ	O
deoxycholate),	NN	O
glucholic	JJ	O
acid	,	O
(sodium	JJ	O
glucholate),	NN	O
glycholic	JJ	O
acid	,	O
(sodium	JJ	O
glycocholate),	NN	O
glycodeoxycholic	JJ	O
acid	,	O
(sodium	JJ	O
glycodeoxycholate),	NN	O
taurocholic	JJ	O
acid	,	O
(sodium	JJ	O
taurocholate),	NN	O
taurodeoxycholic	JJ	O
acid	,	O
(sodium	JJ	O
taurodeoxycholate),	NN	O
chenodeoxycholic	JJ	O
acid	,	O
(CDCA,	JJ	O
sodium	NN	O
chenodeoxycholate),	,	O
ursodeoxycholic	NN	O
acid	,	O
(UDCA),	JJ	O
sodium	NN	O
tauro-24,25-dihydro-fusidate	,	O
(STDHF),	JJ	O
sodium	NN	O
glycodihydrofusidate	,	O
and	JJ	O
polyoxyethylene-9-lauryl	NN	O
ether	CC	O
(POE)	NN	O
Lee	NN	B
et	)	I
al.,	NNP	I
Critical	RB	I
Reviews	,	I
in	JJ	I
Therapeutic	NNP	I
Drug	IN	I
Carrier	NNP	I
Systems,	NNP	I
1991,	NNP	I
page	,	I
92;	,	I
Swinyard,	NN	B
Chapter	:	I
39	,	I
In:	NNP	I
Remington's	CD	I
Pharmaceutical	:	I
Sciences,	POS	I
18th	NNP	I
Ed.,	,	I
Gennaro,	CD	I
ed.,	,	I
Mack	,	I
Publishing	,	I
Co.,	NNP	I
Easton,	NNP	I
Pa.,	,	I
1990,	,	I
pages	,	I
782-783;	,	I
Muranishi,	VBZ	B
Critical	:	I
Reviews	,	I
in	NNP	I
Therapeutic	NNP	I
Drug	IN	I
Carrier	NNP	I
Systems,	NNP	I
1990,	NNP	I
7,	,	I
1;	,	I
Yamamoto	,	B
et	:	I
al.,	NNP	I
J.	FW	I
Pharm.	,	I
Exp.	NNP	I
Ther.,	.	I
1992,	.	I
263,	,	I
25;	,	I
Yamashita	,	B
et	:	I
al.,	NNP	I
J.	FW	I
Pharm.	,	I
Sci.,	NNP	I
1990,	.	I
79,	,	I
579).(	,	O
In	,	O
some	.	O
embodiments,	IN	O
penetration	DT	O
enhancers	,	O
of	NN	O
the	NNS	O
present	IN	O
invention	DT	O
are	JJ	O
mixtures	NN	O
of	VBP	O
penetration	NNS	O
enhancing	IN	O
compounds.	NN	O
One	VBG	O
such	.	O
penetration	CD	O
mixture	JJ	O
is	NN	O
UDCA	NN	O
(and/or	VBZ	O
CDCA)	NNP	O
with	JJ	O
capric	)	O
and/or	IN	O
lauric	JJ	O
acids	NN	O
or	JJ	O
salts	NNS	O
thereof	CC	O
e.g.	NNS	O
sodium.	JJ	O
Such	.	O
mixtures	.	O
are	JJ	O
useful	NNS	O
for	VBP	O
enhancing	JJ	O
the	IN	O
delivery	VBG	O
of	DT	O
biologically	NN	O
active	IN	O
substances	RB	O
across	JJ	O
mucosal	NNS	O
membranes,	IN	O
in	NN	O
particular	,	O
intestinal	IN	O
mucosa.	JJ	O
Other	JJ	O
penetration	.	O
enhancer	JJ	O
mixtures	NN	O
comprise	NN	O
about	NNS	O
5-95%	VBP	O
of	IN	O
bile	NN	O
acid	IN	O
or	JJ	O
salt(s)	NN	O
UDCA	CC	O
and/or	)	O
CDCA	NNP	O
with	VBZ	O
5-95%	NNP	O
capric	IN	O
and/or	NN	O
lauric	JJ	O
acid.	NN	O
Particular	JJ	O
penetration	.	O
enhancers	JJ	O
are	NN	O
mixtures	NNS	O
of	VBP	O
the	NNS	O
sodium	IN	O
salts	DT	O
of	NN	O
UDCA,	NNS	O
capric	IN	O
acid	,	O
and	JJ	O
lauric	NN	O
acid	CC	O
in	JJ	O
a	NN	O
ratio	IN	O
of	DT	O
about	NN	O
1:2:2	IN	O
respectively.	IN	O
Another	CD	O
such	.	O
penetration	DT	O
enhancer	JJ	O
is	NN	O
a	NN	O
mixture	VBZ	O
of	DT	O
capric	NN	O
and	IN	O
lauric	NN	O
acid	CC	O
(or	JJ	O
salts	NN	O
thereof)	CC	O
in	VB	O
a	)	O
0.01:1	IN	O
to	DT	O
1:0.01	CD	O
ratio	TO	O
(mole	CD	O
basis).	NN	O
In	JJ	O
particular	.	O
embodiments	IN	O
capric	JJ	O
acid	NNS	O
and	JJ	O
lauric	NN	O
acid	CC	O
are	JJ	O
present	NN	O
in	VBP	O
molar	JJ	O
ratios	IN	O
of	JJ	O
e.g.	NNS	O
about	IN	O
0.1:1	.	O
to	RB	O
about	CD	O
1:0.1,	TO	O
in	IN	O
particular	,	O
about	IN	O
0.5:1	JJ	O
to	IN	O
about	CD	O
1:0.5.	TO	O
Other	IN	O
excipients	.	O
include	JJ	O
chelating	NNS	O
agents,	VBP	O
i.e.	VBG	O
compounds	,	O
that	.	O
remove	NNS	O
metallic	WDT	O
ions	VBP	O
from	JJ	O
solution	NNS	O
by	IN	O
forming	NN	O
complexes	IN	O
therewith,	VBG	O
with	NNS	O
the	,	O
result	IN	O
that	DT	O
absorption	NN	O
of	IN	O
oligonucleotides	NN	O
through	IN	O
the	NNS	O
alimentary	IN	O
and	DT	O
other	JJ	O
mucosa	CC	O
is	JJ	O
enhanced.	NN	O
With	VBZ	O
regards	.	O
to	IN	O
their	NNS	O
use	TO	O
as	PRP$	O
penetration	NN	O
enhancers	IN	O
in	NN	O
compositions	NNS	O
containing	IN	O
DNA-like	NNS	O
oligonucleotides	VBG	O
of	NNP	O
the	NNS	O
present	IN	O
invention,	DT	O
chelating	JJ	O
agents	,	O
have	VBG	O
the	NNS	O
added	VBP	O
advantage	DT	O
of	JJ	O
also	NN	O
serving	IN	O
as	RB	O
DNase	VBG	O
inhibitors,	IN	O
as	NNP	O
most	,	O
characterized	IN	O
DNA	JJS	O
nucleases	JJ	O
require	NN	O
a	NNS	O
divalent	VBP	O
metal	DT	O
ion	NN	O
for	NN	O
catalysis	NN	O
and	IN	O
are	NN	O
thus	CC	O
inhibited	VBP	O
by	RB	O
chelating	VBN	O
agents	IN	O
Jarrett,	VBG	B
J.	NNS	I
Chromatogr.,	,	I
1993,	.	I
618,	,	I
315).(	,	O
Chelating	,	O
agents	.	O
of	VBG	O
the	NNS	O
invention	IN	O
include,	DT	O
but	NN	O
are	,	O
not	CC	O
limited	VBP	O
to,	RB	O
disodium	VBN	O
ethylenediaminetetraacetate	,	O
(EDTA),	NN	O
citric	NN	O
acid,	,	O
salicylates	JJ	O
(e.g.,	,	O
sodium	NNS	O
salicylate,	,	O
5-methoxysalicylate	NN	O
and	,	O
homovanilate),	JJ	O
N-acyl	CC	O
derivatives	,	O
of	JJ	O
collagen,	NNS	O
laureth-9	IN	O
and	,	O
N-amino	JJ	O
acyl	CC	O
derivatives	JJ	O
of	NN	O
beta-diketones	NNS	O
Lee	IN	B
et	NNS	I
al.,	NNP	I
Critical	RB	I
Reviews	,	I
in	JJ	I
Therapeutic	NNP	I
Drug	IN	I
Carrier	NNP	I
Systems,	NNP	I
1991,	NNP	I
page	,	I
92;	,	I
Muranishi,	NN	B
Critical	:	I
Reviews	,	I
in	NNP	I
Therapeutic	NNP	I
Drug	IN	I
Carrier	NNP	I
Systems,	NNP	I
1990,	NNP	I
7,	,	I
1;	,	I
Buur	,	B
et	:	I
al.,	NNP	I
J.	FW	I
Control	,	I
Rel.,	.	I
1990,	NNP	I
14,	,	I
43).(enamines)(	,	O
As	,	O
used	.	O
herein,	IN	O
non-chelating	VBN	O
non-surfactant	,	O
penetration	JJ	O
enhancers	JJ	O
may	NN	O
be	NNS	O
defined	MD	O
as	VB	O
compounds	VBN	O
that	IN	O
demonstrate	NNS	O
insignificant	WDT	O
activity	VBP	O
as	JJ	O
chelating	NN	O
agents	IN	O
or	VBG	O
as	NNS	O
surfactants	CC	O
but	IN	O
that	NNS	O
nonetheless	CC	O
enhance	DT	O
absorption	RB	O
of	JJ	O
oligonucleotides	NN	O
through	IN	O
the	NNS	O
alimentary	IN	O
and	DT	O
other	JJ	O
mucosal	CC	O
membranes	JJ	O
Muranishi,	NN	B
Critical	NNS	I
Reviews	,	I
in	NNP	I
Therapeutic	NNP	I
Drug	IN	I
Carrier	NNP	I
Systems,	NNP	I
1990,	NNP	I
7,	,	I
1).(	,	O
This	,	O
class	.	O
of	DT	O
penetration	NN	O
enhancers	IN	O
includes,	NN	O
but	NNS	O
is	,	O
not	CC	O
limited	VBZ	O
to,	RB	O
unsaturated	VBN	O
cyclic	,	O
ureas,	JJ	O
1-alkyl-	JJ	O
and	,	O
1-alkenylazacyclo-alkanone	JJ	O
derivatives	CC	O
Lee	JJ	B
et	NNS	I
al.,	NNP	I
Critical	RB	I
Reviews	,	I
in	JJ	I
Therapeutic	NNP	I
Drug	IN	I
Carrier	NNP	I
Systems,	NNP	I
1991,	NNP	I
page	,	I
92);(	,	O
and	VB	O
non-steroidal	:	O
anti-inflammatory	CC	O
agents	JJ	O
such	JJ	O
as	NNS	O
diclofenac	JJ	O
sodium,	IN	O
indomethacin	JJ	O
and	,	O
phenylbutazone	NN	O
Yamashita	CC	B
et	NN	I
al.,	NNP	I
J.	RB	I
Pharm.	,	I
Pharmacol.,	NNP	I
1987,	.	I
39,	,	I
621).(	,	O
In	,	O
some	.	O
embodiments,	IN	O
oligonucleotide	DT	O
compositions	,	O
for	JJ	O
oral	NNS	O
delivery	IN	O
comprise	JJ	O
at	NN	O
least	NN	O
two	IN	O
discrete	JJS	O
phases,	CD	O
which	JJ	O
phases	,	O
may	WDT	O
comprise	VBZ	O
particles,	MD	O
capsules,	VB	O
gel-capsules,	,	O
microspheres,	,	O
etc.	,	O
Each	,	O
phase	.	O
may	DT	O
contain	NN	O
one	MD	O
or	VB	O
more	CD	O
oligonucleotides,	CC	O
penetration	JJR	O
enhancers,	,	O
surfactants,	NN	O
bioadhesives,	,	O
effervescent	,	O
agents,	,	O
or	JJ	O
other	,	O
adjuvant,	CC	O
excipient	JJ	O
or	,	O
diluent.	NN	O
In	CC	O
some	.	O
embodiments,	IN	O
one	DT	O
phase	,	O
comprises	CD	O
at	NN	O
least	VBZ	O
one	IN	O
oligonucleotide	JJS	O
and	CD	O
at	NN	O
least	CC	O
one	IN	O
penetration	JJS	O
enhancer.	CD	O
In	NN	O
some	.	O
embodiments,	IN	O
a	DT	O
first	,	O
phase	DT	O
comprises	JJ	O
at	NN	O
least	NNS	O
one	IN	O
oligonucleotide	JJS	O
and	CD	O
at	NN	O
least	CC	O
one	IN	O
penetration	JJS	O
enhancer,	CD	O
while	NN	O
a	,	O
second	IN	O
phase	DT	O
comprises	JJ	O
at	NN	O
least	NNS	O
one	IN	O
penetration	JJS	O
enhancer.	CD	O
In	NN	O
some	.	O
embodiments,	IN	O
a	DT	O
first	,	O
phase	DT	O
comprises	JJ	O
at	NN	O
least	NNS	O
one	IN	O
oligonucleotide	JJS	O
and	CD	O
at	NN	O
least	CC	O
one	IN	O
penetration	JJS	O
enhancer,	CD	O
while	NN	O
a	,	O
second	IN	O
phase	DT	O
comprises	JJ	O
at	NN	O
least	NNS	O
one	IN	O
penetration	JJS	O
enhancer	CD	O
and	NN	O
substantially	NN	O
no	CC	O
oligonucleotide.	RB	O
In	DT	O
some	.	O
embodiments,	IN	O
at	DT	O
least	,	O
one	IN	O
phase	JJS	O
is	CD	O
compounded	NN	O
with	VBZ	O
at	VBN	O
least	IN	O
one	IN	O
degradation	JJS	O
retardant,	CD	O
such	NN	O
as	,	O
a	JJ	O
coating	IN	O
or	DT	O
a	NN	O
matrix,	CC	O
which	DT	O
delays	,	O
release	WDT	O
of	VBZ	O
the	NN	O
contents	IN	O
of	DT	O
that	NNS	O
phase.	IN	O
In	DT	O
some	.	O
embodiments,	IN	O
a	DT	O
first	,	O
phase	DT	O
comprises	JJ	O
at	NN	O
least	NNS	O
one	IN	O
oligonucleotide	JJS	O
and	CD	O
at	NN	O
least	CC	O
one	IN	O
penetration	JJS	O
enhancer,	CD	O
while	NN	O
a	,	O
second	IN	O
phase	DT	O
comprises	JJ	O
at	NN	O
least	NNS	O
one	IN	O
penetration	JJS	O
enhancer	CD	O
and	NN	O
a	NN	O
release-retardant.	CC	O
In	DT	O
particular	.	O
embodiments,	IN	O
an	JJ	O
oral	,	O
oligonucleotide	DT	O
composition	JJ	O
comprises	NN	O
a	NN	O
first	VBZ	O
phase	DT	O
comprising	JJ	O
particles	NN	O
containing	VBG	O
an	NNS	O
oligonucleotide	VBG	O
and	DT	O
a	NN	O
penetration	CC	O
enhancer,	DT	O
and	NN	O
a	,	O
second	CC	O
phase	DT	O
comprising	JJ	O
particles	NN	O
coated	VBG	O
with	NNS	O
a	VBN	O
release-retarding	IN	O
agent	DT	O
and	JJ	O
containing	NN	O
penetration	CC	O
enhancer.	VBG	O
Agents	NN	O
that	.	O
enhance	NNS	O
uptake	WDT	O
of	VBP	O
oligonucleotides	NN	O
at	IN	O
the	NNS	O
cellular	IN	O
level	DT	O
may	JJ	O
also	NN	O
be	MD	O
added	RB	O
to	VB	O
the	VBN	O
pharmaceutical,	TO	O
therapeutic	DT	O
and	,	O
other	JJ	O
compositions	CC	O
of	JJ	O
the	NNS	O
present	IN	O
invention.	DT	O
For	JJ	O
example,	.	O
cationic	IN	O
lipids,	,	O
such	JJ	O
as	,	O
LIPOFECTIN™	JJ	O
reagent	IN	O
(Junichi	NNP	O
et	NN	O
al,	NNP	O
U.S.	RB	O
Pat.	,	O
No.	NNP	O
5,705,188),	.	O
cationic	.	O
glycerol	,	O
derivatives,	JJ	O
and	NN	O
polycationic	,	O
molecules,	CC	O
such	JJ	O
as	,	O
polylysine	JJ	O
(Lollo	IN	O
et	NN	O
al.,	NNP	O
International	RB	O
Patent	,	O
Publication	NNP	O
No.	NNP	O
WO	NNP	O
97/30731),	.	O
can	NNP	O
be	,	O
used.	MD	O
A	VB	O
“pharmaceutical	.	O
carrier”	DT	O
or	JJ	O
“excipient”	NN	O
may	CC	O
be	NN	O
a	MD	O
pharmaceutically	VB	O
acceptable	DT	O
solvent,	RB	O
suspending	JJ	O
agent	,	O
or	VBG	O
any	NN	O
other	CC	O
pharmacologically	DT	O
inert	JJ	O
vehicle	RB	O
for	JJ	O
delivering	NN	O
one	IN	O
or	VBG	O
more	CD	O
nucleic	CC	O
acids	JJR	O
to	JJ	O
an	NNS	O
animal.	TO	O
The	DT	O
excipient	.	O
may	DT	O
be	NN	O
liquid	MD	O
or	VB	O
solid	JJ	O
and	CC	O
is	JJ	O
selected,	CC	O
with	VBZ	O
the	,	O
planned	IN	O
manner	DT	O
of	JJ	O
administration	NN	O
in	IN	O
mind,	NN	O
so	IN	O
as	,	O
to	RB	O
provide	IN	O
for	TO	O
the	VB	O
desired	IN	O
bulk,	DT	O
consistency,	JJ	O
etc.,	,	O
when	,	O
combined	,	O
with	WRB	O
a	VBN	O
an	IN	O
oligonucleotide	DT	O
and	DT	O
the	NN	O
other	CC	O
components	DT	O
of	JJ	O
a	NNS	O
given	IN	O
pharmaceutical	DT	O
composition.	VBN	O
Typical	JJ	O
pharmaceutical	.	O
carriers	JJ	O
include,	JJ	O
but	NNS	O
are	,	O
not	CC	O
limited	VBP	O
to,	RB	O
binding	VBN	O
agents	,	O
(e.g.,	VBG	O
pregelatinised	NNS	O
maize	,	O
starch,	VBD	O
polyvinylpyrrolidone	NN	O
or	,	O
hydroxypropyl	NN	O
methylcellulose,	CC	O
etc.);	NN	O
fillers	,	O
(e.g.,	:	O
lactose	NNS	O
and	,	O
other	JJ	O
sugars,	CC	O
microcrystalline	JJ	O
cellulose,	,	O
pectin,	NN	O
gelatin,	,	O
calcium	,	O
sulfate,	,	O
ethyl	NN	O
cellulose,	,	O
polyacrylates	FW	O
or	,	O
calcium	VBZ	O
hydrogen	CC	O
phosphate,	NN	O
etc.);	NN	O
lubricants	,	O
(e.g.,	:	O
magnesium	NNS	O
stearate,	,	O
talc,	NN	O
silica,	,	O
colloidal	,	O
silicon	,	O
dioxide,	JJ	O
stearic	NN	O
acid,	,	O
metallic	JJ	O
stearates,	,	O
hydrogenated	JJ	O
vegetable	,	O
oils,	VBD	O
corn	JJ	O
starch,	,	O
polyethylene	NN	O
glycols,	,	O
sodium	NN	O
benzoate,	,	O
sodium	NN	O
acetate,	,	O
etc.);	NN	O
disintegrants	,	O
(e.g.,	:	O
starch,	NNS	O
sodium	,	O
starch	,	O
glycolate,	NN	O
EXPLOTAB™);	NN	O
and	,	O
wetting	:	O
agents	CC	O
(e.g.,	VBG	O
sodium	NNS	O
lauryl	,	O
sulphate,	NN	O
etc.).	NN	O
Oral	,	O
oligonucleotide	.	O
compositions	NNP	O
may	IN	O
additionally	NNS	O
contain	MD	O
other	RB	O
adjunct	VB	O
components	JJ	O
conventionally	JJ	O
found	NNS	O
in	RB	O
pharmaceutical	VBN	O
compositions,	IN	O
at	JJ	O
their	,	O
art-established	IN	O
usage	PRP$	O
levels.	JJ	O
Thus,	NN	O
for	.	O
example,	,	O
the	IN	O
compositions	,	O
may	DT	O
contain	NNS	O
additional,	MD	O
compatible,	VB	O
pharmaceutically-active	,	O
materials	,	O
such	JJ	O
as,	NNS	O
for	JJ	O
example,	,	O
antipruritics,	IN	O
astringents,	,	O
local	,	O
anesthetics	,	O
or	JJ	O
anti-inflammatory	NNS	O
agents,	CC	O
or	JJ	O
may	,	O
contain	CC	O
additional	MD	O
materials	VB	O
useful	JJ	O
in	NNS	O
physically	JJ	O
formulating	IN	O
various	RB	O
dosage	VBG	O
forms	JJ	O
of	NN	O
the	NNS	O
composition	IN	O
of	DT	O
present	NN	O
invention,	IN	O
such	JJ	O
as	,	O
dyes,	JJ	O
flavoring	IN	O
agents,	,	O
preservatives,	VBG	O
antioxidants,	,	O
opacifiers,	,	O
thickening	,	O
agents	,	O
and	VBG	O
stabilizers.	NNS	O
However,	CC	O
such	.	O
materials,	,	O
when	JJ	O
added,	,	O
should	WRB	O
not	,	O
unduly	MD	O
interfere	RB	O
with	VB	O
the	RB	O
biological	IN	O
activities	DT	O
of	JJ	O
the	NNS	O
components	IN	O
of	DT	O
the	NNS	O
compositions	IN	O
of	DT	O
the	NNS	O
present	IN	O
invention.	DT	O
Compositions	JJ	O
and	.	O
formulations	NNS	O
for	CC	O
parenteral,	NNS	O
intrathecal	IN	O
or	,	O
intraventricular	JJ	O
administration	CC	O
may	JJ	O
include	NN	O
sterile	MD	O
aqueous	VB	O
solutions	JJ	O
which	JJ	O
may	NNS	O
also	WDT	O
contain	MD	O
buffers,	RB	O
diluents	VB	O
and	,	O
other	NNS	O
suitable	CC	O
additives	JJ	O
such	JJ	O
as,	NNS	O
but	JJ	O
not	,	O
limited	CC	O
to,	RB	O
penetration	JJ	O
enhancers,	,	O
carrier	NN	O
compounds	,	O
and	NN	O
other	NNS	O
pharmaceutically	CC	O
acceptable	JJ	O
carriers	RB	O
or	JJ	O
excipients.	NNS	O
The	CC	O
pharmaceutical	.	O
formulations	DT	O
of	JJ	O
the	NNS	O
present	IN	O
invention,	DT	O
which	JJ	O
may	,	O
conveniently	WDT	O
be	MD	O
presented	RB	O
in	VB	O
unit	VBN	O
dosage	IN	O
form,	NN	O
may	NN	O
be	,	O
prepared	MD	O
according	VB	O
to	VBN	O
conventional	VBG	O
techniques	TO	O
well	JJ	O
known	NNS	O
in	RB	O
the	VBN	O
pharmaceutical	IN	O
industry.	DT	O
Such	JJ	O
techniques	.	O
include	JJ	O
the	NNS	O
step	VBP	O
of	DT	O
bringing	NN	O
into	IN	O
association	VBG	O
the	IN	O
active	NN	O
ingredients	DT	O
with	JJ	O
the	NNS	O
pharmaceutical	IN	O
carrier(s)	DT	O
or	JJ	O
excipient(s).	)	O
In	CC	O
general,	.	O
the	IN	O
formulations	,	O
are	DT	O
prepared	NNS	O
by	VBP	O
uniformly	VBN	O
and	IN	O
intimately	JJ	O
bringing	CC	O
into	RB	O
association	VBG	O
the	IN	O
active	NN	O
ingredients	DT	O
with	JJ	O
liquid	NNS	O
carriers	IN	O
or	JJ	O
finely	NNS	O
divided	CC	O
solid	RB	O
carriers	VBN	O
or	JJ	O
both,	NNS	O
and	CC	O
then,	,	O
if	CC	O
necessary,	,	O
shaping	IN	O
the	,	O
product.	VBG	O
The	DT	O
compositions	.	O
of	DT	O
the	NNS	O
present	IN	O
invention	DT	O
may	JJ	O
be	NN	O
formulated	MD	O
into	VB	O
any	VBN	O
of	IN	O
many	DT	O
possible	IN	O
dosage	JJ	O
forms	JJ	O
such	NN	O
as,	NNS	O
but	JJ	O
not	,	O
limited	CC	O
to,	RB	O
tablets,	JJ	O
capsules,	,	O
gel	,	O
capsules,	,	O
liquid	NN	O
syrups,	,	O
soft	NN	O
gels,	,	O
suppositories,	JJ	O
and	,	O
enemas.	,	O
The	CC	O
compositions	.	O
of	DT	O
the	NNS	O
present	IN	O
invention	DT	O
may	JJ	O
also	NN	O
be	MD	O
formulated	RB	O
as	VB	O
suspensions	VBN	O
in	IN	O
aqueous,	NNS	O
non-aqueous	IN	O
or	,	O
mixed	JJ	O
media.	CC	O
Aqueous	JJ	O
suspensions	.	O
may	JJ	O
further	NNS	O
contain	MD	O
substances	RB	O
which	VB	O
increase	NNS	O
the	WDT	O
viscosity	VBP	O
of	DT	O
the	NN	O
suspension	IN	O
including,	DT	O
for	NN	O
example,	,	O
sodium	IN	O
carboxymethylcellulose,	,	O
sorbitol	NN	O
and/or	,	O
dextran.	JJ	O
The	NN	O
suspension	.	O
may	DT	O
also	NN	O
contain	MD	O
stabilizers.	RB	O
Pharmaceutical	VB	O
compositions	.	O
of	JJ	O
the	NNS	O
present	IN	O
invention	DT	O
include,	JJ	O
but	NN	O
are	,	O
not	CC	O
limited	VBP	O
to,	RB	O
foams,	VBN	O
solutions,	,	O
emulsions,	,	O
and	,	O
liposome-containing	,	O
formulations.	CC	O
These	JJ	O
compositions	.	O
may	DT	O
be	NNS	O
generated	MD	O
from	VB	O
a	VBN	O
variety	IN	O
of	DT	O
components	NN	O
that	IN	O
include,	NNS	O
but	WDT	O
are	,	O
not	CC	O
limited	VBP	O
to,	RB	O
preformed	VBN	O
liquids,	,	O
self-emulsifying	JJ	O
solids	,	O
and	JJ	O
self-emulsifying	NNS	O
semisolids.	CC	O
The	JJ	O
pharmaceutical	.	O
compositions	DT	O
and	JJ	O
formulations	NNS	O
of	CC	O
the	NNS	O
present	IN	O
invention	DT	O
may	JJ	O
comprise	NN	O
one	MD	O
or	VB	O
more	CD	O
penetration	CC	O
enhancers,	JJR	O
carriers,	NN	O
excipients	,	O
or	,	O
other	NNS	O
active	CC	O
or	JJ	O
inactive	JJ	O
ingredients.	CC	O
In	JJ	O
one	.	O
embodiment	IN	O
of	CD	O
the	NN	O
present	IN	O
invention	DT	O
the	JJ	O
pharmaceutical	NN	O
compositions	DT	O
may	JJ	O
be	NNS	O
formulated	MD	O
and	VB	O
used	VBN	O
as	CC	O
foams.	VBN	O
Pharmaceutical	IN	O
foams	.	O
include	JJ	O
formulations	NNS	O
such	VBP	O
as,	NNS	O
but	JJ	O
not	,	O
limited	CC	O
to,	RB	O
emulsions,	JJ	O
microemulsions,	,	O
creams,	,	O
jellies	,	O
and	,	O
liposomes.	NNS	O
While	CC	O
basically	.	O
similar	IN	O
in	RB	O
nature	JJ	O
these	IN	O
formulations	NN	O
vary	DT	O
in	NNS	O
the	VBP	O
components	IN	O
and	DT	O
the	NNS	O
consistency	CC	O
of	DT	O
the	NN	O
final	IN	O
product.	DT	O
The	JJ	O
preparation	.	O
of	DT	O
such	NN	O
compositions	IN	O
and	JJ	O
formulations	NNS	O
is	CC	O
generally	NNS	O
known	VBZ	O
to	RB	O
those	VBN	O
skilled	TO	O
in	DT	O
the	VBN	O
pharmaceutical	IN	O
and	DT	O
formulation	JJ	O
arts	CC	O
and	NN	O
may	NNS	O
be	CC	O
applied	MD	O
to	VB	O
the	VBN	O
formulation	TO	O
of	DT	O
the	NN	O
compositions	IN	O
of	DT	O
the	NNS	O
present	IN	O
invention.	DT	O
The	JJ	O
compounds	.	O
of	DT	O
the	NNS	O
present	IN	O
invention	DT	O
may	JJ	O
be	NN	O
prepared	MD	O
and	VB	O
formulated	VBN	O
as	CC	O
emulsions.	VBN	O
Emulsions	IN	O
are	.	O
typically	NNS	O
heterogeneous	VBP	O
systems	RB	O
of	JJ	O
one	NNS	O
liquid	IN	O
dispersed	CD	O
in	NN	O
another	VBN	O
in	IN	O
the	DT	O
form	IN	O
of	DT	O
droplets	NN	O
usually	IN	O
exceeding	NNS	O
0.1	RB	O
μm	VBG	O
in	CD	O
diameter	NN	O
Idson,	IN	B
in	NN	I
Pharmaceutical	,	I
Dosage	IN	I
Forms,	JJ	I
Lieberman,	NN	I
Rieger	,	I
and	,	I
Banker	NNP	I
(Eds.),	CC	I
1988,	NNP	I
Marcel	,	I
Dekker,	,	I
Inc.,	NNP	I
New	,	I
York,	,	I
N.Y.,	NNP	I
volume	,	I
1,	,	I
p.	NN	I
199;	,	I
Rosoff,	RB	B
in	:	I
Pharmaceutical	,	I
Dosage	IN	I
Forms,	JJ	I
Lieberman,	NN	I
Rieger	,	I
and	,	I
Banker	NNP	I
(Eds.),	CC	I
1988,	NNP	I
Marcel	,	I
Dekker,	,	I
Inc.,	NNP	I
New	,	I
York,	,	I
N.Y.,	NNP	I
Volume	,	I
1,	,	I
p.	NN	I
245;	,	I
Block	RB	B
in	:	I
Pharmaceutical	NNP	I
Dosage	IN	I
Forms,	NNP	I
Lieberman,	NNP	I
Rieger	,	I
and	,	I
Banker	NNP	I
(Eds.),	CC	I
1988,	NNP	I
Marcel	,	I
Dekker,	,	I
Inc.,	NNP	I
New	,	I
York,	,	I
N.Y.,	NNP	I
volume	,	I
2,	,	I
p.	NN	I
335;	,	I
Higuchi	RB	B
et	:	I
al.,	NNP	I
in	FW	I
Remington's	,	I
Pharmaceutical	IN	I
Sciences,	POS	I
Mack	NNP	I
Publishing	,	I
Co.,	NNP	I
Easton,	NNP	I
Pa.,	,	I
1985,	,	I
p.	,	I
301).(	,	O
Emulsions	VBZ	O
are	.	O
often	NNS	O
biphasic	VBP	O
systems	RB	O
comprising	JJ	O
of	NNS	O
two	VBG	O
immiscible	IN	O
liquid	CD	O
phases	JJ	O
intimately	NN	O
mixed	NNS	O
and	RB	O
dispersed	JJ	O
with	CC	O
each	JJ	O
other.	IN	O
In	DT	O
general,	.	O
emulsions	IN	O
may	,	O
be	NNS	O
either	MD	O
water-in-oil	VB	O
(w/o)	CC	O
or	JJ	O
of	)	O
the	CC	O
oil-in-water	IN	O
(o/w)	DT	O
variety.	NN	O
When	)	O
an	.	O
aqueous	WRB	O
phase	DT	O
is	JJ	O
finely	NN	O
divided	VBZ	O
into	RB	O
and	VBN	O
dispersed	IN	O
as	CC	O
minute	VBD	O
droplets	IN	O
into	JJ	O
a	NNS	O
bulk	IN	O
oily	DT	O
phase	NN	O
the	RB	O
resulting	VBZ	O
composition	DT	O
is	VBG	O
called	NN	O
a	VBZ	O
water-in-oil	VBN	O
(w/o)	DT	O
emulsion.	NN	O
Alternatively,	)	O
when	.	O
an	,	O
oily	WRB	O
phase	DT	O
is	JJ	O
finely	NN	O
divided	VBZ	O
into	RB	O
and	VBN	O
dispersed	IN	O
as	CC	O
minute	VBD	O
droplets	IN	O
into	JJ	O
a	NNS	O
bulk	IN	O
aqueous	DT	O
phase	NN	O
the	JJ	O
resulting	NN	O
composition	DT	O
is	VBG	O
called	NN	O
an	VBZ	O
oil-in-water	VBN	O
(o/w)	DT	O
emulsion.	NN	O
Emulsions	)	O
may	.	O
contain	NNS	O
additional	MD	O
components	VB	O
in	JJ	O
addition	NNS	O
to	IN	O
the	NN	O
dispersed	TO	O
phases	DT	O
and	JJ	O
the	NNS	O
active	CC	O
drug	DT	O
which	JJ	O
may	NN	O
be	WDT	O
present	MD	O
as	VB	O
a	JJ	O
solution	IN	O
in	DT	O
either	NN	O
the	IN	O
aqueous	CC	O
phase,	DT	O
oily	JJ	O
phase	,	O
or	RB	O
itself	NN	O
as	CC	O
a	PRP	O
separate	IN	O
phase.	DT	O
Pharmaceutical	JJ	O
excipients	.	O
such	JJ	O
as	NNS	O
emulsifiers,	JJ	O
stabilizers,	IN	O
dyes,	,	O
and	,	O
anti-oxidants	,	O
may	CC	O
also	NNS	O
be	MD	O
present	RB	O
in	VB	O
emulsions	JJ	O
as	IN	O
needed.	NNS	O
Pharmaceutical	IN	O
emulsions	.	O
may	JJ	O
also	NNS	O
be	MD	O
multiple	RB	O
emulsions	VB	O
that	JJ	O
are	NNS	O
comprised	WDT	O
of	VBP	O
more	VBN	O
than	IN	O
two	JJR	O
phases	IN	O
such	CD	O
as,	NNS	O
for	JJ	O
example,	,	O
in	IN	O
the	,	O
case	IN	O
of	DT	O
oil-in-water-in-oil	NN	O
(o/w/o)	IN	O
and	NN	O
water-in-oil-in-water	)	O
(w/o/w)	CC	O
emulsions.	NN	O
Such	)	O
complex	.	O
formulations	JJ	O
often	JJ	O
provide	NNS	O
certain	RB	O
advantages	VBP	O
that	JJ	O
simple	NNS	O
binary	WDT	O
emulsions	VBP	O
do	JJ	O
not.	NNS	O
Multiple	VBP	O
emulsions	.	O
in	JJ	O
which	NNS	O
individual	IN	O
oil	WDT	O
droplets	JJ	O
of	NN	O
an	NNS	O
o/w	IN	O
emulsion	DT	O
enclose	JJ	O
small	NN	O
water	VB	O
droplets	JJ	O
constitute	NN	O
a	NNS	O
w/o/w	VBP	O
emulsion.	DT	O
Likewise	JJ	O
a	.	O
system	RB	O
of	DT	O
oil	NN	O
droplets	IN	O
enclosed	NN	O
in	NNS	O
globules	VBD	O
of	IN	O
water	NNS	O
stabilized	IN	O
in	NN	O
an	VBN	O
oily	IN	O
continuous	DT	O
provides	RB	O
an	JJ	O
o/w/o	VBZ	O
emulsion.	DT	O
Often,	JJ	O
the	.	O
dispersed	,	O
or	DT	O
discontinuous	JJ	O
phase	CC	O
of	JJ	O
the	NN	O
emulsion	IN	O
is	DT	O
well	NN	O
dispersed	VBZ	O
into	RB	O
the	VBN	O
external	IN	O
or	DT	O
continuous	JJ	O
phase	CC	O
and	JJ	O
maintained	NN	O
in	CC	O
this	VBN	O
form	IN	O
through	DT	O
the	NN	O
means	IN	O
of	DT	O
emulsifiers	NNS	O
or	IN	O
the	NNS	O
viscosity	CC	O
of	DT	O
the	NN	O
formulation.	IN	O
Either	DT	O
of	.	O
the	DT	O
phases	IN	O
of	DT	O
the	NNS	O
emulsion	IN	O
may	DT	O
be	NN	O
a	MD	O
semisolid	VB	O
or	DT	O
a	JJ	O
solid,	CC	O
as	DT	O
is	,	O
the	IN	O
case	VBZ	O
of	DT	O
emulsion-style	NN	O
ointment	IN	O
bases	JJ	O
and	NN	O
creams.	NNS	O
Other	CC	O
means	.	O
of	JJ	O
stabilizing	NNS	O
emulsions	IN	O
entail	VBG	O
the	NNS	O
use	VBP	O
of	DT	O
emulsifiers	NN	O
that	IN	O
may	NNS	O
be	WDT	O
incorporated	MD	O
into	VB	O
either	VBN	O
phase	IN	O
of	DT	O
the	NN	O
emulsion.	IN	O
Emulsifiers	DT	O
may	.	O
broadly	NNS	O
be	MD	O
classified	RB	O
into	VB	O
four	VBN	O
categories:	IN	O
synthetic	CD	O
surfactants,	:	O
naturally	JJ	O
occurring	,	O
emulsifiers,	RB	O
absorption	VBG	O
bases,	,	O
and	NN	O
finely	,	O
dispersed	CC	O
solids	RB	O
Idson,	JJ	B
in	NNS	I
Pharmaceutical	,	I
Dosage	IN	I
Forms,	JJ	I
Lieberman,	NN	I
Rieger	,	I
and	,	I
Banker	NNP	I
(Eds.),	CC	I
1988,	NNP	I
Marcel	,	I
Dekker,	,	I
Inc.,	NNP	I
New	,	I
York,	,	I
N.Y.,	NNP	I
volume	,	I
1,	,	I
p.	NN	I
199).(	,	O
Synthetic	RB	O
surfactants,	.	O
also	JJ	O
known	,	O
as	RB	O
surface	VBN	O
active	IN	O
agents,	NN	O
have	JJ	O
found	,	O
wide	VBP	O
applicability	VBN	O
in	JJ	O
the	NN	O
formulation	IN	O
of	DT	O
emulsions	NN	O
and	IN	O
have	NNS	O
been	CC	O
reviewed	VBP	O
in	VBN	O
the	VBN	O
literature	IN	O
Rieger,	DT	B
in	NN	I
Pharmaceutical	,	I
Dosage	IN	I
Forms,	JJ	I
Lieberman,	NN	I
Rieger	,	I
and	,	I
Banker	NNP	I
(Eds.),	CC	I
1988,	NNP	I
Marcel	,	I
Dekker,	,	I
Inc.,	NNP	I
New	,	I
York,	,	I
N.Y.,	NNP	I
volume	,	I
1,	,	I
p.	NN	I
285;	,	I
Idson,	RB	B
in	:	I
Pharmaceutical	,	I
Dosage	IN	I
Forms,	JJ	I
Lieberman,	NN	I
Rieger	,	I
and	,	I
Banker	NNP	I
(Eds.),	CC	I
Marcel	NNP	I
Dekker,	,	I
Inc.,	NNP	I
New	,	I
York,	,	I
N.Y.,	NNP	I
1988,	,	I
volume	,	I
1,	,	I
p.	NN	I
199).(	,	O
Surfactants	RB	O
are	.	O
typically	NNS	O
amphiphilic	VBP	O
and	RB	O
comprise	JJ	O
a	CC	O
hydrophilic	VB	O
and	DT	O
a	NN	O
hydrophobic	CC	O
portion.	DT	O
The	JJ	O
ratio	.	O
of	DT	O
the	NN	O
hydrophilic	IN	O
to	DT	O
the	NN	O
hydrophobic	TO	O
nature	DT	O
of	JJ	O
the	NN	O
surfactant	IN	O
has	DT	O
been	NN	O
termed	VBZ	O
the	VBN	O
hydrophile/lipophile	VBN	O
balance	DT	O
(HLB)	NN	O
and	NN	O
is	)	O
a	CC	O
valuable	VBZ	O
tool	DT	O
in	JJ	O
categorizing	NN	O
and	IN	O
selecting	VBG	O
surfactants	CC	O
in	VBG	O
the	NNS	O
preparation	IN	O
of	DT	O
formulations.	NN	O
Surfactants	IN	O
may	.	O
be	NNS	O
classified	MD	O
into	VB	O
different	VBN	O
classes	IN	O
based	JJ	O
on	NNS	O
the	VBN	O
nature	IN	O
of	DT	O
the	NN	O
hydrophilic	IN	O
group:	DT	O
nonionic,	JJ	O
anionic,	:	O
cationic	,	O
and	,	O
amphoteric	JJ	O
Rieger,	CC	B
in	JJ	I
Pharmaceutical	,	I
Dosage	IN	I
Forms,	JJ	I
Lieberman,	NN	I
Rieger	,	I
and	,	I
Banker	NNP	I
(Eds.),	CC	I
1988,	NNP	I
Marcel	,	I
Dekker,	,	I
Inc.,	NNP	I
New	,	I
York,	,	I
N.Y.,	NNP	I
volume	,	I
1,	,	I
p.	NN	I
285).(	,	O
Naturally	RB	O
occurring	.	O
emulsifiers	RB	O
used	VBG	O
in	NNS	O
emulsion	VBN	O
formulations	IN	O
include	NN	O
lanolin,	NNS	O
beeswax,	VBP	O
phosphatides,	,	O
lecithin	,	O
and	,	O
acacia.	NN	O
Absorption	CC	O
bases	.	O
possess	NN	O
hydrophilic	NNS	O
properties	VBP	O
such	JJ	O
that	NNS	O
they	JJ	O
can	IN	O
soak	PRP	O
up	MD	O
water	VB	O
to	RP	O
form	NN	O
w/o	TO	O
emulsions	VB	O
yet	JJ	O
retain	NNS	O
their	RB	O
semisolid	VBP	O
consistencies,	PRP$	O
such	JJ	O
as	,	O
anhydrous	JJ	O
lanolin	IN	O
and	JJ	O
hydrophilic	NN	O
petrolatum.	CC	O
Finely	JJ	O
divided	.	O
solids	RB	O
have	VBN	O
also	NNS	O
been	VBP	O
used	RB	O
as	VBN	O
good	VBN	O
emulsifiers	IN	O
especially	JJ	O
in	NNS	O
combination	RB	O
with	IN	O
surfactants	NN	O
and	IN	O
in	NNS	O
viscous	CC	O
preparations.	IN	O
These	JJ	O
include	.	O
polar	DT	O
inorganic	VBP	O
solids,	JJ	O
such	JJ	O
as	,	O
heavy	JJ	O
metal	IN	O
hydroxides,	JJ	O
nonswelling	NN	O
clays	,	O
such	VBG	O
as	NNS	O
bentonite,	JJ	O
attapulgite,	IN	O
hectorite,	,	O
kaolin,	,	O
montmorillonite,	,	O
colloidal	,	O
aluminum	,	O
silicate	JJ	O
and	NN	O
colloidal	NN	O
magnesium	CC	O
aluminum	JJ	O
silicate,	NN	O
pigments	NN	O
and	,	O
nonpolar	NNS	O
solids	CC	O
such	JJ	O
as	NNS	O
carbon	JJ	O
or	IN	O
glyceryl	NN	O
tristearate.	CC	O
A	NN	O
large	.	O
variety	DT	O
of	JJ	O
non-emulsifying	NN	O
materials	IN	O
are	JJ	O
also	NNS	O
included	VBP	O
in	RB	O
emulsion	VBN	O
formulations	IN	O
and	NN	O
contribute	NNS	O
to	CC	O
the	NN	O
properties	TO	O
of	DT	O
emulsions.	NNS	O
These	IN	O
include	.	O
fats,	DT	O
oils,	VBP	O
waxes,	,	O
fatty	,	O
acids,	,	O
fatty	JJ	O
alcohols,	,	O
fatty	JJ	O
esters,	,	O
humectants,	JJ	O
hydrophilic	,	O
colloids,	,	O
preservatives	JJ	O
and	,	O
antioxidants	NNS	O
Block,	CC	B
in	NNS	I
Pharmaceutical	,	I
Dosage	IN	I
Forms,	JJ	I
Lieberman,	NN	I
Rieger	,	I
and	,	I
Banker	NNP	I
(Eds.),	CC	I
1988,	NNP	I
Marcel	,	I
Dekker,	,	I
Inc.,	NNP	I
New	,	I
York,	,	I
N.Y.,	NNP	I
volume	,	I
1,	,	I
p.	NN	I
335;	,	I
Idson,	RB	B
in	:	I
Pharmaceutical	,	I
Dosage	IN	I
Forms,	JJ	I
Lieberman,	NN	I
Rieger	,	I
and	,	I
Banker	NNP	I
(Eds.),	CC	I
1988,	NNP	I
Marcel	,	I
Dekker,	,	I
Inc.,	NNP	I
New	,	I
York,	,	I
N.Y.,	NNP	I
volume	,	I
1,	,	I
p.	NN	I
199).
(	,	O
Hydrophilic	RB	O
colloids	.	O
or	JJ	O
hydrocolloids	NNS	O
include	CC	O
naturally	NNS	O
occurring	VBP	O
gums	RB	O
and	VBG	O
synthetic	NNS	O
polymers	CC	O
such	JJ	O
as	NNS	O
polysaccharides	JJ	O
(for	IN	O
example,	NNS	O
acacia,	IN	O
agar,	,	O
alginic	,	O
acid,	,	O
carrageenan,	JJ	O
guar	,	O
gum,	,	O
karaya	NN	O
gum,	,	O
and	FW	O
tragacanth),	,	O
cellulose	CC	O
derivatives	,	O
(for	JJ	O
example,	NNS	O
carboxymethylcellulose	IN	O
and	,	O
carboxypropylcellulose),	NN	O
and	CC	O
synthetic	,	O
polymers	CC	O
(for	JJ	O
example,	NNS	O
carbomers,	IN	O
cellulose	,	O
ethers,	,	O
and	JJ	O
carboxyvinyl	,	O
polymers).	CC	O
These	JJ	O
disperse	.	O
or	DT	O
swell	NN	O
in	CC	O
water	NN	O
to	IN	O
form	NN	O
colloidal	TO	O
solutions	VB	O
that	JJ	O
stabilize	NNS	O
emulsions	WDT	O
by	VBP	O
forming	NNS	O
strong	IN	O
interfacial	VBG	O
films	JJ	O
around	JJ	O
the	NNS	O
dispersed-phase	IN	O
droplets	DT	O
and	JJ	O
by	NNS	O
increasing	CC	O
the	IN	O
viscosity	VBG	O
of	DT	O
the	NN	O
external	IN	O
phase.	DT	O
Since	JJ	O
emulsions	.	O
often	IN	O
contain	NNS	O
a	RB	O
number	VBP	O
of	DT	O
ingredients	NN	O
such	IN	O
as	NNS	O
carbohydrates,	JJ	O
proteins,	IN	O
sterols	,	O
and	,	O
phosphatides	NNS	O
that	CC	O
may	NNS	O
readily	WDT	O
support	MD	O
the	VB	O
growth	VB	O
of	DT	O
microbes,	NN	O
these	IN	O
formulations	,	O
often	DT	O
incorporate	NNS	O
preservatives.	RB	O
Commonly	VBP	O
used	.	O
preservatives	RB	O
included	VBN	O
in	NNS	O
emulsion	VBD	O
formulations	IN	O
include	NN	O
methyl	NNS	O
paraben,	VBP	O
propyl	JJ	O
paraben,	,	O
quaternary	NN	O
ammonium	,	O
salts,	JJ	O
benzalkonium	NN	O
chloride,	,	O
esters	NN	O
of	,	O
p-hydroxybenzoic	NNS	O
acid,	IN	O
and	JJ	O
boric	,	O
acid.	CC	O
Antioxidants	JJ	O
are	.	O
also	NNS	O
commonly	VBP	O
added	RB	O
to	RB	O
emulsion	VBD	O
formulations	TO	O
to	VB	O
prevent	NNS	O
deterioration	TO	O
of	VB	O
the	NN	O
formulation.	IN	O
Antioxidants	DT	O
used	.	O
may	NNS	O
be	VBN	O
free	MD	O
radical	VB	O
scavengers	JJ	O
such	JJ	O
as	NNS	O
tocopherols,	JJ	O
alkyl	IN	O
gallates,	,	O
butylated	NN	O
hydroxyanisole,	,	O
butylated	VBD	O
hydroxytoluene,	,	O
or	VBN	O
reducing	,	O
agents	CC	O
such	VBG	O
as	NNS	O
ascorbic	JJ	O
acid	IN	O
and	JJ	O
sodium	NN	O
metabisulfite,	CC	O
and	NN	O
antioxidant	,	O
synergists	CC	O
such	JJ	O
as	NNS	O
citric	JJ	O
acid,	IN	O
tartaric	JJ	O
acid,	,	O
and	JJ	O
lecithin.	,	O
The	CC	O
application	.	O
of	DT	O
emulsion	NN	O
formulations	IN	O
via	NN	O
dermatological,	NNS	O
oral	IN	O
and	,	O
parenteral	JJ	O
routes	CC	O
and	JJ	O
methods	NNS	O
for	CC	O
their	NNS	O
manufacture	IN	O
have	PRP$	O
been	NN	O
reviewed	VBP	O
in	VBN	O
the	VBN	O
literature	IN	O
Idson,	DT	B
in	NN	I
Pharmaceutical	,	I
Dosage	IN	I
Forms,	JJ	I
Lieberman,	NN	I
Rieger	,	I
and	,	I
Banker	NNP	I
(Eds.),	CC	I
1988,	NNP	I
Marcel	,	I
Dekker,	,	I
Inc.,	NNP	I
New	,	I
York,	,	I
N.Y.,	NNP	I
volume	,	I
1,	,	I
p.	NN	I
199).(	,	O
Emulsion	RB	O
formulations	.	O
for	NN	O
oral	NNS	O
delivery	IN	O
have	JJ	O
been	NN	O
very	VBP	O
widely	VBN	O
used	RB	O
because	RB	O
of	VBN	O
reasons	IN	O
of	IN	O
ease	NNS	O
of	IN	O
formulation,	NN	O
efficacy	IN	O
from	,	O
an	NN	O
absorption	IN	O
and	DT	O
bioavailability	NN	O
standpoint.	CC	O
Rosoff,	NN	B
in	.	I
Pharmaceutical	,	I
Dosage	IN	I
Forms,	JJ	I
Lieberman,	NN	I
Rieger	,	I
and	,	I
Banker	NNP	I
(Eds.),	CC	I
1988,	NNP	I
Marcel	,	I
Dekker,	,	I
Inc.,	NNP	I
New	,	I
York,	,	I
N.Y.,	NNP	I
volume	,	I
1,	,	I
p.	NN	I
245;	,	I
Idson,	RB	B
in	:	I
Pharmaceutical	,	I
Dosage	IN	I
Forms,	JJ	I
Lieberman,	NN	I
Rieger	,	I
and	,	I
Banker	NNP	I
(Eds.),	CC	I
1988,	NNP	I
Marcel	,	I
Dekker,	,	I
Inc.,	NNP	I
New	,	I
York,	,	I
N.Y.,	NNP	I
volume	,	I
1,	,	I
p.	NN	I
199).(	,	O
Mineral-oil	RB	O
base	.	O
laxatives,	JJ	O
oil-soluble	NN	O
vitamins	,	O
and	JJ	O
high	NNS	O
fat	CC	O
nutritive	JJ	O
preparations	NN	O
are	JJ	O
among	NNS	O
the	VBP	O
materials	IN	O
that	DT	O
have	NNS	O
commonly	WDT	O
been	VBP	O
administered	RB	O
orally	VBN	O
as	VBN	O
o/w	RB	O
emulsions.	IN	O
In	JJ	O
one	.	O
embodiment	IN	O
of	CD	O
the	NN	O
present	IN	O
invention,	DT	O
the	JJ	O
compositions	,	O
of	DT	O
oligonucleotides	NNS	O
are	IN	O
formulated	NNS	O
as	VBP	O
microemulsions.	VBN	O
A	IN	O
microemulsion	.	O
may	DT	O
be	NN	O
defined	MD	O
as	VB	O
a	VBN	O
system	IN	O
of	DT	O
water,	NN	O
oil	IN	O
and	,	O
amphiphile	NN	O
which	CC	O
is	NN	O
a	WDT	O
single	VBZ	O
optically	DT	O
isotropic	JJ	O
and	RB	O
thermodynamically	JJ	O
stable	CC	O
liquid	RB	O
solution	JJ	O
Rosoff,	JJ	B
in	NN	I
Pharmaceutical	,	I
Dosage	IN	I
Forms,	JJ	I
Lieberman,	NN	I
Rieger	,	I
and	,	I
Banker	NNP	I
(Eds.),	CC	I
1988,	NNP	I
Marcel	,	I
Dekker,	,	I
Inc.,	NNP	I
New	,	I
York,	,	I
N.Y.,	NNP	I
volume	,	I
1,	,	I
p.	NN	I
245).(	,	O
Typically	RB	O
microemulsions	.	O
are	RB	O
systems	NNS	O
that	VBP	O
are	NNS	O
prepared	WDT	O
by	VBP	O
first	VBN	O
dispersing	IN	O
an	JJ	O
oil	VBG	O
in	DT	O
an	NN	O
aqueous	IN	O
surfactant	DT	O
solution	JJ	O
and	JJ	O
then	NN	O
adding	CC	O
a	RB	O
sufficient	VBG	O
amount	DT	O
of	JJ	O
a	NN	O
fourth	IN	O
component,	DT	O
generally	JJ	O
an	,	O
intermediate	RB	O
chain-length	DT	O
alcohol	JJ	O
to	NN	O
form	NN	O
a	TO	O
transparent	VB	O
system.	DT	O
Therefore,	NN	O
microemulsions	.	O
have	,	O
also	NNS	O
been	VBP	O
described	RB	O
as	VBN	O
thermodynamically	VBN	O
stable,	IN	O
isotropically	RB	O
clear	,	O
dispersions	RB	O
of	JJ	O
two	NNS	O
immiscible	IN	O
liquids	CD	O
that	JJ	O
are	NNS	O
stabilized	WDT	O
by	VBP	O
interfacial	VBN	O
films	IN	O
of	JJ	O
surface-active	NNS	O
molecules	IN	O
Leung	JJ	B
and	NNS	I
Shah,	NNP	I
in:	CC	I
Controlled	,	I
Release	:	I
of	JJ	I
Drugs:	NNP	I
Polymers	IN	I
and	:	I
Aggregate	NNS	I
Systems,	CC	I
Rosoff,	NNP	I
M.,	,	I
Ed.,	,	I
1989,	,	I
VCH	,	I
Publishers,	,	I
New	NNP	I
York,	,	I
pages	NNP	I
185-215).(	,	O
Microemulsions	VBZ	O
commonly	.	O
are	NNS	O
prepared	RB	O
via	VBP	O
a	JJ	O
combination	IN	O
of	DT	O
three	NN	O
to	IN	O
five	CD	O
components	TO	O
that	CD	O
include	NNS	O
oil,	WDT	O
water,	VBP	O
surfactant,	,	O
cosurfactant	,	O
and	,	O
electrolyte.	NN	O
Whether	CC	O
the	.	O
microemulsion	IN	O
is	DT	O
of	NN	O
the	VBZ	O
water-in-oil	IN	O
(w/o)	DT	O
or	NN	O
an	)	O
oil-in-water	CC	O
(o/w)	DT	O
type	JJ	O
is	)	O
dependent	NN	O
on	VBZ	O
the	JJ	O
properties	IN	O
of	DT	O
the	NNS	O
oil	IN	O
and	DT	O
surfactant	NN	O
used	CC	O
and	NN	O
on	VBN	O
the	CC	O
structure	IN	O
and	DT	O
geometric	NN	O
packing	CC	O
of	JJ	O
the	NN	O
polar	IN	O
heads	DT	O
and	JJ	O
hydrocarbon	NNS	O
tails	CC	O
of	NN	O
the	NNS	O
surfactant	IN	O
molecules	DT	O
Schott,	JJ	B
in	NNS	I
Remington's	,	I
Pharmaceutical	IN	I
Sciences,	POS	I
Mack	NNP	I
Publishing	,	I
Co.,	NNP	I
Easton,	NNP	I
Pa.,	,	I
1985,	,	I
p.	,	I
271).(	,	O
The	VBZ	O
phenomenological	.	O
approach	DT	O
utilizing	JJ	O
phase	NN	O
diagrams	VBG	O
has	NN	O
been	NN	O
extensively	VBZ	O
studied	VBN	O
and	RB	O
has	VBN	O
yielded	CC	O
a	VBZ	O
comprehensive	VBN	O
knowledge,	DT	O
to	JJ	O
one	,	O
skilled	TO	O
in	CD	O
the	VBN	O
art,	IN	O
of	DT	O
how	,	O
to	IN	O
formulate	WRB	O
microemulsions	TO	O
Rosoff,	VB	B
in	NNS	I
Pharmaceutical	,	I
Dosage	IN	I
Forms,	JJ	I
Lieberman,	NN	I
Rieger	,	I
and	,	I
Banker	NNP	I
(Eds.),	CC	I
1988,	NNP	I
Marcel	,	I
Dekker,	,	I
Inc.,	NNP	I
New	,	I
York,	,	I
N.Y.,	NNP	I
volume	,	I
1,	,	I
p.	NN	I
245;	,	I
Block,	RB	B
in	:	I
Pharmaceutical	,	I
Dosage	IN	I
Forms,	JJ	I
Lieberman,	NN	I
Rieger	,	I
and	,	I
Banker	NNP	I
(Eds.),	CC	I
1988,	NNP	I
Marcel	,	I
Dekker,	,	I
Inc.,	NNP	I
New	,	I
York,	,	I
N.Y.,	NNP	I
volume	,	I
1,	,	I
p.	NN	I
335).(	,	O
Compared	RB	O
to	.	O
conventional	VBN	O
emulsions,	TO	O
microemulsions	JJ	O
offer	,	O
the	NNS	O
advantage	VBP	O
of	DT	O
solubilizing	NN	O
water-insoluble	IN	O
drugs	VBG	O
in	JJ	O
a	NNS	O
formulation	IN	O
of	DT	O
thermodynamically	NN	O
stable	IN	O
droplets	RB	O
that	JJ	O
are	NNS	O
formed	WDT	O
spontaneously.	VBP	O
Surfactants	VBN	O
used	.	O
in	NNS	O
the	VBN	O
preparation	IN	O
of	DT	O
microemulsions	NN	O
include,	IN	O
but	NNS	O
are	,	O
not	CC	O
limited	VBP	O
to,	RB	O
ionic	VBN	O
surfactants,	,	O
non-ionic	JJ	O
surfactants,	,	O
Brij	JJ	O
96,	,	O
polyoxyethylene	NNP	O
oleyl	,	O
ethers,	NN	O
polyglycerol	NN	O
fatty	,	O
acid	NN	O
esters,	JJ	O
tetraglycerol	NN	O
monolaurate	,	O
(ML310),	NN	O
tetraglycerol	NN	O
monooleate	,	O
(MO310),	JJ	O
hexaglycerol	NN	O
monooleate	,	O
(PO310),	JJ	O
hexaglycerol	NN	O
pentaoleate	,	O
(PO500),	JJ	O
decaglycerol	NN	O
monocaprate	,	O
(MCA750),	JJ	O
decaglycerol	NN	O
monooleate	,	O
(MO750),	JJ	O
decaglycerol	NN	O
sequioleate	,	O
(SO750),	JJ	O
decaglycerol	NN	O
decaoleate	,	O
(DAO750),	JJ	O
alone	NN	O
or	,	O
in	RB	O
combination	CC	O
with	IN	O
cosurfactants.	NN	O
The	IN	O
cosurfactant,	.	O
usually	DT	O
a	,	O
short-chain	RB	O
alcohol	DT	O
such	JJ	O
as	NN	O
ethanol,	JJ	O
1-propanol,	IN	O
and	,	O
1-butanol,	,	O
serves	CC	O
to	,	O
increase	VBZ	O
the	TO	O
interfacial	VB	O
fluidity	DT	O
by	JJ	O
penetrating	NN	O
into	IN	O
the	VBG	O
surfactant	IN	O
film	DT	O
and	JJ	O
consequently	NN	O
creating	CC	O
a	RB	O
disordered	VBG	O
film	DT	O
because	JJ	O
of	NN	O
the	IN	O
void	IN	O
space	DT	O
generated	JJ	O
among	NN	O
surfactant	VBD	O
molecules.	IN	O
Microemulsions	JJ	O
may,	.	O
however,	NNS	O
be	,	O
prepared	,	O
without	VB	O
the	VBN	O
use	IN	O
of	DT	O
cosurfactants	NN	O
and	IN	O
alcohol-free	NNS	O
self-emulsifying	CC	O
microemulsion	JJ	O
systems	JJ	O
are	NN	O
known	NNS	O
in	VBP	O
the	VBN	O
art.	IN	O
The	DT	O
aqueous	.	O
phase	DT	O
may	JJ	O
typically	NN	O
be,	MD	O
but	RB	O
is	,	O
not	CC	O
limited	VBZ	O
to,	RB	O
water,	VBN	O
an	,	O
aqueous	,	O
solution	DT	O
of	JJ	O
the	NN	O
drug,	IN	O
glycerol,	DT	O
PEG300,	,	O
PEG400,	,	O
polyglycerols,	,	O
propylene	,	O
glycols,	,	O
and	NN	O
derivatives	,	O
of	CC	O
ethylene	NNS	O
glycol.	IN	O
The	NN	O
oil	.	O
phase	DT	O
may	NN	O
include,	NN	O
but	MD	O
is	,	O
not	CC	O
limited	VBZ	O
to,	RB	O
materials	VBN	O
such	,	O
as	NNS	O
Captex	JJ	O
300,	IN	O
Captex	NNP	O
355,	,	O
Capmul	NNP	O
MCM,	,	O
fatty	NNP	O
acid	,	O
esters,	JJ	O
medium	NN	O
chain	,	O
(C8-C12)	NN	O
mono,	NN	O
di,	)	O
and	,	O
tri-glycerides,	,	O
polyoxyethylated	CC	O
glyceryl	,	O
fatty	VBD	O
acid	JJ	O
esters,	JJ	O
fatty	NN	O
alcohols,	,	O
polyglycolized	JJ	O
glycerides,	,	O
saturated	VBN	O
polyglycolized	,	O
C8-C10	VBD	O
glycerides,	JJ	O
vegetable	NNP	O
oils	,	O
and	NN	O
silicone	NNS	O
oil.	CC	O
Microemulsions	NN	O
are	.	O
particularly	NNS	O
of	VBP	O
interest	RB	O
from	IN	O
the	NN	O
standpoint	IN	O
of	DT	O
drug	NN	O
solubilization	IN	O
and	NN	O
the	NN	O
enhanced	CC	O
absorption	DT	O
of	JJ	O
drugs.	NN	O
Lipid	IN	O
based	.	O
microemulsions	NNP	O
(both	VBN	O
o/w	NNS	O
and	DT	O
w/o)	NN	O
have	CC	O
been	)	O
proposed	VBP	O
to	VBN	O
enhance	VBN	O
the	TO	O
oral	VB	O
bioavailability	DT	O
of	JJ	O
drugs,	NN	O
including	IN	O
peptides	,	O
Constantinides	VBG	B
et	NNS	I
al.,	NNP	I
Pharmaceutical	RB	I
Research,	,	I
1994,	NNP	I
11,	,	I
1385-1390;	,	I
Ritschel,	,	B
Meth.	:	I
Find.	,	I
Exp.	.	I
Clin.	.	I
Pharmacol.,	.	I
1993,	.	I
13,	,	I
205).(	,	O
Microemulsions	,	O
afford	.	O
advantages	NNS	O
of	VBP	O
improved	NNS	O
drug	IN	O
solubilization,	JJ	O
protection	NN	O
of	,	O
drug	NN	O
from	IN	O
enzymatic	NN	O
hydrolysis,	IN	O
possible	JJ	O
enhancement	,	O
of	JJ	O
drug	NN	O
absorption	IN	O
due	NN	O
to	NN	O
surfactant-induced	JJ	O
alterations	TO	O
in	JJ	O
membrane	NNS	O
fluidity	IN	O
and	NN	O
permeability,	NN	O
ease	CC	O
of	,	O
preparation,	NN	O
ease	IN	O
of	,	O
oral	NN	O
administration	IN	O
over	JJ	O
solid	NN	O
dosage	IN	O
forms,	JJ	O
improved	NN	O
clinical	,	O
potency,	JJ	O
and	JJ	O
decreased	,	O
toxicity	CC	O
Constantinides	JJ	B
et	NN	I
al.,	NNP	I
Pharmaceutical	RB	I
Research,	,	I
1994,	NNP	I
11,	,	I
1385;	,	I
Ho	,	B
et	:	I
al.,	NNP	I
J.	FW	I
Pharm.	,	I
Sci.,	NNP	I
1996,	.	I
85,	,	I
138-143).(	,	O
Often	,	O
microemulsions	.	O
may	NNP	O
form	NNS	O
spontaneously	MD	O
when	VB	O
their	RB	O
components	WRB	O
are	PRP$	O
brought	NNS	O
together	VBP	O
at	VBN	O
ambient	RB	O
temperature.	IN	O
This	JJ	O
may	.	O
be	DT	O
particularly	MD	O
advantageous	VB	O
when	RB	O
formulating	JJ	O
thermolabile	WRB	O
drugs,	VBG	O
peptides	NN	O
or	,	O
oligonucleotides.	NNS	O
Microemulsions	CC	O
have	.	O
also	NNS	O
been	VBP	O
effective	RB	O
in	VBN	O
the	JJ	O
transdermal	IN	O
delivery	DT	O
of	JJ	O
active	NN	O
components	IN	O
in	JJ	O
both	NNS	O
cosmetic	IN	O
and	DT	O
pharmaceutical	JJ	O
applications.	CC	O
It	JJ	O
is	.	O
expected	PRP	O
that	VBZ	O
the	VBN	O
microemulsion	IN	O
compositions	DT	O
and	NN	O
formulations	NNS	O
of	CC	O
the	NNS	O
present	IN	O
invention	DT	O
will	JJ	O
facilitate	NN	O
the	MD	O
increased	VB	O
systemic	DT	O
absorption	JJ	O
of	JJ	O
oligonucleotides	NN	O
from	IN	O
the	NNS	O
gastrointestinal	IN	O
tract,	DT	O
as	JJ	O
well	,	O
as	RB	O
improve	RB	O
the	IN	O
local	VB	O
cellular	DT	O
uptake	JJ	O
of	JJ	O
oligonucleotides	NN	O
within	IN	O
the	NNS	O
gastrointestinal	IN	O
tract,	DT	O
vagina,	JJ	O
buccal	,	O
cavity	,	O
and	JJ	O
other	NN	O
areas	CC	O
of	JJ	O
administration.	NNS	O
Microemulsions	IN	O
of	.	O
the	NNS	O
present	IN	O
invention	DT	O
may	JJ	O
also	NN	O
contain	MD	O
additional	RB	O
components	VB	O
and	JJ	O
additives	NNS	O
such	CC	O
as	NNS	O
sorbitan	JJ	O
monostearate	IN	O
(Grill	JJ	O
3),	NN	O
Labrasol,	NNP	O
and	,	O
penetration	,	O
enhancers	CC	O
to	NN	O
improve	NNS	O
the	TO	O
properties	VB	O
of	DT	O
the	NNS	O
formulation	IN	O
and	DT	O
to	NN	O
enhance	CC	O
the	TO	O
absorption	VB	O
of	DT	O
the	NN	O
oligonucleotides	IN	O
and	DT	O
nucleic	NNS	O
acids	CC	O
of	JJ	O
the	NNS	O
present	IN	O
invention.	DT	O
Penetration	JJ	O
enhancers	.	O
used	NN	O
in	NNS	O
the	VBN	O
microemulsions	IN	O
of	DT	O
the	NNS	O
present	IN	O
invention	DT	O
may	JJ	O
be	NN	O
classified	MD	O
as	VB	O
belonging	VBN	O
to	IN	O
one	NN	O
of	TO	O
five	CD	O
broad	IN	O
categories	CD	O
described	JJ	O
herein.	NNS	O
There	VBD	O
are	.	O
many	EX	O
organized	VBP	O
surfactant	JJ	O
structures	VBN	O
besides	JJ	O
microemulsions	NNS	O
that	IN	O
have	NNS	O
been	WDT	O
studied	VBP	O
and	VBN	O
used	VBN	O
in	CC	O
the	VBN	O
formulation	IN	O
of	DT	O
drugs.	NN	O
These	IN	O
include	.	O
monolayers,	DT	O
micelles,	VBP	O
bilayers	,	O
and	,	O
vesicles.	NNS	O
Vesicles,	CC	O
such	.	O
as	,	O
liposomes,	JJ	O
have	IN	O
attracted	,	O
great	VBP	O
interest	VBN	O
because	JJ	O
of	NN	O
their	IN	O
specificity	IN	O
and	PRP$	O
the	NN	O
duration	CC	O
of	DT	O
action	NN	O
they	IN	O
offer	NN	O
from	PRP	O
the	VBP	O
standpoint	IN	O
of	DT	O
drug	NN	O
delivery.	IN	O
Formulations	NN	O
of	.	O
the	NNS	O
present	IN	O
invention	DT	O
include	JJ	O
liposomal	NN	O
formulations.	VBP	O
As	JJ	O
used	.	O
in	IN	O
the	VBN	O
present	IN	O
invention,	DT	O
the	JJ	O
term	,	O
“liposome”	DT	O
means	NN	O
a	NNP	O
vesicle	VBZ	O
composed	DT	O
of	NN	O
amphiphilic	VBN	O
lipids	IN	O
arranged	JJ	O
in	NNS	O
a	VBN	O
spherical	IN	O
bilayer	DT	O
or	JJ	O
bilayers.	NN	O
Liposomes	CC	O
are	.	O
unilamellar	NNS	O
or	VBP	O
multilamellar	JJ	O
vesicles	CC	O
which	JJ	O
have	NNS	O
a	WDT	O
membrane	VBP	O
formed	DT	O
from	NN	O
a	VBN	O
lipophilic	IN	O
material	DT	O
and	JJ	O
an	NN	O
aqueous	CC	O
interior	DT	O
that	JJ	O
contains	NN	O
the	WDT	O
composition	VBZ	O
to	DT	O
be	NN	O
delivered.	TO	O
In	VB	O
order	.	O
to	IN	O
cross	NN	O
intact	TO	O
mammalian	VB	O
skin,	JJ	O
lipid	JJ	O
vesicles	,	O
must	JJ	O
pass	NNS	O
through	MD	O
a	VB	O
series	IN	O
of	DT	O
fine	NN	O
pores,	IN	O
each	JJ	O
with	,	O
a	DT	O
diameter	IN	O
less	DT	O
than	NN	O
50	JJR	O
nm,	IN	O
under	CD	O
the	,	O
influence	IN	O
of	DT	O
a	NN	O
suitable	IN	O
transdermal	DT	O
gradient.	JJ	O
Therefore,	JJ	O
it	.	O
is	,	O
desirable	PRP	O
to	VBZ	O
use	JJ	O
a	TO	O
liposome	VB	O
which	DT	O
is	NN	O
highly	WDT	O
deformable	VBZ	O
and	RB	O
able	JJ	O
to	CC	O
pass	JJ	O
through	TO	O
such	VB	O
fine	IN	O
pores.	JJ	O
Further	JJ	O
advantages	.	O
of	JJ	O
liposomes	NNS	O
include:	IN	O
liposomes	NNS	O
obtained	:	O
from	NNS	O
natural	VBN	O
phospholipids	IN	O
are	JJ	O
biocompatible	NNS	O
and	VBP	O
biodegradable;	JJ	O
liposomes	CC	O
can	:	O
incorporate	NNS	O
a	MD	O
wide	VB	O
range	DT	O
of	JJ	O
water	NN	O
and	IN	O
lipid	NN	O
soluble	CC	O
drugs;	JJ	O
and	JJ	O
liposomes	:	O
can	CC	O
protect	NNS	O
encapsulated	MD	O
drugs	VB	O
in	JJ	O
their	NNS	O
internal	IN	O
compartments	PRP$	O
from	JJ	O
metabolism	NNS	O
and	IN	O
degradation	NN	O
Rosoff,	CC	B
in	NN	I
Pharmaceutical	,	I
Dosage	IN	I
Forms,	JJ	I
Lieberman,	NN	I
Rieger	,	I
and	,	I
Banker	NNP	I
(Eds.),	CC	I
1988,	NNP	I
Marcel	,	I
Dekker,	,	I
Inc.,	NNP	I
New	,	I
York,	,	I
N.Y.,	NNP	I
volume	,	I
1,	,	I
p.	NN	I
245).(	,	O
Important	RB	O
considerations	.	O
in	JJ	O
the	NNS	O
preparation	IN	O
of	DT	O
liposome	NN	O
formulations	IN	O
are	JJ	O
the	NNS	O
lipid	VBP	O
surface	DT	O
charge,	JJ	O
vesicle	NN	O
size	,	O
and	NN	O
the	NN	O
aqueous	CC	O
volume	DT	O
of	JJ	O
the	NN	O
liposomes.	IN	O
Liposomes	DT	O
are	.	O
useful	NNS	O
for	VBP	O
the	JJ	O
transfer	IN	O
and	DT	O
delivery	NN	O
of	CC	O
active	NN	O
ingredients	IN	O
to	JJ	O
the	NNS	O
site	TO	O
of	DT	O
action.	NN	O
Because	IN	O
the	.	O
liposomal	IN	O
membrane	DT	O
is	JJ	O
structurally	NN	O
similar	VBZ	O
to	RB	O
biological	JJ	O
membranes,	TO	O
when	JJ	O
liposomes	,	O
are	WRB	O
applied	NNS	O
to	VBP	O
a	VBN	O
tissue,	TO	O
the	DT	O
liposomes	,	O
start	DT	O
to	NNS	O
merge	VBP	O
with	TO	O
the	VB	O
cellular	IN	O
membranes.	DT	O
As	JJ	O
the	.	O
merging	IN	O
of	DT	O
the	NN	O
liposome	IN	O
and	DT	O
cell	NN	O
progresses,	CC	O
the	NN	O
liposomal	,	O
contents	DT	O
are	JJ	O
emptied	NNS	O
into	VBP	O
the	VBN	O
cell	IN	O
where	DT	O
the	NN	O
active	WRB	O
agent	DT	O
may	JJ	O
act.	NN	O
Liposomal	MD	O
formulations	.	O
have	JJ	O
been	NNS	O
the	VBP	O
focus	VBN	O
of	DT	O
extensive	NN	O
investigation	IN	O
as	JJ	O
the	NN	O
mode	IN	O
of	DT	O
delivery	NN	O
for	IN	O
many	NN	O
drugs.	IN	O
There	JJ	O
is	.	O
growing	EX	O
evidence	VBZ	O
that	VBG	O
for	NN	O
topical	IN	O
administration,	IN	O
liposomes	JJ	O
present	,	O
several	VBZ	O
advantages	JJ	O
over	JJ	O
other	NNS	O
formulations.	IN	O
Such	JJ	O
advantages	.	O
include	JJ	O
reduced	NNS	O
side-effects	VBP	O
related	VBN	O
to	NNS	O
high	VBN	O
systemic	TO	O
absorption	JJ	O
of	JJ	O
the	NN	O
administered	IN	O
drug,	DT	O
increased	JJ	O
accumulation	,	O
of	JJ	O
the	NN	O
administered	IN	O
drug	DT	O
at	JJ	O
the	NN	O
desired	IN	O
target,	DT	O
and	JJ	O
the	,	O
ability	CC	O
to	DT	O
administer	NN	O
a	TO	O
wide	VB	O
variety	DT	O
of	JJ	O
drugs,	NN	O
both	IN	O
hydrophilic	,	O
and	DT	O
hydrophobic,	JJ	O
into	CC	O
the	,	O
skin.	IN	O
Several	DT	O
reports	.	O
have	JJ	O
detailed	NNS	O
the	VBP	O
ability	VBN	O
of	DT	O
liposomes	NN	O
to	IN	O
deliver	NNS	O
agents	TO	O
including	VB	O
high-molecular	NNS	O
weight	VBG	O
DNA	JJ	O
into	NN	O
the	NNP	O
skin.	IN	O
Compounds	DT	O
including	.	O
analgesics,	NNS	O
antibodies,	VBG	O
hormones	,	O
and	,	O
high-molecular	NNS	O
weight	CC	O
DNAs	JJ	O
have	NN	O
been	NNP	O
administered	VBP	O
to	VBN	O
the	VBN	O
skin.	TO	O
The	DT	O
majority	.	O
of	DT	O
applications	NN	O
resulted	IN	O
in	NNS	O
the	VBN	O
targeting	IN	O
of	DT	O
the	NN	O
upper	IN	O
epidermis.	DT	O
Liposomes	JJ	O
fall	.	O
into	RB	O
two	VB	O
broad	IN	O
classes,	CD	O
cationic	JJ	O
and	,	O
non-cationic,	JJ	O
both	CC	O
of	,	O
which	DT	O
are	IN	O
useful	WDT	O
for	VBP	O
the	JJ	O
delivery	IN	O
of	DT	O
DNA,	NN	O
RNA	IN	O
or	,	O
any	NNP	O
nucleic	CC	O
acid-based	DT	O
construct	JJ	O
into	JJ	O
cells.	NN	O
Cationic	IN	O
liposomes	.	O
are	JJ	O
positively	NNS	O
charged	VBP	O
liposomes	RB	O
which	VBN	O
interact	NNS	O
with	WDT	O
negatively	VBP	O
charged	IN	O
DNA	RB	O
molecules	VBN	O
to	NNP	O
form	NNS	O
a	TO	O
stable	VB	O
complex.	DT	O
The	JJ	O
positively	.	O
charged	DT	O
DNA/liposome	RB	O
complex	VBN	O
binds	NNP	O
to	JJ	O
the	NNS	O
negatively	TO	O
charged	DT	O
cell	RB	O
surface	VBN	O
and	NN	O
is	NN	O
internalized	CC	O
in	VBZ	O
an	VBN	O
endosome.	IN	O
Due	DT	O
to	.	O
the	JJ	O
acidic	TO	O
pH	DT	O
within	JJ	O
the	NN	O
endosome,	IN	O
the	DT	O
liposomes	,	O
are	DT	O
ruptured,	NNS	O
releasing	VBP	O
their	,	O
contents	VBG	O
into	PRP$	O
the	NNS	O
cell	IN	O
cytoplasm	DT	O
Wang	NN	B
et	NN	I
al.,	NNP	I
Biochem.	RB	I
Biophys.	,	I
Res.	.	I
Commun.,	.	I
1987,	.	I
147,	,	I
980-985).(	,	O
Liposomes	,	O
which	.	O
are	NNS	O
pH-sensitive	WDT	O
or	VBP	O
negatively-charged,	JJ	O
also	CC	O
known	,	O
as	RB	O
non-cationic	VBN	O
liposomes,	IN	O
entrap	JJ	O
DNA	,	O
rather	VBP	O
than	NNP	O
complex	RB	O
with	IN	O
it.	JJ	O
Since	IN	O
both	.	O
the	IN	O
DNA	DT	O
and	DT	O
the	NN	O
lipid	CC	O
are	DT	O
similarly	NN	O
charged,	VBP	O
repulsion	RB	O
rather	,	O
than	NN	O
complex	RB	O
formation	IN	O
occurs.	JJ	O
Nevertheless,	NN	O
some	.	O
DNA	,	O
is	DT	O
entrapped	NN	O
within	VBZ	O
the	VBN	O
aqueous	IN	O
interior	DT	O
of	JJ	O
these	NN	O
liposomes.	IN	O
pH-sensitive	DT	O
liposomes	.	O
have	JJ	O
been	NNS	O
used	VBP	O
to	VBN	O
deliver	VBN	O
DNA	TO	O
encoding	VB	O
the	NNP	O
thymidine	VBG	O
kinase	DT	O
gene	NN	O
to	NN	O
cell	NN	O
monolayers	TO	O
in	VB	O
culture.	NNS	O
Expression	IN	O
of	.	O
the	NN	O
exogenous	IN	O
gene	DT	O
was	JJ	O
detected	NN	O
in	VBD	O
the	VBN	O
target	IN	O
cells	DT	O
Zhou	NN	B
et	NNS	I
al.,	NNP	I
Journal	RB	I
of	,	I
Controlled	NNP	I
Release,	IN	I
1992,	NNP	I
19,	,	I
269-274).(	,	O
One	,	O
major	.	O
type	CD	O
of	JJ	O
liposomal	NN	O
composition	IN	O
includes	JJ	O
phospholipids	NN	O
other	VBZ	O
than	IN	O
naturally-derived	JJ	O
phosphatidylcholine.	IN	O
Neutral	JJ	O
liposome	.	O
compositions,	JJ	O
for	NN	O
example,	,	O
can	IN	O
be	,	O
formed	MD	O
from	VB	O
dimyristoyl	VBN	O
phosphatidylcholine	IN	O
(DMPC)	JJ	O
or	NN	O
dipalmitoyl	)	O
phosphatidylcholine	CC	O
(DPPC).	JJ	O
Anionic	NN	O
liposome	.	O
compositions	NNP	O
generally	NN	O
are	NNS	O
formed	RB	O
from	VBP	O
dimyristoyl	VBN	O
phosphatidylglycerol,	IN	O
while	NN	O
anionic	,	O
fusogenic	IN	O
liposomes	JJ	O
are	JJ	O
formed	NNS	O
primarily	VBP	O
from	VBN	O
dioleoyl	RB	O
phosphatidylethanolamine	IN	O
(DOPE).	JJ	O
Another	NN	O
type	.	O
of	DT	O
liposomal	NN	O
composition	IN	O
is	JJ	O
formed	NN	O
from	VBZ	O
phosphatidylcholine	VBN	O
(PC)	IN	O
such	NN	O
as,	)	O
for	JJ	O
example,	,	O
soybean	IN	O
PC,	,	O
and	JJ	O
egg	,	O
PC.	CC	O
Another	JJ	O
type	.	O
is	DT	O
formed	NN	O
from	VBZ	O
mixtures	VBN	O
of	IN	O
phospholipid	NNS	O
and/or	IN	O
phosphatidylcholine	JJ	O
and/or	JJ	O
cholesterol.	NN	O
Several	NN	O
studies	.	O
have	JJ	O
assessed	NNS	O
the	VBP	O
topical	VBN	O
delivery	DT	O
of	JJ	O
liposomal	NN	O
drug	IN	O
formulations	JJ	O
to	NN	O
the	NNS	O
skin.	TO	O
Application	DT	O
of	.	O
liposomes	NN	O
containing	IN	O
interferon	NNS	O
to	VBG	O
guinea	NN	O
pig	TO	O
skin	VB	O
resulted	JJ	O
in	NN	O
a	VBD	O
reduction	IN	O
of	DT	O
skin	NN	O
herpes	IN	O
sores	NN	O
while	NNS	O
delivery	NNS	O
of	IN	O
interferon	NN	O
via	IN	O
other	NN	O
means	IN	O
(e.g.	JJ	O
as	NNS	O
a	.	O
solution	IN	O
or	DT	O
as	NN	O
an	CC	O
emulsion)	IN	O
were	DT	O
ineffective	)	O
Weiner	VBD	B
et	JJ	I
al.,	NNP	I
Journal	RB	I
of	,	I
Drug	NNP	I
Targeting,	IN	I
1992,	NNP	I
2,	,	I
405-410).(	,	O
Further,	,	O
an	.	O
additional	,	O
study	DT	O
tested	JJ	O
the	NN	O
efficacy	VBD	O
of	DT	O
interferon	NN	O
administered	IN	O
as	NN	O
part	VBN	O
of	IN	O
a	NN	O
liposomal	IN	O
formulation	DT	O
to	JJ	O
the	NN	O
administration	TO	O
of	DT	O
interferon	NN	O
using	IN	O
an	NN	O
aqueous	VBG	O
system,	DT	O
and	JJ	O
concluded	,	O
that	CC	O
the	VBD	O
liposomal	IN	O
formulation	DT	O
was	JJ	O
superior	NN	O
to	VBD	O
aqueous	JJ	O
administration	TO	O
du	JJ	B
Plessis	NN	I
et	JJ	I
al.,	NNP	I
Antiviral	NN	I
Research,	,	I
1992,	NNP	I
18,	,	I
259-265).(	,	O
Non-ionic	,	O
liposomal	.	O
systems	JJ	O
have	JJ	O
also	NNS	O
been	VBP	O
examined	RB	O
to	VBN	O
determine	VBN	O
their	TO	O
utility	VB	O
in	PRP$	O
the	NN	O
delivery	IN	O
of	DT	O
drugs	NN	O
to	IN	O
the	NNS	O
skin,	TO	O
in	DT	O
particular	,	O
systems	IN	O
comprising	JJ	O
non-ionic	NNS	O
surfactant	VBG	O
and	JJ	O
cholesterol.	NN	O
Non-ionic	CC	O
liposomal	.	O
formulations	JJ	O
comprising	JJ	O
the	NNS	O
Novasome™	VBG	O
I	DT	O
(glyceryl	NNP	O
dilaurate/cholesterol/polyoxyethylene-10-stearyl	PRP	O
ether)	JJ	O
and	NN	O
Novasome™	)	O
II	CC	O
(glyceryl	NNP	O
distearate/cholesterol/polyoxyethylene-10-stearyl	NNP	O
ether)	JJ	O
reagents	NN	O
were	)	O
used	NNS	O
to	VBD	O
deliver	VBN	O
cyclosporin-A	TO	O
into	VB	O
the	JJ	O
dermis	IN	O
of	DT	O
mouse	NN	O
skin.	IN	O
Results	NN	O
indicated	.	O
that	NNS	O
such	VBD	O
non-ionic	IN	O
liposomal	JJ	O
systems	JJ	O
were	JJ	O
effective	NNS	O
in	VBD	O
facilitating	JJ	O
the	IN	O
deposition	VBG	O
of	DT	O
cyclosporin-A	NN	O
into	IN	O
different	JJ	O
layers	IN	O
of	JJ	O
the	NNS	O
skin	IN	O
Hu	DT	B
et	NN	I
al.	NNP	I
S.T.P.	RB	I
Pharma.	.	I
Sci.,	.	I
1994,	.	I
4,	,	I
6,	,	I
466).(	,	O
Liposomes	,	O
also	.	O
include	NNS	O
“sterically	RB	O
stabilized”	VBP	O
liposomes,	RB	O
a	JJ	O
term	,	O
which,	DT	O
as	NN	O
used	,	O
herein,	IN	O
refers	VBN	O
to	,	O
liposomes	NNS	O
comprising	TO	O
one	VB	O
or	VBG	O
more	CD	O
specialized	CC	O
lipids	JJR	O
that,	JJ	O
when	NNS	O
incorporated	,	O
into	WRB	O
liposomes,	VBN	O
result	IN	O
in	,	O
enhanced	NN	O
circulation	IN	O
lifetimes	JJ	O
relative	NN	O
to	NNS	O
liposomes	VBP	O
lacking	TO	O
such	VB	O
specialized	VBG	O
lipids.	JJ	O
Examples	JJ	O
of	.	O
sterically	NNS	O
stabilized	IN	O
liposomes	RB	O
are	VBN	O
those	NNS	O
in	VBP	O
which	DT	O
part	IN	O
of	WDT	O
the	NN	O
vesicle-forming	IN	O
lipid	DT	O
portion	JJ	O
of	JJ	O
the	NN	O
liposome	IN	O
(A)	DT	O
comprises	NN	O
one	)	O
or	VBZ	O
more	CD	O
glycolipids,	CC	O
such	JJR	O
as	,	O
monosialoganglioside	JJ	O
GM1,	IN	O
or	NN	O
(B)	,	O
is	CC	O
derivatized	)	O
with	VBZ	O
one	VBN	O
or	IN	O
more	CD	O
hydrophilic	CC	O
polymers,	JJR	O
such	JJ	O
as	,	O
a	JJ	O
polyethylene	IN	O
glycol	DT	O
(PEG)	NN	O
moiety.	NN	O
While	)	O
not	.	O
wishing	IN	O
to	RB	O
be	VBG	O
bound	TO	O
by	VB	O
any	VBN	O
particular	IN	O
theory,	DT	O
it	JJ	O
is	,	O
thought	PRP	O
in	VBZ	O
the	VBN	O
art	IN	O
that,	DT	O
at	NN	O
least	,	O
for	IN	O
sterically	JJS	O
stabilized	IN	O
liposomes	RB	O
containing	VBN	O
gangliosides,	NNS	O
sphingomyelin,	VBG	O
or	,	O
PEG-derivatized	,	O
lipids,	CC	O
the	JJ	O
enhanced	,	O
circulation	DT	O
half-life	JJ	O
of	NN	O
these	NN	O
sterically	IN	O
stabilized	DT	O
liposomes	RB	O
derives	VBN	O
from	NNS	O
a	VBZ	O
reduced	IN	O
uptake	DT	O
into	JJ	O
cells	NN	O
of	IN	O
the	NNS	O
reticuloendothelial	IN	O
system	DT	O
(RES)	JJ	O
Allen	NN	B
et	)	I
al.,	NNP	I
FEBS	RB	I
Letters,	,	I
1987,	NNP	I
223,	,	I
42;	,	I
Wu	,	B
et	:	I
al.,	NNP	I
Cancer	FW	I
Research,	,	I
1993,	NNP	I
53,	,	I
3765).(	,	O
Liposomes	,	O
and	.	O
their	NNS	O
uses	CC	O
are	PRP$	O
further	NNS	O
described	VBP	O
in	JJ	O
U.S.	VBN	O
Pat.	IN	O
No.	NNP	O
6,287,860,	.	O
which	.	O
is	,	O
incorporated	WDT	O
herein	VBZ	O
in	VBN	O
its	NN	O
entirety.	IN	O
Various	PRP$	O
liposomes	.	O
comprising	JJ	O
one	NNS	O
or	VBG	O
more	CD	O
glycolipids	CC	O
are	JJR	O
known	NNS	O
in	VBP	O
the	VBN	O
art.	IN	O
Papahadjopoulos	DT	O
et	.	O
al.	NNP	O
Ann.	CC	B
N.Y.	.	I
Acad.	.	I
Sci.,	NNP	I
1987,	.	I
507,	,	I
64)	,	I
(reported	,	O
the	)	O
ability	VBD	O
of	DT	O
monosialoganglioside	NN	O
GM1,	IN	O
galactocerebroside	NN	O
sulfate	,	O
and	NN	O
phosphatidylinositol	NN	O
to	CC	O
improve	NN	O
blood	TO	O
half-lives	VB	O
of	NN	O
liposomes.	NNS	O
These	IN	O
findings	.	O
were	DT	O
expounded	NNS	O
upon	VBD	O
by	VBN	O
Gabizon	IN	O
et	IN	O
al.	NNP	O
(Proc.	CC	O
Natl.	.	O
Acad.	.	O
Sci.	.	O
U.S.A.,	.	O
1988,	.	O
85,	,	O
6949).	,	O
U.S.	,	O
Pat.	.	O
No.	NNP	O
4,837,028	.	O
and	.	O
WO	CD	O
88/04924,	CC	O
both	NNP	O
to	,	O
Allen	DT	O
et	TO	O
al.,	NNP	O
disclose	FW	O
liposomes	,	O
comprising	VB	O
(1)	NNS	O
sphingomyelin	VBG	O
and	)	O
(2)	NN	O
the	CC	O
ganglioside	)	O
GM1	DT	O
or	JJ	O
a	NNP	O
galactocerebroside	CC	O
sulfate	DT	O
ester.	JJ	O
U.S.	NN	O
Pat.	.	O
No.	NNP	O
5,543,152	.	O
(Webb	.	O
et	CD	O
al.)	NNP	O
discloses	RB	O
liposomes	)	O
comprising	NNS	O
sphingomyelin.	VBZ	O
Liposomes	VBG	O
comprising	.	O
1,2-sn-dimyristoylphosphatidylcholine	NNS	O
are	VBG	O
disclosed	JJ	O
in	VBP	O
WO	VBN	O
97/13499	IN	O
(Lim	NNP	O
et	CD	O
al.).	NNP	O
Many	RB	O
liposomes	.	O
comprising	JJ	O
lipids	NNS	O
derivatized	VBG	O
with	NNS	O
one	VBN	O
or	IN	O
more	CD	O
hydrophilic	CC	O
polymers,	JJR	O
and	JJ	O
methods	,	O
of	CC	O
preparation	NNS	O
thereof,	IN	O
are	NN	O
known	,	O
in	VBP	O
the	VBN	O
art.	IN	O
Sunamoto	DT	B
et	.	I
al.	NNP	I
(Bull.	CC	I
Chem.	.	I
Soc.	.	I
Jpn.,	.	I
1980,	.	I
53,	,	I
2778)	,	I
described	,	O
liposomes	)	O
comprising	VBD	O
a	NNS	O
nonionic	VBG	O
detergent,	DT	O
2C1215G,	JJ	O
that	,	O
contains	,	O
a	WDT	O
PEG	VBZ	O
moiety.	DT	O
Illum	NNP	B
et	.	I
al.	NNP	I
(FEBS	CC	I
Lett.,	.	I
1984,	NNP	I
167,	,	I
79)	,	I
noted	,	O
that	)	O
hydrophilic	VBD	O
coating	IN	O
of	JJ	O
polystyrene	NN	O
particles	IN	O
with	NN	O
polymeric	NNS	O
glycols	IN	O
results	JJ	O
in	NNS	O
significantly	NNS	O
enhanced	IN	O
blood	RB	O
half-lives.	VBN	O
Synthetic	NN	O
phospholipids	.	O
modified	JJ	O
by	NNS	O
the	VBN	O
attachment	IN	O
of	DT	O
carboxylic	NN	O
groups	IN	O
of	JJ	O
polyalkylene	NNS	O
glycols	IN	O
(e.g.,	NN	O
PEG)	NNS	O
are	,	O
described	)	O
by	VBP	O
Sears	VBN	O
(U.S.	IN	O
Pat.	NNP	O
Nos.	NNP	O
4,426,330	.	O
and	.	O
4,534,899).	CD	O
Klibanov	CC	B
et	.	I
al.	NNP	I
(FEBS	CC	I
Lett.,	.	I
1990,	NNP	I
268,	,	I
235)	,	I
described	,	O
experiments	)	O
demonstrating	VBD	O
that	NNS	O
liposomes	VBG	O
comprising	IN	O
phosphatidylethanolamine	VBZ	O
(PE)	VBG	O
derivatized	NN	O
with	)	O
PEG	VBD	O
or	IN	O
PEG	NNP	O
stearate	CC	O
have	NNP	O
significant	VBP	O
increases	VBP	O
in	JJ	O
blood	NNS	O
circulation	IN	O
half-lives.	NN	O
Blume	NN	B
et	.	I
al.	NNP	I
(Biochimica	CC	I
et	.	I
Biophysica	NNP	I
Acta,	VBZ	I
1990,	NNP	I
1029,	,	I
91)	,	I
extended	,	O
such	)	O
observations	VBD	O
to	JJ	O
other	NNS	O
PEG-derivatized	TO	O
phospholipids,	JJ	O
e.g.,	JJ	O
DSPE-PEG,	,	O
formed	,	O
from	,	O
the	VBN	O
combination	IN	O
of	DT	O
distearoylphosphatidylethanolamine	NN	O
(DSPE)	IN	O
and	NN	O
PEG.	)	O
Liposomes	CC	O
having	.	O
covalently	NNS	O
bound	VBG	O
PEG	RB	O
moieties	VBN	O
on	NNP	O
their	NNS	O
external	IN	O
surface	PRP$	O
are	JJ	O
described	NN	O
in	VBP	O
European	VBN	O
Patent	IN	O
No.	JJ	O
EP	NNP	O
0	.	O
445	NNP	O
131	CD	O
B1	CD	O
and	CD	O
WO	NNP	O
90/04384	CC	O
to	NNP	O
Fisher.	CD	O
Liposome	TO	O
compositions	.	O
containing	NNP	O
1-20	NNS	O
mole	VBG	O
percent	JJ	O
of	JJ	O
PE	NN	O
derivatized	IN	O
with	NNP	O
PEG,	VBD	O
and	IN	O
methods	,	O
of	CC	O
use	NNS	O
thereof,	IN	O
are	NN	O
described	,	O
by	VBP	O
Woodle	VBN	O
et	IN	O
al.	NNP	O
(U.S.	CC	O
Pat.	.	O
Nos.	NNP	O
5,013,556	.	O
and	.	O
5,356,633)	CD	O
and	CC	O
Martin	)	O
et	CC	O
al.	NNP	O
(U.S.	VBP	O
Pat.	.	O
No.	NNP	O
5,213,804	.	O
and	.	O
European	CD	O
Patent	CC	O
No.	JJ	O
EP	NNP	O
0	.	O
496	NNP	O
813	CD	O
B1).	CD	O
Liposomes	CD	O
comprising	.	O
a	RB	O
number	VBG	O
of	DT	O
other	NN	O
lipid-polymer	IN	O
conjugates	JJ	O
are	JJ	O
disclosed	NNS	O
in	VBP	O
WO	VBN	O
91/05545	IN	O
and	NNP	O
U.S.	CD	O
Pat.	CC	O
No.	NNP	O
5,225,212	.	O
(both	.	O
to	CD	O
Martin	DT	O
et	TO	O
al.)	NNP	O
and	FW	O
in	)	O
WO	CC	O
94/20073	IN	O
(Zalipsky	NNP	O
et	CD	O
al.)	NNP	O
Liposomes	VBZ	O
comprising	)	O
PEG-modified	NNS	O
ceramide	VBG	O
lipids	JJ	O
are	NN	O
described	NNS	O
in	VBP	O
WO	VBN	O
96/10391	IN	O
(Choi	NNP	O
et	CD	O
al.).	NNP	O
U.S.	RB	O
Pat.	.	O
Nos.	NNP	O
5,540,935	.	O
(Miyazaki	.	O
et	CD	O
al.)	NNP	O
and	RB	O
5,556,948	)	O
(Tagawa	CC	O
et	CD	O
al.)	NNP	O
describe	RB	O
PEG-containing	)	O
liposomes	JJ	O
that	NNP	O
can	NNS	O
be	WDT	O
further	MD	O
derivatized	VB	O
with	JJ	O
functional	VBN	O
moieties	IN	O
on	JJ	O
their	NNS	O
surfaces.	IN	O
International	PRP$	O
Patent	.	O
Publication	NNP	O
No.	NNP	O
WO	NNP	O
96/40062	.	O
to	$	O
Thierry	CD	O
et	TO	O
al.	NNP	O
refers	NNP	O
to	.	O
methods	NNS	O
for	TO	O
encapsulating	NNS	O
high	IN	O
molecular	VBG	O
weight	JJ	O
nucleic	JJ	O
acids	NN	O
in	JJ	O
liposomes.	NNS	O
U.S.	IN	O
Pat.	.	O
No.	NNP	O
5,264,221	.	O
to	.	O
Tagawa	CD	O
et	TO	O
al.	NNP	O
refers	FW	O
to	.	O
protein-bonded	NNS	O
liposomes	TO	O
and	JJ	O
asserts	NNS	O
that	CC	O
the	VBZ	O
contents	IN	O
of	DT	O
such	NNS	O
liposomes	IN	O
may	JJ	O
include	NNS	O
an	MD	O
antisense	VB	O
RNA.	DT	O
U.S.	JJ	O
Pat.	.	O
No.	NNP	O
5,665,710	.	O
to	.	O
Rahman	CD	O
et	TO	O
al.	NNP	O
refers	FW	O
to	.	O
certain	NNS	O
methods	TO	O
of	JJ	O
encapsulating	NNS	O
oligodeoxynucleotides	IN	O
in	VBG	O
liposomes.	NNS	O
International	IN	O
Patent	.	O
Publication	NNP	O
No.	NNP	O
WO	NNP	O
97/04787	.	O
to	$	O
Love	CD	O
et	TO	O
al.	NNP	O
refers	FW	O
to	.	O
liposomes	NNS	O
comprising	TO	O
antisense	NNS	O
oligonucleotides	VBG	O
targeted	NN	O
to	NNS	O
the	VBD	O
raf	TO	O
gene.	DT	O
Transfersomes	NN	O
are	.	O
yet	NNS	O
another	VBP	O
type	RB	O
of	DT	O
liposome,	NN	O
and	IN	O
are	,	O
highly	CC	O
deformable	VBP	O
lipid	RB	O
aggregates	JJ	O
which	NN	O
are	NNS	O
attractive	WDT	O
candidates	VBP	O
for	JJ	O
drug	NNS	O
delivery	IN	O
vehicles.	NN	O
Transfersomes	NN	O
may	.	O
be	NNS	O
described	MD	O
as	VB	O
lipid	VBN	O
droplets	IN	O
which	JJ	O
are	NNS	O
so	WDT	O
highly	VBP	O
deformable	RB	O
that	RB	O
they	JJ	O
are	IN	O
easily	PRP	O
able	VBP	O
to	RB	O
penetrate	JJ	O
through	TO	O
pores	VB	O
which	IN	O
are	NNS	O
smaller	WDT	O
than	VBP	O
the	JJR	O
droplet.	IN	O
Transfersomes	DT	O
are	.	O
adaptable	NNS	O
to	VBP	O
the	JJ	O
environment	TO	O
in	DT	O
which	NN	O
they	IN	O
are	WDT	O
used,	PRP	O
e.g.	VBP	O
they	,	O
are	.	O
self-optimizing	PRP	O
(adaptive	VBP	O
to	JJ	O
the	JJ	O
shape	TO	O
of	DT	O
pores	NN	O
in	IN	O
the	NNS	O
skin),	IN	O
self-repairing,	DT	O
frequently	,	O
reach	,	O
their	RB	O
targets	VBP	O
without	PRP$	O
fragmenting,	NNS	O
and	IN	O
often	,	O
self-loading.	CC	O
To	RB	O
make	.	O
transfersomes	TO	O
it	VB	O
is	NNS	O
possible	PRP	O
to	VBZ	O
add	JJ	O
surface	TO	O
edge-activators,	VB	O
usually	JJ	O
surfactants,	,	O
to	RB	O
a	,	O
standard	TO	O
liposomal	DT	O
composition.	JJ	O
Transfersomes	JJ	O
have	.	O
been	NNS	O
used	VBP	O
to	VBN	O
deliver	VBN	O
serum	TO	O
albumin	VB	O
to	JJ	O
the	NN	O
skin.	TO	O
The	DT	O
transfersome-mediated	.	O
delivery	DT	O
of	JJ	O
serum	NN	O
albumin	IN	O
has	NN	O
been	NN	O
shown	VBZ	O
to	VBN	O
be	VBN	O
as	TO	O
effective	VB	O
as	RB	O
subcutaneous	JJ	O
injection	IN	O
of	JJ	O
a	NN	O
solution	IN	O
containing	DT	O
serum	NN	O
albumin.	VBG	O
Surfactants	NN	O
find	.	O
wide	NNS	O
application	VBP	O
in	JJ	O
formulations	NN	O
such	IN	O
as	NNS	O
emulsions	JJ	O
(including	IN	O
microemulsions)	NNS	O
and	VBG	O
liposomes.	)	O
The	CC	O
most	.	O
common	DT	O
way	RBS	O
of	JJ	O
classifying	NN	O
and	IN	O
ranking	NN	O
the	CC	O
properties	VBG	O
of	DT	O
the	NNS	O
many	IN	O
different	DT	O
types	JJ	O
of	JJ	O
surfactants,	NNS	O
both	IN	O
natural	,	O
and	DT	O
synthetic,	JJ	O
is	CC	O
by	,	O
the	VBZ	O
use	IN	O
of	DT	O
the	NN	O
hydrophile/lipophile	IN	O
balance	DT	O
(HLB).	JJ	O
The	NN	O
nature	.	O
of	DT	O
the	NN	O
hydrophilic	IN	O
group	DT	O
(also	JJ	O
known	NN	O
as	RB	O
the	VBN	O
“head”)	IN	O
provides	DT	O
the	)	O
most	VBZ	O
useful	DT	O
means	RBS	O
for	JJ	O
categorizing	NNS	O
the	IN	O
different	VBG	O
surfactants	DT	O
used	JJ	O
in	NNS	O
formulations	VBN	O
Rieger,	IN	B
in	NNS	I
Pharmaceutical	,	I
Dosage	IN	I
Forms,	JJ	I
Marcel	NN	I
Dekker,	,	I
Inc.,	NNP	I
New	,	I
York,	,	I
N.Y.,	NNP	I
1988,	,	I
p.	,	I
285).(	,	O
If	VBZ	O
the	.	O
surfactant	IN	O
molecule	DT	O
is	NN	O
not	NN	O
ionized,	VBZ	O
it	RB	O
is	,	O
classified	PRP	O
as	VBZ	O
a	VBN	O
nonionic	IN	O
surfactant.	DT	O
Nonionic	JJ	O
surfactants	.	O
find	JJ	O
wide	NNS	O
application	VBP	O
in	JJ	O
pharmaceutical	NN	O
and	IN	O
cosmetic	JJ	O
products	CC	O
and	JJ	O
are	NNS	O
usable	CC	O
over	VBP	O
a	JJ	O
wide	IN	O
range	DT	O
of	JJ	O
pH	NN	O
values.	IN	O
In	NN	O
general	.	O
their	IN	O
HLB	JJ	O
values	PRP$	O
range	NN	O
from	NNS	O
2	VBP	O
to	IN	O
about	CD	O
18	TO	O
depending	IN	O
on	CD	O
their	VBG	O
structure.	IN	O
Nonionic	PRP$	O
surfactants	.	O
include	JJ	O
nonionic	NNS	O
esters	VBP	O
such	JJ	O
as	NNS	O
ethylene	JJ	O
glycol	IN	O
esters,	JJ	O
propylene	NN	O
glycol	,	O
esters,	NN	O
glyceryl	NN	O
esters,	,	O
polyglyceryl	NN	O
esters,	,	O
sorbitan	NN	O
esters,	,	O
sucrose	JJ	O
esters,	,	O
and	JJ	O
ethoxylated	,	O
esters.	CC	O
Nonionic	VBD	O
alkanolamides	.	O
and	NNP	O
ethers	NNS	O
such	CC	O
as	NNS	O
fatty	JJ	O
alcohol	IN	O
ethoxylates,	JJ	O
propoxylated	NN	O
alcohols,	,	O
and	VBD	O
ethoxylated/propoxylated	,	O
block	CC	O
polymers	VBD	O
are	NN	O
also	NNS	O
included	VBP	O
in	RB	O
this	VBN	O
class.	IN	O
The	DT	O
polyoxyethylene	.	O
surfactants	DT	O
are	NN	O
the	NNS	O
most	VBP	O
popular	DT	O
members	RBS	O
of	JJ	O
the	NNS	O
nonionic	IN	O
surfactant	DT	O
class.	JJ	O
If	JJ	O
the	.	O
surfactant	IN	O
molecule	DT	O
carries	NN	O
a	NN	O
negative	VBZ	O
charge	DT	O
when	JJ	O
it	NN	O
is	WRB	O
dissolved	PRP	O
or	VBZ	O
dispersed	VBN	O
in	CC	O
water,	VBN	O
the	IN	O
surfactant	,	O
is	DT	O
classified	NN	O
as	VBZ	O
anionic.	VBN	O
Anionic	IN	O
surfactants	.	O
include	JJ	O
carboxylates	NNS	O
such	VBP	O
as	NNS	O
soaps,	JJ	O
acyl	IN	O
lactylates,	,	O
acyl	NN	O
amides	,	O
of	JJ	O
amino	NNS	O
acids,	IN	O
esters	NN	O
of	,	O
sulfuric	NNS	O
acid	IN	O
such	JJ	O
as	NNS	O
alkyl	JJ	O
sulfates	IN	O
and	NN	O
ethoxylated	NNS	O
alkyl	CC	O
sulfates,	VBD	O
sulfonates	NN	O
such	,	O
as	NNS	O
alkyl	JJ	O
benzene	IN	O
sulfonates,	JJ	O
acyl	NN	O
isethionates,	,	O
acyl	NN	O
taurates	,	O
and	NN	O
sulfosuccinates,	NNS	O
and	CC	O
phosphates.	,	O
The	CC	O
most	.	O
important	DT	O
members	RBS	O
of	JJ	O
the	NNS	O
anionic	IN	O
surfactant	DT	O
class	JJ	O
are	JJ	O
the	NN	O
alkyl	VBP	O
sulfates	DT	O
and	JJ	O
the	NNS	O
soaps.	CC	O
If	DT	O
the	.	O
surfactant	IN	O
molecule	DT	O
carries	NN	O
a	NN	O
positive	VBZ	O
charge	DT	O
when	JJ	O
it	NN	O
is	WRB	O
dissolved	PRP	O
or	VBZ	O
dispersed	VBN	O
in	CC	O
water,	VBN	O
the	IN	O
surfactant	,	O
is	DT	O
classified	NN	O
as	VBZ	O
cationic.	VBN	O
Cationic	IN	O
surfactants	.	O
include	JJ	O
quaternary	NNS	O
ammonium	VBP	O
salts	JJ	O
and	NN	O
ethoxylated	NNS	O
amines.	CC	O
The	VBN	O
quaternary	.	O
ammonium	DT	O
salts	JJ	O
are	NN	O
the	NNS	O
most	VBP	O
used	DT	O
members	RBS	O
of	JJ	O
this	NNS	O
class.	IN	O
If	DT	O
the	.	O
surfactant	IN	O
molecule	DT	O
has	NN	O
the	NN	O
ability	VBZ	O
to	DT	O
carry	NN	O
either	TO	O
a	VB	O
positive	RB	O
or	DT	O
negative	JJ	O
charge,	CC	O
the	JJ	O
surfactant	,	O
is	DT	O
classified	NN	O
as	VBZ	O
amphoteric.	VBN	O
Amphoteric	IN	O
surfactants	.	O
include	JJ	O
acrylic	NNS	O
acid	VBP	O
derivatives,	JJ	O
substituted	JJ	O
alkylamides,	,	O
N-alkylbetaines	VBD	O
and	,	O
phosphatides.	NNS	O
The	CC	O
use	.	O
of	DT	O
surfactants	NN	O
in	IN	O
drug	NNS	O
products,	IN	O
formulations	NN	O
and	,	O
in	NNS	O
emulsions	CC	O
has	IN	O
been	NNS	O
reviewed	VBZ	O
Rieger,	VBN	B
in	VBN	I
Pharmaceutical	,	I
Dosage	IN	I
Forms,	JJ	I
Marcel	NN	I
Dekker,	,	I
Inc.,	NNP	I
New	,	I
York,	,	I
N.Y.,	NNP	I
1988,	,	I
p.	,	I
285).(	,	O
In	VBZ	O
one	.	O
embodiment,	IN	O
the	CD	O
present	,	O
invention	DT	O
employs	JJ	O
various	NN	O
penetration	VBZ	O
enhancers	JJ	O
to	NN	O
effect	NNS	O
the	TO	O
efficient	NN	O
delivery	DT	O
of	JJ	O
nucleic	NN	O
acids,	IN	O
particularly	JJ	O
oligonucleotides,	,	O
to	RB	O
the	,	O
skin	TO	O
of	DT	O
animals.	NN	O
Most	IN	O
drugs	.	O
are	JJS	O
present	NNS	O
in	VBP	O
solution	JJ	O
in	IN	O
both	NN	O
ionized	IN	O
and	DT	O
nonionized	JJ	O
forms.	CC	O
However,	JJ	O
usually	.	O
only	,	O
lipid	RB	O
soluble	RB	O
or	JJ	O
lipophilic	JJ	O
drugs	CC	O
readily	JJ	O
cross	NNS	O
cell	RB	O
membranes.	VBP	O
It	NN	O
has	.	O
been	PRP	O
discovered	VBZ	O
that	VBN	O
even	VBN	O
non-lipophilic	IN	O
drugs	RB	O
may	JJ	O
cross	NNS	O
cell	MD	O
membranes	VB	O
if	NN	O
the	NNS	O
membrane	IN	O
to	DT	O
be	NN	O
crossed	TO	O
is	VB	O
treated	VBN	O
with	VBZ	O
a	VBN	O
penetration	IN	O
enhancer.	DT	O
In	NN	O
addition	.	O
to	IN	O
aiding	NN	O
the	TO	O
diffusion	VBG	O
of	DT	O
non-lipophilic	NN	O
drugs	IN	O
across	JJ	O
cell	NNS	O
membranes,	IN	O
penetration	NN	O
enhancers	,	O
also	NN	O
enhance	NNS	O
the	RB	O
permeability	VBP	O
of	DT	O
lipophilic	NN	O
drugs.	IN	O
Other	JJ	O
agents	.	O
may	JJ	O
be	NNS	O
utilized	MD	O
to	VB	O
enhance	VBN	O
the	TO	O
penetration	VB	O
of	DT	O
the	NN	O
administered	IN	O
nucleic	DT	O
acids,	JJ	O
including	JJ	O
glycols	,	O
such	VBG	O
as	NNS	O
ethylene	JJ	O
glycol	IN	O
and	NN	O
propylene	NN	O
glycol,	CC	O
pyrrols	NN	O
such	,	O
as	NNS	O
2-pyrrol,	JJ	O
azones,	IN	O
and	,	O
terpenes	,	O
such	CC	O
as	NNS	O
limonene	JJ	O
and	IN	O
menthone.	NN	O
The	CC	O
pharmaceutical	.	O
formulations	DT	O
and	JJ	O
compositions	NNS	O
of	CC	O
the	NNS	O
present	IN	O
invention	DT	O
may	JJ	O
also	NN	O
include	MD	O
surfactants.	RB	O
The	VB	O
use	.	O
of	DT	O
surfactants	NN	O
in	IN	O
drug	NNS	O
products,	IN	O
formulations	NN	O
and	,	O
in	NNS	O
emulsions	CC	O
is	IN	O
well	NNS	O
known	VBZ	O
in	RB	O
the	VBN	O
art.	IN	O
Surfactants	DT	O
and	.	O
their	NNS	O
uses	CC	O
are	PRP$	O
further	NNS	O
described	VBP	O
in	JJ	O
U.S.	VBN	O
Pat.	IN	O
No.	NNP	O
6,287,860,	.	O
which	.	O
is	,	O
incorporated	WDT	O
herein	VBZ	O
in	VBN	O
its	NN	O
entirety.	IN	O
One	PRP$	O
of	.	O
skill	CD	O
in	IN	O
the	NN	O
art	IN	O
will	DT	O
recognize	NN	O
that	MD	O
formulations	VB	O
are	IN	O
routinely	NNS	O
designed	VBP	O
according	RB	O
to	VBN	O
their	VBG	O
intended	TO	O
use,	PRP$	O
i.e.,	VBN	O
route	,	O
of	,	O
administration.	NN	O
Preferred	IN	O
formulations	.	O
for	JJ	O
topical	NNS	O
administration	IN	O
include	JJ	O
those	NN	O
in	VBP	O
which	DT	O
the	IN	O
oligonucleotides	WDT	O
of	DT	O
the	NNS	O
invention	IN	O
are	DT	O
in	NN	O
admixture	VBP	O
with	IN	O
a	NN	O
topical	IN	O
delivery	DT	O
agent	JJ	O
such	NN	O
as	NN	O
lipids,	JJ	O
liposomes,	IN	O
fatty	,	O
acids,	,	O
fatty	JJ	O
acid	,	O
esters,	JJ	O
steroids,	NN	O
chelating	,	O
agents	,	O
and	VBG	O
surfactants.	NNS	O
Preferred	CC	O
lipids	.	O
and	NNP	O
liposomes	NNS	O
include	CC	O
neutral	NNS	O
(e.g.	VBP	O
dioleoylphosphatidyl	JJ	O
DOPE	.	O
ethanolamine,	NNS	O
dimyristoylphosphatidyl	NNP	O
choline	,	O
DMPC,	JJ	O
distearolyphosphatidyl	NN	O
choline)	,	O
negative	JJ	O
(e.g.	)	O
dimyristoylphosphatidyl	NN	O
glycerol	.	O
DMPG)	NN	O
and	NN	O
cationic	)	O
(e.g.	CC	O
dioleoyltetramethylaminopropyl	JJ	O
DOTAP	.	O
and	NN	O
dioleoylphosphatidyl	NNP	O
ethanolamine	CC	O
DOTMA).	JJ	O
For	NN	O
topical	.	O
or	IN	O
other	JJ	O
administration,	CC	O
oligonucleotides	JJ	O
of	,	O
the	NNS	O
invention	IN	O
may	DT	O
be	NN	O
encapsulated	MD	O
within	VB	O
liposomes	VBN	O
or	IN	O
may	NNS	O
form	CC	O
complexes	MD	O
thereto,	VB	O
in	NNS	O
particular	,	O
to	IN	O
cationic	JJ	O
liposomes.	TO	O
Alternatively,	JJ	O
oligonucleotides	.	O
may	,	O
be	NNS	O
complexed	MD	O
to	VB	O
lipids,	VBN	O
in	TO	O
particular	,	O
to	IN	O
cationic	JJ	O
lipids.	TO	O
Preferred	JJ	O
fatty	.	O
acids	NNP	O
and	JJ	O
esters,	NNS	O
pharmaceutically	CC	O
acceptable	,	O
salts	RB	O
thereof,	JJ	O
and	NNS	O
their	,	O
uses	CC	O
are	PRP$	O
further	NNS	O
described	VBP	O
in	JJ	O
U.S.	VBN	O
Pat.	IN	O
No.	NNP	O
6,287,860,	.	O
which	.	O
is	,	O
incorporated	WDT	O
herein	VBZ	O
in	VBN	O
its	NN	O
entirety	IN	O
Topical	PRP$	O
formulations	NN	O
are	JJ	O
described	NNS	O
in	VBP	O
detail	VBN	O
in	IN	O
U.S.	NN	O
Pat.	IN	O
No.	NNP	O
6,747,014,	.	O
which	.	O
is	,	O
incorporated	WDT	O
herein	VBZ	O
by	VBN	O
reference	NN	O
in	IN	O
its	NN	O
entirety.	IN	O
Compositions	PRP$	O
and	.	O
formulations	NNS	O
for	CC	O
oral	NNS	O
administration	IN	O
include	JJ	O
powders	NN	O
or	VBP	O
granules,	NNS	O
microparticulates,	CC	O
nanoparticulates,	,	O
suspensions	,	O
or	,	O
solutions	NNS	O
in	CC	O
water	NNS	O
or	IN	O
non-aqueous	NN	O
media,	CC	O
capsules,	JJ	O
gel	,	O
capsules,	,	O
sachets,	NN	O
tablets	,	O
or	,	O
minitablets.	NNS	O
Thickeners,	CC	O
flavoring	.	O
agents,	,	O
diluents,	VBG	O
emulsifiers,	,	O
dispersing	,	O
aids	,	O
or	VBG	O
binders	NNS	O
may	CC	O
be	NNS	O
desirable.	MD	O
Preferred	VB	O
oral	.	O
formulations	NNP	O
are	JJ	O
those	NNS	O
in	VBP	O
which	DT	O
oligonucleotides	IN	O
of	WDT	O
the	NNS	O
invention	IN	O
are	DT	O
administered	NN	O
in	VBP	O
conjunction	VBN	O
with	IN	O
one	NN	O
or	IN	O
more	CD	O
penetration	CC	O
enhancers	JJR	O
surfactants	NN	O
and	NNS	O
chelators.	NNS	O
Preferred	CC	O
surfactants	.	O
include	JJ	O
fatty	NNS	O
acids	VBP	O
and/or	JJ	O
esters	NNS	O
or	VBP	O
salts	NNS	O
thereof,	CC	O
bile	NNS	O
acids	,	O
and/or	JJ	O
salts	NNS	O
thereof.	VBP	O
Preferred	NNS	O
bile	.	O
acids/salts	NNP	O
and	NN	O
fatty	NNS	O
acids	CC	O
and	JJ	O
their	NNS	O
uses	CC	O
are	PRP$	O
further	NNS	O
described	VBP	O
in	JJ	O
U.S.	VBN	O
Pat.	IN	O
No.	NNP	O
6,287,860,	.	O
which	.	O
is	,	O
incorporated	WDT	O
herein	VBZ	O
in	VBN	O
its	NN	O
entirety.	IN	O
Also	PRP$	O
preferred	.	O
are	RB	O
combinations	VBN	O
of	VBP	O
penetration	NNS	O
enhancers,	IN	O
for	NN	O
example,	,	O
fatty	IN	O
acids/salts	,	O
in	JJ	O
combination	NNS	O
with	IN	O
bile	NN	O
acids/salts.	IN	O
A	JJ	O
particularly	.	O
preferred	DT	O
combination	RB	O
is	JJ	O
the	NN	O
sodium	VBZ	O
salt	DT	O
of	NN	O
lauric	NN	O
acid,	IN	O
capric	JJ	O
acid	,	O
and	JJ	O
UDCA.	NN	O
Further	CC	O
penetration	.	O
enhancers	JJ	O
include	NN	O
polyoxyethylene-9-lauryl	NNS	O
ether,	VBP	O
polyoxyethylene-20-cetyl	JJ	O
ether.	,	O
Oligonucleotides	JJ	O
of	.	O
the	NNS	O
invention	IN	O
may	DT	O
be	NN	O
delivered	MD	O
orally,	VB	O
in	VBN	O
granular	,	O
form	IN	O
including	JJ	O
sprayed	NN	O
dried	VBG	O
particles,	VBN	O
or	JJ	O
complexed	,	O
to	CC	O
form	VBN	O
micro	TO	O
or	VB	O
nanoparticles.	NN	O
Oligonucleotide	CC	O
complexing	.	O
agents	IN	O
and	VBG	O
their	NNS	O
uses	CC	O
are	PRP$	O
further	NNS	O
described	VBP	O
in	JJ	O
U.S.	VBN	O
Pat.	IN	O
No.	NNP	O
6,287,860,	.	O
which	.	O
is	,	O
incorporated	WDT	O
herein	VBZ	O
in	VBN	O
its	NN	O
entirety.	IN	O
Oral	PRP$	O
formulations	.	O
for	JJ	O
oligonucleotides	NNS	O
and	IN	O
their	NNS	O
preparation	CC	O
are	PRP$	O
described	NN	O
in	VBP	O
detail	VBN	O
in	IN	O
U.S.	NN	O
Pat.	IN	O
No.	NNP	O
6,747,014;	.	O
U.S.	.	O
Patent	:	O
Publication	NNP	O
No.	NNP	O
2003/0027780	NNP	O
(Feb.	.	O
6,	CD	O
2003)	NNP	O
and	,	O
its	)	O
parent	CC	O
applications;	PRP$	O
and	NN	O
U.S.	:	O
patent	CC	O
application	NNP	O
Ser.	NN	O
No.	NN	O
09/082,624	.	O
(filed	.	O
May	CD	O
21,	VBN	O
1998),	NNP	O
each	,	O
of	,	O
which	DT	O
is	IN	O
incorporated	WDT	O
herein	VBZ	O
by	VBN	O
reference	NN	O
in	IN	O
its	NN	O
entirety.	IN	O
Compositions	PRP$	O
and	.	O
formulations	NNS	O
for	CC	O
parenteral,	NNS	O
intrathecal	IN	O
or	,	O
intraventricular	JJ	O
administration	CC	O
may	JJ	O
include	NN	O
sterile	MD	O
aqueous	VB	O
solutions	JJ	O
which	JJ	O
may	NNS	O
also	WDT	O
contain	MD	O
buffers,	RB	O
diluents	VB	O
and	,	O
other	NNS	O
suitable	CC	O
additives	JJ	O
such	JJ	O
as,	NNS	O
but	JJ	O
not	,	O
limited	CC	O
to,	RB	O
penetration	JJ	O
enhancers,	,	O
carrier	NN	O
compounds	,	O
and	NN	O
other	NNS	O
pharmaceutically	CC	O
acceptable	JJ	O
carriers	RB	O
or	JJ	O
excipients.	NNS	O
Oligonucleotides	CC	O
may	.	O
be	NNS	O
formulated	MD	O
for	VB	O
delivery	VBN	O
in	IN	O
vivo	NN	O
in	IN	O
an	NN	O
acceptable	IN	O
dosage	DT	O
form,	JJ	O
e.g.	NN	O
as	,	O
parenteral	.	O
or	IN	O
non-parenteral	JJ	O
formulations.	CC	O
Parenteral	JJ	O
formulations	.	O
include	JJ	O
intravenous	NNS	O
(IV),	VBP	O
subcutaneous	JJ	O
(SC),	,	O
intraperitoneal	JJ	O
(IP),	,	O
intravitreal	JJ	O
and	,	O
intramuscular	JJ	O
(IM)	CC	O
formulations,	JJ	O
as	)	O
well	,	O
as	RB	O
formulations	RB	O
for	IN	O
delivery	NNS	O
via	IN	O
pulmonary	NN	O
inhalation,	IN	O
intranasal	JJ	O
administration,	,	O
topical	JJ	O
administration,	,	O
etc.	JJ	O
Non-parenteral	,	O
formulations	.	O
include	JJ	O
formulations	NNS	O
for	VBP	O
delivery	NNS	O
via	IN	O
the	NN	O
alimentary	IN	O
canal,	DT	O
e.g.	JJ	O
oral	,	O
administration,	.	O
rectal	JJ	O
administration,	,	O
intrajejunal	JJ	O
instillation,	,	O
etc.	JJ	O
Rectal	,	O
administration	.	O
includes	JJ	O
administration	NN	O
as	VBZ	O
an	NN	O
enema	IN	O
or	DT	O
a	NN	O
suppository.	CC	O
Oral	DT	O
administration	.	O
includes	JJ	O
administration	NN	O
as	VBZ	O
a	NN	O
capsule,	IN	O
a	DT	O
gel	,	O
capsule,	DT	O
a	NN	O
pill,	,	O
an	DT	O
elixir,	,	O
etc.	DT	O
The	,	O
compounds	.	O
of	DT	O
the	NNS	O
present	IN	O
invention	DT	O
may	JJ	O
also	NN	O
be	MD	O
administered	RB	O
by	VB	O
pulsatile	VBN	O
delivery.	IN	O
“Pulsatile	JJ	O
delivery”	.	O
refers	JJ	O
to	NN	O
a	NNS	O
pharmaceutical	TO	O
formulation	DT	O
that	JJ	O
delivers	NN	O
a	IN	O
first	VBZ	O
pulse	DT	O
of	JJ	O
drug	NN	O
(e.g.	IN	O
an	NN	O
antisense	.	O
compound)	DT	O
combined	JJ	O
with	)	O
a	VBN	O
penetration	IN	O
enhancer	DT	O
and	NN	O
a	NN	O
second	CC	O
pulse	DT	O
of	JJ	O
penetration	NN	O
enhancer	IN	O
to	NN	O
promote	NN	O
absorption	TO	O
of	VB	O
drug	NN	O
which	IN	O
is	NN	O
not	WDT	O
absorbed	VBZ	O
upon	RB	O
release	VBN	O
with	IN	O
the	NN	O
first	IN	O
pulse	DT	O
of	JJ	O
penetration	NN	O
enhancer.	IN	O
One	NN	O
embodiment	.	O
of	CD	O
the	NN	O
present	IN	O
invention	DT	O
is	JJ	O
a	NN	O
delayed	VBZ	O
release	DT	O
oral	JJ	O
formulation	NN	O
for	JJ	O
enhanced	NN	O
intestinal	IN	O
drug	JJ	O
absorption,	JJ	O
comprising:	NN	O
(a)	,	O
a	:	O
first	)	O
population	DT	O
of	JJ	O
carrier	NN	O
particles	IN	O
comprising	NN	O
said	NNS	O
drug	VBG	O
and	VBD	O
a	NN	O
penetration	CC	O
enhancer,	DT	O
wherein	NN	O
said	,	O
drug	NN	O
and	VBD	O
said	NN	O
penetration	CC	O
enhancer	VBD	O
are	NN	O
released	NN	O
at	VBP	O
a	VBN	O
first	IN	O
location	DT	O
in	JJ	O
the	NN	O
intestine;	IN	O
and	DT	O
(b)	:	O
a	CC	O
second	)	O
population	DT	O
of	JJ	O
carrier	NN	O
particles	IN	O
comprising	NN	O
a	NNS	O
penetration	VBG	O
enhancer	DT	O
and	NN	O
a	NN	O
delayed	CC	O
release	DT	O
coating	JJ	O
or	NN	O
matrix,	NN	O
wherein	CC	O
the	,	O
penetration	VBP	O
enhancer	DT	O
is	NN	O
released	NN	O
at	VBZ	O
a	VBN	O
second	IN	O
location	DT	O
in	JJ	O
the	NN	O
intestine	IN	O
downstream	DT	O
from	JJ	O
the	NN	O
first	IN	O
location,	DT	O
whereby	JJ	O
absorption	,	O
of	WRB	O
the	NN	O
drug	IN	O
is	DT	O
enhanced	NN	O
when	VBZ	O
the	VBN	O
drug	WRB	O
reaches	DT	O
the	NN	O
second	VBZ	O
location.	DT	O
Alternatively,	JJ	O
the	.	O
penetration	,	O
enhancer	DT	O
in	NN	O
(a)	NN	O
and	IN	O
(b)	)	O
is	CC	O
different.	)	O
This	VBZ	O
enhancement	.	O
is	DT	O
obtained	NN	O
by	VBZ	O
encapsulating	VBN	O
at	IN	O
least	VBG	O
two	IN	O
populations	JJS	O
of	CD	O
carrier	NNS	O
particles.	IN	O
The	NN	O
first	.	O
population	DT	O
of	JJ	O
carrier	NN	O
particles	IN	O
comprises	NN	O
a	NNS	O
biologically	VBZ	O
active	DT	O
substance	RB	O
and	JJ	O
a	NN	O
penetration	CC	O
enhancer,	DT	O
and	NN	O
the	,	O
second	CC	O
(and	DT	O
optionally	JJ	O
additional)	CC	O
population	RB	O
of	)	O
carrier	NN	O
particles	IN	O
comprises	NN	O
a	NNS	O
penetration	VBZ	O
enhancer	DT	O
and	NN	O
a	NN	O
delayed	CC	O
release	DT	O
coating	JJ	O
or	NN	O
matrix.	NN	O
A	CC	O
“first	.	O
pass	DT	O
effect”	JJ	O
that	NN	O
applies	NN	O
to	WDT	O
orally	VBZ	O
administered	TO	O
drugs	RB	O
is	VBN	O
degradation	NNS	O
due	VBZ	O
to	NN	O
the	JJ	O
action	TO	O
of	DT	O
gastric	NN	O
acid	IN	O
and	JJ	O
various	NN	O
digestive	CC	O
enzymes.	JJ	O
One	JJ	O
means	.	O
of	CD	O
ameliorating	VBZ	O
first	IN	O
pass	VBG	O
clearance	JJ	O
effects	NN	O
is	NN	O
to	NNS	O
increase	VBZ	O
the	TO	O
dose	VB	O
of	DT	O
administered	NN	O
drug,	IN	O
thereby	JJ	O
compensating	,	O
for	RB	O
proportion	VBG	O
of	IN	O
drug	NN	O
lost	IN	O
to	NN	O
first	VBN	O
pass	TO	O
clearance.	JJ	O
This	NN	O
may	.	O
be	DT	O
readily	MD	O
achieved	VB	O
with	RB	O
i.v.	VBN	O
administration	IN	O
by,	.	O
for	NN	O
example,	,	O
simply	IN	O
providing	,	O
more	RB	O
of	VBG	O
the	JJR	O
drug	IN	O
to	DT	O
an	NN	O
animal.	TO	O
However,	DT	O
other	.	O
factors	,	O
influence	JJ	O
the	NNS	O
bioavailability	VBP	O
of	DT	O
drugs	NN	O
administered	IN	O
via	NNS	O
non-parenteral	VBN	O
means.	IN	O
For	JJ	O
example,	.	O
a	IN	O
drug	,	O
may	DT	O
be	NN	O
enzymatically	MD	O
or	VB	O
chemically	RB	O
degraded	CC	O
in	RB	O
the	VBN	O
alimentary	IN	O
canal	DT	O
or	JJ	O
blood	NN	O
stream	CC	O
and/or	NN	O
may	NN	O
be	NN	O
impermeable	MD	O
or	VB	O
semipermeable	JJ	O
to	CC	O
various	JJ	O
mucosal	TO	O
membranes.	JJ	O
These	JJ	O
pharmaceutical	.	O
compositions	DT	O
are	JJ	O
capable	NNS	O
of	VBP	O
enhancing	JJ	O
absorption	IN	O
of	VBG	O
biologically	NN	O
active	IN	O
substances	RB	O
when	JJ	O
administered	NNS	O
via	WRB	O
the	VBN	O
rectal,	IN	O
vaginal,	DT	O
nasal	,	O
or	,	O
pulmonary	JJ	O
routes.	CC	O
Release	JJ	O
of	.	O
the	NN	O
biologically	IN	O
active	DT	O
substance	RB	O
can	JJ	O
be	NN	O
achieved	MD	O
in	VB	O
any	VBN	O
part	IN	O
of	DT	O
the	NN	O
gastrointestinal	IN	O
tract.	DT	O
Liquid	JJ	O
pharmaceutical	.	O
compositions	NNP	O
of	JJ	O
oligonucleotide	NNS	O
can	IN	O
be	NN	O
prepared	MD	O
by	VB	O
combining	VBN	O
the	IN	O
oligonucleotide	VBG	O
with	DT	O
a	NN	O
suitable	IN	O
vehicle,	DT	O
for	JJ	O
example	,	O
sterile	IN	O
pyrogen	NN	O
free	JJ	O
water,	NN	O
or	JJ	O
saline	,	O
solution.	CC	O
Other	JJ	O
therapeutic	.	O
compounds	JJ	O
may	JJ	O
optionally	NNS	O
be	MD	O
included.	RB	O
The	VB	O
present	.	O
invention	DT	O
also	JJ	O
contemplates	NN	O
the	RB	O
use	VBZ	O
of	DT	O
solid	NN	O
particulate	IN	O
compositions.	JJ	O
Such	NN	O
compositions	.	O
preferably	JJ	O
comprise	NNS	O
particles	RB	O
of	VBP	O
oligonucleotide	NNS	O
that	IN	O
are	NN	O
of	WDT	O
respirable	VBP	O
size.	IN	O
Such	JJ	O
particles	.	O
can	JJ	O
be	NNS	O
prepared	MD	O
by,	VB	O
for	VBN	O
example,	,	O
grinding	IN	O
dry	,	O
oligonucleotide	VBG	O
by	JJ	O
conventional	NN	O
means,	IN	O
fore	JJ	O
example	,	O
with	RB	O
a	NN	O
mortar	IN	O
and	DT	O
pestle,	NN	O
and	CC	O
then	,	O
passing	CC	O
the	RB	O
resulting	VBG	O
powder	DT	O
composition	VBG	O
through	NN	O
a	NN	O
400	IN	O
mesh	DT	O
screen	CD	O
to	NN	O
segregate	NN	O
large	TO	O
particles	VB	O
and	JJ	O
agglomerates.	NNS	O
A	CC	O
solid	.	O
particulate	DT	O
composition	JJ	O
comprised	NN	O
of	NN	O
an	VBD	O
active	IN	O
oligonucleotide	DT	O
can	JJ	O
optionally	NN	O
contain	MD	O
a	RB	O
dispersant	VB	O
which	DT	O
serves	NN	O
to	WDT	O
facilitate	VBZ	O
the	TO	O
formation	VB	O
of	DT	O
an	NN	O
aerosol,	IN	O
for	DT	O
example	,	O
lactose.	IN	O
In	NN	O
accordance	.	O
with	IN	O
the	NN	O
present	IN	O
invention,	DT	O
oligonucleotide	JJ	O
compositions	,	O
can	IN	O
be	NNS	O
aerosolized.	MD	O
Aerosolization	VB	O
of	.	O
liquid	NN	O
particles	IN	O
can	JJ	O
be	NNS	O
produced	MD	O
by	VB	O
any	VBN	O
suitable	IN	O
means,	DT	O
such	JJ	O
as	,	O
with	JJ	O
a	IN	O
nebulizer.	IN	O
See,	DT	O
for	.	O
example,	,	O
U.S.	IN	O
Pat.	,	O
No.	NNP	O
4,501,729.	.	O
Nebulizers	.	O
are	.	O
commercially	NNS	O
available	VBP	O
devices	RB	O
which	JJ	O
transform	NNS	O
solutions	WDT	O
or	VBP	O
suspensions	NNS	O
into	CC	O
a	NNS	O
therapeutic	IN	O
aerosol	DT	O
mist	JJ	O
either	NN	O
by	NN	O
means	CC	O
of	IN	O
acceleration	NNS	O
of	IN	O
a	NN	O
compressed	IN	O
gas,	DT	O
typically	JJ	O
air	,	O
or	RB	O
oxygen,	NN	O
through	CC	O
a	,	O
narrow	IN	O
venturi	DT	O
orifice	JJ	O
or	NN	O
by	NN	O
means	CC	O
of	IN	O
ultrasonic	NNS	O
agitation.	IN	O
Suitable	JJ	O
nebulizers	.	O
include	JJ	O
those	NNS	O
sold	VBP	O
by	DT	O
Blairex®	VBN	O
under	IN	O
the	NNP	O
name	IN	O
PARI	DT	O
LC	NN	O
PLUS,	NNP	O
PARI	NNP	O
DURA-NEB	,	O
2000,	NNP	O
PARI-BABY	NNP	O
Size,	,	O
PARI	NNP	O
PRONEB	,	O
Compressor	NNP	O
with	NNP	O
LC	NNP	O
PLUS,	IN	O
PARI	NNP	O
WALKHALER	,	O
Compressor/Nebulizer	NNP	O
System,	NNP	O
PARI	NNP	O
LC	,	O
PLUS	NNP	O
Reusable	NNP	O
Nebulizer,	NNP	O
and	NNP	O
PARI	,	O
LC	CC	O
Jet+	NNP	O
®Nebulizer.	NNP	O
Formulations	NNP	O
for	.	O
use	NNS	O
in	IN	O
nebulizers	NN	O
may	IN	O
consist	NNS	O
of	MD	O
an	VB	O
oligonucleotide	IN	O
in	DT	O
a	NN	O
liquid,	IN	O
such	DT	O
as	,	O
sterile,	JJ	O
pyragen	IN	O
free	,	O
water,	JJ	O
or	JJ	O
saline	,	O
solution,	CC	O
wherein	JJ	O
the	,	O
oligonucleotide	VBP	O
comprises	DT	O
up	NN	O
to	VBZ	O
about	RP	O
40%	TO	O
w/w	IN	O
of	NN	O
the	NN	O
formulation.	IN	O
Preferably,	DT	O
the	.	O
oligonucleotide	,	O
comprises	DT	O
less	JJ	O
than	VBZ	O
20%	JJR	O
w/w.	IN	O
If	NN	O
desired,	.	O
further	IN	O
additives	,	O
such	JJ	O
as	NNS	O
preservatives	JJ	O
(for	IN	O
example,	NNS	O
methyl	IN	O
hydroxybenzoate)	,	O
antioxidants,	VB	O
and	)	O
flavoring	,	O
agents	CC	O
can	VBG	O
be	NNS	O
added	MD	O
to	VB	O
the	VBN	O
composition.	TO	O
Solid	DT	O
particles	.	O
comprising	JJ	O
an	NNS	O
oligonucleotide	VBG	O
can	DT	O
also	NN	O
be	MD	O
aerosolized	RB	O
using	VB	O
any	VBN	O
solid	VBG	O
particulate	DT	O
medicament	JJ	O
aerosol	NN	O
generator	NN	O
known	JJ	O
in	NN	O
the	VBN	O
art.	IN	O
Such	DT	O
aerosol	.	O
generators	JJ	O
produce	JJ	O
respirable	NNS	O
particles,	VBP	O
as	JJ	O
described	,	O
above,	IN	O
and	VBN	O
further	,	O
produce	CC	O
reproducible	RB	O
metered	VB	O
dose	JJ	O
per	VBN	O
unit	JJ	O
volume	IN	O
of	NN	O
aerosol.	NN	O
Suitable	IN	O
solid	.	O
particulate	JJ	O
aerosol	JJ	O
generators	NN	O
include	JJ	O
insufflators	NNS	O
and	VBP	O
metered	NNS	O
dose	CC	O
inhalers.	VBD	O
Metered	JJ	O
dose	.	O
inhalers	NNP	O
are	NN	O
used	NNS	O
in	VBP	O
the	VBN	O
art	IN	O
and	DT	O
are	NN	O
useful	CC	O
in	VBP	O
the	JJ	O
present	IN	O
invention.	DT	O
Preferably,	JJ	O
liquid	.	O
or	,	O
solid	NN	O
aerosols	CC	O
are	JJ	O
produced	NNS	O
at	VBP	O
a	VBN	O
rate	IN	O
of	DT	O
from	NN	O
about	IN	O
10	IN	O
to	IN	O
150	CD	O
liters	TO	O
per	CD	O
minute,	NNS	O
more	IN	O
preferably	,	O
from	JJR	O
about	RB	O
30	IN	O
to	RB	O
150	CD	O
liters	TO	O
per	CD	O
minute,	NNS	O
and	IN	O
most	,	O
preferably	CC	O
about	JJS	O
60	RB	O
liters	IN	O
per	CD	O
minute.	NNS	O
Enhanced	IN	O
bioavailability	.	O
of	NNP	O
biologically	NN	O
active	IN	O
substances	RB	O
is	JJ	O
also	NNS	O
achieved	VBZ	O
via	RB	O
the	VBN	O
oral	IN	O
administration	DT	O
of	JJ	O
the	NN	O
compositions	IN	O
and	DT	O
methods	NNS	O
of	CC	O
the	NNS	O
present	IN	O
invention.	DT	O
The	JJ	O
compositions	.	O
of	DT	O
the	NNS	O
present	IN	O
invention	DT	O
may	JJ	O
additionally	NN	O
contain	MD	O
other	RB	O
adjunct	VB	O
components	JJ	O
conventionally	JJ	O
found	NNS	O
in	RB	O
pharmaceutical	VBN	O
compositions,	IN	O
at	JJ	O
their	,	O
art-established	IN	O
usage	PRP$	O
levels.	JJ	O
Thus,	NN	O
for	.	O
example,	,	O
the	IN	O
compositions	,	O
may	DT	O
contain	NNS	O
additional,	MD	O
compatible,	VB	O
pharmaceutically-active	,	O
materials	,	O
such	JJ	O
as,	NNS	O
for	JJ	O
example,	,	O
antipruritics,	IN	O
astringents,	,	O
local	,	O
anesthetics	,	O
or	JJ	O
anti-inflammatory	NNS	O
agents,	CC	O
or	JJ	O
may	,	O
contain	CC	O
additional	MD	O
materials	VB	O
useful	JJ	O
in	NNS	O
physically	JJ	O
formulating	IN	O
various	RB	O
dosage	VBG	O
forms	JJ	O
of	NN	O
the	NNS	O
compositions	IN	O
of	DT	O
the	NNS	O
present	IN	O
invention,	DT	O
such	JJ	O
as	,	O
dyes,	JJ	O
flavoring	IN	O
agents,	,	O
preservatives,	VBG	O
antioxidants,	,	O
opacifiers,	,	O
thickening	,	O
agents	,	O
and	VBG	O
stabilizers.	NNS	O
However,	CC	O
such	.	O
materials,	,	O
when	JJ	O
added,	,	O
should	WRB	O
not	,	O
unduly	MD	O
interfere	RB	O
with	VB	O
the	RB	O
biological	IN	O
activities	DT	O
of	JJ	O
the	NNS	O
components	IN	O
of	DT	O
the	NNS	O
compositions	IN	O
of	DT	O
the	NNS	O
present	IN	O
invention.	DT	O
The	JJ	O
formulations	.	O
can	DT	O
be	NNS	O
sterilized	MD	O
and,	VB	O
if	VBN	O
desired,	,	O
mixed	IN	O
with	,	O
auxiliary	JJ	O
agents,	IN	O
e.g.,	JJ	O
lubricants,	,	O
preservatives,	,	O
stabilizers,	,	O
wetting	,	O
agents,	,	O
emulsifiers,	VBG	O
salts	,	O
for	,	O
influencing	NNS	O
osmotic	IN	O
pressure,	VBG	O
buffers,	JJ	O
colorings,	,	O
flavorings	,	O
and/or	,	O
aromatic	NNS	O
substances	VBP	O
and	JJ	O
the	NNS	O
like	CC	O
which	DT	O
do	JJ	O
not	WDT	O
deleteriously	VBP	O
interact	RB	O
with	RB	O
the	JJ	O
nucleic	IN	O
acid(s)	DT	O
of	JJ	O
the	)	O
formulation.	IN	O
Aqueous	DT	O
suspensions	.	O
may	JJ	O
contain	NNS	O
substances	MD	O
which	VB	O
increase	NNS	O
the	WDT	O
viscosity	VBP	O
of	DT	O
the	NN	O
suspension	IN	O
including,	DT	O
for	NN	O
example,	,	O
sodium	IN	O
carboxymethylcellulose,	,	O
sorbitol	NN	O
and/or	,	O
dextran.	JJ	O
The	NN	O
suspension	.	O
may	DT	O
also	NN	O
contain	MD	O
stabilizers.	RB	O
Certain	VB	O
embodiments	.	O
of	NNP	O
the	NNS	O
invention	IN	O
provide	DT	O
pharmaceutical	NN	O
compositions	RB	O
containing	JJ	O
one	NNS	O
or	VBG	O
more	CD	O
oligomeric	CC	O
compounds	JJR	O
and	JJ	O
one	NNS	O
or	CC	O
more	CD	O
other	CC	O
chemotherapeutic	JJR	O
agents	JJ	O
which	JJ	O
function	NNS	O
by	WDT	O
a	NN	O
non-antisense	IN	O
mechanism.	DT	O
Examples	JJ	O
of	.	O
such	NNS	O
chemotherapeutic	IN	O
agents	JJ	O
include	JJ	O
but	NNS	O
are	VBP	O
not	CC	O
limited	VBP	O
to	RB	O
cancer	VBN	O
chemotherapeutic	TO	O
drugs	NN	O
such	JJ	O
as	NNS	O
daunorubicin,	JJ	O
daunomycin,	IN	O
dactinomycin,	,	O
doxorubicin,	,	O
epirubicin,	,	O
idarubicin,	,	O
esorubicin,	,	O
bleomycin,	,	O
mafosfamide,	,	O
ifosfamide,	,	O
cytosine	,	O
arabinoside,	,	O
bis-chloroethylnitrosurea,	NN	O
busulfan,	,	O
mitomycin	,	O
C,	,	O
actinomycin	FW	O
D,	,	O
mithramycin,	JJ	O
prednisone,	,	O
hydroxyprogesterone,	,	O
testosterone,	,	O
tamoxifen,	,	O
dacarbazine,	,	O
procarbazine,	,	O
hexamethylmelamine,	,	O
pentamethylmelamine,	,	O
mitoxantrone,	,	O
amsacrine,	,	O
chlorambucil,	,	O
methylcyclohexylnitrosurea,	,	O
nitrogen	,	O
mustards,	,	O
melphalan,	NN	O
cyclophosphamide,	,	O
6-mercaptopurine,	,	O
6-thioguanine,	,	O
cytarabine,	,	O
5-azacytidine,	,	O
hydroxyurea,	,	O
deoxycoformycin,	,	O
4-hydroxyperoxycyclophosphoramide,	,	O
5-fluorouracil	,	O
(5-FU),	,	O
5-fluorodeoxyuridine	JJ	O
(5-FUdR),	,	O
methotrexate	JJ	O
(MTX),	,	O
colchicine,	NN	O
taxol,	,	O
vincristine,	,	O
vinblastine,	,	O
etoposide	,	O
(VP-16),	,	O
trimetrexate,	RB	O
irinotecan,	,	O
topotecan,	,	O
gemcitabine,	,	O
teniposide,	,	O
cisplatin	,	O
and	,	O
diethylstilbestrol	NN	O
(DES).	CC	O
When	NN	O
used	.	O
with	WRB	O
the	VBN	O
compounds	IN	O
of	DT	O
the	NNS	O
invention,	IN	O
such	DT	O
chemotherapeutic	,	O
agents	JJ	O
may	JJ	O
be	NNS	O
used	MD	O
individually	VB	O
(e.g.,	VBN	O
5-FU	RB	O
and	,	O
oligonucleotide),	JJ	O
sequentially	CC	O
(e.g.,	,	O
5-FU	RB	O
and	,	O
oligonucleotide	JJ	O
for	CC	O
a	NN	O
period	IN	O
of	DT	O
time	NN	O
followed	IN	O
by	NN	O
MTX	VBN	O
and	IN	O
oligonucleotide),	NNP	O
or	CC	O
in	,	O
combination	CC	O
with	IN	O
one	NN	O
or	IN	O
more	CD	O
other	CC	O
such	JJR	O
chemotherapeutic	JJ	O
agents	JJ	O
(e.g.,	JJ	O
5-FU,	NNS	O
MTX	,	O
and	,	O
oligonucleotide,	NNP	O
or	CC	O
5-FU,	,	O
radiotherapy	CC	O
and	,	O
oligonucleotide).	NN	O
Anti-inflammatory	CC	O
drugs,	.	O
including	JJ	O
but	,	O
not	VBG	O
limited	CC	O
to	RB	O
nonsteroidal	JJ	O
anti-inflammatory	TO	O
drugs	VB	O
and	JJ	O
corticosteroids,	NNS	O
and	CC	O
antiviral	,	O
drugs,	CC	O
including	JJ	O
but	,	O
not	VBG	O
limited	CC	O
to	RB	O
ribivirin,	JJ	O
vidarabine,	TO	O
acyclovir	,	O
and	,	O
ganciclovir,	NN	O
may	CC	O
also	,	O
be	MD	O
combined	RB	O
in	VB	O
compositions	VBN	O
of	IN	O
the	NNS	O
invention.	IN	O
Combinations	DT	O
of	.	O
antisense	NNS	O
compounds	IN	O
and	JJ	O
other	NNS	O
non-antisense	CC	O
drugs	JJ	O
are	JJ	O
also	NNS	O
within	VBP	O
the	RB	O
scope	IN	O
of	DT	O
this	NN	O
invention.	IN	O
Two	DT	O
or	.	O
more	CD	O
combined	CC	O
compounds	JJR	O
may	JJ	O
be	NNS	O
used	MD	O
together	VB	O
or	VBN	O
sequentially.	RB	O
In	CC	O
another	.	O
related	IN	O
embodiment,	DT	O
compositions	JJ	O
of	,	O
the	NNS	O
invention	IN	O
may	DT	O
contain	NN	O
one	MD	O
or	VB	O
more	CD	O
antisense	CC	O
compounds,	JJR	O
particularly	JJ	O
oligonucleotides,	,	O
targeted	RB	O
to	,	O
a	VBN	O
first	TO	O
nucleic	DT	O
acid	JJ	O
and	JJ	O
one	NN	O
or	CC	O
more	CD	O
additional	CC	O
antisense	JJR	O
compounds	JJ	O
targeted	NN	O
to	NNS	O
a	VBN	O
second	TO	O
nucleic	DT	O
acid	JJ	O
target.	JJ	O
Alternatively,	NN	O
compositions	.	O
of	,	O
the	NNS	O
invention	IN	O
may	DT	O
contain	NN	O
two	MD	O
or	VB	O
more	CD	O
antisense	CC	O
compounds	JJR	O
targeted	JJ	O
to	NNS	O
different	VBN	O
regions	TO	O
of	JJ	O
the	NNS	O
same	IN	O
nucleic	DT	O
acid	JJ	O
target.	JJ	O
Numerous	NN	O
examples	.	O
of	JJ	O
antisense	NNS	O
compounds	IN	O
are	JJ	O
known	NNS	O
in	VBP	O
the	VBN	O
art.	IN	O
Two	DT	O
or	.	O
more	CD	O
combined	CC	O
compounds	JJR	O
may	JJ	O
be	NNS	O
used	MD	O
together	VB	O
or	VBN	O
sequentially.	RB	O
H.	CC	O
Dosing	.	O
The	NNP	O
formulation	VBG	O
of	DT	O
therapeutic	NN	O
compositions	IN	O
and	JJ	O
their	NNS	O
subsequent	CC	O
administration	PRP$	O
(dosing)	JJ	O
is	NN	O
believed	)	O
to	VBZ	O
be	VBN	O
within	TO	O
the	VB	O
skill	IN	O
of	DT	O
those	NN	O
in	IN	O
the	DT	O
art.	IN	O
Dosing	DT	O
is	.	O
dependent	VBG	O
on	VBZ	O
severity	JJ	O
and	IN	O
responsiveness	NN	O
of	CC	O
the	NN	O
disease	IN	O
state	DT	O
to	NN	O
be	NN	O
treated,	TO	O
with	VB	O
the	,	O
course	IN	O
of	DT	O
treatment	NN	O
lasting	IN	O
from	NN	O
several	VBG	O
days	IN	O
to	JJ	O
several	NNS	O
months,	TO	O
or	JJ	O
until	,	O
a	CC	O
cure	IN	O
is	DT	O
effected	NN	O
or	VBZ	O
a	VBN	O
diminution	CC	O
of	DT	O
the	NN	O
disease	IN	O
state	DT	O
is	NN	O
achieved.	NN	O
Optimal	VBZ	O
dosing	.	O
schedules	JJ	O
can	VBG	O
be	NNS	O
calculated	MD	O
from	VB	O
measurements	VBN	O
of	IN	O
drug	NNS	O
accumulation	IN	O
in	NN	O
the	NN	O
body	IN	O
of	DT	O
the	NN	O
patient.	IN	O
Persons	DT	O
of	.	O
ordinary	NNS	O
skill	IN	O
can	JJ	O
easily	NN	O
determine	MD	O
optimum	RB	O
dosages,	VB	O
dosing	JJ	O
methodologies	,	O
and	VBG	O
repetition	NNS	O
rates.	CC	O
Optimum	NN	O
dosages	.	O
may	NNP	O
vary	NNS	O
depending	MD	O
on	VB	O
the	VBG	O
relative	IN	O
potency	DT	O
of	JJ	O
individual	NN	O
oligonucleotides,	IN	O
and	JJ	O
can	,	O
generally	CC	O
be	MD	O
estimated	RB	O
based	VB	O
on	VBN	O
EC50s	VBN	O
found	IN	O
to	NNP	O
be	VBD	O
effective	TO	O
in	VB	O
in	JJ	O
vitro	IN	O
and	IN	O
in	NN	O
vivo	CC	O
animal	IN	O
models.	NN	O
In	NN	O
general,	.	O
dosage	IN	O
is	,	O
from	NN	O
0.01	VBZ	O
μg	IN	O
to	CD	O
100	NNS	O
g	TO	O
per	CD	O
kg	NNS	O
of	IN	O
body	NN	O
weight,	IN	O
from	NN	O
0.1	,	O
μg	IN	O
to	CD	O
10	NNS	O
g	TO	O
per	CD	O
kg	NNS	O
of	IN	O
body	NN	O
weight,	IN	O
from	NN	O
1.0	,	O
μg	IN	O
to	CD	O
1	NNS	O
g	TO	O
per	CD	O
kg	NNS	O
of	IN	O
body	NN	O
weight,	IN	O
from	NN	O
10.0	,	O
μg	IN	O
to	CD	O
100	NNS	O
mg	TO	O
per	CD	O
kg	NNS	O
of	IN	O
body	NN	O
weight,	IN	O
from	NN	O
100	,	O
μg	IN	O
to	CD	O
10	NNS	O
mg	TO	O
per	CD	O
kg	NNS	O
of	IN	O
body	NN	O
weight,	IN	O
or	NN	O
from	,	O
1	CC	O
mg	IN	O
to	CD	O
5	NNS	O
mg	TO	O
per	CD	O
kg	NNS	O
of	IN	O
body	NN	O
weight,	IN	O
and	NN	O
may	,	O
be	CC	O
given	MD	O
once	VB	O
or	VBN	O
more	RB	O
daily,	CC	O
weekly,	JJR	O
monthly	,	O
or	,	O
yearly,	JJ	O
or	CC	O
even	,	O
once	CC	O
every	RB	O
2	RB	O
to	DT	O
20	CD	O
years.	TO	O
Persons	CD	O
of	.	O
ordinary	NNS	O
skill	IN	O
in	JJ	O
the	NN	O
art	IN	O
can	DT	O
easily	NN	O
estimate	MD	O
repetition	RB	O
rates	VB	O
for	NN	O
dosing	NNS	O
based	IN	O
on	VBG	O
measured	VBN	O
residence	IN	O
times	JJ	O
and	NN	O
concentrations	NNS	O
of	CC	O
the	NNS	O
drug	IN	O
in	DT	O
bodily	NN	O
fluids	IN	O
or	JJ	O
tissues.	NNS	O
Following	CC	O
successful	.	O
treatment,	VBG	O
it	JJ	O
may	,	O
be	PRP	O
desirable	MD	O
to	VB	O
have	JJ	O
the	TO	O
patient	VB	O
undergo	DT	O
maintenance	NN	O
therapy	JJ	O
to	NN	O
prevent	NN	O
the	TO	O
recurrence	VB	O
of	DT	O
the	NN	O
disease	IN	O
state,	DT	O
wherein	NN	O
the	,	O
oligonucleotide	VBD	O
is	DT	O
administered	NN	O
in	VBZ	O
maintenance	VBN	O
doses,	IN	O
ranging	NN	O
from	,	O
0.01	VBG	O
ug	IN	O
to	CD	O
100	NNS	O
g	TO	O
per	CD	O
kg	NNS	O
of	IN	O
body	NN	O
weight,	IN	O
once	NN	O
or	,	O
more	RB	O
daily,	CC	O
to	JJR	O
once	,	O
every	TO	O
20	RB	O
years.	DT	O
The	CD	O
effects	.	O
of	DT	O
treatments	NNS	O
with	IN	O
therapeutic	NNS	O
compositions	IN	O
can	JJ	O
be	NNS	O
assessed	MD	O
following	VB	O
collection	VBN	O
of	VBG	O
tissues	NN	O
or	IN	O
fluids	NNS	O
from	CC	O
a	NNS	O
patient	IN	O
or	DT	O
subject	NN	O
receiving	CC	O
said	JJ	O
treatments.	NN	O
It	VBD	O
is	.	O
known	PRP	O
in	VBZ	O
the	VBN	O
art	IN	O
that	DT	O
a	NN	O
biopsy	IN	O
sample	DT	O
can	JJ	O
be	NN	O
procured	MD	O
from	VB	O
certain	VBN	O
tissues	IN	O
without	JJ	O
resulting	NNS	O
in	IN	O
detrimental	VBG	O
effects	IN	O
to	JJ	O
a	NNS	O
patient	TO	O
or	DT	O
subject.	NN	O
In	CC	O
certain	.	O
embodiments,	IN	O
a	JJ	O
tissue	,	O
and	DT	O
its	NN	O
constituent	CC	O
cells	PRP$	O
comprise,	NN	O
but	NNS	O
are	,	O
not	CC	O
limited	VBP	O
to,	RB	O
blood	VBN	O
(e.g.,	,	O
hematopoietic	NN	O
cells,	,	O
such	JJ	O
as	,	O
human	JJ	O
hematopoietic	IN	O
progenitor	JJ	O
cells,	JJ	O
human	NN	O
hematopoietic	,	O
stem	JJ	O
cells,	JJ	O
CD34+	NN	O
cells	,	O
CD4+	NNP	O
cells),	NNS	O
lymphocytes	NNP	O
and	,	O
other	NNS	O
blood	CC	O
lineage	JJ	O
cells,	NN	O
bone	NN	O
marrow,	,	O
breast,	NN	O
cervix,	,	O
colon,	,	O
esophagus,	,	O
lymph	,	O
node,	,	O
muscle,	JJ	O
peripheral	,	O
blood,	,	O
oral	JJ	O
mucosa	,	O
and	JJ	O
skin.	NN	O
In	CC	O
other	.	O
embodiments,	IN	O
a	JJ	O
fluid	,	O
and	DT	O
its	NN	O
constituent	CC	O
cells	PRP$	O
comprise,	NN	O
but	NNS	O
are	,	O
not	CC	O
limited	VBP	O
to,	RB	O
blood,	VBN	O
urine,	,	O
semen,	,	O
synovial	,	O
fluid,	,	O
lymphatic	JJ	O
fluid	,	O
and	JJ	O
cerebro-spinal	NN	O
fluid.	CC	O
Tissues	JJ	O
or	.	O
fluids	NNS	O
procured	CC	O
from	NNS	O
patients	VBN	O
can	IN	O
be	NNS	O
evaluated	MD	O
for	VB	O
expression	VBN	O
levels	IN	O
of	NN	O
the	NNS	O
target	IN	O
mRNA	DT	O
or	NN	O
protein.	NN	O
Additionally,	CC	O
the	.	O
mRNA	,	O
or	DT	O
protein	NN	O
expression	CC	O
levels	JJ	O
of	NN	O
other	NNS	O
genes	IN	O
known	JJ	O
or	NNS	O
suspected	VBN	O
to	CC	O
be	VBN	O
associated	TO	O
with	VB	O
the	VBN	O
specific	IN	O
disease	DT	O
state,	JJ	O
condition	NN	O
or	,	O
phenotype	NN	O
can	CC	O
be	NN	O
assessed.	MD	O
mRNA	VB	O
levels	.	O
can	NN	O
be	NNS	O
measured	MD	O
or	VB	O
evaluated	VBN	O
by	CC	O
real-time	VBN	O
PCR,	IN	O
Northern	JJ	O
blot,	,	O
in	NNP	O
situ	,	O
hybridization	IN	O
or	JJ	O
DNA	NN	O
array	CC	O
analysis.	NNP	O
Protein	JJ	O
levels	.	O
can	NNP	O
be	NNS	O
measured	MD	O
or	VB	O
evaluated	VBN	O
by	CC	O
ELISA,	VBN	O
immunoblotting,	IN	O
quantitative	,	O
protein	,	O
assays,	JJ	O
protein	NN	O
activity	,	O
assays	NN	O
(for	NN	O
example,	NNS	O
caspase	IN	O
activity	,	O
assays)	NN	O
immunohistochemistry	NN	O
or	)	O
immunocytochemistry.	NN	O
Furthermore,	CC	O
the	.	O
effects	,	O
of	DT	O
treatment	NNS	O
can	IN	O
be	NN	O
assessed	MD	O
by	VB	O
measuring	VBN	O
biomarkers	IN	O
associated	VBG	O
with	NNS	O
the	VBN	O
disease	IN	O
or	DT	O
condition	NN	O
in	CC	O
the	NN	O
aforementioned	IN	O
tissues	DT	O
and	JJ	O
fluids,	NNS	O
collected	CC	O
from	,	O
a	VBN	O
patient	IN	O
or	DT	O
subject	NN	O
receiving	CC	O
treatment,	JJ	O
by	NN	O
routine	,	O
clinical	IN	O
methods	JJ	O
known	JJ	O
in	NNS	O
the	VBN	O
art.	IN	O
These	DT	O
biomarkers	.	O
include	DT	O
but	NNS	O
are	VBP	O
not	CC	O
limited	VBP	O
to:	RB	O
glucose,	VBN	O
cholesterol,	:	O
lipoproteins,	,	O
triglycerides,	,	O
free	,	O
fatty	,	O
acids	JJ	O
and	JJ	O
other	NNS	O
markers	CC	O
of	JJ	O
glucose	NNS	O
and	IN	O
lipid	NN	O
metabolism;	CC	O
lipoprotein(a)	JJ	O
or	:	O
Lp(a)	)	O
or	CC	O
apolipoprotein	)	O
B;	CC	O
liver	JJ	O
transaminases,	:	O
bilirubin,	NN	O
albumin,	,	O
blood	,	O
urea	,	O
nitrogen,	NN	O
creatine	JJ	O
and	,	O
other	NN	O
markers	CC	O
of	JJ	O
kidney	NNS	O
and	IN	O
liver	NN	O
function;	CC	O
interleukins,	NN	O
tumor	:	O
necrosis	,	O
factors,	NN	O
intracellular	NN	O
adhesion	,	O
molecules,	JJ	O
C-reactive	NN	O
protein	,	O
and	JJ	O
other	NN	O
markers	CC	O
of	JJ	O
inflammation;	NNS	O
testosterone,	IN	O
estrogen	:	O
and	,	O
other	NN	O
hormones;	CC	O
tumor	JJ	O
markers;	:	O
vitamins,	NN	O
minerals	:	O
and	,	O
electrolytes.	NNS	O
While	CC	O
the	.	O
present	IN	O
invention	DT	O
has	JJ	O
been	NN	O
described	VBZ	O
with	VBN	O
specificity	VBN	O
in	IN	O
accordance	NN	O
with	IN	O
certain	NN	O
of	IN	O
its	JJ	O
preferred	IN	O
embodiments,	PRP$	O
the	JJ	O
following	,	O
examples	DT	O
serve	JJ	O
only	NNS	O
to	VBP	O
illustrate	RB	O
the	TO	O
invention	VB	O
and	DT	O
are	NN	O
not	CC	O
intended	VBP	O
to	RB	O
limit	VBN	O
the	TO	O
same.	VB	O
Each	DT	O
of	.	O
the	DT	O
references,	IN	O
GENBANK®	DT	O
accession	,	O
numbers,	NNP	O
and	NN	O
the	,	O
like	CC	O
recited	DT	O
in	JJ	O
the	VBN	O
present	IN	O
application	DT	O
is	JJ	O
incorporated	NN	O
herein	VBZ	O
by	VBN	O
reference	NN	O
in	IN	O
its	NN	O
entirety.	IN	O
EXAMPLES	PRP$	O
Example	.	O
1	NNP	O
Synthesis	NNP	O
of	CD	O
Nucleoside	NNP	O
Phosphoramidites	IN	O
The	NNP	O
following	NNP	O
compounds,	DT	O
including	JJ	O
amidites	,	O
and	VBG	O
their	NNS	O
intermediates	CC	O
were	PRP$	O
prepared	NNS	O
as	VBD	O
described	VBN	O
in	IN	O
U.S.	VBN	O
Pat.	IN	O
No.	NNP	O
6,426,220	.	O
and	.	O
International	CD	O
Patent	CC	O
Publication	NNP	O
No.	NNP	O
WO	NNP	O
02/36743;	.	O
5′-O-Dimethoxytrityl-thymidine	NNP	O
intermediate	:	O
for	JJ	O
5-methyl	NN	O
dC	IN	O
amidite,	JJ	O
5′-O-Dimethoxytrityl-2′-deoxy-5-methylcytidine	NN	O
intermediate	,	O
for	JJ	O
5-methyl-dC	NN	O
amidite,	IN	O
5′-O-Dimethoxytrityl-2′-deoxy-N4-benzoyl-5-methylcytidine	JJ	O
penultimate	,	O
intermediate	JJ	O
for	NN	O
5-methyl	NN	O
dC	IN	O
amidite,	JJ	O
[5′-O-(4,4′-Dimethoxytriphenylmethyl)-2′-deoxy-N4-benzoyl-5-methylcytidin-3′-O-yl]-2-cyanoethyl-N,N-diisopropylphosphoramidite	NN	O
(5-methyl	,	O
dC	NNP	O
amidite),	JJ	O
2′-Fluorodeoxyadenosine,	NN	O
2′-Fluorodeoxyguanosine,	,	O
2′-Fluorouridine,	,	O
2′-Fluorodeoxycytidine,	,	O
2′-O-(2-Methoxyethyl)	,	O
modified	,	O
amidites,	)	O
2′-O-(2-methoxyethyl)-5-methyluridine	VBN	O
intermediate,	,	O
5′-O-DMT-2′-O-(2-methoxyethyl)-5-methyluridine	NN	O
penultimate	,	O
intermediate,	NN	O
[5′-O-(4,4′-Dimethoxytriphenylmethyl)-2′-O-(2-methoxyethyl)-5-methyluridin-3′-O-yl]-2-cyanoethyl-N,N-diisopropylphosphoramidite	NN	O
(MOE	,	O
T	NNP	O
amidite),	NNP	O
5′-O-Dimethoxytrityl-2′-O-(2-methoxyethyl)-5-methylcytidine	NNP	O
intermediate,	,	O
5′-O-dimethoxytrityl-2′-O-(2-methoxyethyl)-N4-benzoyl-5-methyl-cytidine	NN	O
penultimate	,	O
intermediate,	NN	O
[5′-O-(4,4′-Dimethoxytriphenylmethyl)-2′-O-(2-methoxyethyl)-N4-benzoyl-5-methylcytidin-3′-O-yl]-2-cyanoethyl-N,N-diisopropylphosphoramidite	NN	O
(MOE	,	O
5-Me-C	NNP	O
amidite),	NNP	O
[5′-O-(4,4′-Dimethoxytriphenylmethyl)-2′-O-(2-methoxyethyl)-N6-benzoyladenosin-3′-O-yl]-2-cyanoethyl-N,N-diisopropylphosphoramidite	NNP	O
(MOE	,	O
A	NNP	O
amidite),	NNP	O
[5′-O-(4,4′-Dimethoxytriphenylmethyl)-2′-O-(2-methoxyethyl)-N4-isobutyrylguanosin-3′-O-yl]-2-cyanoethyl-N,N-diisopropylphosphoramidite	NNP	O
(MOE	,	O
G	NNP	O
amidite),	NNP	O
2′-O-(Aminooxyethyl)	NNP	O
nucleoside	,	O
amidites	)	O
and	NN	O
2′-O-(dimethylaminooxyethyl)	NNS	O
nucleoside	CC	O
amidites,	)	O
2′-(Dimethylaminooxyethoxy)	NN	O
nucleoside	,	O
amidites,	)	O
5′-O-tert-Butyldiphenylsilyl-O2-2′-anhydro-5-methyluridine,	RB	O
5′-O-tert-Butyldiphenylsilyl-2′-O-(2-hydroxyethyl)-5-methyluridine,	,	O
2′-O-([2-phthalimidoxy)ethyl]-5′-t-butyldiphenylsilyl-5-methyluridine,	,	O
5′-O-tert-butyldiphenylsilyl-2′-O-[(2-formadoximinooxy)ethyl]-5-methyluridine,	,	O
5′-O-tert-Butyldiphenylsilyl-2′-O-[N,N	,	O
dimethylaminooxyethyl]-5-methyluridine,	,	O
2′-O-(dimethylaminooxyethyl)-5-methyluridine,	NNP	O
5′-O-DMT-2′-O-(dimethylaminooxyethyl)-5-methyluridine,	,	O
5′-O-DMT-2′-O-(2-N,N-dimethylaminooxyethyl)-5-methyluridine-3′-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite],	,	O
2′-(Aminooxyethoxy)	,	O
nucleoside	,	O
amidites,	)	O
N2-isobutyryl-6-O-diphenylcarbamoyl-2′-O-(2-ethylacetyl)-5′-O-(4,4′-dimethoxytrityl)guanosine-3′-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite],	RB	O
2′-dimethylaminoethoxyethoxy	,	O
(2′-DMAEOE)	,	O
nucleoside	JJ	O
amidites,	)	O
2′-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl	NN	O
uridine,	,	O
5′-O-dimethoxytrityl-2′-O-[2(2-N,N-dimethylaminoethoxy)-ethyl)]-5-methyl	NNP	O
uridine	,	O
and	JJ	O
5′-O-Dimethoxytrityl-2′-O-[2(2-N,N-dimethylaminoethoxy)-ethyl)]-5-methyl	JJ	O
uridine-3′-O-(cyanoethyl-N,N-diisopropyl)phosphoramidite.	CC	O
Example	JJ	O
2	.	O
Oligonucleotide	RB	O
and	CD	O
Oligonucleoside	NNP	O
Synthesis	CC	O
The	NNP	O
antisense	NNP	O
compounds	DT	O
used	NN	O
in	NNS	O
accordance	VBN	O
with	IN	O
this	NN	O
invention	IN	O
may	DT	O
be	NN	O
conveniently	MD	O
and	VB	O
routinely	RB	O
made	CC	O
through	RB	O
the	VBD	O
well-known	IN	O
technique	DT	O
of	JJ	O
solid	NN	O
phase	IN	O
synthesis.	JJ	O
Equipment	NN	O
for	.	O
such	NN	O
synthesis	IN	O
is	JJ	O
sold	NN	O
by	VBZ	O
several	VBN	O
vendors	IN	O
including,	JJ	O
for	NNS	O
example,	,	O
Applied	IN	O
Biosystems	,	O
(Foster	NNP	O
City,	NNP	O
Calif.).	NNP	O
Any	,	O
other	.	O
means	DT	O
for	JJ	O
such	NNS	O
synthesis	IN	O
known	JJ	O
in	NN	O
the	VBN	O
art	IN	O
may	DT	O
additionally	NN	O
or	MD	O
alternatively	RB	O
be	CC	O
employed.	RB	O
It	VB	O
is	.	O
well	PRP	O
known	VBZ	O
to	RB	O
use	VBN	O
similar	TO	O
techniques	VB	O
to	JJ	O
prepare	NNS	O
oligonucleotides	TO	O
such	VB	O
as	NNS	O
the	JJ	O
phosphorothioates	IN	O
and	DT	O
alkylated	NNS	O
derivatives.	CC	O
Oligonucleotides:	JJ	O
Unsubstituted	.	O
and	:	O
substituted	VBN	O
phosphodiester	CC	O
(P═O)	VBN	O
oligonucleotides	NN	O
are	)	O
synthesized	NNS	O
on	VBP	O
an	VBN	O
automated	IN	O
DNA	DT	O
synthesizer	VBN	O
(Applied	NNP	O
Biosystems	NN	O
model	NNP	O
394)	NNP	O
using	FW	O
standard	)	O
phosphoramidite	VBG	O
chemistry	JJ	O
with	JJ	O
oxidation	NN	O
by	IN	O
iodine.	NN	O
Phosphorothioates	IN	O
(P═S)	.	O
are	NNS	O
synthesized	)	O
similar	VBP	O
to	VBN	O
phosphodiester	JJ	O
oligonucleotides	TO	O
with	VB	O
the	NNS	O
following	IN	O
exceptions:	DT	O
thiation	JJ	O
was	:	O
effected	NN	O
by	VBD	O
utilizing	VBN	O
a	IN	O
10%	VBG	O
w/v	DT	O
solution	NN	O
of	JJ	O
3,H-1,2-benzodithiole-3-one	NN	O
1,1-dioxide	IN	O
in	CD	O
acetonitrile	JJ	O
for	IN	O
the	NN	O
oxidation	IN	O
of	DT	O
the	NN	O
phosphite	IN	O
linkages.	DT	O
The	JJ	O
thiation	.	O
reaction	DT	O
step	NN	O
time	NN	O
was	NN	O
increased	NN	O
to	VBD	O
180	VBN	O
sec	TO	O
and	CD	O
preceded	NN	O
by	CC	O
the	VBN	O
normal	IN	O
capping	DT	O
step.	JJ	O
After	JJ	O
cleavage	.	O
from	IN	O
the	NN	O
CPG	IN	O
column	DT	O
and	NNP	O
deblocking	NN	O
in	CC	O
concentrated	NN	O
ammonium	IN	O
hydroxide	JJ	O
at	NN	O
55°	NN	O
C.	IN	O
(12-16	CD	O
hr),	NNP	O
the	JJ	O
oligonucleotides	,	O
were	DT	O
recovered	NNS	O
by	VBD	O
precipitating	VBN	O
with	IN	O
>3	VBG	O
volumes	IN	O
of	CD	O
ethanol	NNS	O
from	IN	O
a	NN	O
1	IN	O
M	DT	O
NH4OAc	CD	O
solution.	NNP	O
Phosphinate	NNP	O
oligonucleotides	.	O
are	NNP	O
prepared	NNS	O
as	VBP	O
described	JJ	O
in	IN	O
U.S.	VBN	O
Pat.	IN	O
No.	NNP	O
5,508,270,	.	O
herein	.	O
incorporated	,	O
by	RB	O
reference.	VBN	O
Alkyl	IN	O
phosphonate	.	O
oligonucleotides	NNP	O
are	NN	O
prepared	NNS	O
as	VBP	O
described	JJ	O
in	IN	O
U.S.	VBN	O
Pat.	IN	O
No.	NNP	O
4,469,863,	.	O
herein	.	O
incorporated	,	O
by	RB	O
reference.	VBN	O
3′-Deoxy-3′-methylene	IN	O
phosphonate	.	O
oligonucleotides	JJ	O
are	NN	O
prepared	NNS	O
as	VBP	O
described	JJ	O
in	IN	O
U.S.	VBN	O
Pat.	IN	O
No.	NNP	O
5,610,289	.	O
or	.	O
5,625,050,	CD	O
herein	CC	O
incorporated	,	O
by	RB	O
reference.	VBN	O
Phosphoramidite	IN	O
oligonucleotides	.	O
are	NNP	O
prepared	NNS	O
as	VBP	O
described	JJ	O
in	IN	O
U.S.	VBN	O
Pat.	IN	O
No.	NNP	O
5,256,775	.	O
or	.	O
5,366,878,	CD	O
herein	CC	O
incorporated	,	O
by	RB	O
reference.	VBN	O
Alkylphosphonothioate	IN	O
oligonucleotides	.	O
are	NNP	O
prepared	NNS	O
as	VBP	O
described	JJ	O
in	IN	O
International	NN	O
Patent	IN	O
Application	NNP	O
Nos.	NNP	O
PCT/US94/00902	NNP	O
and	.	O
PCT/US93/06976	NNP	O
(published	CC	O
as	NNP	O
International	VBN	O
Patent	IN	O
Publication	NNP	O
Nos.	NNP	O
WO	NNP	O
94/17093	.	O
and	$	O
WO	CD	O
94/02499,	CC	O
respectively),	NNP	O
herein	,	O
incorporated	,	O
by	RB	O
reference.	VBN	O
3′-Deoxy-3′-amino	IN	O
phosphoramidate	.	O
oligonucleotides	JJ	O
are	NN	O
prepared	NNS	O
as	VBP	O
described	JJ	O
in	IN	O
U.S.	VBN	O
Pat.	IN	O
No.	NNP	O
5,476,925,	.	O
herein	.	O
incorporated	,	O
by	RB	O
reference.	VBN	O
Phosphotriester	IN	O
oligonucleotides	.	O
are	NNP	O
prepared	NNS	O
as	VBP	O
described	JJ	O
in	IN	O
U.S.	VBN	O
Pat.	IN	O
No.	NNP	O
5,023,243,	.	O
herein	.	O
incorporated	,	O
by	RB	O
reference.	VBN	O
Borano	IN	O
phosphate	.	O
oligonucleotides	NNP	O
are	NN	O
prepared	NNS	O
as	VBP	O
described	JJ	O
in	IN	O
U.S.	VBN	O
Pat.	IN	O
Nos.	NNP	O
5,130,302	.	O
and	.	O
5,177,198,	CD	O
both	CC	O
herein	,	O
incorporated	DT	O
by	NNS	O
reference.	VBN	O
Oligonucleosides:	IN	O
Methylenemethylimino	.	O
linked	:	O
oligonucleosides,	NN	O
also	VBD	O
identified	,	O
as	RB	O
MMI	VBN	O
linked	IN	O
oligonucleosides,	NNP	O
methylenedimethylhydrazo	VBD	O
linked	,	O
oligonucleosides,	NN	O
also	VBD	O
identified	,	O
as	RB	O
MDH	VBN	O
linked	IN	O
oligonucleosides,	NNP	O
and	VBD	O
methylenecarbonylamino	,	O
linked	CC	O
oligonucleosides,	NN	O
also	VBD	O
identified	,	O
as	RB	O
amide-3	VBN	O
linked	IN	O
oligonucleosides,	JJ	O
and	VBD	O
methyleneaminocarbonyl	,	O
linked	CC	O
oligonucleosides,	NN	O
also	VBN	O
identified	,	O
as	RB	O
amide-4	VBN	O
linked	IN	O
oligonucleosides,	JJ	O
as	VBD	O
well	,	O
as	RB	O
mixed	RB	O
backbone	IN	O
compounds	JJ	O
having,	NN	O
for	VBZ	O
instance,	,	O
alternating	IN	O
MMI	,	O
and	VBG	O
P═O	NNP	O
or	CC	O
P═S	NNP	O
linkages	CC	O
are	NNP	O
prepared	NNS	O
as	VBP	O
described	JJ	O
in	IN	O
U.S.	VBN	O
Pat.	IN	O
Nos.	NNP	O
5,378,825,	.	O
5,386,023,	.	O
5,489,677,	,	O
5,602,240	,	O
and	,	O
5,610,289,	CD	O
all	CC	O
of	,	O
which	DT	O
are	IN	O
herein	WDT	O
incorporated	VBP	O
by	RB	O
reference.	VBN	O
Formacetal	IN	O
and	.	O
thioformacetal	NNP	O
linked	CC	O
oligonucleosides	JJ	O
are	VBN	O
prepared	NNS	O
as	VBP	O
described	JJ	O
in	IN	O
U.S.	VBN	O
Pat.	IN	O
Nos.	NNP	O
5,264,562	.	O
and	.	O
5,264,564,	CD	O
herein	CC	O
incorporated	,	O
by	RB	O
reference.	VBN	O
Ethylene	IN	O
oxide	.	O
linked	NNP	O
oligonucleosides	NN	O
are	VBD	O
prepared	NNS	O
as	VBP	O
described	JJ	O
in	IN	O
U.S.	VBN	O
Pat.	IN	O
No.	NNP	O
5,223,618,	.	O
herein	.	O
incorporated	,	O
by	RB	O
reference.	VBN	O
Example	IN	O
3	.	O
RNA	RB	O
Synthesis	CD	O
In	NNP	O
general,	NNP	O
RNA	IN	O
synthesis	,	O
chemistry	NNP	O
is	NN	O
based	NN	O
on	VBZ	O
the	VBN	O
selective	IN	O
incorporation	DT	O
of	JJ	O
various	NN	O
protecting	IN	O
groups	JJ	O
at	VBG	O
strategic	NNS	O
intermediary	IN	O
reactions.	JJ	O
Although	JJ	O
one	.	O
of	IN	O
ordinary	CD	O
skill	IN	O
in	JJ	O
the	NN	O
art	IN	O
will	DT	O
understand	NN	O
the	MD	O
use	VB	O
of	DT	O
protecting	NN	O
groups	IN	O
in	VBG	O
organic	NNS	O
synthesis,	IN	O
a	JJ	O
useful	,	O
class	DT	O
of	JJ	O
protecting	NN	O
groups	IN	O
includes	VBG	O
silyl	NNS	O
ethers.	VBZ	O
In	JJ	O
particular	.	O
bulky	IN	O
silyl	JJ	O
ethers	NN	O
are	NN	O
used	NNS	O
to	VBP	O
protect	VBN	O
the	TO	O
5′-hydroxyl	VB	O
in	DT	O
combination	JJ	O
with	IN	O
an	NN	O
acid-labile	IN	O
orthoester	DT	O
protecting	JJ	O
group	NN	O
on	VBG	O
the	NN	O
2′-hydroxyl.	IN	O
This	DT	O
set	.	O
of	DT	O
protecting	NN	O
groups	IN	O
is	VBG	O
then	NNS	O
used	VBZ	O
with	RB	O
standard	VBN	O
solid-phase	IN	O
synthesis	JJ	O
technology.	JJ	O
It	NN	O
is	.	O
important	PRP	O
to	VBZ	O
lastly	JJ	O
remove	TO	O
the	RB	O
acid	VB	O
labile	DT	O
orthoester	NN	O
protecting	NN	O
group	NN	O
after	VBG	O
all	NN	O
other	IN	O
synthetic	DT	O
steps.	JJ	O
Moreover,	JJ	O
the	.	O
early	,	O
use	DT	O
of	JJ	O
the	NN	O
silyl	IN	O
protecting	DT	O
groups	NN	O
during	VBG	O
synthesis	NNS	O
ensures	IN	O
facile	NN	O
removal	NNS	O
when	VBP	O
desired,	NN	O
without	WRB	O
undesired	,	O
deprotection	IN	O
of	JJ	O
2′	NN	O
hydroxyl.	IN	O
Following	CD	O
this	.	O
procedure	VBG	O
for	DT	O
the	NN	O
sequential	IN	O
protection	DT	O
of	JJ	O
the	NN	O
5′-hydroxyl	IN	O
in	DT	O
combination	JJ	O
with	IN	O
protection	NN	O
of	IN	O
the	NN	O
2′-hydroxyl	IN	O
by	DT	O
protecting	JJ	O
groups	IN	O
that	VBG	O
are	NNS	O
differentially	WDT	O
removed	VBP	O
and	RB	O
are	VBN	O
differentially	CC	O
chemically	VBP	O
labile,	RB	O
RNA	RB	O
oligonucleotides	,	O
were	NNP	O
synthesized.	NNS	O
RNA	VBD	O
oligonucleotides	.	O
are	NNP	O
synthesized	NNS	O
in	VBP	O
a	VBN	O
stepwise	IN	O
fashion.	DT	O
Each	NN	O
nucleotide	.	O
is	DT	O
added	NN	O
sequentially	VBZ	O
(3′-	VBN	O
to	RB	O
5′-direction)	JJ	O
to	TO	O
a	)	O
solid	TO	O
support-bound	DT	O
oligonucleotide.	JJ	O
The	JJ	O
first	.	O
nucleoside	DT	O
at	JJ	O
the	NN	O
3′-end	IN	O
of	DT	O
the	CD	O
chain	IN	O
is	DT	O
covalently	NN	O
attached	VBZ	O
to	RB	O
a	VBN	O
solid	TO	O
support.	DT	O
The	JJ	O
nucleotide	.	O
precursor,	DT	O
a	NN	O
ribonucleoside	,	O
phosphoramidite,	DT	O
and	NN	O
activator	,	O
are	CC	O
added,	NN	O
coupling	VBP	O
the	,	O
second	VBG	O
base	DT	O
onto	JJ	O
the	NN	O
5′-end	IN	O
of	DT	O
the	JJ	O
first	IN	O
nucleoside.	DT	O
The	JJ	O
support	.	O
is	DT	O
washed	NN	O
and	VBZ	O
any	VBN	O
unreacted	CC	O
5′-hydroxyl	DT	O
groups	JJ	O
are	JJ	O
capped	NNS	O
with	VBP	O
acetic	VBN	O
anhydride	IN	O
to	JJ	O
yield	NN	O
5′-acetyl	TO	O
moieties.	VB	O
The	JJ	O
linkage	.	O
is	DT	O
then	NN	O
oxidized	VBZ	O
to	RB	O
the	VBN	O
more	TO	O
stable	DT	O
and	RBR	O
ultimately	JJ	O
desired	CC	O
P(V)	RB	O
linkage.	VBN	O
At	)	O
the	.	O
end	IN	O
of	DT	O
the	NN	O
nucleotide	IN	O
addition	DT	O
cycle,	JJ	O
the	NN	O
5′-silyl	,	O
group	DT	O
is	JJ	O
cleaved	NN	O
with	VBZ	O
fluoride.	VBN	O
The	IN	O
cycle	.	O
is	DT	O
repeated	NN	O
for	VBZ	O
each	VBN	O
subsequent	IN	O
nucleotide.	DT	O
Following	JJ	O
synthesis,	.	O
the	VBG	O
methyl	,	O
protecting	DT	O
groups	NN	O
on	VBG	O
the	NNS	O
phosphates	IN	O
are	DT	O
cleaved	NNS	O
in	VBP	O
30	VBN	O
minutes	IN	O
utilizing	CD	O
1	NNS	O
M	VBG	O
disodium-2-carbamoyl-2-cyanoethylene-1,1-dithiolate	CD	O
trihydrate	NNP	O
(S2Na2)	JJ	O
in	NN	O
DMF.	)	O
The	IN	O
deprotection	.	O
solution	DT	O
is	NN	O
washed	NN	O
from	VBZ	O
the	VBN	O
solid	IN	O
support-bound	DT	O
oligonucleotide	JJ	O
using	NN	O
water.	IN	O
The	VBG	O
support	.	O
is	DT	O
then	NN	O
treated	VBZ	O
with	RB	O
40%	VBN	O
methylamine	IN	O
in	NN	O
water	NN	O
for	IN	O
10	NN	O
minutes	IN	O
at	CD	O
55°	NNS	O
C.	IN	O
This	CD	O
releases	NNP	O
the	DT	O
RNA	VBZ	O
oligonucleotides	DT	O
into	NNP	O
solution,	VBZ	O
deprotects	IN	O
the	,	O
exocyclic	VBZ	O
amines,	DT	O
and	JJ	O
modifies	,	O
the	CC	O
2′-groups.	VBZ	O
The	DT	O
oligonucleotides	.	O
can	DT	O
be	NNS	O
analyzed	MD	O
by	VB	O
anion	VBN	O
exchange	IN	O
HPLC	NN	O
at	NN	O
this	NNP	O
stage.	IN	O
The	DT	O
2′-orthoester	.	O
groups	DT	O
are	JJ	O
the	NNS	O
last	VBP	O
protecting	DT	O
groups	JJ	O
to	NN	O
be	NNS	O
removed.	TO	O
The	VB	O
ethylene	.	O
glycol	DT	O
monoacetate	NN	O
orthoester	NN	O
protecting	NN	O
group	NN	O
developed	VBG	O
by	NN	O
Dharmacon	VBN	O
Research,	IN	O
Inc.	NNP	O
(Lafayette,	,	O
Colo.),	NNP	O
is	,	O
one	,	O
example	VBZ	O
of	CD	O
a	NN	O
useful	IN	O
orthoester	DT	O
protecting	JJ	O
group	NN	O
which,	VBG	O
has	NN	O
the	,	O
following	VBZ	O
important	DT	O
properties.	JJ	O
It	JJ	O
is	.	O
stable	PRP	O
to	VBZ	O
the	JJ	O
conditions	TO	O
of	DT	O
nucleoside	NNS	O
phosphoramidite	IN	O
synthesis	JJ	O
and	JJ	O
oligonucleotide	NN	O
synthesis.	CC	O
However,	JJ	O
after	.	O
oligonucleotide	,	O
synthesis	IN	O
the	JJ	O
oligonucleotide	NN	O
is	DT	O
treated	NN	O
with	VBZ	O
methylamine	VBN	O
which	IN	O
not	NN	O
only	WDT	O
cleaves	RB	O
the	RB	O
oligonucleotide	VBZ	O
from	DT	O
the	NN	O
solid	IN	O
support	DT	O
but	JJ	O
also	NN	O
removes	CC	O
the	RB	O
acetyl	VBZ	O
groups	DT	O
from	NN	O
the	NNS	O
orthoesters.	IN	O
The	DT	O
resulting	.	O
2-ethyl-hydroxyl	DT	O
substituents	VBG	O
on	JJ	O
the	NNS	O
orthoester	IN	O
are	DT	O
less	NN	O
electron	VBP	O
withdrawing	RBR	O
than	IN	O
the	VBG	O
acetylated	IN	O
precursor.	DT	O
As	JJ	O
a	.	O
result,	IN	O
the	DT	O
modified	,	O
orthoester	DT	O
becomes	JJ	O
more	NN	O
labile	VBZ	O
to	RBR	O
acid-catalyzed	JJ	O
hydrolysis.	TO	O
Specifically,	JJ	O
the	.	O
rate	,	O
of	DT	O
cleavage	NN	O
is	IN	O
approximately	NN	O
10	VBZ	O
times	RB	O
faster	CD	O
after	NNS	O
the	RBR	O
acetyl	IN	O
groups	DT	O
are	NN	O
removed.	NNS	O
Therefore,	VBP	O
this	.	O
orthoester	,	O
possesses	DT	O
sufficient	NN	O
stability	VBZ	O
in	JJ	O
order	NN	O
to	IN	O
be	NN	O
compatible	TO	O
with	VB	O
oligonucleotide	JJ	O
synthesis	IN	O
and	JJ	O
yet,	NN	O
when	CC	O
subsequently	,	O
modified,	WRB	O
permits	RB	O
deprotection	,	O
to	VBZ	O
be	NN	O
carried	TO	O
out	VB	O
under	VBN	O
relatively	RP	O
mild	IN	O
aqueous	RB	O
conditions	JJ	O
compatible	JJ	O
with	NNS	O
the	JJ	O
final	IN	O
RNA	DT	O
oligonucleotide	JJ	O
product.	NNP	O
Additionally,	NN	O
methods	.	O
of	,	O
RNA	NNS	O
synthesis	IN	O
are	NNP	O
well	NN	O
known	VBP	O
in	RB	O
the	VBN	O
art	IN	O
Scaringe,	DT	B
S.	NN	I
A.	,	I
Ph.D.	NNP	I
Thesis,	NNP	I
University	NNP	I
of	,	I
Colorado,	NNP	I
1996;	IN	I
Scaringe,	,	B
S.	:	I
A.,	,	I
et	NNP	I
al.,	,	I
J.	FW	I
Am.	,	I
Chem.	.	I
Soc.,	.	I
1998,	.	I
120,	,	I
11820-11821;	,	I
Matteucci,	,	B
M.	:	I
D.	,	I
and	NNP	I
Caruthers,	NNP	I
M.	CC	I
H.	,	I
J.	NNP	I
Am.	NNP	I
Chem.	.	I
Soc.,	.	I
1981,	.	I
103,	,	I
3185-3191;	,	I
Beaucage,	,	B
S.	:	I
L.	,	I
and	NNP	I
Caruthers,	NNP	I
M.	CC	I
H.	,	I
Tetrahedron	NNP	I
Lett.,	NNP	I
1981,	NNP	I
22,	,	I
1859-1862;	,	I
Dahl,	,	B
B.	:	I
J.,	,	I
et	NNP	I
al.,	,	I
Acta	FW	I
Chem.	,	I
Scand.,	NNP	I
1990,	.	I
44,	,	I
639-641;	,	I
Reddy,	,	B
M.	:	I
P.,	,	I
et	NNP	I
al.,	,	I
Tetrahedron	FW	I
Lett.,	,	I
1994,	NNP	I
25,	,	I
4311-4314;	,	I
Wincott,	,	B
F.	:	I
et	,	I
al.,	NNP	I
Nucleic	FW	I
Acids	,	I
Res.,	NNP	I
1995,	NNP	I
23,	,	I
2677-2684;	,	I
Griffin,	,	B
B.	:	I
E.,	,	I
et	NNP	I
al.,	,	I
Tetrahedron,	FW	I
1967,	,	I
23,	,	I
2301-2313;	,	I
Griffin,	,	B
B.	:	I
E.,	,	I
et	NNP	I
al.,	,	I
Tetrahedron,	FW	I
1967,	,	I
23,	,	I
2315-2331).(	,	O
RNA	,	O
antisense	.	O
compounds	NNP	O
(RNA	NN	O
oligonucleotides)	NNS	O
of	NNP	O
the	)	O
present	IN	O
invention	DT	O
can	JJ	O
be	NN	O
synthesized	MD	O
by	VB	O
the	VBN	O
methods	IN	O
herein	DT	O
or	NNS	O
purchased	NN	O
from	CC	O
Dharmacon	VBN	O
Research,	IN	O
Inc	NNP	O
(Lafayette,	,	O
Colo.).	NNP	O
Once	,	O
synthesized,	.	O
complementary	RB	O
RNA	,	O
antisense	JJ	O
compounds	NNP	O
can	NN	O
then	NNS	O
be	MD	O
annealed	RB	O
by	VB	O
methods	VBN	O
known	IN	O
in	NNS	O
the	VBN	O
art	IN	O
to	DT	O
form	NN	O
double	TO	O
stranded	VB	O
(duplexed)	RB	O
antisense	VBN	O
compounds.	)	O
For	NN	O
example,	.	O
duplexes	IN	O
can	,	O
be	NNS	O
formed	MD	O
by	VB	O
combining	VBN	O
30	IN	O
μl	VBG	O
of	CD	O
each	NN	O
of	IN	O
the	DT	O
complementary	IN	O
strands	DT	O
of	JJ	O
RNA	NNS	O
oligonucleotides	IN	O
(50	NNP	O
μM	NNS	O
RNA	CD	O
oligonucleotide	NNP	O
solution)	NNP	O
and	IN	O
15	)	O
μl	CC	O
of	CD	O
5×	NN	O
annealing	IN	O
buffer	CD	O
(100	VBG	O
mM	NN	O
potassium	CD	O
acetate,	NN	O
30	NN	O
mM	,	O
HEPES-KOH	CD	O
pH	JJ	O
7.4,	NNP	O
2	NN	O
mM	,	O
magnesium	CD	O
acetate)	NN	O
followed	NN	O
by	)	O
heating	VBN	O
for	IN	O
1	VBG	O
minute	IN	O
at	CD	O
90°	NN	O
C.,	IN	O
then	CD	O
1	,	O
hour	RB	O
at	CD	O
37°	NN	O
C.	IN	O
The	CD	O
resulting	NNP	O
duplexed	DT	O
antisense	VBG	O
compounds	JJ	O
can	NN	O
be	NNS	O
used	MD	O
in	VB	O
kits,	VBN	O
assays,	IN	O
screens,	,	O
or	,	O
other	,	O
methods	CC	O
to	JJ	O
investigate	NNS	O
the	TO	O
role	VB	O
of	DT	O
a	NN	O
target	IN	O
nucleic	DT	O
acid,	NN	O
or	JJ	O
for	,	O
diagnostic	CC	O
or	IN	O
therapeutic	JJ	O
purposes.	CC	O
Example	JJ	O
4	.	O
Synthesis	RB	O
of	CD	O
Chimeric	NN	O
Compounds	IN	O
Chimeric	NNP	O
oligonucleotides,	NNP	O
oligonucleosides	NNP	O
or	,	O
mixed	NNS	O
oligonucleotides/oligonucleosides	CC	O
of	JJ	O
the	NNS	O
invention	IN	O
can	DT	O
be	NN	O
of	MD	O
several	VB	O
different	IN	O
types.	JJ	O
These	JJ	O
include	.	O
a	DT	O
first	VBP	O
type	DT	O
wherein	JJ	O
the	NN	O
“gap”	VBP	O
segment	DT	O
of	NNP	O
linked	NN	O
nucleosides	IN	O
is	VBN	O
positioned	NNS	O
between	VBZ	O
5′	VBN	O
and	IN	O
3′	CD	O
“wing”	CC	O
segments	CD	O
of	JJ	O
linked	NNS	O
nucleosides	IN	O
and	VBN	O
a	NNS	O
second	CC	O
“open	DT	O
end”	JJ	O
type	JJ	O
wherein	NN	O
the	NN	O
“gap”	VBD	O
segment	DT	O
is	NNP	O
located	NN	O
at	VBZ	O
either	VBN	O
the	IN	O
3′	CC	O
or	DT	O
the	CD	O
5′	CC	O
terminus	DT	O
of	CD	O
the	NN	O
oligomeric	IN	O
compound.	DT	O
Oligonucleotides	JJ	O
of	.	O
the	NNS	O
first	IN	O
type	DT	O
are	JJ	O
also	NN	O
known	VBP	O
in	RB	O
the	VBN	O
art	IN	O
as	DT	O
“gapmers”	NN	O
or	IN	O
gapped	NN	O
oligonucleotides.	CC	O
Oligonucleotides	VBD	O
of	.	O
the	NNS	O
second	IN	O
type	DT	O
are	JJ	O
also	NN	O
known	VBP	O
in	RB	O
the	VBN	O
art	IN	O
as	DT	O
“hemimers”	NN	O
or	IN	O
“wingmers”.	NN	O
[2′-O-Me]-[2′-deoxy]-[2′-O-Me]	CC	O
Chimeric	.	O
Phosphorothioate	NN	O
Oligonucleotides	NNP	O
Chimeric	NNP	O
oligonucleotides	NNP	O
having	NNP	O
2′-O-alkyl	IN	O
phosphorothioate	VBG	O
and	JJ	O
2′-deoxy	NN	O
phosphorothioate	CC	O
oligo-nucleotide	JJ	O
segments	NN	O
are	JJ	O
synthesized	NNS	O
using	VBP	O
an	VBN	O
Applied	VBG	O
Biosystems	DT	O
automated	NNP	O
DNA	NNP	O
synthesizer	VBD	O
Model	NNP	O
394,	NN	O
as	NNP	O
above.	,	O
Oligonucleotides	IN	O
are	.	O
synthesized	NNS	O
using	VBP	O
the	VBN	O
automated	VBG	O
synthesizer	DT	O
and	JJ	O
2′-deoxy-5′-dimethoxytrityl-3′-O-phosphoramidite	NN	O
for	CC	O
the	JJ	O
DNA	IN	O
portion	DT	O
and	NNP	O
5′-dimethoxytrityl-2′-O-methyl-3′-O-phosphoramidite	NN	O
for	CC	O
5′	JJ	O
and	IN	O
3′	CD	O
wings.	CC	O
The	CD	O
standard	.	O
synthesis	DT	O
cycle	JJ	O
is	NN	O
modified	NN	O
by	VBZ	O
incorporating	VBN	O
coupling	IN	O
steps	VBG	O
with	VBG	O
increased	NNS	O
reaction	IN	O
times	VBN	O
for	NN	O
the	NNS	O
5′-dimethoxytrityl-2′-O-methyl-3′-O-phosphoramidite.	IN	O
The	DT	O
fully	.	O
protected	DT	O
oligonucleotide	RB	O
is	VBN	O
cleaved	NN	O
from	VBZ	O
the	VBN	O
support	IN	O
and	DT	O
deprotected	NN	O
in	CC	O
concentrated	VBN	O
ammonia	IN	O
(NH4OH)	JJ	O
for	NN	O
12-16	)	O
hr	IN	O
at	JJ	O
55°	NN	O
C.	IN	O
The	CD	O
deprotected	NNP	O
oligo	DT	O
is	JJ	O
then	NN	O
recovered	VBZ	O
by	RB	O
an	VBN	O
appropriate	IN	O
method	DT	O
(precipitation,	JJ	O
column	NN	O
chromatography,	,	O
volume	NN	O
reduced	,	O
in	NN	O
vacuo	VBN	O
and	IN	O
analyzed	NN	O
spectrophotometrically	CC	O
for	VBD	O
yield	RB	O
and	IN	O
for	NN	O
purity	CC	O
by	IN	O
capillary	NN	O
electrophoresis	IN	O
and	JJ	O
by	NN	O
mass	CC	O
spectrometry).	IN	O
[2′-O-(2-Methoxyethyl)]-[2′-deoxy]-[2′-O-(Methoxyethyl)]	NN	O
Chimeric	.	O
Phosphorothioate	VBP	O
Oligonucleotides	JJ	O
[2′-O-(2-methoxyethyl)]-[2′-deoxy]-[-2′-O-(methoxyethyl)]	NNP	O
chimeric	NNP	O
phosphorothioate	VBZ	O
oligonucleotides	JJ	O
were	NN	O
prepared	NNS	O
as	VBD	O
per	VBN	O
the	IN	O
procedure	IN	O
above	DT	O
for	NN	O
the	IN	O
2′-O-methyl	IN	O
chimeric	DT	O
oligonucleotide,	JJ	O
with	JJ	O
the	,	O
substitution	IN	O
of	DT	O
2′-O-(methoxyethyl)	NN	O
amidites	IN	O
for	)	O
the	VBZ	O
2′-O-methyl	IN	O
amidites.	DT	O
[2′-O-(2-Methoxyethyl)Phosphodiester]-[2′-deoxy	JJ	O
Phosphorothioate]-[2′-O-(2-Methoxyethyl)	.	O
Phosphodiester]	JJ	O
Chimeric	)	O
Oligonucleotides	NNP	O
[2′-O-(2-methoxyethyl	NNP	O
phosphodiester]-[2′-deoxy	NNP	O
phosphorothioate]-[2′-O-(methoxyethyl)	JJ	O
phosphodiester]	JJ	O
chimeric	)	O
oligonucleotides	NNP	O
are	NN	O
prepared	NNS	O
as	VBP	O
per	JJ	O
the	IN	O
above	IN	O
procedure	DT	O
for	JJ	O
the	NN	O
2′-O-methyl	IN	O
chimeric	DT	O
oligonucleotide	JJ	O
with	JJ	O
the	NN	O
substitution	IN	O
of	DT	O
2′-O-(methoxyethyl)	NN	O
amidites	IN	O
for	)	O
the	VBZ	O
2′-O-methyl	IN	O
amidites,	DT	O
oxidation	JJ	O
with	,	O
iodine	NN	O
to	IN	O
generate	NN	O
the	TO	O
phosphodiester	VB	O
internucleotide	DT	O
linkages	NN	O
within	NN	O
the	VBZ	O
wing	IN	O
portions	DT	O
of	JJ	O
the	NNS	O
chimeric	IN	O
structures	DT	O
and	JJ	O
sulfurization	NNS	O
utilizing	CC	O
3,H-1,2	NN	O
benzodithiole-3-one	VBG	O
1,1	NNP	O
dioxide	NN	O
(Beaucage	CD	O
Reagent)	NN	O
to	NNP	O
generate	)	O
the	TO	O
phosphorothioate	VB	O
internucleotide	DT	O
linkages	NN	O
for	NN	O
the	VBZ	O
center	IN	O
gap.	DT	O
Other	NN	O
chimeric	.	O
oligonucleotides,	JJ	O
chimeric	JJ	O
oligonucleosides	,	O
and	JJ	O
mixed	NNS	O
chimeric	CC	O
oligonucleotides/oligonucleosides	JJ	O
are	NN	O
synthesized	NNS	O
according	VBP	O
to	VBN	O
U.S.	VBG	O
Pat.	TO	O
No.	NNP	O
5,623,065,	.	O
herein	.	O
incorporated	,	O
by	RB	O
reference.	VBN	O
Example	IN	O
5	.	O
Design	JJ	O
and	CD	O
Screening	NNP	O
of	CC	O
Duplexed	NNP	O
Antisense	IN	O
Compounds	NNP	O
Targeting	NNP	O
Diacylglycerol	NNP	O
Acyltransferase	NNP	O
2	NNP	O
In	NNP	O
accordance	CD	O
with	IN	O
the	NN	O
present	IN	O
invention,	DT	O
a	JJ	O
series	,	O
of	DT	O
nucleic	NN	O
acid	IN	O
duplexes,	JJ	O
also	NN	O
known	,	O
as	RB	O
double-strand	VBN	O
RNAs	IN	O
(dsRNAs)	NN	O
or	NNP	O
small	)	O
interfering	CC	O
RNAs	JJ	O
(siRNAs),	NN	O
comprising	NNP	O
the	,	O
antisense	VBG	O
compounds	DT	O
of	JJ	O
the	NNS	O
present	IN	O
invention	DT	O
and	JJ	O
their	NN	O
complements	CC	O
can	PRP$	O
be	NNS	O
designed	MD	O
to	VB	O
target	VBN	O
diacylglycerol	TO	O
acyltransferase	VB	O
2.	JJ	O
The	NN	O
nucleobase	.	O
sequence	DT	O
of	JJ	O
the	NN	O
antisense	IN	O
strand	DT	O
of	JJ	O
the	NN	O
duplex	IN	O
comprises	DT	O
at	JJ	O
least	NNS	O
an	IN	O
8-nucleobase	JJS	O
portion	DT	O
of	JJ	O
an	NN	O
oligonucleotide	IN	O
in	DT	O
Table	NN	O
1.	IN	O
The	JJ	O
ends	.	O
of	DT	O
the	NNS	O
strands	IN	O
may	DT	O
be	NNS	O
modified	MD	O
by	VB	O
the	VBN	O
addition	IN	O
of	DT	O
one	NN	O
or	IN	O
more	CD	O
natural	CC	O
or	JJR	O
modified	JJ	O
nucleobases	CC	O
to	JJ	O
form	NNS	O
an	TO	O
overhang.	VB	O
The	DT	O
sense	.	O
strand	DT	O
of	NN	O
the	NN	O
dsRNA	IN	O
is	DT	O
then	NN	O
designed	VBZ	O
and	RB	O
synthesized	VBN	O
as	CC	O
the	VBN	O
complement	IN	O
of	DT	O
the	NN	O
antisense	IN	O
strand	DT	O
and	NN	O
may	NN	O
also	CC	O
contain	MD	O
modifications	RB	O
or	VB	O
additions	NNS	O
to	CC	O
either	NNS	O
terminus.	TO	O
For	DT	O
example,	.	O
in	IN	O
one	,	O
embodiment,	IN	O
both	CD	O
strands	,	O
of	DT	O
the	NNS	O
dsRNA	IN	O
duplex	DT	O
would	NN	O
be	NN	O
complementary	MD	O
over	VB	O
the	JJ	O
central	IN	O
nucleobases,	DT	O
each	JJ	O
having	,	O
overhangs	DT	O
at	VBG	O
one	NNS	O
or	IN	O
both	CD	O
termini.	CC	O
The	DT	O
antisense	.	O
and	DT	O
sense	NN	O
strands	CC	O
of	NN	O
the	NNS	O
duplex	IN	O
comprise	DT	O
from	JJ	O
about	NN	O
17	IN	O
to	RB	O
25	CD	O
nucleotides,	TO	O
or	CD	O
from	,	O
about	CC	O
19	IN	O
to	RB	O
23	CD	O
nucleotides.	TO	O
Alternatively,	CD	O
the	.	O
antisense	,	O
and	DT	O
sense	NN	O
strands	CC	O
comprise	NN	O
20,	NNS	O
21	VBP	O
or	,	O
22	CD	O
nucleotides.	CC	O
For	CD	O
example,	.	O
a	IN	O
duplex	,	O
comprising	DT	O
an	JJ	O
antisense	VBG	O
strand	DT	O
having	NN	O
the	NN	O
sequence	VBG	O
CGAGAGGCGGACGGGACCG	DT	O
(SEQ	NN	O
ID	NNP	O
NO:	NNP	O
489)	NNP	O
and	:	O
having	)	O
a	CC	O
two-nucleobase	VBG	O
overhang	DT	O
of	JJ	O
deoxythymidine(dT)	NN	O
has	IN	O
the	)	O
following	VBZ	O
structure	DT	O
(Antisense	JJ	O
SEQ	NN	O
ID	NNP	O
NO:	NNP	O
490	NNP	O
and	:	O
Complement	CD	O
SEQ	CC	O
ID	NNP	O
NO:	NNP	O
491):	NNP	O
Overhangs	:	O
can	:	O
range	NNS	O
from	MD	O
1	VB	O
to	IN	O
6	CD	O
nucleobases	TO	O
and	CD	O
these	NNS	O
nucleobases	CC	O
may	DT	O
or	NNS	O
may	MD	O
not	CC	O
be	MD	O
complementary	RB	O
to	VB	O
the	JJ	O
target	TO	O
nucleic	DT	O
acid.	NN	O
One	JJ	O
of	.	O
skill	CD	O
in	IN	O
the	NN	O
art	IN	O
will	DT	O
understand	NN	O
that	MD	O
the	VB	O
overhang	IN	O
may	DT	O
be	NN	O
1,	MD	O
2,	VB	O
3,	,	O
4,	,	O
5	,	O
or	,	O
6	CD	O
nucleobases	CC	O
in	CD	O
length.	NNS	O
In	IN	O
another	.	O
embodiment,	IN	O
the	DT	O
duplexes	,	O
may	DT	O
have	NNS	O
an	MD	O
overhang	VB	O
on	DT	O
only	NN	O
one	IN	O
terminus.	RB	O
In	CD	O
another	.	O
embodiment,	IN	O
a	DT	O
duplex	,	O
comprising	DT	O
an	JJ	O
antisense	VBG	O
strand	DT	O
having	NN	O
the	NN	O
same	VBG	O
sequence	DT	O
CGAGAGGCGGACGGGACCG	JJ	O
(SEQ	NN	O
ID	NNP	O
NO:	NNP	O
489)	NNP	O
may	:	O
be	)	O
prepared	MD	O
with	VB	O
blunt	VBN	O
ends	IN	O
(no	NN	O
single	NNS	O
stranded	DT	O
overhang)	JJ	O
as	VBD	O
shown	)	O
(Antisense	IN	O
SEQ	VBN	O
ID	NNP	O
NO:	NNP	O
489	NNP	O
and	:	O
Complement	CD	O
SEQ	CC	O
ID	NNP	O
NO:	NNP	O
492):	NNP	O
The	:	O
RNA	:	O
duplex	DT	O
can	NNP	O
be	NN	O
unimolecular	MD	O
or	VB	O
bimolecular;	JJ	O
i.e.,	CC	O
the	:	O
two	,	O
strands	DT	O
can	CD	O
be	NNS	O
part	MD	O
of	VB	O
a	NN	O
single	IN	O
molecule	DT	O
or	JJ	O
may	NN	O
be	CC	O
separate	MD	O
molecules.	VB	O
RNA	JJ	O
strands	.	O
of	NNP	O
the	NNS	O
duplex	IN	O
can	DT	O
be	NN	O
synthesized	MD	O
by	VB	O
methods	VBN	O
disclosed	IN	O
herein	NNS	O
or	VBN	O
purchased	NN	O
from	CC	O
Dharmacon	VBN	O
Research	IN	O
Inc.,	NNP	O
(Lafayette,	NNP	O
Colo.).	,	O
Once	,	O
synthesized,	.	O
the	RB	O
complementary	,	O
strands	DT	O
are	JJ	O
annealed.	NNS	O
The	VBP	O
single	.	O
strands	DT	O
are	JJ	O
aliquoted	NNS	O
and	VBP	O
diluted	VBN	O
to	CC	O
a	VBN	O
concentration	TO	O
of	DT	O
50	NN	O
μM.	IN	O
Once	CD	O
diluted,	.	O
30	RB	O
μL	,	O
of	CD	O
each	NN	O
strand	IN	O
is	DT	O
combined	NN	O
with	VBZ	O
15	VBN	O
μL	IN	O
of	CD	O
a	NNS	O
5×	IN	O
solution	DT	O
of	CD	O
annealing	NN	O
buffer.	IN	O
The	VBG	O
final	.	O
concentration	DT	O
of	JJ	O
said	NN	O
buffer	IN	O
is	VBD	O
100	NN	O
mM	VBZ	O
potassium	CD	O
acetate,	NN	O
30	NN	O
mM	,	O
HEPES-KOH	CD	O
pH	JJ	O
7.4,	NNP	O
and	NN	O
2	,	O
mM	CC	O
magnesium	CD	O
acetate.	NN	O
The	NN	O
final	.	O
volume	DT	O
is	JJ	O
75	NN	O
μL.	VBZ	O
This	CD	O
solution	.	O
is	DT	O
incubated	NN	O
for	VBZ	O
1	VBN	O
minute	IN	O
at	CD	O
90°	NN	O
C.	IN	O
and	CD	O
then	NNP	O
centrifuged	CC	O
for	RB	O
15	VBD	O
seconds.	IN	O
The	CD	O
tube	.	O
is	DT	O
allowed	NN	O
to	VBZ	O
sit	VBN	O
for	TO	O
1	VB	O
hour	IN	O
at	CD	O
37°	NN	O
C.	IN	O
at	CD	O
which	NNP	O
time	IN	O
the	WDT	O
dsRNA	NN	O
duplexes	DT	O
are	NN	O
used	NNS	O
in	VBP	O
experimentation.	VBN	O
The	IN	O
final	.	O
concentration	DT	O
of	JJ	O
the	NN	O
dsRNA	IN	O
duplex	DT	O
is	NN	O
20	NN	O
μM.	VBZ	O
This	CD	O
solution	.	O
can	DT	O
be	NN	O
stored	MD	O
frozen	VB	O
(−20°	VBN	O
C.)	JJ	O
and	NNP	O
freeze-thawed	)	O
up	CC	O
to	JJ	O
5	NN	O
times.	TO	O
Once	CD	O
prepared,	.	O
the	RB	O
duplexed	,	O
antisense	DT	O
compounds	JJ	O
are	NN	O
evaluated	NNS	O
for	VBP	O
their	VBN	O
ability	IN	O
to	PRP$	O
modulate	NN	O
diacylglycerol	TO	O
acyltransferase	VB	O
2	NN	O
expression.	NN	O
When	CD	O
cells	.	O
reached	WRB	O
80%	NNS	O
confluency,	VBD	O
they	NN	O
are	,	O
treated	PRP	O
with	VBP	O
duplexed	VBN	O
antisense	IN	O
compounds	JJ	O
of	JJ	O
the	NNS	O
invention.	IN	O
For	DT	O
cells	.	O
grown	IN	O
in	NNS	O
96-well	VBN	O
plates,	IN	O
wells	CD	O
are	,	O
washed	NNS	O
once	VBP	O
with	VBN	O
200	RB	O
μL	IN	O
OPTI-MEM-1	CD	O
reduced-serum	JJ	O
medium	JJ	O
(Gibco	JJ	O
BRL)	NN	O
and	NNP	O
then	)	O
treated	CC	O
with	RB	O
130	VBD	O
μL	IN	O
of	CD	O
OPTI-MEM-1	NNS	O
containing	IN	O
12	NNP	O
μg/mL	VBG	O
LIPOFECTIN™	CD	O
reagent	JJ	O
(Gibco	NNP	O
BRL)	NN	O
and	NNP	O
the	)	O
desired	CC	O
duplex	DT	O
antisense	JJ	O
compound	JJ	O
at	NN	O
a	NN	O
final	IN	O
concentration	DT	O
of	JJ	O
200	NN	O
nM.	IN	O
After	CD	O
5	.	O
hours	IN	O
of	CD	O
treatment,	NNS	O
the	IN	O
medium	,	O
is	DT	O
replaced	NN	O
with	VBZ	O
fresh	VBN	O
medium.	IN	O
Cells	JJ	O
are	.	O
harvested	NNS	O
16	VBP	O
hours	VBN	O
after	CD	O
treatment,	NNS	O
at	IN	O
which	,	O
time	IN	O
RNA	WDT	O
is	NN	O
isolated	NNP	O
and	VBZ	O
target	VBN	O
reduction	CC	O
measured	VB	O
by	NN	O
RT-PCR.	VBN	O
Example	IN	O
6	.	O
Oligonucleotide	RB	O
Isolation	CD	O
After	NNP	O
cleavage	NNP	O
from	IN	O
the	NN	O
controlled	IN	O
pore	DT	O
glass	VBN	O
solid	NN	O
support	NN	O
and	JJ	O
deblocking	NN	O
in	CC	O
concentrated	NN	O
ammonium	IN	O
hydroxide	JJ	O
at	NN	O
55°	NN	O
C.	IN	O
for	CD	O
12-16	NNP	O
hours,	IN	O
the	JJ	O
oligonucleotides	,	O
or	DT	O
oligonucleosides	NNS	O
are	CC	O
recovered	NNS	O
by	VBP	O
precipitation	VBN	O
out	IN	O
of	NN	O
1	IN	O
M	IN	O
NH4OAc	CD	O
with	NNP	O
>3	NNP	O
volumes	IN	O
of	CD	O
ethanol.	NNS	O
Synthesized	IN	O
oligonucleotides	.	O
were	VBN	O
analyzed	NNS	O
by	VBD	O
electrospray	VBN	O
mass	IN	O
spectroscopy	JJ	O
(molecular	NN	O
weight	NN	O
determination)	JJ	O
and	NN	O
by	)	O
capillary	CC	O
gel	IN	O
electrophoresis	JJ	O
and	NN	O
judged	NN	O
to	CC	O
be	VBD	O
at	TO	O
least	VB	O
70%	IN	O
full-length	JJS	O
material.	NN	O
The	JJ	O
relative	.	O
amounts	DT	O
of	JJ	O
phosphorothioate	NNS	O
and	IN	O
phosphodiester	NN	O
linkages	CC	O
obtained	NN	O
in	NNS	O
the	VBN	O
synthesis	IN	O
was	DT	O
determined	NN	O
by	VBD	O
the	VBN	O
ratio	IN	O
of	DT	O
correct	NN	O
molecular	IN	O
weight	JJ	O
relative	JJ	O
to	NN	O
the	NN	O
−16	TO	O
amu	DT	O
product	NNP	O
(+/−32+/−48).	JJ	O
For	NN	O
some	.	O
studies	IN	O
oligonucleotides	DT	O
were	NNS	O
purified	NNS	O
by	VBD	O
HPLC,	VBN	O
as	IN	O
described	,	O
by	IN	O
Chiang	VBN	B
et	IN	I
al.,	NNP	I
J.	FW	I
Biol.	,	I
Chem.	NNP	I
1991,	.	I
266,	.	I
18162-18171.	,	I
Results	,	O
obtained	.	O
with	NNS	O
HPLC-purified	VBD	O
material	IN	O
were	NNP	O
similar	NN	O
to	VBD	O
those	JJ	O
obtained	TO	O
with	DT	O
non-HPLC	VBN	O
purified	IN	O
material.	JJ	O
Example	JJ	O
7	.	O
Oligonucleotide	RB	O
Synthesis—96	CD	O
Well	NNP	O
Plate	NNP	O
Format	NNP	O
Oligonucleotides	NNP	O
were	NNP	O
synthesized	NNP	O
via	VBD	O
solid	VBN	O
phase	IN	O
P(III)	JJ	O
phosphoramidite	NN	O
chemistry	)	O
on	VBP	O
an	NN	O
automated	IN	O
synthesizer	DT	O
capable	JJ	O
of	NN	O
assembling	JJ	O
96	IN	O
sequences	VBG	O
simultaneously	CD	O
in	NNS	O
a	RB	O
96-well	IN	O
format.	DT	O
Phosphodiester	JJ	O
internucleotide	.	O
linkages	NNP	O
were	NN	O
afforded	NNS	O
by	VBD	O
oxidation	VBN	O
with	IN	O
aqueous	NN	O
iodine.	IN	O
Phosphorothioate	JJ	O
internucleotide	.	O
linkages	NNP	O
were	NN	O
generated	NNS	O
by	VBD	O
sulfurization	VBN	O
utilizing	IN	O
3,H-1,2	NN	O
benzodithiole-3-one	VBG	O
1,1	NNP	O
dioxide	NN	O
(Beaucage	CD	O
Reagent)	NN	O
in	NNP	O
anhydrous	)	O
acetonitrile.	IN	O
Standard	JJ	O
base-protected	.	O
beta-cyanoethyl-diiso-propyl	JJ	O
phosphoramidites	JJ	O
were	JJ	O
purchased	NNS	O
from	VBD	O
commercial	VBN	O
vendors	IN	O
(e.g.	JJ	O
PE-Applied	NNS	O
Biosystems,	.	O
Foster	JJ	O
City,	,	O
Calif.,	NNP	O
or	,	O
Pharmacia,	,	O
Piscataway,	CC	O
N.J.).	,	O
Non-standard	,	O
nucleosides	.	O
are	NNP	O
synthesized	NNS	O
as	VBP	O
per	VBN	O
standard	IN	O
or	JJ	O
patented	NN	O
methods.	CC	O
They	VBN	O
are	.	O
utilized	PRP	O
as	VBP	O
base	JJ	O
protected	IN	O
beta-cyanoethyldiisopropyl	NN	O
phosphoramidites.	VBD	O
Oligonucleotides	JJ	O
were	.	O
cleaved	NNS	O
from	VBD	O
support	VBN	O
and	IN	O
deprotected	NN	O
with	CC	O
concentrated	VBN	O
NH4OH	IN	O
at	JJ	O
elevated	NNP	O
temperature	IN	O
(55-60°	JJ	O
C.)	NN	O
for	JJ	O
12-16	)	O
hours	IN	O
and	JJ	O
the	NNS	O
released	CC	O
product	DT	O
then	VBN	O
dried	NN	O
in	RB	O
vacuo.	VBD	O
The	IN	O
dried	.	O
product	DT	O
was	JJ	O
then	NN	O
re-suspended	VBD	O
in	RB	O
sterile	JJ	O
water	IN	O
to	JJ	O
afford	NN	O
a	TO	O
master	VB	O
plate	DT	O
from	NN	O
which	NN	O
all	IN	O
analytical	WDT	O
and	DT	O
test	JJ	O
plate	CC	O
samples	NN	O
are	NN	O
then	NNS	O
diluted	VBP	O
utilizing	RB	O
robotic	VBN	O
pipettors.	JJ	O
Example	JJ	O
8	.	O
Oligonucleotide	RB	O
Analysis—96-Well	CD	O
Plate	NNP	O
Format	NNP	O
The	NNP	O
concentration	NNP	O
of	DT	O
oligonucleotide	NN	O
in	IN	O
each	NN	O
well	IN	O
was	DT	O
assessed	NN	O
by	VBD	O
dilution	VBN	O
of	IN	O
samples	NN	O
and	IN	O
UV	NNS	O
absorption	CC	O
spectroscopy.	NNP	O
The	NN	O
full-length	.	O
integrity	DT	O
of	JJ	O
the	NN	O
individual	IN	O
products	DT	O
was	JJ	O
evaluated	NNS	O
by	VBD	O
capillary	VBN	O
electrophoresis	IN	O
(CE)	JJ	O
in	NN	O
either	)	O
the	IN	O
96-well	CC	O
format	DT	O
(Beckman	JJ	O
P/ACE™	NN	O
MDQ	NNP	O
apparatus)	NNP	O
or,	NNP	O
for	)	O
individually	,	O
prepared	IN	O
samples,	RB	O
on	JJ	O
a	,	O
commercial	IN	O
CE	DT	O
apparatus	JJ	O
(e.g.,	NNP	O
Beckman	NN	O
P/ACE™	,	O
5000,	NNP	O
ABI	NNP	O
270	,	O
apparatus).	NNP	O
Base	CD	O
and	.	O
backbone	NNP	O
composition	CC	O
was	NN	O
confirmed	NN	O
by	VBD	O
mass	VBN	O
analysis	IN	O
of	NN	O
the	NN	O
compounds	IN	O
utilizing	DT	O
electrospray-mass	NNS	O
spectroscopy.	JJ	O
All	JJ	O
assay	.	O
test	DT	O
plates	VBP	O
were	NN	O
diluted	NNS	O
from	VBD	O
the	VBN	O
master	IN	O
plate	DT	O
using	NN	O
single	NN	O
and	VBG	O
multi-channel	JJ	O
robotic	CC	O
pipettors.	JJ	O
Plates	JJ	O
were	.	O
judged	NNS	O
to	VBD	O
be	VBN	O
acceptable	TO	O
if	VB	O
at	JJ	O
least	IN	O
85%	IN	O
of	JJS	O
the	NN	O
compounds	IN	O
on	DT	O
the	NNS	O
plate	IN	O
were	DT	O
at	NN	O
least	VBD	O
85%	IN	O
full	JJS	O
length.	NN	O
Example	JJ	O
9	.	O
Cell	RB	O
Culture	CD	O
and	NNP	O
Oligonucleotide	NNP	O
Treatment	CC	O
The	NNP	O
effect	NNP	O
of	DT	O
antisense	NN	O
compounds	IN	O
on	NN	O
target	NNS	O
nucleic	IN	O
acid	NN	O
expression	JJ	O
can	JJ	O
be	NN	O
tested	MD	O
in	VB	O
any	VBN	O
of	IN	O
a	DT	O
variety	IN	O
of	DT	O
cell	NN	O
types	IN	O
provided	NN	O
that	NNS	O
the	VBD	O
target	IN	O
nucleic	DT	O
acid	NN	O
is	JJ	O
present	NN	O
at	VBZ	O
measurable	JJ	O
levels.	IN	O
This	JJ	O
can	.	O
be	DT	O
routinely	MD	O
determined	VB	O
using,	RB	O
for	VBN	O
example,	,	O
PCR	IN	O
or	,	O
Northern	NNP	O
blot	CC	O
analysis.	NNP	O
The	NN	O
following	.	O
cell	DT	O
types	VBG	O
are	NN	O
provided	NNS	O
for	VBP	O
illustrative	VBN	O
purposes,	IN	O
but	JJ	O
other	,	O
cell	CC	O
types	JJ	O
can	NN	O
be	NNS	O
routinely	MD	O
used,	VB	O
provided	RB	O
that	,	O
the	VBD	O
target	IN	O
is	DT	O
expressed	NN	O
in	VBZ	O
the	VBN	O
cell	IN	O
type	DT	O
chosen.	NN	O
This	NN	O
can	.	O
be	DT	O
readily	MD	O
determined	VB	O
by	RB	O
methods	VBN	O
routine	IN	O
in	NNS	O
the	JJ	O
art,	IN	O
for	DT	O
example	,	O
Northern	IN	O
blot	NN	O
analysis,	NNP	O
ribonuclease	NN	O
protection	,	O
assays,	NN	O
or	NN	O
real-time	,	O
PCR.	CC	O
T-24	JJ	O
Cells:	.	O
The	JJ	O
human	:	O
transitional	DT	O
cell	JJ	O
bladder	JJ	O
carcinoma	NN	O
cell	NN	O
line	NN	O
T-24	NN	O
was	NN	O
obtained	NNP	O
from	VBD	O
the	VBN	O
American	IN	O
Type	DT	O
Culture	JJ	O
Collection	NNP	O
(ATCC)	NNP	O
(Manassas,	NNP	O
Va.).	)	O
T-24	,	O
cells	.	O
were	JJ	O
routinely	NNS	O
cultured	VBD	O
in	RB	O
complete	VBN	O
McCoy's	IN	O
5A	JJ	O
basal	POS	O
media	CD	O
(Invitrogen	JJ	O
Corporation,	NNS	O
Carlsbad,	NNP	O
Calif.)	,	O
supplemented	,	O
with	)	O
10%	VBD	O
fetal	IN	O
bovine	NN	O
serum	JJ	O
(Invitrogen	NN	O
Corporation,	NN	O
Carlsbad,	NNP	O
Calif.),	,	O
penicillin	,	O
100	,	O
units	$	O
per	CD	O
mL,	NNS	O
and	IN	O
streptomycin	,	O
100	CC	O
micrograms	VBD	O
per	CD	O
mL	NNS	O
(Invitrogen	IN	O
Corporation,	NN	O
Carlsbad,	NNP	O
Calif.).	,	O
Cells	,	O
were	.	O
routinely	NNS	O
passaged	VBD	O
by	RB	O
trypsinization	VBN	O
and	IN	O
dilution	NN	O
when	CC	O
they	NN	O
reached	WRB	O
90%	PRP	O
confluence.	VBD	O
Cells	NN	O
were	.	O
seeded	NNS	O
into	VBD	O
96-well	VBN	O
plates	IN	O
(Falcon-Primaria	JJ	O
#353872)	NNS	O
at	NNP	O
a	)	O
density	IN	O
of	DT	O
7000	NN	O
cells/well	IN	O
for	CD	O
use	NN	O
in	IN	O
RT-PCR	NN	O
analysis.	IN	O
For	JJ	O
Northern	.	O
blotting	IN	O
or	NNP	O
other	NN	O
analysis,	CC	O
cells	JJ	O
may	,	O
be	NNS	O
seeded	MD	O
onto	VB	O
100	VBN	O
mm	IN	O
or	CD	O
other	NNS	O
standard	CC	O
tissue	JJ	O
culture	JJ	O
plates	NN	O
and	NN	O
treated	NNS	O
similarly,	CC	O
using	VBD	O
appropriate	,	O
volumes	VBG	O
of	JJ	O
medium	NNS	O
and	IN	O
oligonucleotide.	NN	O
A549	CC	O
Cells:	.	O
The	NNP	O
human	:	O
lung	DT	O
carcinoma	JJ	O
cell	NN	O
line	NN	O
A549	NN	O
was	NN	O
obtained	NNP	O
from	VBD	O
the	VBN	O
American	IN	O
Type	DT	O
Culture	JJ	O
Collection	NNP	O
(ATCC)	NNP	O
(Manassas,	NNP	O
Va.).	)	O
A549	,	O
cells	.	O
were	NNP	O
routinely	NNS	O
cultured	VBD	O
in	RB	O
DMEM	VBN	O
basal	IN	O
media	NNP	O
(Invitrogen	NN	O
Corporation,	NNS	O
Carlsbad,	NNP	O
Calif.)	,	O
supplemented	,	O
with	)	O
10%	VBD	O
fetal	IN	O
bovine	NN	O
serum	JJ	O
(Invitrogen	NN	O
Corporation,	NN	O
Carlsbad,	NNP	O
Calif.),	,	O
penicillin	,	O
100	,	O
units	$	O
per	CD	O
mL,	NNS	O
and	IN	O
streptomycin	,	O
100	CC	O
micrograms	VBD	O
per	CD	O
mL	NNS	O
(Invitrogen	IN	O
Corporation,	NN	O
Carlsbad,	NNP	O
Calif.).	,	O
Cells	,	O
were	.	O
routinely	NNS	O
passaged	VBD	O
by	RB	O
trypsinization	VBN	O
and	IN	O
dilution	NN	O
when	CC	O
they	NN	O
reached	WRB	O
90%	PRP	O
confluence.	VBD	O
NHDF	NN	O
Cells:	.	O
Human	NNP	O
neonatal	:	O
dermal	NNP	O
fibroblast	JJ	O
(NHDF)	NN	O
were	NN	O
obtained	)	O
from	VBD	O
the	VBN	O
Clonetics	IN	O
Corporation	DT	O
(Walkersville,	NNPS	O
Md.).	NNP	O
NHDFs	,	O
were	.	O
routinely	NNP	O
maintained	VBD	O
in	RB	O
Fibroblast	VBN	O
Growth	IN	O
Medium	NNP	O
(Clonetics	NNP	O
Corporation,	NNP	O
Walkersville,	NNPS	O
Md.)	,	O
supplemented	,	O
as	)	O
recommended	VBN	O
by	IN	O
the	VBN	O
supplier.	IN	O
Cells	DT	O
were	.	O
maintained	NNS	O
for	VBD	O
up	VBN	O
to	IN	O
10	RB	O
passages	TO	O
as	CD	O
recommended	NNS	O
by	IN	O
the	VBN	O
supplier.	IN	O
HEK	DT	O
Cells:	.	O
Human	NNP	O
embryonic	:	O
keratinocytes	NNP	O
(HEK)	VBZ	O
were	NNS	O
obtained	)	O
from	VBD	O
the	VBN	O
Clonetics	IN	O
Corporation	DT	O
(Walkersville,	NNPS	O
Md.).	NNP	O
HEKs	,	O
were	.	O
routinely	NNP	O
maintained	VBD	O
in	RB	O
Keratinocyte	VBN	O
Growth	IN	O
Medium	NNP	O
(Clonetics	NNP	O
Corporation,	NNP	O
Walkersville,	NNPS	O
Md.)	,	O
formulated	,	O
as	)	O
recommended	VBN	O
by	IN	O
the	VBN	O
supplier.	IN	O
Cells	DT	O
were	.	O
routinely	NNS	O
maintained	VBD	O
for	RB	O
up	VBN	O
to	IN	O
10	RB	O
passages	TO	O
as	CD	O
recommended	NNS	O
by	IN	O
the	VBN	O
supplier.	IN	O
3T3-L1	DT	O
Cells:	.	O
The	JJ	O
mouse	:	O
embryonic	DT	O
adipocyte-like	NN	O
cell	JJ	O
line	JJ	O
3T3-L1	NN	O
was	NN	O
obtained	CD	O
from	VBD	O
the	VBN	O
American	IN	O
Type	DT	O
Culture	JJ	O
Collection	NNP	O
(Manassas,	NNP	O
Va.).	NNP	O
3T3-L1	,	O
cells	.	O
were	JJ	O
routinely	NNS	O
cultured	VBD	O
in	RB	O
DMEM,	VBN	O
high	IN	O
glucose	,	O
(Invitrogen	JJ	O
Corporation,	NN	O
Carlsbad,	NNP	O
Calif.)	,	O
supplemented	,	O
with	)	O
10%	VBD	O
fetal	IN	O
bovine	NN	O
serum	JJ	O
(Invitrogen	NN	O
Corporation,	NN	O
Carlsbad,	NNP	O
Calif.).	,	O
Cells	,	O
were	.	O
routinely	NNS	O
passaged	VBD	O
by	RB	O
trypsinization	VBN	O
and	IN	O
dilution	NN	O
when	CC	O
they	NN	O
reached	WRB	O
80%	PRP	O
confluence.	VBD	O
Cells	NN	O
were	.	O
seeded	NNS	O
into	VBD	O
96-well	VBN	O
plates	IN	O
(Falcon-Primaria	JJ	O
#3872)	NNS	O
at	NNP	O
a	)	O
density	IN	O
of	DT	O
4000	NN	O
cells/well	IN	O
for	CD	O
use	NN	O
in	IN	O
RT-PCR	NN	O
analysis.	IN	O
For	JJ	O
Northern	.	O
blotting	IN	O
or	NNP	O
other	NN	O
analyses,	CC	O
cells	JJ	O
may	,	O
be	NNS	O
seeded	MD	O
onto	VB	O
100	VBN	O
mm	IN	O
or	CD	O
other	NNS	O
standard	CC	O
tissue	JJ	O
culture	JJ	O
plates	NN	O
and	NN	O
treated	NNS	O
similarly,	CC	O
using	VBD	O
appropriate	,	O
volumes	VBG	O
of	JJ	O
medium	NNS	O
and	IN	O
oligonucleotide.	NN	O
Primary	CC	O
Mouse	.	O
Hepatocytes:	JJ	O
Primary	NNP	O
mouse	:	O
hepatocytes	JJ	O
were	NN	O
prepared	NNS	O
from	VBD	O
CD-1	VBN	O
mice	IN	O
purchased	NNP	O
from	NNS	O
Charles	VBD	O
River	IN	O
Labs.	NNP	O
Primary	NNP	O
mouse	.	O
hepatocytes	JJ	O
were	NN	O
routinely	NNS	O
cultured	VBD	O
in	RB	O
Hepatocyte	VBN	O
Attachment	IN	O
Media	NNP	O
supplemented	NNP	O
with	NNP	O
10%	VBD	O
fetal	IN	O
bovine	NN	O
serum,	JJ	O
1%	NN	O
penicillin/streptomycin,	,	O
1%	NN	O
antibiotic-antimitotic	,	O
(Invitrogen	NN	O
Life	JJ	O
Technologies,	NNP	O
Carlsbad,	NNP	O
Calif.)	,	O
and	,	O
10	)	O
nM	CC	O
bovine	CD	O
insulin	JJ	O
(Sigma-Aldrich,	NN	O
St.	NN	O
Louis,	,	O
Mo.).	NNP	O
Cells	,	O
were	.	O
seeded	NNS	O
into	VBD	O
96-well	VBN	O
plates	IN	O
(Falcon-Primaria	JJ	O
#3872)	NNS	O
coated	NNP	O
with	)	O
0.1	VBN	O
mg/ml	IN	O
collagen	CD	O
at	NNS	O
a	NN	O
density	IN	O
of	DT	O
approximately	NN	O
10,000	IN	O
cells/well	RB	O
for	CD	O
use	NN	O
in	IN	O
oligomeric	NN	O
compound	IN	O
transfection	JJ	O
experiments.	NN	O
Treatment	NN	O
with	.	O
Antisense	NN	O
Compounds:	IN	O
When	NNP	O
cells	:	O
reached	WRB	O
65-75%	NNS	O
confluency,	VBD	O
they	NN	O
were	,	O
treated	PRP	O
with	VBD	O
oligonucleotide.	VBN	O
For	IN	O
cells	.	O
grown	IN	O
in	NNS	O
96-well	VBN	O
plates,	IN	O
wells	CD	O
were	,	O
washed	NNS	O
once	VBD	O
with	VBN	O
100	RB	O
μL	IN	O
OPTI-MEM™-1	CD	O
reduced-serum	JJ	O
medium	JJ	O
(Invitrogen	JJ	O
Corporation,	NN	O
Carlsbad,	NNP	O
Calif.)	,	O
and	,	O
then	)	O
treated	CC	O
with	RB	O
130	VBD	O
μL	IN	O
of	CD	O
the	NNS	O
OPTI-MEM™-1	IN	O
medium	DT	O
containing	NNP	O
2.5	NN	O
or	VBG	O
3	CD	O
μg/mL	CC	O
LIPOFECTIN™	CD	O
reagent	JJ	O
(Invitrogen	NNP	O
Corporation,	NN	O
Carlsbad,	NNP	O
Calif.)	,	O
per	,	O
100	)	O
nM	IN	O
of	CD	O
oligonucleotide.	NN	O
Cells	IN	O
are	.	O
treated	NNS	O
and	VBP	O
data	VBN	O
are	CC	O
obtained	NNS	O
in	VBP	O
triplicate.	VBN	O
After	IN	O
4-7	.	O
hours	IN	O
of	JJ	O
treatment	NNS	O
at	IN	O
37°	NN	O
C.,	IN	O
the	CD	O
medium	,	O
was	DT	O
replaced	NN	O
with	VBD	O
fresh	VBN	O
medium.	IN	O
Cells	JJ	O
were	.	O
harvested	NNS	O
16-24	VBD	O
hours	VBN	O
after	JJ	O
oligonucleotide	NNS	O
treatment.	IN	O
The	JJ	O
concentration	.	O
of	DT	O
oligonucleotide	NN	O
used	IN	O
varies	NN	O
from	VBN	O
cell	NNS	O
line	IN	O
to	NN	O
cell	NN	O
line.	TO	O
To	VB	O
determine	.	O
the	TO	O
optimal	VB	O
oligonucleotide	DT	O
concentration	JJ	O
for	JJ	O
a	NN	O
particular	IN	O
cell	DT	O
line,	JJ	O
the	NN	O
cells	,	O
are	DT	O
treated	NNS	O
with	VBP	O
a	VBN	O
positive	IN	O
control	DT	O
oligonucleotide	JJ	O
at	NN	O
a	NN	O
range	IN	O
of	DT	O
concentrations.	NN	O
For	IN	O
human	.	O
cells	IN	O
the	JJ	O
positive	NNS	O
control	DT	O
oligonucleotide	JJ	O
is	NN	O
selected	NN	O
from	VBZ	O
either	VBN	O
ISIS	IN	O
13920	CC	O
(TCCGTCATCGCTCCTCAGGG,	NNP	O
SEQ	CD	O
ID	,	O
NO:	NNP	O
1)	NNP	O
which	:	O
is	)	O
targeted	WDT	O
to	VBZ	O
human	VBN	O
H-ras,	TO	O
or	JJ	O
ISIS	,	O
18078,	CC	O
(GTGCGCGCGAGCCCGAAATC,	NNP	O
SEQ	,	O
ID	,	O
NO:	NNP	O
2)	NNP	O
which	:	O
is	)	O
targeted	WDT	O
to	VBZ	O
human	VBN	O
Jun-N-terminal	TO	O
kinase-2	JJ	O
(JNK2).	JJ	O
Both	NN	O
controls	.	O
are	DT	O
2′-O-methoxyethyl	NNS	O
gapmers	VBP	O
(2′-O-methoxyethyls	JJ	O
shown	NNS	O
in	JJ	O
bold)	VBN	O
with	IN	O
a	)	O
phosphorothioate	IN	O
backbone.	DT	O
For	NN	O
mouse	.	O
or	IN	O
rat	NN	O
cells	CC	O
the	NN	O
positive	NNS	O
control	DT	O
oligonucleotide	JJ	O
is	NN	O
ISIS	NN	O
15770,	VBZ	O
ATGCATTCTGCCCCCAAGGA,	NNP	O
SEQ	,	O
ID	,	O
NO:	NNP	O
3,	NNP	O
a	:	O
2′-O-methoxyethyl	,	O
gapmer	DT	O
(2′-O-methoxyethyls	JJ	O
shown	NN	O
in	JJ	O
bold)	VBN	O
with	IN	O
a	)	O
phosphorothioate	IN	O
backbone	DT	O
which	NN	O
is	NN	O
targeted	WDT	O
to	VBZ	O
both	VBN	O
mouse	TO	O
and	DT	O
rat	NN	O
c-raf.	CC	O
The	VB	O
concentration	.	O
of	DT	O
positive	NN	O
control	IN	O
oligonucleotide	JJ	O
that	NN	O
results	IN	O
in	DT	O
80%	NNS	O
inhibition	IN	O
of	NN	O
c-H-ras	NN	O
(for	IN	O
ISIS	NNS	O
13920),	IN	O
JNK2	NNP	O
(for	,	O
ISIS	NNP	O
18078)	IN	O
or	NNP	O
c-raf	)	O
(for	CC	O
ISIS	JJ	O
15770)	IN	O
mRNA	NNP	O
is	)	O
then	NN	O
utilized	VBZ	O
as	RB	O
the	JJ	O
screening	IN	O
concentration	DT	O
for	NN	O
new	NN	O
oligonucleotides	IN	O
in	JJ	O
subsequent	NNS	O
experiments	IN	O
for	JJ	O
that	NNS	O
cell	IN	O
line.	DT	O
If	NN	O
80%	.	O
inhibition	IN	O
is	NN	O
not	NN	O
achieved,	VBZ	O
the	RB	O
lowest	,	O
concentration	DT	O
of	JJS	O
positive	NN	O
control	IN	O
oligonucleotide	JJ	O
that	NN	O
results	IN	O
in	DT	O
60%	NNS	O
inhibition	IN	O
of	NN	O
c-H-ras,	NN	O
JNK2	IN	O
or	,	O
c-raf	NNP	O
mRNA	CC	O
is	JJ	O
then	NN	O
utilized	VBZ	O
as	RB	O
the	JJ	O
oligonucleotide	IN	O
screening	DT	O
concentration	NN	O
in	VBG	O
subsequent	NN	O
experiments	IN	O
for	JJ	O
that	NNS	O
cell	IN	O
line.	DT	O
If	NN	O
60%	.	O
inhibition	IN	O
is	NN	O
not	NN	O
achieved,	VBZ	O
that	RB	O
particular	,	O
cell	IN	O
line	JJ	O
is	NN	O
deemed	NN	O
as	VBZ	O
unsuitable	VBN	O
for	IN	O
oligonucleotide	JJ	O
transfection	IN	O
experiments.	JJ	O
The	NN	O
concentrations	.	O
of	DT	O
antisense	NNS	O
oligonucleotides	IN	O
used	NN	O
herein	NNS	O
are	VBN	O
from	NNS	O
50	VBP	O
nM	IN	O
to	CD	O
300	NNS	O
nM.	TO	O
Example	CD	O
10	.	O
Analysis	RB	O
of	CD	O
Oligonucleotide	NN	O
Inhibition	IN	O
of	NNP	O
Diacylglycerol	NNP	O
Acyltransferase	IN	O
2	NNP	O
Expression	NNP	O
Antisense	CD	O
modulation	NNP	O
of	NNP	O
diacylglycerol	NN	O
acyltransferase	IN	O
2	NN	O
expression	NN	O
can	CD	O
be	NN	O
assayed	MD	O
in	VB	O
a	VBN	O
variety	IN	O
of	DT	O
ways	NN	O
known	IN	O
in	NNS	O
the	VBN	O
art.	IN	O
For	DT	O
example,	.	O
diacylglycerol	IN	O
acyltransferase	,	O
2	VB	O
mRNA	NN	O
levels	CD	O
can	NN	O
be	NNS	O
quantitated	MD	O
by,	VB	O
e.g.,	VBN	O
Northern	,	O
blot	,	O
analysis,	NNP	O
competitive	NN	O
polymerase	,	O
chain	JJ	O
reaction	NN	O
(PCR),	NN	O
or	NN	O
real-time	,	O
PCR.	CC	O
Quantitative	JJ	O
real-time	.	O
PCR	JJ	O
is	JJ	O
presently	NNP	O
preferred.	VBZ	O
RNA	RB	O
analysis	.	O
can	JJ	O
be	NN	O
performed	MD	O
on	VB	O
total	VBN	O
cellular	IN	O
RNA	JJ	O
or	JJ	O
poly(A)+	NNP	O
mRNA.	CC	O
The	NN	O
preferred	.	O
method	DT	O
of	JJ	O
RNA	NN	O
analysis	IN	O
of	NNP	O
the	NN	O
present	IN	O
invention	DT	O
is	JJ	O
the	NN	O
use	VBZ	O
of	DT	O
total	NN	O
cellular	IN	O
RNA	JJ	O
as	JJ	O
described	NNP	O
in	IN	O
other	VBN	O
examples	IN	O
herein.	JJ	O
Methods	NNS	O
of	.	O
RNA	NNS	O
isolation	IN	O
are	NNP	O
well	NN	O
known	VBP	O
in	RB	O
the	VBN	O
art.	IN	O
Northern	DT	O
blot	.	O
analysis	NNP	O
is	NN	O
also	NN	O
routine	VBZ	O
in	RB	O
the	JJ	O
art.	IN	O
Real-time	DT	O
quantitative	.	O
(PCR)	JJ	O
can	NN	O
be	)	O
conveniently	MD	O
accomplished	VB	O
using	RB	O
the	VBN	O
commercially	VBG	O
available	DT	O
ABI	RB	O
PRISM™	JJ	O
7600,	NNP	O
7700,	NNP	O
or	,	O
7900	,	O
Sequence	CC	O
Detection	CD	O
System,	NNP	O
available	NNP	O
from	,	O
PE-Applied	JJ	O
Biosystems,	IN	O
Foster	NNP	O
City,	,	O
Calif.	NNP	O
and	,	O
used	NNP	O
according	CC	O
to	VBD	O
manufacturer's	VBG	O
instructions.	TO	O
Protein	POS	O
levels	.	O
of	NNP	O
diacylglycerol	NNS	O
acyltransferase	IN	O
2	NN	O
can	NN	O
be	CD	O
quantitated	MD	O
in	VB	O
a	VBN	O
variety	IN	O
of	DT	O
ways	NN	O
well	IN	O
known	NNS	O
in	RB	O
the	VBN	O
art,	IN	O
such	DT	O
as	,	O
immunoprecipitation,	JJ	O
Western	IN	O
blot	,	O
analysis	JJ	O
(immunoblotting),	NN	O
enzyme-linked	NN	O
immunosorbent	,	O
assay	JJ	O
(ELISA)	NN	O
or	NN	O
fluorescence-activated	)	O
cell	CC	O
sorting	JJ	O
(FACS).	NN	O
Antibodies	VBG	O
directed	.	O
to	NNS	O
diacylglycerol	VBD	O
acyltransferase	TO	O
2	VB	O
can	JJ	O
be	CD	O
identified	MD	O
and	VB	O
obtained	VBN	O
from	CC	O
a	VBN	O
variety	IN	O
of	DT	O
sources,	NN	O
such	IN	O
as	,	O
the	JJ	O
MSRS	IN	O
catalog	DT	O
of	NNP	O
antibodies	NN	O
(Aerie	IN	O
Corporation,	NNS	O
Birmingham,	NNP	O
Mich.),	,	O
or	,	O
can	,	O
be	CC	O
prepared	MD	O
via	VB	O
conventional	JJ	O
monoclonal	IN	O
or	JJ	O
polyclonal	JJ	O
antibody	CC	O
generation	JJ	O
methods	NN	O
well	NN	O
known	NNS	O
in	RB	O
the	VBN	O
art.	IN	O
Example	DT	O
11	.	O
Design	JJ	O
of	CD	O
Phenotypic	NNP	O
Assays	IN	O
for	NNP	O
the	NNP	O
Use	IN	O
of	DT	O
Diacylglycerol	NNP	O
Acyltransferase	IN	O
2	NNP	O
Inhibitors	NNP	O
Once	CD	O
diacylglycerol	NNPS	O
acyltransferase	RB	O
2	JJ	O
inhibitors	NN	O
have	CD	O
been	NNS	O
identified	VBP	O
by	VBN	O
the	VBN	O
methods	IN	O
disclosed	DT	O
herein,	NNS	O
the	VBD	O
compounds	,	O
are	DT	O
further	NNS	O
investigated	VBP	O
in	RB	O
one	VBN	O
or	IN	O
more	CD	O
phenotypic	CC	O
assays,	JJR	O
each	NN	O
having	,	O
measurable	DT	O
endpoints	VBG	O
predictive	JJ	O
of	NNS	O
efficacy	NN	O
in	IN	O
the	NN	O
treatment	IN	O
of	DT	O
a	NN	O
particular	IN	O
disease	DT	O
state	JJ	O
or	NN	O
condition.	NN	O
Phenotypic	CC	O
assays,	.	O
kits	NNP	O
and	,	O
reagents	NNS	O
for	CC	O
their	NNS	O
use	IN	O
are	PRP$	O
well	NN	O
known	VBP	O
to	RB	O
those	VBN	O
skilled	TO	O
in	DT	O
the	VBN	O
art	IN	O
and	DT	O
are	NN	O
herein	CC	O
used	VBP	O
to	NNS	O
investigate	VBN	O
the	TO	O
role	VB	O
and/or	DT	O
association	NN	O
of	NN	O
diacylglycerol	NN	O
acyltransferase	IN	O
2	NN	O
in	NN	O
health	CD	O
and	IN	O
disease.	NN	O
Representative	CC	O
phenotypic	.	O
assays,	JJ	O
which	NN	O
can	,	O
be	WDT	O
purchased	MD	O
from	VB	O
any	VBN	O
one	IN	O
of	DT	O
several	CD	O
commercial	IN	O
vendors,	JJ	O
include	JJ	O
those	,	O
for	VBP	O
determining	DT	O
cell	IN	O
viability,	VBG	O
cytotoxicity,	NN	O
proliferation	,	O
or	,	O
cell	NN	O
survival	CC	O
(Molecular	NN	O
Probes,	NN	O
Eugene,	JJ	O
Oreg.;	,	O
PerkinElmer,	,	O
Boston,	:	O
Mass.),	,	O
protein-based	,	O
assays	,	O
including	JJ	O
enzymatic	NNS	O
assays	VBG	O
(Panvera,	JJ	O
LLC,	NNS	O
Madison,	,	O
Wis.;	,	O
BD	,	O
Biosciences,	:	O
Franklin	NNP	O
Lakes,	,	O
N.J.;	NNP	O
Oncogene	,	O
Research	:	O
Products,	NNP	O
San	NNP	O
Diego,	,	O
Calif.),	NNP	O
cell	,	O
regulation,	,	O
signal	NN	O
transduction,	,	O
inflammation,	JJ	O
oxidative	,	O
processes	,	O
and	JJ	O
apoptosis	NNS	O
(Assay	CC	O
Designs	NN	O
Inc.,	NNP	O
Ann	NNP	O
Arbor,	,	O
Mich.),	NNP	O
triglyceride	,	O
accumulation	,	O
(Sigma-Aldrich,	JJ	O
St.	NN	O
Louis,	,	O
Mo.),	NNP	O
angiogenesis	,	O
assays,	,	O
tube	NN	O
formation	,	O
assays,	NN	O
cytokine	NN	O
and	,	O
hormone	NN	O
assays	CC	O
and	NN	O
metabolic	NNS	O
assays	CC	O
(Chemicon	JJ	O
International	NNS	O
Inc.,	NNP	O
Temecula,	NNP	O
Calif.;	,	O
Amersham	,	O
Biosciences,	:	O
Piscataway,	NNP	O
N.J.).	,	O
In	,	O
one	.	O
non-limiting	IN	O
example,	CD	O
cells	JJ	O
determined	,	O
to	NNS	O
be	VBD	O
appropriate	TO	O
for	VB	O
a	JJ	O
particular	IN	O
phenotypic	DT	O
assay	JJ	O
(i.e.,	NN	O
MCF-7	NN	O
cells	,	O
selected	NNP	O
for	NNS	O
breast	VBN	O
cancer	IN	O
studies;	NN	O
adipocytes	NN	O
for	:	O
obesity	NNS	O
studies)	IN	O
are	NN	O
treated	)	O
with	VBP	O
diacylglycerol	VBN	O
acyltransferase	IN	O
2	NN	O
inhibitors	NN	O
identified	CD	O
from	NNS	O
the	VBN	O
in	IN	O
vitro	DT	O
studies	IN	O
as	JJ	O
well	NNS	O
as	RB	O
control	RB	O
compounds	IN	O
at	NN	O
optimal	VBZ	O
concentrations	IN	O
which	JJ	O
are	NNS	O
determined	WDT	O
by	VBP	O
the	VBN	O
methods	IN	O
described	DT	O
above.	NNS	O
At	VBN	O
the	.	O
end	IN	O
of	DT	O
the	NN	O
treatment	IN	O
period,	DT	O
treated	NN	O
and	,	O
untreated	VBN	O
cells	CC	O
are	JJ	O
analyzed	NNS	O
by	VBP	O
one	VBN	O
or	IN	O
more	CD	O
methods	CC	O
specific	JJR	O
for	NNS	O
the	JJ	O
assay	IN	O
to	DT	O
determine	NN	O
phenotypic	TO	O
outcomes	VB	O
and	NN	O
endpoints.	NNS	O
Phenotypic	CC	O
endpoints	.	O
include	NNP	O
changes	NNS	O
in	VBP	O
cell	NNS	O
morphology	IN	O
over	NN	O
time	NN	O
or	IN	O
treatment	NN	O
dose	CC	O
as	NN	O
well	NN	O
as	RB	O
changes	RB	O
in	IN	O
levels	NNS	O
of	IN	O
cellular	NNS	O
components	IN	O
such	JJ	O
as	NNS	O
proteins,	JJ	O
lipids,	IN	O
nucleic	,	O
acids,	,	O
hormones,	JJ	O
saccharides	,	O
or	,	O
metals.	NNS	O
Measurements	CC	O
of	.	O
cellular	NNS	O
status	IN	O
which	JJ	O
include	NN	O
pH,	WDT	O
stage	VBP	O
of	,	O
the	NN	O
cell	IN	O
cycle,	DT	O
intake	NN	O
or	,	O
excretion	NN	O
of	CC	O
biological	NN	O
indicators	IN	O
by	JJ	O
the	NNS	O
cell,	IN	O
are	DT	O
also	,	O
endpoints	VBP	O
of	RB	O
interest.	NNS	O
Analysis	IN	O
of	.	O
the	NN	O
expression	IN	O
of	DT	O
one	NN	O
or	IN	O
more	CD	O
genes	CC	O
in	JJR	O
the	NNS	O
cell	IN	O
after	DT	O
treatment	NN	O
is	IN	O
also	NN	O
used	VBZ	O
as	RB	O
an	VBN	O
indicator	IN	O
of	DT	O
the	NN	O
efficacy	IN	O
or	DT	O
potency	NN	O
of	CC	O
the	NN	O
diacylglycerol	IN	O
acyltransferase	DT	O
2	NN	O
inhibitors.	NN	O
Hallmark	CD	O
genes,	.	O
or	NNP	O
those	,	O
genes	CC	O
suspected	DT	O
to	NNS	O
be	VBD	O
associated	TO	O
with	VB	O
a	VBN	O
specific	IN	O
disease	DT	O
state,	JJ	O
condition,	NN	O
or	,	O
phenotype,	,	O
are	CC	O
measured	,	O
in	VBP	O
both	VBN	O
treated	IN	O
and	DT	O
untreated	JJ	O
cells.	CC	O
Example	JJ	O
12	.	O
RNA	RB	O
Isolation	CD	O
Poly(A)+	NNP	O
mRNA	NNP	O
Isolation	NN	O
Poly(A)+	JJ	O
mRNA	NNP	O
was	NN	O
isolated	NN	O
according	VBD	O
to	VBN	O
Miura	VBG	B
et	TO	I
al.,	NNP	I
(Clin.	FW	I
Chem.,	,	I
1996,	.	I
42,	,	I
1758-1764).	,	I
Other	,	O
methods	.	O
for	JJ	O
poly(A)+	NNS	O
mRNA	IN	O
isolation	NN	O
are	JJ	O
routine	NN	O
in	VBP	O
the	JJ	O
art.	IN	O
Briefly,	DT	O
for	.	O
cells	,	O
grown	IN	O
on	NNS	O
96-well	VBN	O
plates,	IN	O
growth	CD	O
medium	,	O
was	NN	O
removed	NN	O
from	VBD	O
the	VBN	O
cells	IN	O
and	DT	O
each	NNS	O
well	CC	O
was	DT	O
washed	NN	O
with	VBD	O
200	VBN	O
μL	IN	O
cold	CD	O
PBS.	NNS	O
60	JJ	O
μL	.	O
lysis	CD	O
buffer	JJ	O
(10	NN	O
mM	NN	O
Tris-HCl,	CD	O
pH	RB	O
7.6,	,	O
1	NN	O
mM	,	O
EDTA,	CD	O
0.5	NN	O
M	,	O
NaCl,	CD	O
0.5%	NNP	O
NP-40,	,	O
20	NN	O
mM	,	O
vanadyl-ribonucleoside	CD	O
complex)	JJ	O
was	JJ	O
added	)	O
to	VBD	O
each	VBN	O
well,	TO	O
the	DT	O
plate	,	O
was	DT	O
gently	NN	O
agitated	VBD	O
and	RB	O
then	VBN	O
incubated	CC	O
at	RB	O
room	VBD	O
temperature	IN	O
for	NN	O
five	NN	O
minutes.	IN	O
55	CD	O
μL	.	O
of	CD	O
lysate	NN	O
was	IN	O
transferred	NN	O
to	VBD	O
Oligo	VBN	O
d(T)	TO	O
coated	NNP	O
96-well	)	O
plates	VBD	O
(AGCT	CD	O
Inc.,	NNS	O
Irvine	NNP	O
Calif.).	,	O
Plates	NNP	O
were	.	O
incubated	NNS	O
for	VBD	O
60	VBN	O
minutes	IN	O
at	CD	O
room	NNS	O
temperature,	IN	O
washed	NN	O
3	,	O
times	VBD	O
with	CD	O
200	NNS	O
μL	IN	O
of	CD	O
wash	NNS	O
buffer	IN	O
(10	NN	O
mM	NN	O
Tris-HCl	CD	O
pH	RB	O
7.6,	NNP	O
1	NN	O
mM	,	O
EDTA,	CD	O
0.3	NN	O
M	,	O
NaCl).	CD	O
After	NNP	O
the	.	O
final	IN	O
wash,	DT	O
the	JJ	O
plate	,	O
was	DT	O
blotted	NN	O
on	VBD	O
paper	VBN	O
towels	IN	O
to	NN	O
remove	NNS	O
excess	TO	O
wash	VB	O
buffer	JJ	O
and	NN	O
then	NN	O
air-dried	CC	O
for	RB	O
5	JJ	O
minutes.	IN	O
60	CD	O
μL	.	O
of	CD	O
elution	NN	O
buffer	IN	O
(5	NN	O
mM	NN	O
Tris-HCl	CD	O
pH	RB	O
7.6),	NNP	O
preheated	NN	O
to	,	O
70°	VBD	O
C.,	TO	O
was	CD	O
added	,	O
to	VBD	O
each	VBN	O
well,	TO	O
the	DT	O
plate	,	O
was	DT	O
incubated	NN	O
on	VBD	O
a	VBN	O
90°	IN	O
C.	DT	O
hot	CD	O
plate	NNP	O
for	JJ	O
5	NN	O
minutes,	IN	O
and	CD	O
the	,	O
eluate	CC	O
was	DT	O
then	NN	O
transferred	VBD	O
to	RB	O
a	VBN	O
fresh	TO	O
96-well	DT	O
plate.	JJ	O
Cells	CD	O
grown	.	O
on	NNP	O
100	VBN	O
mm	IN	O
or	CD	O
other	NN	O
standard	CC	O
plates	JJ	O
may	JJ	O
be	NNS	O
treated	MD	O
similarly,	VB	O
using	VBN	O
appropriate	,	O
volumes	VBG	O
of	JJ	O
all	NNS	O
solutions.	IN	O
Total	DT	O
RNA	.	O
Isolation	JJ	O
Total	NNP	O
RNA	NNP	O
was	NNP	O
isolated	NNP	O
using	VBD	O
an	VBN	O
RNEASY™	VBG	O
96	DT	O
kit	NNP	O
and	CD	O
buffers	NN	O
purchased	CC	O
from	NNS	O
Qiagen,	VBN	O
Inc.	IN	O
(Valencia,	,	O
Calif.)	NNP	O
following	,	O
the	)	O
manufacturer's	VBG	O
recommended	DT	O
procedures.	POS	O
Briefly,	JJ	O
for	.	O
cells	,	O
grown	IN	O
on	NNS	O
96-well	VBN	O
plates,	IN	O
growth	CD	O
medium	,	O
was	NN	O
removed	NN	O
from	VBD	O
the	VBN	O
cells	IN	O
and	DT	O
each	NNS	O
well	CC	O
was	DT	O
washed	NN	O
with	VBD	O
200	VBN	O
μL	IN	O
cold	CD	O
PBS.	NNS	O
150	JJ	O
μL	.	O
Buffer	CD	O
RLT	JJ	O
was	NNP	O
added	NNP	O
to	VBD	O
each	VBN	O
well	TO	O
and	DT	O
the	NN	O
plate	CC	O
vigorously	DT	O
agitated	NN	O
for	RB	O
20	VBD	O
seconds.	IN	O
150	CD	O
μL	.	O
of	CD	O
70%	NN	O
ethanol	IN	O
was	NN	O
then	NN	O
added	VBD	O
to	RB	O
each	VBN	O
well	TO	O
and	DT	O
the	NN	O
contents	CC	O
mixed	DT	O
by	NNS	O
pipetting	VBN	O
three	IN	O
times	VBG	O
up	CD	O
and	NNS	O
down.	RB	O
The	CC	O
samples	.	O
were	DT	O
then	NNS	O
transferred	VBD	O
to	RB	O
the	VBN	O
RNEASY™	TO	O
96	DT	O
well	NNP	O
plate	CD	O
attached	RB	O
to	VB	O
a	VBN	O
QIAVAC™	TO	O
manifold	DT	O
fitted	NNP	O
with	NN	O
a	VBN	O
waste	IN	O
collection	DT	O
tray	NN	O
and	NN	O
attached	NN	O
to	CC	O
a	VBN	O
vacuum	TO	O
source.	DT	O
Vacuum	NN	O
was	.	O
applied	NNP	O
for	VBD	O
1	VBN	O
minute.	IN	O
500	CD	O
μL	.	O
of	CD	O
Buffer	NN	O
RW1	IN	O
was	NNP	O
added	NNP	O
to	VBD	O
each	VBN	O
well	TO	O
of	DT	O
the	NN	O
RNEASY™	IN	O
96	DT	O
plate	NNP	O
and	CD	O
incubated	NN	O
for	CC	O
15	VBN	O
minutes	IN	O
and	CD	O
the	NNS	O
vacuum	CC	O
was	DT	O
again	NN	O
applied	VBD	O
for	RB	O
1	VBN	O
minute.	IN	O
An	CD	O
additional	.	O
500	DT	O
μL	JJ	O
of	CD	O
Buffer	NN	O
RW1	IN	O
was	NNP	O
added	NNP	O
to	VBD	O
each	VBN	O
well	TO	O
of	DT	O
the	NN	O
RNEASY™	IN	O
96	DT	O
plate	NNP	O
and	CD	O
the	NN	O
vacuum	CC	O
was	DT	O
applied	NN	O
for	VBD	O
2	VBN	O
minutes.	IN	O
1	CD	O
mL	.	O
of	CD	O
Buffer	NN	O
RPE	IN	O
was	NNP	O
then	NNP	O
added	VBD	O
to	RB	O
each	VBN	O
well	TO	O
of	DT	O
the	NN	O
RNEASY™	IN	O
96	DT	O
plate	NNP	O
and	CD	O
the	NN	O
vacuum	CC	O
applied	DT	O
for	NN	O
a	VBD	O
period	IN	O
of	DT	O
90	NN	O
seconds.	IN	O
The	CD	O
Buffer	.	O
RPE	DT	O
wash	NNP	O
was	NNP	O
then	NN	O
repeated	VBD	O
and	RB	O
the	VBN	O
vacuum	CC	O
was	DT	O
applied	NN	O
for	VBD	O
an	VBN	O
additional	IN	O
3	DT	O
minutes.	JJ	O
The	CD	O
plate	.	O
was	DT	O
then	NN	O
removed	VBD	O
from	RB	O
the	VBN	O
QIAVAC™	IN	O
manifold	DT	O
and	NNP	O
blotted	NN	O
dry	CC	O
on	VBD	O
paper	NNS	O
towels.	IN	O
The	NN	O
plate	.	O
was	DT	O
then	NN	O
re-attached	VBD	O
to	RB	O
the	JJ	O
QIAVAC™	TO	O
manifold	DT	O
fitted	NNP	O
with	NN	O
a	VBN	O
collection	IN	O
tube	DT	O
rack	NN	O
containing	NN	O
1.2	NN	O
mL	VBG	O
collection	CD	O
tubes.	JJ	O
RNA	NN	O
was	.	O
then	NNP	O
eluted	VBD	O
by	RB	O
pipetting	VBN	O
140	IN	O
μL	VBG	O
of	CD	O
RNase	NN	O
free	IN	O
water	NNP	O
into	JJ	O
each	NN	O
well,	IN	O
incubating	DT	O
1	,	O
minute,	VBG	O
and	CD	O
then	,	O
applying	CC	O
the	RB	O
vacuum	VBG	O
for	DT	O
3	NN	O
minutes.	IN	O
The	CD	O
repetitive	.	O
pipetting	DT	O
and	JJ	O
elution	NN	O
steps	CC	O
may	NN	O
be	NNS	O
automated	MD	O
using	VB	O
a	VBN	O
QIAGEN®	VBG	O
Bio-Robot™	DT	O
9604	NNP	O
instrument	NNP	O
(Qiagen,	CD	O
Inc.,	NN	O
Valencia	,	O
Calif.).	,	O
Essentially,	NNP	O
after	.	O
lysing	,	O
of	IN	O
the	VBG	O
cells	IN	O
on	DT	O
the	NNS	O
culture	IN	O
plate,	DT	O
the	NN	O
plate	,	O
is	DT	O
transferred	NN	O
to	VBZ	O
the	VBN	O
robot	TO	O
deck	DT	O
where	NN	O
the	NN	O
pipetting,	WRB	O
DNase	DT	O
treatment	,	O
and	NNP	O
elution	NN	O
steps	CC	O
are	NN	O
carried	NNS	O
out.	VBP	O
Example	VBN	O
13	.	O
Real-Time	JJ	O
Quantitative	CD	O
PCR	JJ	O
Analysis	NNP	O
of	NNP	O
Diacylglycerol	NNP	O
Acyltransferase	IN	O
2	NNP	O
mRNA	NNP	O
Levels	CD	O
Quantitation	NN	O
of	NNP	O
diacylglycerol	NNP	O
acyltransferase	IN	O
2	NN	O
mRNA	NN	O
levels	CD	O
was	NN	O
accomplished	NNS	O
by	VBD	O
real-time	VBN	O
quantitative	IN	O
PCR	JJ	O
using	JJ	O
the	NNP	O
ABI	VBG	O
PRISM™	DT	O
7600,	NNP	O
7700,	NNP	O
or	,	O
7900	,	O
Sequence	CC	O
Detection	CD	O
System	NNP	O
(PE-Applied	NNP	O
Biosystems,	NNP	O
Foster	JJ	O
City,	,	O
Calif.)	NNP	O
according	,	O
to	)	O
manufacturer's	VBG	O
instructions.	TO	O
This	POS	O
is	.	O
a	DT	O
closed-tube,	VBZ	O
non-gel-based,	DT	O
fluorescence	,	O
detection	,	O
system	NN	O
which	NN	O
allows	NN	O
high-throughput	WDT	O
quantitation	VBZ	O
of	NN	O
polymerase	NN	O
chain	IN	O
reaction	NN	O
(PCR)	NN	O
products	NN	O
in	)	O
real-time.	NNS	O
As	IN	O
opposed	.	O
to	IN	O
standard	VBN	O
PCR	TO	O
in	VB	O
which	NNP	O
amplification	IN	O
products	WDT	O
are	NN	O
quantitated	NNS	O
after	VBP	O
the	VBN	O
PCR	IN	O
is	DT	O
completed,	NNP	O
products	VBZ	O
in	,	O
real-time	NNS	O
quantitative	IN	O
PCR	JJ	O
are	JJ	O
quantitated	NNP	O
as	VBP	O
they	VBN	O
accumulate.	IN	O
This	PRP	O
is	.	O
accomplished	DT	O
by	VBZ	O
including	VBN	O
in	IN	O
the	VBG	O
PCR	IN	O
reaction	DT	O
an	NNP	O
oligonucleotide	NN	O
probe	DT	O
that	JJ	O
anneals	NN	O
specifically	IN	O
between	VBZ	O
the	RB	O
forward	IN	O
and	DT	O
reverse	NN	O
PCR	CC	O
primers,	NN	O
and	NNP	O
contains	,	O
two	CC	O
fluorescent	VBZ	O
dyes.	CD	O
A	JJ	O
reporter	.	O
dye	DT	O
(e.g.,	NN	O
FAM	NN	O
or	,	O
JOE,	NNP	O
obtained	CC	O
from	,	O
either	VBN	O
PE-Applied	IN	O
Biosystems,	DT	O
Foster	JJ	O
City,	,	O
Calif.,	NNP	O
Operon	,	O
Technologies	,	O
Inc.,	NNP	O
Alameda,	NNPS	O
Calif.	,	O
or	,	O
Integrated	NNP	O
DNA	CC	O
Technologies	VBN	O
Inc.,	NNP	O
Coralville,	NNPS	O
Iowa)	,	O
is	,	O
attached	)	O
to	VBZ	O
the	VBN	O
5′	TO	O
end	DT	O
of	CD	O
the	NN	O
probe	IN	O
and	DT	O
a	NN	O
quencher	CC	O
dye	DT	O
(e.g.,	NN	O
TAMRA,	NN	O
obtained	,	O
from	,	O
either	VBN	O
PE-Applied	IN	O
Biosystems,	DT	O
Foster	JJ	O
City,	,	O
Calif.,	NNP	O
Operon	,	O
Technologies	,	O
Inc.,	NNP	O
Alameda,	NNPS	O
Calif.	,	O
or	,	O
Integrated	NNP	O
DNA	CC	O
Technologies	VBN	O
Inc.,	NNP	O
Coralville,	NNPS	O
Iowa)	,	O
is	,	O
attached	)	O
to	VBZ	O
the	VBN	O
3′	TO	O
end	DT	O
of	CD	O
the	NN	O
probe.	IN	O
When	DT	O
the	.	O
probe	WRB	O
and	DT	O
dyes	NN	O
are	CC	O
intact,	NNS	O
reporter	VBP	O
dye	,	O
emission	JJ	O
is	NN	O
quenched	NN	O
by	VBZ	O
the	VBN	O
proximity	IN	O
of	DT	O
the	NN	O
3′	IN	O
quencher	DT	O
dye.	CD	O
During	NN	O
amplification,	.	O
annealing	IN	O
of	,	O
the	VBG	O
probe	IN	O
to	DT	O
the	NN	O
target	TO	O
sequence	DT	O
creates	NN	O
a	NN	O
substrate	VBZ	O
that	DT	O
can	NN	O
be	WDT	O
cleaved	MD	O
by	VB	O
the	VBN	O
5′-exonuclease	IN	O
activity	DT	O
of	JJ	O
Taq	NN	O
polymerase.	IN	O
During	NNP	O
the	.	O
extension	IN	O
phase	DT	O
of	NN	O
the	NN	O
PCR	IN	O
amplification	DT	O
cycle,	NNP	O
cleavage	NN	O
of	,	O
the	NN	O
probe	IN	O
by	DT	O
Taq	NN	O
polymerase	IN	O
releases	NNP	O
the	NN	O
reporter	VBZ	O
dye	DT	O
from	NN	O
the	NN	O
remainder	IN	O
of	DT	O
the	NN	O
probe	IN	O
(and	DT	O
hence	NN	O
from	CC	O
the	RB	O
quencher	IN	O
moiety)	DT	O
and	JJR	O
a	)	O
sequence-specific	CC	O
fluorescent	DT	O
signal	JJ	O
is	JJ	O
generated.	NN	O
With	VBZ	O
each	.	O
cycle,	IN	O
additional	DT	O
reporter	,	O
dye	JJ	O
molecules	NN	O
are	NN	O
cleaved	NNS	O
from	VBP	O
their	VBN	O
respective	IN	O
probes,	PRP$	O
and	JJ	O
the	,	O
fluorescence	CC	O
intensity	DT	O
is	NN	O
monitored	NN	O
at	VBZ	O
regular	VBN	O
intervals	IN	O
by	JJ	O
laser	NNS	O
optics	IN	O
built	NN	O
into	NNS	O
the	VBN	O
ABI	IN	O
PRISM™	DT	O
Sequence	NNP	O
Detection	NNP	O
System.	NNP	O
In	NNP	O
each	.	O
assay,	IN	O
a	DT	O
series	,	O
of	DT	O
parallel	NN	O
reactions	IN	O
containing	JJ	O
serial	NNS	O
dilutions	VBG	O
of	JJ	O
mRNA	NNS	O
from	IN	O
untreated	NN	O
control	IN	O
samples	JJ	O
generates	NN	O
a	VBZ	O
standard	VBZ	O
curve	DT	O
that	JJ	O
is	NN	O
used	WDT	O
to	VBZ	O
quantitate	VBN	O
the	TO	O
percent	VB	O
inhibition	DT	O
after	NN	O
antisense	NN	O
oligonucleotide	IN	O
treatment	JJ	O
of	JJ	O
test	NN	O
samples.	IN	O
Prior	NN	O
to	.	O
quantitative	RB	O
PCR	TO	O
analysis,	VB	O
primer-probe	NNP	O
sets	,	O
specific	JJ	O
to	NNS	O
the	JJ	O
target	TO	O
gene	DT	O
being	NN	O
measured	NN	O
are	VBG	O
evaluated	VBN	O
for	VBP	O
their	VBN	O
ability	IN	O
to	PRP$	O
be	NN	O
“multiplexed”	TO	O
with	VB	O
a	VBN	O
GAPDH	IN	O
amplification	DT	O
reaction.	NNP	O
In	NN	O
multiplexing,	.	O
both	IN	O
the	,	O
target	CC	O
gene	DT	O
and	NN	O
the	NN	O
internal	CC	O
standard	DT	O
gene	JJ	O
GAPDH	NN	O
are	NN	O
amplified	NNP	O
concurrently	VBP	O
in	VBN	O
a	RB	O
single	IN	O
sample.	DT	O
In	JJ	O
this	.	O
analysis,	IN	O
mRNA	DT	O
isolated	,	O
from	RB	O
untreated	VBN	O
cells	IN	O
is	JJ	O
serially	NNS	O
diluted.	VBZ	O
Each	RB	O
dilution	.	O
is	DT	O
amplified	NN	O
in	VBZ	O
the	VBN	O
presence	IN	O
of	DT	O
primer-probe	NN	O
sets	IN	O
specific	JJ	O
for	NNS	O
GAPDH	JJ	O
only,	IN	O
target	NNP	O
gene	,	O
only	VB	O
(“single-plexing”),	NN	O
or	RB	O
both	,	O
(multiplexing).	CC	O
Following	DT	O
PCR	.	O
amplification,	VBG	O
standard	NNP	O
curves	,	O
of	JJ	O
GAPDH	NNS	O
and	IN	O
target	NNP	O
mRNA	CC	O
signal	VB	O
as	JJ	O
a	NN	O
function	IN	O
of	DT	O
dilution	NN	O
are	IN	O
generated	NN	O
from	VBP	O
both	VBN	O
the	IN	O
single-plexed	DT	O
and	DT	O
multiplexed	JJ	O
samples.	CC	O
If	JJ	O
both	.	O
the	IN	O
slope	DT	O
and	DT	O
correlation	NN	O
coefficient	CC	O
of	NN	O
the	NN	O
GAPDH	IN	O
and	DT	O
target	NNP	O
signals	CC	O
generated	NN	O
from	NNS	O
the	VBD	O
multiplexed	IN	O
samples	DT	O
fall	JJ	O
within	NNS	O
10%	VBP	O
of	IN	O
their	NN	O
corresponding	IN	O
values	PRP$	O
generated	NN	O
from	NNS	O
the	VBD	O
single-plexed	IN	O
samples,	DT	O
the	JJ	O
primer-probe	,	O
set	DT	O
specific	NN	O
for	NN	O
that	NN	O
target	IN	O
is	DT	O
deemed	NN	O
multiplexable.	VBZ	O
Other	VBN	O
methods	.	O
of	JJ	O
PCR	NNS	O
are	IN	O
also	NNP	O
known	VBP	O
in	RB	O
the	VBN	O
art.	IN	O
Gene	DT	O
target	.	O
quantities	NNP	O
are	NN	O
obtained	NNS	O
by	VBP	O
real-time	VBN	O
PCR.	IN	O
Prior	JJ	O
to	.	O
the	RB	O
real-time	TO	O
PCR,	DT	O
isolated	JJ	O
RNA	,	O
is	JJ	O
subjected	NNP	O
to	VBZ	O
a	VBN	O
reverse	TO	O
transcriptase	DT	O
(RT)	NN	O
reaction,	NN	O
for	)	O
the	,	O
purpose	IN	O
of	DT	O
generating	NN	O
complementary	IN	O
DNA	VBG	O
(cDNA).	JJ	O
The	NNP	O
real-time	.	O
PCR	DT	O
is	JJ	O
then	NNP	O
performed	VBZ	O
on	RB	O
the	VBN	O
resulting	IN	O
cDNA.	DT	O
Reverse	VBG	O
transcriptase	.	O
and	JJ	O
PCR	NN	O
reagents	CC	O
were	NNP	O
obtained	NNS	O
from	VBD	O
Invitrogen	VBN	O
Corporation,	IN	O
(Carlsbad,	NNP	O
Calif.).	,	O
RT,	,	O
real-time	.	O
PCR	,	O
reactions	JJ	O
were	NNP	O
carried	NNS	O
out	VBD	O
by	VBN	O
adding	RP	O
20	IN	O
μL	VBG	O
PCR	CD	O
cocktail	JJ	O
(2.5×PCR	NNP	O
buffer	NN	O
minus	CD	O
MgCl2,	NN	O
6.6	NN	O
mM	,	O
MgCl2,	CD	O
375	NN	O
μM	,	O
each	CD	O
of	JJ	O
dATP,	DT	O
dCTP,	IN	O
dCTP	,	O
and	,	O
dGTP,	NN	O
375	CC	O
nM	,	O
each	CD	O
of	JJ	O
forward	DT	O
primer	IN	O
and	RB	O
reverse	NN	O
primer,	CC	O
125	VB	O
nM	,	O
of	CD	O
probe,	NN	O
4	IN	O
Units	,	O
RNase	CD	O
inhibitor,	NNS	O
1.25	NNP	O
Units	,	O
PLATINUM®	CD	O
Taq	NNS	O
polymerase,	NNP	O
5	NNP	O
Units	,	O
MuLV	CD	O
reverse	NNS	O
transcriptase,	NNP	O
and	NN	O
2.5×ROX	,	O
dye)	CC	O
to	CD	O
96-well	)	O
plates	TO	O
containing	CD	O
30	NNS	O
μL	VBG	O
total	CD	O
RNA	JJ	O
solution	JJ	O
(20-200	NNP	O
ng).	NN	O
The	JJ	O
RT	.	O
reaction	DT	O
was	NNP	O
carried	NN	O
out	VBD	O
by	VBN	O
incubation	RP	O
for	IN	O
30	NN	O
minutes	IN	O
at	CD	O
48°	NNS	O
C.	IN	O
Following	CD	O
a	NNP	O
10	VBG	O
minute	DT	O
incubation	CD	O
at	NN	O
95°	NN	O
C.	IN	O
to	CD	O
activate	NNP	O
the	TO	O
PLATINUM®	VB	O
Taq	DT	O
polymerase,	NNP	O
40	NNP	O
cycles	,	O
of	CD	O
a	NNS	O
two-step	IN	O
PCR	DT	O
protocol	JJ	O
were	NNP	O
carried	NN	O
out:	VBD	O
95°	VBN	O
C.	:	O
for	CD	O
15	NNP	O
seconds	IN	O
(denaturation)	CD	O
followed	NNS	O
by	)	O
60°	VBN	O
C.	IN	O
for	CD	O
1.5	NNP	O
minutes	IN	O
(annealing/extension).	CD	O
The	NNS	O
method	.	O
of	DT	O
obtaining	NN	O
gene	IN	O
target	VBG	O
quantities	NN	O
by	NN	O
RT,	NNS	O
real-time	IN	O
PCR	,	O
is	JJ	O
often	NNP	O
referred	VBZ	O
to	RB	O
as	VBN	O
simply	TO	O
real-time	IN	O
PCR.	RB	O
Gene	JJ	O
target	.	O
quantities	NNP	O
obtained	NN	O
by	NNS	O
real-time	VBN	O
PCR	IN	O
are	JJ	O
normalized	NNP	O
using	VBP	O
either	VBN	O
the	VBG	O
expression	CC	O
level	DT	O
of	NN	O
GAPDH,	NN	O
a	IN	O
gene	,	O
whose	DT	O
expression	NN	O
is	WP$	O
constant,	NN	O
or	VBZ	O
by	,	O
quantifying	CC	O
total	IN	O
RNA	VBG	O
using	JJ	O
the	NNP	O
RIBOGREEN™	VBG	O
reagent	DT	O
(Molecular	NNP	O
Probes,	NN	O
Inc.	JJ	O
Eugene,	,	O
Oreg.).	NNP	O
GAPDH	,	O
expression	.	O
is	NNP	O
quantified	NN	O
by	VBZ	O
real	VBN	O
time	IN	O
real-time	JJ	O
PCR,	NN	O
by	JJ	O
being	,	O
run	IN	O
simultaneously	VBG	O
with	VBN	O
the	RB	O
target,	IN	O
multiplexing,	DT	O
or	,	O
separately.	,	O
Total	CC	O
RNA	.	O
is	JJ	O
quantified	NNP	O
using	VBZ	O
RIBOGREEN™	VBN	O
RNA	VBG	O
quantification	NNP	O
reagent	NNP	O
(Molecular	NN	O
Probes,	NN	O
Inc.	JJ	O
Eugene,	,	O
Oreg.).	NNP	O
Methods	,	O
of	.	O
RNA	NNS	O
quantification	IN	O
by	NNP	O
the	NN	O
RIBOGREEN™	IN	O
reagent	DT	O
are	NNP	O
taught	NN	O
in	VBP	O
Jones,	VBN	B
L.	IN	I
J.,	,	I
et	NNP	I
al,	,	I
(Analytical	FW	I
Biochemistry,	,	I
1998,	JJ	I
265,	,	I
368-374).
In	,	O
this	,	O
assay,	.	O
170	IN	O
μL	DT	O
of	,	O
RiboGreen™	CD	O
working	NN	O
reagent	IN	O
(the	NNP	O
RIBOGREEN™	VBG	O
reagent	NN	O
diluted	DT	O
1:350	NNP	O
in	NN	O
10	VBD	O
mM	CD	O
Tris-HCl,	IN	O
1	CD	O
mM	JJ	O
EDTA,	,	O
pH	CD	O
7.5)	NN	O
was	,	O
pipetted	RB	O
into	)	O
a	VBD	O
96-well	VBN	O
plate	IN	O
containing	DT	O
30	JJ	O
μL	NN	O
purified,	VBG	O
cellular	CD	O
RNA.	JJ	O
The	,	O
plate	JJ	O
was	.	O
read	DT	O
in	NN	O
a	VBD	O
CytoFluor	VBN	O
4000	IN	O
apparatus	DT	O
(PE	NNP	O
Applied	CD	O
Biosystems)	NN	O
with	NNP	O
excitation	NNP	O
at	)	O
485	IN	O
nm	NN	O
and	IN	O
emission	CD	O
at	NNS	O
530	CC	O
nm.	NN	O
Probes	IN	O
and	CD	O
primers	.	O
to	NNS	O
human	CC	O
diacylglycerol	NNS	O
acyltransferase	TO	O
2	JJ	O
were	NN	O
designed	NN	O
to	CD	O
hybridize	VBD	O
to	VBN	O
a	TO	O
human	VB	O
diacylglycerol	TO	O
acyltransferase	DT	O
2	JJ	O
sequence,	NN	O
using	NN	O
published	CD	O
sequence	,	O
information	VBG	O
(GENBANK®	VBN	O
accession	NN	O
number	NN	O
NM—032564.2,	NNP	O
incorporated	NN	O
herein	NN	O
as	,	O
SEQ	JJ	O
ID	NN	O
NO:	IN	O
4).	NNP	O
For	NNP	O
human	:	O
diacylglycerol	.	O
acyltransferase	IN	O
2	JJ	O
the	NN	O
PCR	NN	O
primers	CD	O
were:	DT	O
forward	NNP	O
primer:	NNS	O
CATACGGCCTTACCTGGCTACA	:	O
(SEQ	JJ	O
ID	:	O
NO:	NNP	O
5)	NNP	O
reverse	NNP	O
primer:	:	O
CAGACATCAGGTACTCCCTCAACA	)	O
(SEQ	NN	O
ID	:	O
NO:	NNP	O
6)	NNP	O
and	NNP	O
the	:	O
PCR	)	O
probe	CC	O
was:	DT	O
FAM-TGGCAGGCAACTTCCGAATGCC-TAMRA	NNP	O
(SEQ	NN	O
ID	:	O
NO:	JJ	O
7)	NNP	O
where	NNP	O
FAM	:	O
is	)	O
the	WRB	O
fluorescent	NNP	O
dye	VBZ	O
and	DT	O
TAMRA	JJ	O
is	NN	O
the	CC	O
quencher	NNP	O
dye.	VBZ	O
For	DT	O
human	NN	O
GAPDH	.	O
the	IN	O
PCR	JJ	O
primers	NNP	O
were:	DT	O
forward	NNP	O
primer:	NNS	O
GAAGGTGAAGGTCGGAGTC	:	O
(SEQ	JJ	O
ID	:	O
NO:8)	NNP	O
reverse	NNP	O
primer:	NNP	O
GAAGATGGTGATGGGATTTC	)	O
(SEQ	VBZ	O
ID	:	O
NO:9)	NNP	O
and	NNP	O
the	NNP	O
PCR	)	O
probe	CC	O
was:	DT	O
5′	NNP	O
JOE-CAAGCTTCCCGTTCTCAGCC-TAMRA	NN	O
3′	:	O
(SEQ	CD	O
ID	JJ	O
NO:	CD	O
10)	NNP	O
where	NNP	O
JOE	:	O
is	)	O
the	WRB	O
fluorescent	NNP	O
reporter	VBZ	O
dye	DT	O
and	JJ	O
TAMRA	NN	O
is	NN	O
the	CC	O
quencher	NNP	O
dye.	VBZ	O
Probes	DT	O
and	NN	O
primers	.	O
to	NNS	O
mouse	CC	O
diacylglycerol	NNS	O
acyltransferase	TO	O
2	VB	O
were	NN	O
designed	NN	O
to	CD	O
hybridize	VBD	O
to	VBN	O
a	TO	O
mouse	VB	O
diacylglycerol	TO	O
acyltransferase	DT	O
2	NN	O
sequence,	NN	O
using	NN	O
published	CD	O
sequence	,	O
information	VBG	O
(GENBANK®	VBN	O
accession	NN	O
number	NN	O
AK002443.1,	NNP	O
incorporated	NN	O
herein	NN	O
as	,	O
SEQ	JJ	O
ID	NN	O
NO:11).	IN	O
For	NNP	O
mouse	NNP	O
diacylglycerol	.	O
acyltransferase	IN	O
2	NN	O
the	NN	O
PCR	NN	O
primers	CD	O
were:	DT	O
forward	NNP	O
primer:	NNS	O
ACTCTGGAGGTTGGCACCAT	:	O
(SEQ	JJ	O
ID	:	O
NO:12)	NNP	O
reverse	NNP	O
primer:	NNP	O
GGGTGTGGCTCAGGAGGAT	)	O
(SEQ	VBZ	O
ID	:	O
NO:	NNP	O
13)	NNP	O
and	NNP	O
the	:	O
PCR	)	O
probe	CC	O
was:	DT	O
FAM-CAGCGTTGCTCTGGCGCA-TAMRA	NNP	O
(SEQ	NN	O
ID	:	O
NO:	JJ	O
14)	NNP	O
where	NNP	O
FAM	:	O
is	)	O
the	WRB	O
fluorescent	NNP	O
reporter	VBZ	O
dye	DT	O
and	JJ	O
TAMRA	NN	O
is	NN	O
the	CC	O
quencher	NNP	O
dye.	VBZ	O
For	DT	O
mouse	NN	O
GAPDH	.	O
the	IN	O
PCR	NN	O
primers	NNP	O
were:	DT	O
forward	NNP	O
primer:	NNS	O
GGCAAATTCAACGGCACAGT(SEQ	:	O
ID	JJ	O
NO:15)	:	O
reverse	NNP	O
primer:	NNP	O
GGGTCTCGCTCCTGGAAGAT(SEQ	)	O
ID	VBZ	O
NO:16)	:	O
and	NNP	O
the	NNP	O
PCR	)	O
probe	CC	O
was:	DT	O
5′	NNP	O
JOE-AAGGCCGAGAATGGGAAGCTTGTCATC-TAMRA	NN	O
3′	:	O
(SEQ	CD	O
ID	JJ	O
NO:	CD	O
17)	NNP	O
where	NNP	O
JOE	:	O
is	)	O
the	WRB	O
fluorescent	NNP	O
reporter	VBZ	O
dye	DT	O
and	JJ	O
TAMRA	NN	O
is	NN	O
the	CC	O
quencher	NNP	O
dye.	VBZ	O
Example	DT	O
14	NN	O
Northern	.	O
Blot	RB	O
Analysis	CD	O
of	NNP	O
Diacylglycerol	NNP	O
Acyltransferase	NNP	O
2	IN	O
mRNA	NNP	O
Levels	NNP	O
Eighteen	CD	O
hours	NN	O
after	NNP	O
antisense	NNP	O
treatment,	NNS	O
cell	IN	O
monolayers	JJ	O
were	,	O
washed	NN	O
twice	NNS	O
with	VBD	O
cold	VBN	O
PBS	RB	O
and	IN	O
lysed	JJ	O
in	NNP	O
1	CC	O
mL	VBN	O
RNAZOL™	IN	O
reagent	CD	O
(TEL-TEST	NNS	O
“B”	NNP	O
Inc.,	NN	O
Friendswood,	NNP	O
Tex.).	NNP	O
Total	,	O
RNA	,	O
was	.	O
prepared	JJ	O
following	NNP	O
manufacturer's	VBD	O
recommended	VBN	O
protocols.	VBG	O
Twenty	POS	O
micrograms	JJ	O
of	.	O
total	NNP	O
RNA	NNS	O
was	IN	O
fractionated	JJ	O
by	NNP	O
electrophoresis	VBD	O
through	VBN	O
1.2%	IN	O
agarose	NN	O
gels	IN	O
containing	NN	O
1.1%	JJ	O
formaldehyde	NNS	O
using	VBG	O
a	NN	O
MOPS	NN	O
buffer	VBG	O
system	DT	O
(AMRESCO,	NNP	O
Inc.	NN	O
Solon,	NN	O
Ohio).	,	O
RNA	NNP	O
was	,	O
transferred	.	O
from	NNP	O
the	VBD	O
gel	VBN	O
to	IN	O
HYBOND™-N+	DT	O
nylon	NN	O
membranes	TO	O
(Amersham	NNP	O
Pharmacia	NN	O
Biotech,	NNS	O
Piscataway,	NNP	O
N.J.)	NNP	O
by	,	O
overnight	,	O
capillary	)	O
transfer	IN	O
using	JJ	O
a	JJ	O
Northern/Southern	NN	O
Transfer	VBG	O
buffer	DT	O
system	NNP	O
(TEL-TEST	NNP	O
“B”	NN	O
Inc.,	NN	O
Friendswood,	NNP	O
Tex.).	NNP	O
RNA	,	O
transfer	,	O
was	.	O
confirmed	NNP	O
by	NN	O
UV	VBD	O
visualization.	VBN	O
Membranes	IN	O
were	NNP	O
fixed	.	O
by	NNS	O
UV	VBD	O
cross-linking	VBN	O
using	IN	O
a	NNP	O
STRATALINKER™	NN	O
UV	VBG	O
Crosslinker	DT	O
2400	NNP	O
instrument	NNP	O
(Stratagene,	NNP	O
Inc,	CD	O
La	NN	O
Jolla,	,	O
Calif.)	,	O
and	NNP	O
then	,	O
probed	)	O
using	CC	O
QUICKHYB™	RB	O
hybridization	VBD	O
solution	VBG	O
(Stratagene,	NNP	O
La	NN	O
Jolla,	NN	O
Calif.)	,	O
using	NNP	O
manufacturer's	,	O
recommendations	)	O
for	VBG	O
stringent	POS	O
conditions.	NNS	O
To	IN	O
detect	JJ	O
human	.	O
diacylglycerol	TO	O
acyltransferase	VB	O
2,	JJ	O
a	NN	O
human	NN	O
diacylglycerol	,	O
acyltransferase	DT	O
2	JJ	O
specific	NN	O
probe	NN	O
was	CD	O
prepared	JJ	O
by	NN	O
PCR	VBD	O
using	VBN	O
the	IN	O
forward	NNP	O
primer	VBG	O
CATACGGCCTTACCTGGCTACA	DT	O
(SEQ	NN	O
ID	NN	O
NO:	NNP	O
5)	NNP	O
and	NNP	O
the	:	O
reverse	)	O
primer	CC	O
CAGACATCAGGTACTCCCTCAACA	DT	O
(SEQ	NN	O
ID	NN	O
NO:	NNP	O
6).	NNP	O
To	NNP	O
normalize	:	O
for	.	O
variations	TO	O
in	VB	O
loading	IN	O
and	NNS	O
transfer	IN	O
efficiency	NN	O
membranes	CC	O
were	VB	O
stripped	NN	O
and	NNS	O
probed	VBD	O
for	VBN	O
human	CC	O
glyceraldehyde-3-phosphate	VBN	O
dehydrogenase	IN	O
(GAPDH)	JJ	O
RNA	JJ	O
(Clontech,	NN	O
Palo	)	O
Alto,	NNP	O
Calif.).	,	O
To	NNP	O
detect	,	O
mouse	.	O
diacylglycerol	TO	O
acyltransferase	VB	O
2,	NN	O
a	NN	O
mouse	NN	O
diacylglycerol	,	O
acyltransferase	DT	O
2	NN	O
specific	NN	O
probe	NN	O
was	CD	O
prepared	JJ	O
by	NN	O
PCR	VBD	O
using	VBN	O
the	IN	O
forward	NNP	O
primer	VBG	O
ACTCTGGAGGTTGGCACCAT	DT	O
(SEQ	NN	O
ID	NN	O
NO:	NNP	O
12)	NNP	O
and	NNP	O
the	:	O
reverse	)	O
primer	CC	O
GGGTGTGGCTCAGGAGGAT	DT	O
(SEQ	NN	O
ID	NN	O
NO:	NNP	O
13).	NNP	O
To	NNP	O
normalize	:	O
for	.	O
variations	TO	O
in	VB	O
loading	IN	O
and	NNS	O
transfer	IN	O
efficiency	NN	O
membranes	CC	O
were	VB	O
stripped	NN	O
and	NNS	O
probed	VBD	O
for	VBN	O
mouse	CC	O
glyceraldehyde-3-phosphate	VBN	O
dehydrogenase	IN	O
(GAPDH)	NN	O
RNA	JJ	O
(Clontech,	NN	O
Palo	)	O
Alto,	NNP	O
Calif.).	,	O
Hybridized	NNP	O
membranes	,	O
were	.	O
visualized	VBN	O
and	NNS	O
quantitated	VBD	O
using	VBN	O
PHOSPHORIMAGER™	CC	O
and	VBN	O
IMAGEQUANT™	VBG	O
Software	NNP	O
V3.3	CC	O
(Molecular	NNP	O
Dynamics,	NNP	O
Sunnyvale,	NNP	O
Calif.).	NNP	O
Data	,	O
was	,	O
normalized	.	O
to	NNP	O
GAPDH	VBD	O
levels	VBN	O
in	TO	O
untreated	NNP	O
controls.	NNS	O
Example	IN	O
15	JJ	O
Antisense	.	O
Inhibition	RB	O
of	CD	O
Human	NNP	O
Diacylglycerol	NNP	O
Acyltransferase	IN	O
2	NNP	O
Expression	NNP	O
by	NNP	O
Chimeric	CD	O
Phosphorothioate	NNP	O
Oligonucleotides	IN	O
Having	NNP	O
2′-MOE	NNP	O
Wings	NNP	O
and	NNP	O
a	JJ	O
Deoxy	NNP	O
Gap	CC	O
In	DT	O
accordance	NNP	O
with	NNP	O
the	IN	O
present	NN	O
invention,	IN	O
a	DT	O
series	JJ	O
of	,	O
antisense	DT	O
compounds	NN	O
was	IN	O
designed	JJ	O
to	NNS	O
target	VBD	O
different	VBN	O
regions	TO	O
of	VB	O
the	JJ	O
human	NNS	O
diacylglycerol	IN	O
acyltransferase	DT	O
2	JJ	O
RNA,	NN	O
using	NN	O
published	CD	O
sequences	,	O
(GENBANK®	VBG	O
accession	VBN	O
number	NNS	O
NM—032564.2,	NNP	O
incorporated	NN	O
herein	NN	O
as	,	O
SEQ	JJ	O
ID	NN	O
NO:	IN	O
4,	NNP	O
nucleotides	NNP	O
5669186	:	O
to	,	O
5712008	NNS	O
of	CD	O
the	TO	O
nucleotide	CD	O
sequence	IN	O
with	DT	O
the	JJ	O
GenBank	NN	O
accession	IN	O
number	DT	O
NT—033927.5,	NNP	O
incorporated	NN	O
herein	NN	O
as	,	O
SEQ	JJ	O
ID	NN	O
NO:	IN	O
18).	NNP	O
The	NNP	O
compounds	:	O
are	.	O
shown	DT	O
in	NNS	O
Table	VBP	O
1.	VBN	O
“Target	IN	O
site”	JJ	O
indicates	.	O
the	VB	O
first	NN	O
(5′-most)	VBZ	O
nucleotide	DT	O
number	JJ	O
on	)	O
the	IN	O
particular	NN	O
target	IN	O
sequence	DT	O
to	JJ	O
which	NN	O
the	NN	O
compound	TO	O
binds.	WDT	O
All	DT	O
compounds	NN	O
in	.	O
Table	DT	O
1	NNS	O
are	IN	O
chimeric	JJ	O
oligonucleotides	CD	O
(“gapmers”)	VBP	O
20	JJ	O
nucleotides	NNS	O
in	)	O
length,	CD	O
composed	NNS	O
of	IN	O
a	,	O
central	VBN	O
“gap”	IN	O
region	DT	O
consisting	JJ	O
of	JJ	O
ten	NN	O
2′-deoxynucleotides,	VBG	O
which	IN	O
is	JJ	O
flanked	,	O
on	WDT	O
both	VBZ	O
sides	VBN	O
(5′	IN	O
and	DT	O
3′	NNS	O
directions)	CD	O
by	CC	O
five-nucleotide	CD	O
“wings”.	)	O
The	IN	O
wings	JJ	O
are	.	O
composed	DT	O
of	NNS	O
2′-O-methoxyethyl	VBP	O
(2′-MOE)	VBN	O
nucleotides.	IN	O
The	JJ	O
internucleoside	)	O
(backbone)	.	O
linkages	DT	O
are	NN	O
phosphorothioate	)	O
(P═S)	NNS	O
throughout	VBP	O
the	JJ	O
oligonucleotide.	)	O
All	IN	O
cytidine	DT	O
residues	.	O
are	DT	O
5-methylcytidines.	NN	O
The	NNS	O
compounds	VBP	O
were	.	O
analyzed	DT	O
for	NNS	O
their	VBD	O
effect	VBN	O
on	IN	O
human	PRP$	O
diacylglycerol	NN	O
acyltransferase	IN	O
2	JJ	O
mRNA	NN	O
levels	NN	O
by	CD	O
quantitative	NN	O
real-time	NNS	O
PCR	IN	O
as	JJ	O
described	JJ	O
in	NNP	O
other	IN	O
examples	VBN	O
herein.	IN	O
Data	JJ	O
are	NNS	O
averages	.	O
from	NNS	O
three	VBP	O
experiments	NNS	O
in	IN	O
which	CD	O
A549	NNS	O
cells	IN	O
were	WDT	O
treated	NNP	O
with	NNS	O
125	VBD	O
nM	VBN	O
of	IN	O
the	CD	O
antisense	NNS	O
oligonucleotides	IN	O
of	DT	O
the	JJ	O
present	NNS	O
invention.	IN	O
If	DT	O
present,	JJ	O
“N.D.”	.	O
indicates	IN	O
“no	,	O
data”.	JJ	O
ISIS	VBZ	O
18078	JJ	O
(SEQ	.	O
ID	NNP	O
NO:	CD	O
2)	NNP	O
was	NNP	O
used	:	O
in	)	O
this	VBD	O
assay	VBN	O
as	IN	O
a	DT	O
negative	NN	O
control.	IN	O
As	DT	O
shown	JJ	O
in	.	O
Table	IN	O
1,	VBN	O
SEQ	IN	O
ID	JJ	O
Nos:	,	O
20,	NNP	O
21,	NNP	O
23,	:	O
24,	,	O
25,	,	O
26,	,	O
27,	,	O
28,	,	O
29,	,	O
30,	,	O
31,	,	O
32,	,	O
33,	,	O
34,	,	O
35,	,	O
36,	,	O
37,	,	O
38,	,	O
39,	,	O
40,	,	O
41,	,	O
42,	,	O
43,	,	O
44,	,	O
45,	,	O
46,	,	O
47,	,	O
48,	,	O
49,	,	O
50,	,	O
51,	,	O
52,	,	O
53,	,	O
54,	,	O
56,	,	O
57,	,	O
58,	,	O
60,	,	O
61,	,	O
62,	,	O
63,	,	O
64,	,	O
65,	,	O
66,	,	O
68,	,	O
69,	,	O
70,	,	O
71,	,	O
72,	,	O
73,	,	O
75,	,	O
76,	,	O
77,	,	O
78,	,	O
80,	,	O
81,	,	O
82,	,	O
83,	,	O
84,	,	O
85,	,	O
86,	,	O
87,	,	O
88,	,	O
89,	,	O
90,	,	O
91,	,	O
92,	,	O
94,	,	O
95,	,	O
96	,	O
and	,	O
97	,	O
demonstrated	CD	O
at	CC	O
least	CD	O
40%	VBN	O
inhibition	IN	O
of	JJS	O
human	NN	O
diacylglycerol	NN	O
acyltransferase	IN	O
2	JJ	O
expression	NN	O
in	NN	O
this	CD	O
assay	NN	O
and	IN	O
are	DT	O
therefore	NN	O
preferred.	CC	O
More	VBP	O
preferred	RB	O
are	.	O
SEQ	RBR	O
ID	JJ	O
Nos:	VBP	O
65,	NNP	O
26,	NNP	O
29	:	O
and	,	O
35.	,	O
The	CD	O
target	CC	O
regions	.	O
to	DT	O
which	NN	O
these	NNS	O
preferred	TO	O
sequences	WDT	O
are	DT	O
complementary	JJ	O
are	NNS	O
herein	VBP	O
referred	JJ	O
to	VBP	O
as	RB	O
“preferred	VBN	O
target	TO	O
segments”	IN	O
and	JJ	O
are	NN	O
therefore	NN	O
preferred	CC	O
for	VBP	O
targeting	RB	O
by	JJ	O
compounds	IN	O
of	VBG	O
the	IN	O
present	NNS	O
invention.	IN	O
These	DT	O
preferred	JJ	O
target	.	O
segments	DT	O
are	JJ	O
shown	NN	O
in	NNS	O
Table	VBP	O
3.	VBN	O
These	IN	O
sequences	JJ	O
are	.	O
shown	DT	O
to	NNS	O
contain	VBP	O
thymine	VBN	O
(T)	TO	O
but	VB	O
one	NN	O
of	)	O
skill	CC	O
in	CD	O
the	IN	O
art	NN	O
will	IN	O
appreciate	DT	O
that	NN	O
thymine	MD	O
(T)	VB	O
is	DT	O
generally	NN	O
replaced	)	O
by	VBZ	O
uracil	RB	O
(U)	VBN	O
in	IN	O
RNA	NN	O
sequences.	)	O
The	IN	O
sequences	NNP	O
represent	.	O
the	DT	O
reverse	NNS	O
complement	VBP	O
of	DT	O
the	NN	O
preferred	NN	O
antisense	IN	O
compounds	DT	O
shown	JJ	O
in	NN	O
Table	NNS	O
1.	VBN	O
“Target	IN	O
site”	JJ	O
indicates	.	O
the	VB	O
first	NN	O
(5′-most)	VBZ	O
nucleotide	DT	O
number	JJ	O
on	)	O
the	IN	O
particular	NN	O
target	IN	O
nucleic	DT	O
acid	JJ	O
to	NN	O
which	JJ	O
the	NN	O
oligonucleotide	TO	O
binds.	WDT	O
Also	DT	O
shown	NN	O
in	.	O
Table	RB	O
3	VBN	O
is	IN	O
the	JJ	O
species	CD	O
in	VBZ	O
which	DT	O
each	NNS	O
of	IN	O
the	WDT	O
preferred	DT	O
target	IN	O
segments	DT	O
was	JJ	O
found.	NN	O
Example	NNS	O
16	VBD	O
Antisense	.	O
Inhibition	RB	O
of	CD	O
Mouse	NNP	O
Diacylglycerol	NNP	O
Acyltransferase	IN	O
2	NNP	O
Expression	NNP	O
by	NNP	O
Chimeric	CD	O
Phosphorothioate	NNP	O
Oligonucleotides	IN	O
Having	NNP	O
2′-MOE	NNP	O
Wings	NNP	O
and	NNP	O
a	JJ	O
Deoxy	NNP	O
Gap	CC	O
In	DT	O
accordance	NNP	O
with	NNP	O
the	IN	O
present	NN	O
invention,	IN	O
a	DT	O
series	JJ	O
of	,	O
antisense	DT	O
compounds	NN	O
was	IN	O
designed	JJ	O
to	NNS	O
target	VBD	O
different	VBN	O
regions	TO	O
of	VB	O
the	JJ	O
mouse	NNS	O
diacylglycerol	IN	O
acyltransferase	DT	O
2	NN	O
RNA,	NN	O
using	NN	O
published	CD	O
sequences	,	O
(GENBANK®	VBG	O
accession	VBN	O
number	NNS	O
AK002443.1,	NNP	O
incorporated	NN	O
herein	NN	O
as	,	O
SEQ	JJ	O
ID	NN	O
NO:	IN	O
11).	NNP	O
The	NNP	O
compounds	:	O
are	.	O
shown	DT	O
in	NNS	O
Table	VBP	O
2.	VBN	O
“Target	IN	O
site”	JJ	O
indicates	.	O
the	VB	O
first	NN	O
(5′-most)	VBZ	O
nucleotide	DT	O
number	JJ	O
on	)	O
the	IN	O
particular	NN	O
target	IN	O
nucleic	DT	O
acid	JJ	O
to	NN	O
which	JJ	O
the	NN	O
compound	TO	O
binds.	WDT	O
All	DT	O
compounds	NN	O
in	.	O
Table	DT	O
2	NNS	O
are	IN	O
chimeric	JJ	O
oligonucleotides	CD	O
(“gapmers”)	VBP	O
20	JJ	O
nucleotides	NNS	O
in	)	O
length,	CD	O
composed	NNS	O
of	IN	O
a	,	O
central	VBN	O
“gap”	IN	O
region	DT	O
consisting	JJ	O
of	JJ	O
ten	NN	O
2′-deoxynucleotides,	VBG	O
which	IN	O
is	JJ	O
flanked	,	O
on	WDT	O
both	VBZ	O
sides	VBN	O
(5′	IN	O
and	DT	O
3′	NNS	O
directions)	CD	O
by	CC	O
five-nucleotide	CD	O
“wings”.	)	O
The	IN	O
wings	JJ	O
are	.	O
composed	DT	O
of	NNS	O
2′-β-methoxyethyl	VBP	O
(2′-MOE)nucleotides.	VBN	O
The	IN	O
internucleoside	JJ	O
(backbone)	.	O
linkages	DT	O
are	NN	O
phosphorothioate	)	O
(P═S)	NNS	O
throughout	VBP	O
the	JJ	O
oligonucleotide.	)	O
All	IN	O
cytidine	DT	O
residues	.	O
are	DT	O
5-methylcytidines.	NN	O
The	NNS	O
compounds	VBP	O
were	.	O
analyzed	DT	O
for	NNS	O
their	VBD	O
effect	VBN	O
on	IN	O
mouse	PRP$	O
diacylglycerol	NN	O
acyltransferase	IN	O
2	NN	O
mRNA	NN	O
levels	NN	O
by	CD	O
quantitative	NN	O
real-time	NNS	O
PCR	IN	O
as	JJ	O
described	JJ	O
in	NNP	O
other	IN	O
examples	VBN	O
herein.	IN	O
Data	JJ	O
are	NNS	O
averages	.	O
from	NNS	O
three	VBP	O
experiments	NNS	O
in	IN	O
which	CD	O
3T3-L1	NNS	O
cells	IN	O
were	WDT	O
treated	JJ	O
with	NNS	O
150	VBD	O
nM	VBN	O
of	IN	O
the	CD	O
antisense	NNS	O
oligonucleotides	IN	O
of	DT	O
the	JJ	O
present	NNS	O
invention.	IN	O
If	DT	O
present,	JJ	O
“N.D.”	.	O
indicates	IN	O
“no	,	O
data”.	JJ	O
ISIS	VBZ	O
18078	JJ	O
(SEQ	.	O
ID	NNP	O
NO:	CD	O
2)	NNP	O
was	NNP	O
used	:	O
as	)	O
a	VBD	O
negative	VBN	O
control	IN	O
in	DT	O
this	JJ	O
assay.	NN	O
As	IN	O
shown	DT	O
in	.	O
Table	IN	O
2,	VBN	O
SEQ	IN	O
ID	JJ	O
Nos:	,	O
21,	NNP	O
25,	NNP	O
26,	:	O
38,	,	O
39,	,	O
47,	,	O
101,	,	O
109,	,	O
114,	,	O
115,	,	O
120,	,	O
121,	,	O
122,	,	O
123,	,	O
124,	,	O
127,	,	O
128,	,	O
130,	,	O
133,	,	O
136	,	O
and	,	O
142	,	O
demonstrated	CD	O
at	CC	O
least	CD	O
35%	VBN	O
inhibition	IN	O
of	JJS	O
mouse	NN	O
diacylglycerol	NN	O
acyltransferase	IN	O
2	NN	O
expression	NN	O
in	NN	O
this	CD	O
experiment	NN	O
and	IN	O
are	DT	O
therefore	NN	O
preferred.	CC	O
More	VBP	O
preferred	RB	O
are	.	O
SEQ	RBR	O
ID	JJ	O
Nos:	VBP	O
142,	NNP	O
109	NNP	O
and	:	O
121.	,	O
The	CD	O
target	CC	O
regions	.	O
to	DT	O
which	NN	O
these	NNS	O
preferred	TO	O
sequences	WDT	O
are	DT	O
complementary	JJ	O
are	NNS	O
herein	VBP	O
referred	JJ	O
to	VBP	O
as	RB	O
“preferred	VBN	O
target	TO	O
segments”	IN	O
and	JJ	O
are	NN	O
therefore	NN	O
preferred	CC	O
for	VBP	O
targeting	RB	O
by	JJ	O
compounds	IN	O
of	VBG	O
the	IN	O
present	NNS	O
invention.	IN	O
These	DT	O
preferred	JJ	O
target	.	O
segments	DT	O
are	JJ	O
shown	NN	O
in	NNS	O
Table	VBP	O
3.	VBN	O
These	IN	O
sequences	JJ	O
are	.	O
shown	DT	O
to	NNS	O
contain	VBP	O
thymine	VBN	O
(T)	TO	O
but	VB	O
one	NN	O
of	)	O
skill	CC	O
in	CD	O
the	IN	O
art	NN	O
will	IN	O
appreciate	DT	O
that	NN	O
thymine	MD	O
(T)	VB	O
is	DT	O
generally	NN	O
replaced	)	O
by	VBZ	O
uracil	RB	O
(U)	VBN	O
in	IN	O
RNA	NN	O
sequences.	)	O
The	IN	O
sequences	NNP	O
represent	.	O
the	DT	O
reverse	NNS	O
complement	VBP	O
of	DT	O
the	NN	O
preferred	NN	O
antisense	IN	O
compounds	DT	O
shown	JJ	O
in	NN	O
Tables	NNS	O
1	VBN	O
and	IN	O
2.	NNP	O
“Target	CD	O
site”	CC	O
indicates	.	O
the	VB	O
first	NN	O
(5′-most)	VBZ	O
nucleotide	DT	O
number	JJ	O
on	)	O
the	IN	O
particular	NN	O
target	IN	O
nucleic	DT	O
acid	JJ	O
to	NN	O
which	JJ	O
the	NN	O
oligonucleotide	TO	O
binds.	WDT	O
Also	DT	O
shown	NN	O
in	.	O
Table	RB	O
3	VBN	O
is	IN	O
the	JJ	O
species	CD	O
in	VBZ	O
which	DT	O
each	NNS	O
of	IN	O
the	WDT	O
preferred	DT	O
target	IN	O
segments	DT	O
was	JJ	O
found.	NN	O
As	NNS	O
these	VBD	O
“preferred	.	O
target	IN	O
segments”	DT	O
have	NNP	O
been	NN	O
found	NN	O
by	VBP	O
experimentation	VBN	O
to	VBN	O
be	IN	O
open	NN	O
to,	TO	O
and	VB	O
accessible	JJ	O
for,	,	O
hybridization	CC	O
with	JJ	O
the	,	O
antisense	NN	O
compounds	IN	O
of	DT	O
the	JJ	O
present	NNS	O
invention,	IN	O
one	DT	O
of	JJ	O
skill	,	O
in	CD	O
the	IN	O
art	NN	O
will	IN	O
recognize	DT	O
or	NN	O
be	MD	O
able	VB	O
to	CC	O
ascertain,	VB	O
using	JJ	O
no	TO	O
more	,	O
than	VBG	O
routine	DT	O
experimentation,	JJR	O
further	IN	O
embodiments	JJ	O
of	,	O
the	JJ	O
invention	NNS	O
that	IN	O
encompass	DT	O
other	NN	O
compounds	IN	O
that	VBZ	O
specifically	JJ	O
hybridize	NNS	O
to	WDT	O
these	RB	O
preferred	VBP	O
target	TO	O
segments	DT	O
and	VBN	O
consequently	NN	O
inhibit	NNS	O
the	CC	O
expression	RB	O
of	VB	O
diacylglycerol	DT	O
acyltransferase	NN	O
2.	IN	O
According	NN	O
to	NN	O
the	.	O
present	VBG	O
invention,	TO	O
antisense	DT	O
compounds	JJ	O
include	,	O
antisense	JJ	O
oligomeric	NNS	O
compounds,	VBP	O
antisense	JJ	O
oligonucleotides,	JJ	O
siRNAs,	,	O
external	NN	O
guide	,	O
sequence	,	O
(EGS)	JJ	O
oligonucleotides,	NN	O
alternate	NN	O
splicers,	)	O
and	,	O
other	JJ	O
short	,	O
oligomeric	CC	O
compounds	JJ	O
which	JJ	O
hybridize	NN	O
to	NNS	O
at	WDT	O
least	VBP	O
a	TO	O
portion	IN	O
of	JJS	O
the	DT	O
target	NN	O
nucleic	IN	O
acid.	DT	O
Example	NN	O
17	JJ	O
Western	.	O
Blot	RB	O
Analysis	CD	O
of	JJ	O
Diacylglycerol	NNP	O
Acyltransferase	NNP	O
2	IN	O
Protein	NNP	O
Levels	NNP	O
Western	CD	O
blot	NNP	O
analysis	NNP	O
(immunoblot	NNP	O
analysis)	NN	O
is	NN	O
carried	JJ	O
out	)	O
using	VBZ	O
standard	VBN	O
methods.	IN	O
Cells	VBG	O
are	JJ	O
harvested	.	O
16-20	NNS	O
h	VBP	O
after	VBN	O
oligonucleotide	JJ	O
treatment,	NN	O
washed	IN	O
once	JJ	O
with	,	O
PBS,	VBD	O
suspended	RB	O
in	IN	O
Laemmli	,	O
buffer	VBN	O
(100	IN	O
ul/well),	NNP	O
boiled	NN	O
for	CD	O
5	,	O
minutes	VBD	O
and	IN	O
loaded	CD	O
on	NNS	O
a	CC	O
16%	VBN	O
SDS-PAGE	IN	O
gel.	DT	O
Gels	NN	O
are	JJ	O
run	.	O
for	NNS	O
1.5	VBP	O
hours	VBN	O
at	IN	O
150	CD	O
V,	NNS	O
and	IN	O
transferred	CD	O
to	,	O
membrane	CC	O
for	VBD	O
western	TO	O
blotting.	VB	O
Appropriate	IN	O
primary	JJ	O
antibody	.	O
directed	NNP	O
to	JJ	O
diacylglycerol	NN	O
acyltransferase	VBD	O
2	TO	O
is	VB	O
used,	JJ	O
with	CD	O
a	VBZ	O
radiolabeled	,	O
or	IN	O
fluorescently	DT	O
labeled	JJ	O
secondary	CC	O
antibody	RB	O
directed	VBN	O
against	JJ	O
the	NN	O
primary	VBN	O
antibody	IN	O
species.	DT	O
Bands	JJ	O
are	NN	O
visualized	.	O
using	NNS	O
a	VBP	O
PHOSPHORIMAGER™	VBN	O
instrument	VBG	O
(Molecular	DT	O
Dynamics,	NNP	O
Sunnyvale	NN	O
Calif.).	JJ	O
Example	,	O
18	NNP	O
Effects	.	O
of	JJ	O
Antisense	CD	O
Inhibition	NNS	O
on	IN	O
Diacylglycerol	NNP	O
Acyltransferase	NNP	O
2	IN	O
Levels:	NNP	O
In	NNP	O
Vivo	CD	O
Studies	:	O
in	IN	O
a	NNP	O
Diet-Induced	NNPS	O
Model	IN	O
of	DT	O
Obesity	JJ	O
The	NNP	O
C57BL/6	IN	O
mouse	NNP	O
strain	DT	O
is	NNP	O
reported	NN	O
to	NN	O
be	VBZ	O
susceptible	VBN	O
to	TO	O
hyperlipidemia-induced	VB	O
atherosclerotic	JJ	O
plaque	TO	O
formation.	JJ	O
Accordingly,	JJ	O
these	NN	O
mice	.	O
were	,	O
fed	DT	O
a	NNS	O
high-fat	VBD	O
diet	VBN	O
and	DT	O
used	JJ	O
in	NN	O
the	CC	O
following	VBN	O
studies	IN	O
to	DT	O
evaluate	JJ	O
the	NNS	O
effects	TO	O
of	VB	O
diacylglycerol	DT	O
acyltransferase	NNS	O
2	IN	O
antisense	NN	O
oligonucleotides	NN	O
on	CD	O
mRNA	NN	O
expression	NNS	O
in	IN	O
a	JJ	O
model	NN	O
of	IN	O
diet-induced	DT	O
obesity.	NN	O
Male	IN	O
C57BL/6	JJ	O
mice	.	O
at	JJ	O
6	NNP	O
weeks	NN	O
of	IN	O
age	CD	O
were	NNS	O
purchased	IN	O
from	NN	O
Jackson	VBD	O
Laboratories	VBN	O
(Ben	IN	O
Harbor,	NNP	O
Me.).	NNPS	O
Mice	NNP	O
were	,	O
fed	.	O
regular	NNP	O
rodent	VBD	O
chow	VBN	O
(#8604,	JJ	O
Harlan-Teklad,	NN	O
Madison,	NN	O
Wis.)	,	O
for	,	O
5	,	O
days	)	O
and	IN	O
were	CD	O
subsequently	NNS	O
placed	CC	O
on	VBD	O
a	RB	O
high-fat	VBN	O
diet	IN	O
containing	DT	O
60%	JJ	O
calories	JJ	O
from	VBG	O
fat	NN	O
(Research	NNS	O
Diet	IN	O
D12492,	NN	O
Research	NNP	O
Diets	NNP	O
Inc.,	,	O
New	NNP	O
Brunswick,	NNP	O
N.J.).	,	O
After	NNP	O
8	,	O
weeks	.	O
on	IN	O
the	CD	O
high-fat	NNS	O
diet,	IN	O
mice	DT	O
were	JJ	O
divided	,	O
into	NN	O
one	VBD	O
of	VBN	O
three	IN	O
treatment	CD	O
groups	IN	O
of	CD	O
eight	NN	O
animals	NNS	O
each,	IN	O
based	CD	O
on	NNS	O
body	,	O
weight.	VBN	O
One	IN	O
group	NN	O
received	.	O
subcutaneous	CD	O
injections	NN	O
of	VBD	O
ISIS	JJ	O
217376	NNS	O
(SEQ	IN	O
ID	NNP	O
No:	CD	O
142)	NNP	O
at	NNP	O
a	:	O
dose	)	O
of	IN	O
25	DT	O
mg/kg	NN	O
twice	IN	O
per	CD	O
week	JJ	O
for	RB	O
7	IN	O
weeks.	NN	O
The	IN	O
second	CD	O
group	.	O
received	DT	O
subcutaneous	JJ	O
injections	NN	O
of	VBD	O
control	JJ	O
oligonucleotide	NNS	O
ISIS	IN	O
141923	NN	O
(CCTTCCCTGAAGGTTCCTCC,	IN	O
SEQ	NNP	O
ID	CD	O
NO:	,	O
229)	NNP	O
at	NNP	O
a	:	O
dose	)	O
of	IN	O
25	DT	O
mg/kg	NN	O
twice	IN	O
per	CD	O
week	JJ	O
for	RB	O
7	IN	O
weeks.	NN	O
Oligonucleotides	IN	O
were	CD	O
dissolved	.	O
in	NNS	O
0.9%	VBD	O
saline	VBN	O
for	IN	O
injection.	NN	O
The	NN	O
third	IN	O
group	.	O
received	DT	O
subcutaneous	JJ	O
injections	NN	O
of	VBD	O
saline	JJ	O
twice	NNS	O
weekly	IN	O
for	JJ	O
7	JJ	O
weeks.	NN	O
This	IN	O
saline-injected	CD	O
group	.	O
served	DT	O
as	JJ	O
the	NN	O
control	VBD	O
group	IN	O
to	DT	O
which	NN	O
the	NN	O
oligonucleotide-treated	TO	O
groups	WDT	O
were	DT	O
compared.	JJ	O
A	NNS	O
group	VBD	O
of	.	O
8	DT	O
C57B1/6	NN	O
mice,	IN	O
fed	CD	O
regular	NNP	O
rodent	,	O
chow	VBD	O
and	JJ	O
treated	NN	O
with	NN	O
saline,	CC	O
was	VBN	O
used	IN	O
as	,	O
a	VBD	O
normal,	VBN	O
lean	IN	O
group.	DT	O
ISIS	,	O
141923,	JJ	O
which	.	O
is	NNP	O
not	,	O
complementary	WDT	O
to	VBZ	O
any	RB	O
known	JJ	O
gene,	TO	O
is	DT	O
a	VBN	O
chimeric	,	O
oligonucleotide	VBZ	O
(“gapmer”)	DT	O
20	JJ	O
nucleotides	NN	O
in	)	O
length,	CD	O
composed	NNS	O
of	IN	O
a	,	O
central	VBN	O
“gap”	IN	O
region	DT	O
consisting	JJ	O
of	JJ	O
ten	NN	O
2′-deoxynucleotides,	VBG	O
which	IN	O
is	JJ	O
flanked	,	O
on	WDT	O
both	VBZ	O
sides	VBN	O
(5′	IN	O
and	DT	O
3′	NNS	O
directions)	CD	O
by	CC	O
five-nucleotide	CD	O
“wings”.	)	O
The	IN	O
wings	JJ	O
are	.	O
composed	DT	O
of	NNS	O
2′-O-methoxyethyl	VBP	O
(2′-MOE)	VBN	O
nucleotides.	IN	O
The	JJ	O
internucleoside	)	O
(backbone)	.	O
linkages	DT	O
are	NN	O
phosphorothioate	)	O
(P═S)	NNS	O
throughout	VBP	O
the	JJ	O
oligonucleotide.	)	O
All	IN	O
cytidine	DT	O
residues	.	O
are	DT	O
5-methylcytidines.	NN	O
After	NNS	O
the	VBP	O
7	.	O
week	IN	O
treatment	DT	O
period,	CD	O
the	NN	O
mice	NN	O
were	,	O
sacrificed	DT	O
and	NN	O
diacylglycerol	VBD	O
acyltransferase	VBN	O
2	CC	O
(DGAT2)	VB	O
mRNA	NN	O
levels	CD	O
were	)	O
evaluated	NN	O
in	NNS	O
liver,	VBD	O
brown	VBN	O
adipose	IN	O
tissue	,	O
(BAT)	IN	O
and	JJ	O
white	NN	O
adipose	)	O
tissue	CC	O
(WAT).	JJ	O
In	JJ	O
addition,	NN	O
diacylglycerol	.	O
acyltransferase	IN	O
1	,	O
(DGAT1)	NN	O
mRNA	NN	O
levels	CD	O
were	)	O
measured	NN	O
in	NNS	O
these	VBD	O
tissues.	VBN	O
mRNA	IN	O
expression	DT	O
levels	.	O
were	JJ	O
quantitated	NN	O
by	NNS	O
real-time	VBD	O
PCR	VBN	O
as	IN	O
described	JJ	O
in	NNP	O
other	IN	O
examples	VBN	O
herein.	IN	O
The	JJ	O
results	NNS	O
are	.	O
presented	DT	O
in	NNS	O
Table	VBP	O
4	VBN	O
and	IN	O
are	JJ	O
expressed	CD	O
as	CC	O
percent	VBP	O
inhibition	VBN	O
relative	IN	O
to	NN	O
saline-treated	NN	O
mice	JJ	O
receiving	TO	O
a	JJ	O
high	NN	O
fat	VBG	O
diet.	DT	O
A	JJ	O
“+”	NN	O
preceding	.	O
the	DT	O
number	NN	O
indicates	VBG	O
that	DT	O
gene	NN	O
expression	VBZ	O
was	IN	O
increased,	NN	O
rather	NN	O
than	VBD	O
inhibited.	,	O
The	RB	O
data	IN	O
demonstrate	.	O
that	DT	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	WDT	O
antisense	VBZ	O
oligonucleotide	VBZ	O
treatment	CD	O
can	JJ	O
effectively	RB	O
inhibit	NN	O
target	MD	O
mRNA	RB	O
expression	VB	O
in	NN	O
liver,	JJ	O
brown	NN	O
adipose	IN	O
and	,	O
white	VBN	O
adipose	JJ	O
tissue.	CC	O
Diacylglycerol	JJ	O
acyltransferase	JJ	O
1	.	O
expression	NNP	O
levels	VBD	O
were	CD	O
lowered	NN	O
in	NNS	O
liver	VBD	O
and	VBN	O
brown	IN	O
adipose	NN	O
tissue.	CC	O
Body	JJ	O
weight	JJ	O
and	.	O
food	NN	O
intake	NN	O
were	CC	O
monitored	NN	O
throughout	NN	O
the	VBD	O
study.	VBN	O
Metabolic	IN	O
rate	DT	O
was	.	O
measured	JJ	O
using	NN	O
indirect	VBD	O
calorimetry	VBN	O
in	VBG	O
a	JJ	O
metabolic	NN	O
chamber	IN	O
(Oxymax	DT	O
System,	JJ	O
Columbus	NN	O
Instruments,	NNP	O
Columbus,	,	O
Ohio).	NNP	O
Adipose	,	O
tissue	,	O
weight	.	O
was	NNP	O
also	NN	O
measured	NN	O
at	VBD	O
the	RB	O
end	VBN	O
of	IN	O
the	DT	O
study.	NN	O
Body	IN	O
weight,	DT	O
adipose	.	O
tissue	NN	O
weight,	,	O
food	JJ	O
intake	NN	O
and	,	O
metabolic	NN	O
rate	NN	O
were	CC	O
not	JJ	O
changed	NN	O
in	VBD	O
diet-induced	RB	O
obese	VBN	O
mice	IN	O
treated	JJ	O
with	JJ	O
ISIS	NNS	O
217376.	VBN	O
In	IN	O
a	NNP	O
similar	.	O
study,	IN	O
animals	DT	O
received	JJ	O
twice	,	O
weekly,	NNS	O
subcutaneous	VBD	O
injections	RB	O
of	,	O
saline,	JJ	O
25	NNS	O
mg/kg	IN	O
ISIS	,	O
217376	CD	O
or	NN	O
25	NNP	O
mg/kg	CD	O
ISIS	CC	O
141923,	CD	O
for	JJ	O
a	NNP	O
period	,	O
of	IN	O
5	DT	O
weeks.	NN	O
In	IN	O
these	CD	O
mice,	.	O
diacylglycerol	IN	O
acyltransferase	DT	O
2	,	O
mRNA	NN	O
was	NN	O
reduced	CD	O
by	NN	O
approximately	VBD	O
90%	VBN	O
in	IN	O
liver	RB	O
and	NN	O
white	IN	O
adipose	NN	O
fat	CC	O
tissues.	JJ	O
Example	JJ	O
19	NN	O
Effects	.	O
of	JJ	O
Antisense	CD	O
Inhibition	NNS	O
of	IN	O
Diacylglycerol	NNP	O
Acyltransferase	NNP	O
2	IN	O
on	NNP	O
Markers	NNP	O
of	CD	O
Lipid	IN	O
and	NNS	O
Glucose	IN	O
Metabolism	NNP	O
In	CC	O
accordance	NNP	O
with	NNP	O
the	IN	O
present	NN	O
invention,	IN	O
ISIS	DT	O
217376	JJ	O
(SEQ	,	O
ID	NNP	O
NO:	CD	O
142)	NNP	O
was	NNP	O
tested	:	O
for	)	O
its	VBD	O
ability	VBN	O
to	IN	O
affect	PRP$	O
lipid	NN	O
and	TO	O
glucose	VB	O
metabolism	JJ	O
in	CC	O
the	JJ	O
diet-induced	NN	O
obese	IN	O
mice	DT	O
that	JJ	O
received	JJ	O
antisense	NN	O
oligonucleotide	WDT	O
treatment,	VBD	O
as	JJ	O
described	RB	O
in	,	O
Example	IN	O
18.	VBN	O
These	IN	O
mice	NNP	O
were	.	O
further	DT	O
evaluated	NNS	O
at	VBD	O
the	RB	O
end	VBN	O
of	IN	O
the	DT	O
7	NN	O
week	IN	O
treatment	DT	O
period	CD	O
for	NN	O
levels	NN	O
of	NN	O
serum	IN	O
free	NNS	O
fatty	IN	O
acids,	NN	O
which	JJ	O
were	JJ	O
measured	,	O
using	WDT	O
a	VBD	O
NEFA	VBN	O
C	VBG	O
assay	DT	O
kit	NNP	O
(part	NNP	O
#994-75409,	VBP	O
Wako	NN	O
Chemicals,	NN	O
GmbH,	,	O
Germany).	NNP	O
Also	,	O
measured	,	O
at	.	O
the	RB	O
end	VBN	O
of	IN	O
the	DT	O
7	NN	O
week	IN	O
treatment	DT	O
period	CD	O
were	NN	O
triglycerides	NN	O
(TRIG),	NN	O
cholesterol,	VBD	O
including	NNS	O
total	,	O
cholesterol	,	O
(CHOL)	VBG	O
and	JJ	O
high	NN	O
(HDL)	)	O
and	CC	O
low	JJ	O
(LDL)	)	O
density	CC	O
lipoprotein	JJ	O
cholesterol,	)	O
all	NN	O
of	NN	O
which	,	O
were	DT	O
measured	IN	O
using	WDT	O
the	VBD	O
Hitachi	VBN	O
717®	VBG	O
analyzer	DT	O
instrument	NNP	O
(Roche	CD	O
Diagnostics,	NN	O
Indianapolis,	NN	O
Ind.).	NNP	O
The	,	O
data,	,	O
expressed	.	O
as	DT	O
percent	,	O
reduction	VBN	O
relative	IN	O
to	NN	O
the	NN	O
saline	NN	O
control,	TO	O
are	DT	O
presented	NN	O
in	,	O
Table	VBP	O
5.	VBN	O
The	IN	O
results	JJ	O
demonstrate	.	O
that	DT	O
antisense	NNS	O
inhibition	VBP	O
of	IN	O
diacylglycerol	JJ	O
acyltransferase	NN	O
2	IN	O
expression,	NN	O
which	NN	O
was	CD	O
presented	,	O
in	WDT	O
Example	VBD	O
18,	VBN	O
leads	IN	O
to	NNP	O
significant	,	O
reductions	VBZ	O
in	TO	O
of	JJ	O
335,	NNS	O
41%	IN	O
and	IN	O
31%	,	O
in	NN	O
serum	CC	O
free	NN	O
fatty	IN	O
acids,	JJ	O
serum	JJ	O
triglycerides	NN	O
and	,	O
total	NN	O
cholesterol,	NNS	O
respectively.	CC	O
Furthermore,	JJ	O
HDL	,	O
cholesterol	.	O
was	,	O
reduced.	NNP	O
No	NN	O
significant	VBD	O
change	.	O
was	DT	O
observed	JJ	O
in	NN	O
LDL	VBD	O
cholesterol	VBN	O
levels.	IN	O
Plasma	NNP	O
glucose	NN	O
concentrations	.	O
(n=8	NNP	O
mice)	JJ	O
were	NNS	O
measured	JJ	O
at	)	O
0	VBD	O
(beginning	VBN	O
of	IN	O
study),	CD	O
3	VBG	O
and	IN	O
7	,	O
(end	CD	O
of	CC	O
study)	CD	O
weeks	NN	O
of	IN	O
treatment	)	O
by	NNS	O
routine	IN	O
clinical	NN	O
analysis	IN	O
using	JJ	O
a	JJ	O
YSI2700	NN	O
Select™	VBG	O
Biochemistry	DT	O
Analyzer	NNP	O
(YSI	NNP	O
Inc.,	NNP	O
Yellow	NNP	O
Spring,	NNP	O
Ohio).	,	O
Plasma	NNP	O
insulin	,	O
levels	.	O
(n=6	NNP	O
to	NN	O
8	NNS	O
mice)	NN	O
were	TO	O
measured	CD	O
in	)	O
the	VBD	O
fed	VBN	O
state	IN	O
at	DT	O
0,	NN	O
3	NN	O
and	IN	O
7	,	O
weeks	CD	O
and	CC	O
following	CD	O
a	NNS	O
4-hour	CC	O
fast	VBG	O
at	DT	O
4	JJ	O
weeks,	NN	O
using	IN	O
an	CD	O
insulin	,	O
ELISA	VBG	O
kit	DT	O
(#10-1137-10,	NN	O
ALPCO	NNP	O
Diagnostics,	NNP	O
Windham,	,	O
N.	NNP	O
H.)	,	O
according	,	O
to	NNP	O
the	)	O
manufacturer's	VBG	O
instructions.	TO	O
After	DT	O
4	POS	O
weeks	.	O
of	IN	O
treatment,	CD	O
an	NNS	O
insulin	IN	O
tolerance	,	O
test	DT	O
(n=8	NN	O
mice)	NN	O
was	NN	O
performed	JJ	O
after	)	O
a	VBD	O
3-hour	VBN	O
fast.	IN	O
After	DT	O
5	JJ	O
weeks	.	O
of	IN	O
treatment,	CD	O
a	NNS	O
glucose	IN	O
tolerance	,	O
test	DT	O
(n=8	JJ	O
mice)	NN	O
was	NN	O
performed	JJ	O
after	)	O
an	VBD	O
overnight	VBN	O
fast.	IN	O
For	DT	O
the	JJ	O
tolerance	.	O
tests,	IN	O
a	DT	O
baseline	NN	O
tail	,	O
blood	DT	O
glucose	NN	O
measurement	NN	O
was	NN	O
obtained,	JJ	O
after	NN	O
which	VBD	O
1.0	,	O
g/kg	IN	O
glucose	WDT	O
or	CD	O
0.5	NN	O
units/kg	NN	O
insulin	CC	O
was	CD	O
administered	JJ	O
intraperitoneally.	NN	O
Tail	VBD	O
blood	VBN	O
glucose	.	O
levels	NNP	O
were	NN	O
measured	NN	O
at	NNS	O
15,	VBD	O
30,	VBN	O
60,	IN	O
90	,	O
and	,	O
120	,	O
minutes	CD	O
following	CC	O
the	CD	O
challenge	NNS	O
with	VBG	O
glucose	DT	O
or	NN	O
insulin,	IN	O
using	NN	O
a	CC	O
Glucometer®	,	O
instrument	VBG	O
(Abbott	DT	O
Laboratories,	NNP	O
Bedford,	NN	O
Mass.).	NNP	O
Treatment	,	O
with	,	O
an	.	O
antisense	NN	O
oligonucleotide	IN	O
targeted	DT	O
to	JJ	O
diacylglycerol	NN	O
acyltransferase	VBD	O
2	TO	O
reduced	VB	O
plasma	NN	O
insulin	CD	O
levels	VBD	O
by	JJ	O
50%	NN	O
in	NNS	O
the	IN	O
fasted	NN	O
state	IN	O
at	DT	O
4	JJ	O
weeks	NN	O
and	IN	O
by	CD	O
69%	NNS	O
in	CC	O
the	IN	O
fed	NN	O
state	IN	O
at	DT	O
the	NN	O
7	NN	O
weeks.	IN	O
Plasma	DT	O
glucose	CD	O
levels	.	O
were	NNP	O
unchanged	NN	O
by	NNS	O
treatment	VBD	O
with	JJ	O
ISIS	IN	O
217376	NN	O
in	IN	O
diet-induced	NNP	O
obese	CD	O
mice.	IN	O
Neither	JJ	O
insulin	JJ	O
sensitivity	.	O
nor	DT	O
glucose	NN	O
tolerance	NN	O
was	CC	O
improved	JJ	O
by	NN	O
treatment	VBD	O
with	VBN	O
ISIS	IN	O
217376.	NN	O
Example	IN	O
20	NNP	O
Effects	.	O
of	JJ	O
Antisense	CD	O
Inhibition	NNS	O
of	IN	O
Diacylglycerol	NNP	O
Acyltransferase	NNP	O
2	IN	O
on	NNP	O
Hepatic	NNP	O
Triglycerides	CD	O
and	IN	O
Steatosis	NNP	O
in	NNP	O
Diet-Induced	CC	O
Obese	NNP	O
Mice	IN	O
In	NNP	O
accordance	NNP	O
with	NNP	O
the	IN	O
present	NN	O
invention,	IN	O
ISIS	DT	O
217376	JJ	O
(SEQ	,	O
ID	NNP	O
NO:	CD	O
142)	NNP	O
was	NNP	O
tested	:	O
for	)	O
its	VBD	O
ability	VBN	O
to	IN	O
affect	PRP$	O
triglyceride	NN	O
and	TO	O
glycogen	VB	O
content	NN	O
in	CC	O
the	NN	O
livers	NN	O
of	IN	O
diet-induced	DT	O
obese	NNS	O
mice.	IN	O
The	JJ	O
diet-induced	JJ	O
obese	.	O
mice	DT	O
that	JJ	O
received	JJ	O
antisense	NN	O
oligonucleotide	WDT	O
treatment,	VBD	O
as	JJ	O
described	RB	O
in	,	O
Example	IN	O
18,	VBN	O
were	IN	O
further	NNP	O
evaluated	,	O
at	VBD	O
the	RB	O
end	VBN	O
of	IN	O
the	DT	O
7	NN	O
week	IN	O
treatment	DT	O
period	CD	O
for	NN	O
hepatic	NN	O
triglycerides	NN	O
and	IN	O
glycogen	JJ	O
content.	NNS	O
Hepatic	CC	O
triglyceride	NN	O
content,	.	O
which	JJ	O
is	NN	O
evaluated	,	O
by	WDT	O
biochemical	VBZ	O
analysis	VBN	O
of	IN	O
liver	JJ	O
triglyceride	NN	O
concentration	IN	O
and	NN	O
histological	NN	O
examination	NN	O
of	CC	O
liver	JJ	O
tissue,	NN	O
was	IN	O
used	JJ	O
to	,	O
assess	VBD	O
hepatic	VBN	O
steatosis,	TO	O
or	VB	O
accumulation	JJ	O
of	,	O
lipids	CC	O
in	NN	O
the	IN	O
liver.	NNS	O
To	IN	O
measure	DT	O
liver	.	O
tissue	TO	O
triglyceride	VB	O
concentration,	JJ	O
triglycerides	NN	O
were	IN	O
extracted	,	O
from	NNS	O
liver	VBD	O
tissue	VBN	O
in	IN	O
HPLC-grade	JJ	O
acetone,	NN	O
using	IN	O
a	NNP	O
weight:volume	,	O
ratio	VBG	O
of	DT	O
1:20.	NN	O
Triglycerides	NN	O
were	IN	O
measured	.	O
using	NNS	O
an	VBD	O
Infinity	VBN	O
Triglycerides	VBG	O
Reagent	DT	O
Kit	NNP	O
(Sigma-Aldrich,	NNP	O
St.	NNP	O
Louis,	NNP	O
Mo.).	,	O
Liver	NNP	O
and	,	O
muscle	.	O
glycogen	NNP	O
concentrations	CC	O
were	NN	O
measured	NN	O
as	NNS	O
described	VBD	O
by	VBN	O
Desai,	IN	B
et	VBN	I
al.	IN	I
(Diabetes,	,	I
2001,	RB	I
50,	.	I
2287-2295).	,	I
